{
    "640f857d201352f04a00002b_0001": [
        {
            "start_logit": 5.772079944610596,
            "end_logit": 6.009465217590332,
            "text": "CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies",
            "probability": 0.7125006318092346
        },
        {
            "start_logit": 4.300780773162842,
            "end_logit": 6.009465217590332,
            "text": "data extraction for systematic Reviews of prediction Modelling Studies",
            "probability": 0.16360922157764435
        },
        {
            "start_logit": 5.772079944610596,
            "end_logit": 3.2243716716766357,
            "text": "CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS).",
            "probability": 0.04397787153720856
        },
        {
            "start_logit": 5.772079944610596,
            "end_logit": 2.471738338470459,
            "text": "CHecklist for critical Appraisal",
            "probability": 0.020719047635793686
        },
        {
            "start_logit": 2.106421947479248,
            "end_logit": 6.009465217590332,
            "text": "systematic Reviews of prediction Modelling Studies",
            "probability": 0.018230970948934555
        },
        {
            "start_logit": 5.772079944610596,
            "end_logit": 2.1178832054138184,
            "text": "CHecklist for critical Appraisal and data extraction for systematic Reviews",
            "probability": 0.014544287696480751
        },
        {
            "start_logit": 4.300780773162842,
            "end_logit": 3.2243716716766357,
            "text": "data extraction for systematic Reviews of prediction Modelling Studies (CHARMS).",
            "probability": 0.010098504833877087
        },
        {
            "start_logit": 5.772079944610596,
            "end_logit": 0.70259690284729,
            "text": "CHecklist for critical Appraisal and data extraction",
            "probability": 0.003532169619575143
        },
        {
            "start_logit": 4.300780773162842,
            "end_logit": 2.1178832054138184,
            "text": "data extraction for systematic Reviews",
            "probability": 0.0033397607039660215
        },
        {
            "start_logit": 5.772079944610596,
            "end_logit": 0.408186137676239,
            "text": "CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling",
            "probability": 0.002631360897794366
        },
        {
            "start_logit": 2.106421947479248,
            "end_logit": 3.2243716716766357,
            "text": "systematic Reviews of prediction Modelling Studies (CHARMS).",
            "probability": 0.0011252763215452433
        },
        {
            "start_logit": 5.772079944610596,
            "end_logit": -0.5309898853302002,
            "text": "CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction",
            "probability": 0.001028729951940477
        },
        {
            "start_logit": 4.300780773162842,
            "end_logit": 0.70259690284729,
            "text": "data extraction",
            "probability": 0.0008110813214443624
        },
        {
            "start_logit": 5.772079944610596,
            "end_logit": -0.8992573618888855,
            "text": "CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS)",
            "probability": 0.0007118114735931158
        },
        {
            "start_logit": 4.300780773162842,
            "end_logit": 0.408186137676239,
            "text": "data extraction for systematic Reviews of prediction Modelling",
            "probability": 0.0006042314344085753
        },
        {
            "start_logit": 5.772079944610596,
            "end_logit": -1.0659077167510986,
            "text": "CHecklist for critical Appraisal and data extraction for",
            "probability": 0.0006025451002642512
        },
        {
            "start_logit": -1.3133455514907837,
            "end_logit": 6.009465217590332,
            "text": "critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies",
            "probability": 0.0005965185118839145
        },
        {
            "start_logit": 5.772079944610596,
            "end_logit": -1.08089280128479,
            "text": "CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (",
            "probability": 0.0005935831577517092
        },
        {
            "start_logit": 2.106421947479248,
            "end_logit": 2.1178832054138184,
            "text": "systematic Reviews",
            "probability": 0.0003721495158970356
        },
        {
            "start_logit": 5.772079944610596,
            "end_logit": -1.5531284809112549,
            "text": "CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS",
            "probability": 0.0003701623936649412
        }
    ],
    "640f857d201352f04a00002b_0002": [
        {
            "start_logit": 4.52725887298584,
            "end_logit": 3.70766544342041,
            "text": "Checklist for\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies",
            "probability": 0.36811065673828125
        },
        {
            "start_logit": 3.701366424560547,
            "end_logit": 3.70766544342041,
            "text": "Data Extraction for Systematic Reviews of Prediction Modeling Studies",
            "probability": 0.16117507219314575
        },
        {
            "start_logit": 4.52725887298584,
            "end_logit": 2.815840005874634,
            "text": "Checklist for\u00a0Critical Appraisal and Data Extraction for Systematic Reviews",
            "probability": 0.1508910357952118
        },
        {
            "start_logit": 4.52725887298584,
            "end_logit": 2.6117191314697266,
            "text": "Checklist for\u00a0Critical Appraisal",
            "probability": 0.1230311170220375
        },
        {
            "start_logit": 3.701366424560547,
            "end_logit": 2.815840005874634,
            "text": "Data Extraction for Systematic Reviews",
            "probability": 0.06606673449277878
        },
        {
            "start_logit": 2.3076205253601074,
            "end_logit": 3.70766544342041,
            "text": "Systematic Reviews of Prediction Modeling Studies",
            "probability": 0.039994630962610245
        },
        {
            "start_logit": 4.52725887298584,
            "end_logit": 1.458985447883606,
            "text": "Checklist for\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling",
            "probability": 0.03884982317686081
        },
        {
            "start_logit": 3.701366424560547,
            "end_logit": 1.458985447883606,
            "text": "Data Extraction for Systematic Reviews of Prediction Modeling",
            "probability": 0.01701016165316105
        },
        {
            "start_logit": 2.3076205253601074,
            "end_logit": 2.815840005874634,
            "text": "Systematic Reviews",
            "probability": 0.016394075006246567
        },
        {
            "start_logit": 2.3076205253601074,
            "end_logit": 1.458985447883606,
            "text": "Systematic Reviews of Prediction Modeling",
            "probability": 0.004220970440655947
        },
        {
            "start_logit": -0.1928008794784546,
            "end_logit": 3.70766544342041,
            "text": "the Checklist for\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies",
            "probability": 0.003281575860455632
        },
        {
            "start_logit": 4.52725887298584,
            "end_logit": -1.5225317478179932,
            "text": "Checklist for\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS",
            "probability": 0.001970301615074277
        },
        {
            "start_logit": 4.52725887298584,
            "end_logit": -1.739190936088562,
            "text": "Checklist for\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS),",
            "probability": 0.0015864947345107794
        },
        {
            "start_logit": -0.1928008794784546,
            "end_logit": 2.815840005874634,
            "text": "the Checklist for\u00a0Critical Appraisal and Data Extraction for Systematic Reviews",
            "probability": 0.001345140626654029
        },
        {
            "start_logit": 4.52725887298584,
            "end_logit": -2.0039560794830322,
            "text": "Checklist for\u00a0Critical Appraisal and Data Extraction",
            "probability": 0.0012174546718597412
        },
        {
            "start_logit": -0.1928008794784546,
            "end_logit": 2.6117191314697266,
            "text": "the Checklist for\u00a0Critical Appraisal",
            "probability": 0.0010967786656692624
        },
        {
            "start_logit": 4.52725887298584,
            "end_logit": -2.1984310150146484,
            "text": "Checklist for\u00a0Critical Appraisal and Data Extraction for",
            "probability": 0.0010022898204624653
        },
        {
            "start_logit": 4.52725887298584,
            "end_logit": -2.2237682342529297,
            "text": "Checklist for\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS)",
            "probability": 0.0009772134944796562
        },
        {
            "start_logit": 4.52725887298584,
            "end_logit": -2.2887461185455322,
            "text": "Checklist for\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction",
            "probability": 0.0009157354361377656
        },
        {
            "start_logit": 3.701366424560547,
            "end_logit": -1.5225317478179932,
            "text": "Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS",
            "probability": 0.0008626849157735705
        }
    ],
    "640f857d201352f04a00002b_0003": [
        {
            "start_logit": 5.800362586975098,
            "end_logit": 4.560596942901611,
            "text": "Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies",
            "probability": 0.4043038487434387
        },
        {
            "start_logit": 5.800362586975098,
            "end_logit": 4.34268045425415,
            "text": "Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF).",
            "probability": 0.3251381814479828
        },
        {
            "start_logit": 5.800362586975098,
            "end_logit": 2.6537084579467773,
            "text": "Checklist for Critical Appraisal and Data Extraction for Systematic Reviews",
            "probability": 0.060056012123823166
        },
        {
            "start_logit": 3.7862958908081055,
            "end_logit": 4.560596942901611,
            "text": "Data Extraction for Systematic Reviews of Prediction Modeling Studies",
            "probability": 0.05395227670669556
        },
        {
            "start_logit": 5.800362586975098,
            "end_logit": 2.546011447906494,
            "text": "Checklist for Critical Appraisal",
            "probability": 0.05392429977655411
        },
        {
            "start_logit": 3.7862958908081055,
            "end_logit": 4.34268045425415,
            "text": "Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF).",
            "probability": 0.04338802769780159
        },
        {
            "start_logit": 5.800362586975098,
            "end_logit": 1.6820085048675537,
            "text": "Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling",
            "probability": 0.02272755280137062
        },
        {
            "start_logit": 5.800362586975098,
            "end_logit": 0.6585279703140259,
            "text": "Checklist for Critical Appraisal and Data Extraction",
            "probability": 0.008166964165866375
        },
        {
            "start_logit": 3.7862958908081055,
            "end_logit": 2.6537084579467773,
            "text": "Data Extraction for Systematic Reviews",
            "probability": 0.008014168590307236
        },
        {
            "start_logit": 5.800362586975098,
            "end_logit": 0.24950405955314636,
            "text": "Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF)",
            "probability": 0.005425300914794207
        },
        {
            "start_logit": 0.9234640598297119,
            "end_logit": 4.560596942901611,
            "text": "Systematic Reviews of Prediction Modeling Studies",
            "probability": 0.0030810425523668528
        },
        {
            "start_logit": 3.7862958908081055,
            "end_logit": 1.6820085048675537,
            "text": "Data Extraction for Systematic Reviews of Prediction Modeling",
            "probability": 0.003032875945791602
        },
        {
            "start_logit": 0.9234640598297119,
            "end_logit": 4.34268045425415,
            "text": "Systematic Reviews of Prediction Modeling Studies (CHARMS-PF).",
            "probability": 0.0024777513463050127
        },
        {
            "start_logit": 5.800362586975098,
            "end_logit": -1.301672339439392,
            "text": "Checklist for Critical Appraisal and Data Extraction for",
            "probability": 0.001150155090726912
        },
        {
            "start_logit": 5.800362586975098,
            "end_logit": -1.3145537376403809,
            "text": "Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction",
            "probability": 0.0011354346061125398
        },
        {
            "start_logit": 3.7862958908081055,
            "end_logit": 0.6585279703140259,
            "text": "Data Extraction",
            "probability": 0.0010898393811658025
        },
        {
            "start_logit": -0.2350614070892334,
            "end_logit": 4.560596942901611,
            "text": "Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies",
            "probability": 0.0009672894375398755
        },
        {
            "start_logit": -0.2350614070892334,
            "end_logit": 4.34268045425415,
            "text": "Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF).",
            "probability": 0.0007778870640322566
        },
        {
            "start_logit": 3.7862958908081055,
            "end_logit": 0.24950405955314636,
            "text": "Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF)",
            "probability": 0.0007239787373691797
        },
        {
            "start_logit": 5.800362586975098,
            "end_logit": -2.20293927192688,
            "text": "Checklist for",
            "probability": 0.0004670262860599905
        }
    ],
    "640f857d201352f04a00002b_0004": [
        {
            "start_logit": 5.496005535125732,
            "end_logit": 6.435942649841309,
            "text": "Systematic Reviews of Prediction Modeling Studies",
            "probability": 0.8655417561531067
        },
        {
            "start_logit": 2.995554208755493,
            "end_logit": 6.435942649841309,
            "text": "Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies",
            "probability": 0.07101594656705856
        },
        {
            "start_logit": 1.9796874523162842,
            "end_logit": 6.435942649841309,
            "text": "Data Extraction for Systematic Reviews of Prediction Modeling Studies",
            "probability": 0.02571406587958336
        },
        {
            "start_logit": 5.496005535125732,
            "end_logit": 2.643000602722168,
            "text": "Systematic Reviews",
            "probability": 0.01949998177587986
        },
        {
            "start_logit": 5.496005535125732,
            "end_logit": 2.049952507019043,
            "text": "Systematic Reviews of Prediction Modeling",
            "probability": 0.010776478797197342
        },
        {
            "start_logit": 2.995554208755493,
            "end_logit": 2.643000602722168,
            "text": "Critical Appraisal and Data Extraction for Systematic Reviews",
            "probability": 0.001599934184923768
        },
        {
            "start_logit": 2.995554208755493,
            "end_logit": 2.049952507019043,
            "text": "Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling",
            "probability": 0.0008841879316605628
        },
        {
            "start_logit": 5.496005535125732,
            "end_logit": -0.520817756652832,
            "text": "Systematic Reviews of Prediction Modeling Studies (",
            "probability": 0.0008241485920734704
        },
        {
            "start_logit": 1.9796874523162842,
            "end_logit": 2.643000602722168,
            "text": "Data Extraction for Systematic Reviews",
            "probability": 0.0005793179152533412
        },
        {
            "start_logit": -1.8509142398834229,
            "end_logit": 6.435942649841309,
            "text": "Reviews of Prediction Modeling Studies",
            "probability": 0.0005579066928476095
        },
        {
            "start_logit": 5.496005535125732,
            "end_logit": -1.0301209688186646,
            "text": "Systematic Reviews of Prediction",
            "probability": 0.000495242653414607
        },
        {
            "start_logit": -2.1516499519348145,
            "end_logit": 6.435942649841309,
            "text": "Prediction Modeling Studies",
            "probability": 0.00041300340672023594
        },
        {
            "start_logit": -2.201648235321045,
            "end_logit": 6.435942649841309,
            "text": "for Systematic Reviews of Prediction Modeling Studies",
            "probability": 0.00039286166429519653
        },
        {
            "start_logit": 5.496005535125732,
            "end_logit": -1.2653343677520752,
            "text": "Systematic Reviews of Prediction Modeling Studies (CHARMS)",
            "probability": 0.00039144069887697697
        },
        {
            "start_logit": 5.496005535125732,
            "end_logit": -1.337571144104004,
            "text": "Systematic Reviews of Prediction Modeling Studies (CHARMS",
            "probability": 0.0003641615330707282
        },
        {
            "start_logit": 1.9796874523162842,
            "end_logit": 2.049952507019043,
            "text": "Data Extraction for Systematic Reviews of Prediction Modeling",
            "probability": 0.000320154387736693
        },
        {
            "start_logit": 2.995554208755493,
            "end_logit": 0.7851486206054688,
            "text": "Critical Appraisal",
            "probability": 0.00024960152222774923
        },
        {
            "start_logit": 5.496005535125732,
            "end_logit": -2.099370002746582,
            "text": "Systematic Reviews of",
            "probability": 0.0001699999556876719
        },
        {
            "start_logit": 2.995554208755493,
            "end_logit": 0.223478764295578,
            "text": "Critical Appraisal and Data Extraction",
            "probability": 0.00014233683759812266
        },
        {
            "start_logit": 2.995554208755493,
            "end_logit": -0.520817756652832,
            "text": "Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (",
            "probability": 6.761970143998042e-05
        }
    ],
    "6410eb95201352f04a00002e_0001": [
        {
            "start_logit": -3.7569124698638916,
            "end_logit": -4.508844375610352,
            "text": "Our work suggests that an intricate interplay of programs controlling gene expression",
            "probability": 0.1418408900499344
        },
        {
            "start_logit": -3.7569124698638916,
            "end_logit": -4.709478378295898,
            "text": "Our work suggests that an intricate interplay of programs controlling gene expression levels",
            "probability": 0.11605589836835861
        },
        {
            "start_logit": -3.7569124698638916,
            "end_logit": -5.340541839599609,
            "text": "Our work suggests that an intricate interplay of programs controlling gene expression levels and",
            "probability": 0.06174471974372864
        },
        {
            "start_logit": -3.7569124698638916,
            "end_logit": -5.3424763679504395,
            "text": "Our work suggests that an intricate interplay of programs controlling gene expression levels and AS",
            "probability": 0.06162535771727562
        },
        {
            "start_logit": -3.7569124698638916,
            "end_logit": -5.4368977546691895,
            "text": "Our work suggests that an intricate interplay",
            "probability": 0.05607287213206291
        },
        {
            "start_logit": -4.7656755447387695,
            "end_logit": -4.508844375610352,
            "text": "intricate interplay of programs controlling gene expression",
            "probability": 0.05172506719827652
        },
        {
            "start_logit": -3.7569124698638916,
            "end_logit": -5.601052761077881,
            "text": "Our work suggests that an intricate interplay of programs controlling gene expression levels and AS is fundamental to organ",
            "probability": 0.04758401960134506
        },
        {
            "start_logit": -3.7569124698638916,
            "end_logit": -5.620253086090088,
            "text": "Our",
            "probability": 0.04667910933494568
        },
        {
            "start_logit": -4.7656755447387695,
            "end_logit": -4.709478378295898,
            "text": "intricate interplay of programs controlling gene expression levels",
            "probability": 0.0423220656812191
        },
        {
            "start_logit": -5.0412774085998535,
            "end_logit": -4.508844375610352,
            "text": "an intricate interplay of programs controlling gene expression",
            "probability": 0.03926530107855797
        },
        {
            "start_logit": -5.0719895362854,
            "end_logit": -4.508844375610352,
            "text": "interplay of programs controlling gene expression",
            "probability": 0.0380777083337307
        },
        {
            "start_logit": -5.100813388824463,
            "end_logit": -4.508844375610352,
            "text": "suggests that an intricate interplay of programs controlling gene expression",
            "probability": 0.03699583187699318
        },
        {
            "start_logit": -3.7569124698638916,
            "end_logit": -5.902600288391113,
            "text": "Our work suggests that an intricate interplay of programs",
            "probability": 0.03519661724567413
        },
        {
            "start_logit": -5.161016464233398,
            "end_logit": -4.508844375610352,
            "text": "programs controlling gene expression",
            "probability": 0.03483426943421364
        },
        {
            "start_logit": -3.7569124698638916,
            "end_logit": -5.9307332038879395,
            "text": "Our work suggests that an intricate interplay of programs controlling gene expression levels and AS is fundamental to organ development",
            "probability": 0.034220218658447266
        },
        {
            "start_logit": -5.0412774085998535,
            "end_logit": -4.709478378295898,
            "text": "an intricate interplay of programs controlling gene expression levels",
            "probability": 0.03212733566761017
        },
        {
            "start_logit": -3.7569124698638916,
            "end_logit": -6.002907752990723,
            "text": "Our work suggests that an intricate interplay of programs controlling gene expression levels and AS is fundamental to organ development, especially for the brain and heart.",
            "probability": 0.031837426126003265
        },
        {
            "start_logit": -5.0719895362854,
            "end_logit": -4.709478378295898,
            "text": "interplay of programs controlling gene expression levels",
            "probability": 0.031155632808804512
        },
        {
            "start_logit": -3.7569124698638916,
            "end_logit": -6.050121307373047,
            "text": "Our work",
            "probability": 0.03036920167505741
        },
        {
            "start_logit": -5.100813388824463,
            "end_logit": -4.709478378295898,
            "text": "suggests that an intricate interplay of programs controlling gene expression levels",
            "probability": 0.030270427465438843
        }
    ],
    "6410eb95201352f04a00002e_0002": [
        {
            "start_logit": 6.186031818389893,
            "end_logit": 5.66581392288208,
            "text": "Srrm4",
            "probability": 0.34455132484436035
        },
        {
            "start_logit": 6.212727069854736,
            "end_logit": 5.599518299102783,
            "text": "Nova1",
            "probability": 0.3311735987663269
        },
        {
            "start_logit": 6.186031818389893,
            "end_logit": 5.599518299102783,
            "text": "Srrm4 and Nova1",
            "probability": 0.32244980335235596
        },
        {
            "start_logit": 6.212727069854736,
            "end_logit": -1.0847914218902588,
            "text": "Nov",
            "probability": 0.00041409197729080915
        },
        {
            "start_logit": 6.186031818389893,
            "end_logit": -1.0847914218902588,
            "text": "Srrm4 and Nov",
            "probability": 0.0004031839198432863
        },
        {
            "start_logit": 6.186031818389893,
            "end_logit": -1.2075037956237793,
            "text": "Srrm",
            "probability": 0.0003566235245671123
        },
        {
            "start_logit": 6.186031818389893,
            "end_logit": -1.3908319473266602,
            "text": "Sr",
            "probability": 0.00029688727227039635
        },
        {
            "start_logit": 6.186031818389893,
            "end_logit": -2.7260775566101074,
            "text": "Srr",
            "probability": 7.810912211425602e-05
        },
        {
            "start_logit": -2.79891037940979,
            "end_logit": 5.599518299102783,
            "text": "a1",
            "probability": 4.039719351567328e-05
        },
        {
            "start_logit": -2.9021191596984863,
            "end_logit": 5.66581392288208,
            "text": "4",
            "probability": 3.893320172210224e-05
        },
        {
            "start_logit": -2.9021191596984863,
            "end_logit": 5.599518299102783,
            "text": "4 and Nova1",
            "probability": 3.643580203060992e-05
        },
        {
            "start_logit": -3.149357795715332,
            "end_logit": 5.66581392288208,
            "text": "rm4",
            "probability": 3.0405037250602618e-05
        },
        {
            "start_logit": -3.149357795715332,
            "end_logit": 5.599518299102783,
            "text": "rm4 and Nova1",
            "probability": 2.8454678613343276e-05
        },
        {
            "start_logit": -3.5165390968322754,
            "end_logit": 5.66581392288208,
            "text": "Bioinformatical analysis pointed to the tissue-specific splicing factors Srrm4",
            "probability": 2.1061096049379557e-05
        },
        {
            "start_logit": -3.5165390968322754,
            "end_logit": 5.599518299102783,
            "text": "Bioinformatical analysis pointed to the tissue-specific splicing factors Srrm4 and Nova1",
            "probability": 1.971011261048261e-05
        },
        {
            "start_logit": -3.73478627204895,
            "end_logit": 5.66581392288208,
            "text": "m4",
            "probability": 1.6931571735767648e-05
        },
        {
            "start_logit": -3.73478627204895,
            "end_logit": 5.599518299102783,
            "text": "m4 and Nova1",
            "probability": 1.584548044775147e-05
        },
        {
            "start_logit": 6.212727069854736,
            "end_logit": -4.842820167541504,
            "text": "Nova1 as likely upstream regulators of the observed splicing changes in the PLN-R14del cardiomyocytes.",
            "probability": 9.660631803853903e-06
        },
        {
            "start_logit": 6.186031818389893,
            "end_logit": -4.842820167541504,
            "text": "Srrm4 and Nova1 as likely upstream regulators of the observed splicing changes in the PLN-R14del cardiomyocytes.",
            "probability": 9.406149729329627e-06
        },
        {
            "start_logit": 6.212727069854736,
            "end_logit": -4.914980411529541,
            "text": "Nova1 as likely upstream regulators",
            "probability": 8.988080480776262e-06
        }
    ],
    "64162fb0690f196b5100001a_0001": [
        {
            "start_logit": 5.861641883850098,
            "end_logit": 6.04679536819458,
            "text": "deletions",
            "probability": 0.27908605337142944
        },
        {
            "start_logit": 5.861641883850098,
            "end_logit": 5.793781757354736,
            "text": "deletions, 18% duplications and 18% point mutations",
            "probability": 0.21669837832450867
        },
        {
            "start_logit": 5.861641883850098,
            "end_logit": 5.612539768218994,
            "text": "deletions, 18% duplications",
            "probability": 0.18077704310417175
        },
        {
            "start_logit": 5.393839359283447,
            "end_logit": 5.793781757354736,
            "text": "duplications and 18% point mutations",
            "probability": 0.13573488593101501
        },
        {
            "start_logit": 5.393839359283447,
            "end_logit": 5.612539768218994,
            "text": "duplications",
            "probability": 0.11323456466197968
        },
        {
            "start_logit": 4.629967212677002,
            "end_logit": 5.793781757354736,
            "text": "point mutations",
            "probability": 0.06323332339525223
        },
        {
            "start_logit": 2.049182891845703,
            "end_logit": 5.793781757354736,
            "text": "18% duplications and 18% point mutations",
            "probability": 0.0047876848839223385
        },
        {
            "start_logit": 2.049182891845703,
            "end_logit": 5.612539768218994,
            "text": "18% duplications",
            "probability": 0.003994046710431576
        },
        {
            "start_logit": -0.08274295181035995,
            "end_logit": 6.04679536819458,
            "text": "64% deletions",
            "probability": 0.0007313483511097729
        },
        {
            "start_logit": -0.08274295181035995,
            "end_logit": 5.793781757354736,
            "text": "64% deletions, 18% duplications and 18% point mutations",
            "probability": 0.0005678607267327607
        },
        {
            "start_logit": -0.08274295181035995,
            "end_logit": 5.612539768218994,
            "text": "64% deletions, 18% duplications",
            "probability": 0.000473728432552889
        },
        {
            "start_logit": -0.9764838218688965,
            "end_logit": 5.793781757354736,
            "text": "18% point mutations",
            "probability": 0.00023232460080180317
        },
        {
            "start_logit": 5.861641883850098,
            "end_logit": -1.7389695644378662,
            "text": "deletions, 18% duplications and 18% point",
            "probability": 0.00011599066783674061
        },
        {
            "start_logit": 5.861641883850098,
            "end_logit": -2.0876264572143555,
            "text": "deletions, 18% duplications and 18% point mutations.",
            "probability": 8.184710895875469e-05
        },
        {
            "start_logit": 5.393839359283447,
            "end_logit": -1.7389695644378662,
            "text": "duplications and 18% point",
            "probability": 7.265395106514916e-05
        },
        {
            "start_logit": 5.393839359283447,
            "end_logit": -2.0876264572143555,
            "text": "duplications and 18% point mutations.",
            "probability": 5.126718679093756e-05
        },
        {
            "start_logit": -2.53735613822937,
            "end_logit": 5.793781757354736,
            "text": "mutations",
            "probability": 4.8777223128126934e-05
        },
        {
            "start_logit": 4.629967212677002,
            "end_logit": -1.7389695644378662,
            "text": "point",
            "probability": 3.3846496080514044e-05
        },
        {
            "start_logit": 4.629967212677002,
            "end_logit": -2.0876264572143555,
            "text": "point mutations.",
            "probability": 2.388328721281141e-05
        },
        {
            "start_logit": 5.861641883850098,
            "end_logit": -3.4715681076049805,
            "text": "deletions, 18",
            "probability": 2.0509975001914427e-05
        }
    ],
    "64162fb0690f196b5100001a_0002": [
        {
            "start_logit": 5.43612003326416,
            "end_logit": 5.394835472106934,
            "text": "exonic deletions, 64 (11.1%) were exonic duplications",
            "probability": 0.29867079854011536
        },
        {
            "start_logit": 5.43612003326416,
            "end_logit": 5.164331436157227,
            "text": "exonic deletions",
            "probability": 0.23718442022800446
        },
        {
            "start_logit": 4.963563919067383,
            "end_logit": 5.394835472106934,
            "text": "exonic duplications",
            "probability": 0.18619337677955627
        },
        {
            "start_logit": 5.43612003326416,
            "end_logit": 4.19032096862793,
            "text": "exonic deletions, 64 (11.1%) were exonic duplications, and one was a deletion/duplication complex rearrangement",
            "probability": 0.08955271542072296
        },
        {
            "start_logit": 4.963563919067383,
            "end_logit": 4.19032096862793,
            "text": "exonic duplications, and one was a deletion/duplication complex rearrangement",
            "probability": 0.05582776665687561
        },
        {
            "start_logit": 4.884423732757568,
            "end_logit": 4.0573954582214355,
            "text": "nonsense/frameshift",
            "probability": 0.0451597236096859
        },
        {
            "start_logit": 4.884423732757568,
            "end_logit": 3.7774808406829834,
            "text": "nonsense/frameshift types (75.2%). Mutations in splice sites",
            "probability": 0.03413389250636101
        },
        {
            "start_logit": 4.884423732757568,
            "end_logit": 3.0430150032043457,
            "text": "nonsense",
            "probability": 0.016376137733459473
        },
        {
            "start_logit": 3.393369674682617,
            "end_logit": 4.0573954582214355,
            "text": "frameshift",
            "probability": 0.010167044587433338
        },
        {
            "start_logit": 4.884423732757568,
            "end_logit": 2.4756295680999756,
            "text": "nonsense/frameshift types",
            "probability": 0.009285365231335163
        },
        {
            "start_logit": 3.393369674682617,
            "end_logit": 3.7774808406829834,
            "text": "frameshift types (75.2%). Mutations in splice sites",
            "probability": 0.007684744894504547
        },
        {
            "start_logit": 3.393369674682617,
            "end_logit": 2.4756295680999756,
            "text": "frameshift types",
            "probability": 0.0020904638804495335
        },
        {
            "start_logit": 1.7478492259979248,
            "end_logit": 3.7774808406829834,
            "text": "Mutations in splice sites",
            "probability": 0.0014824803220108151
        },
        {
            "start_logit": 1.2221624851226807,
            "end_logit": 4.19032096862793,
            "text": "deletion/duplication complex rearrangement",
            "probability": 0.001324281096458435
        },
        {
            "start_logit": -0.3087991178035736,
            "end_logit": 5.394835472106934,
            "text": "deletions, 64 (11.1%) were exonic duplications",
            "probability": 0.0009554457501508296
        },
        {
            "start_logit": 1.1792144775390625,
            "end_logit": 3.7774808406829834,
            "text": "splice sites",
            "probability": 0.0008395257755182683
        },
        {
            "start_logit": 5.43612003326416,
            "end_logit": -0.499319851398468,
            "text": "exonic deletions, 64 (11.1%) were exonic duplications, and one was a deletion",
            "probability": 0.0008229880477301776
        },
        {
            "start_logit": 5.43612003326416,
            "end_logit": -0.5252238512039185,
            "text": "exonic deletions, 64 (11.1%) were exonic duplications, and one was a deletion/duplication",
            "probability": 0.000801943417172879
        },
        {
            "start_logit": -0.3087991178035736,
            "end_logit": 5.164331436157227,
            "text": "deletions",
            "probability": 0.0007587511790916324
        },
        {
            "start_logit": -0.6369425058364868,
            "end_logit": 5.394835472106934,
            "text": "duplications",
            "probability": 0.0006881692679598927
        }
    ],
    "64162fb0690f196b5100001a_0003": [
        {
            "start_logit": 5.745833396911621,
            "end_logit": 5.376193523406982,
            "text": "gene duplication",
            "probability": 0.37697872519493103
        },
        {
            "start_logit": 5.68460750579834,
            "end_logit": 5.376193523406982,
            "text": "gene deletion rate was 54.3% (391/720), and gene duplication",
            "probability": 0.3545902371406555
        },
        {
            "start_logit": 5.68460750579834,
            "end_logit": 5.086733818054199,
            "text": "gene deletion",
            "probability": 0.2654704749584198
        },
        {
            "start_logit": 5.68460750579834,
            "end_logit": -1.0405677556991577,
            "text": "gene deletion rate",
            "probability": 0.0005793792079202831
        },
        {
            "start_logit": -1.2684799432754517,
            "end_logit": 5.376193523406982,
            "text": "deletion rate was 54.3% (391/720), and gene duplication",
            "probability": 0.00033887496101669967
        },
        {
            "start_logit": -1.2947026491165161,
            "end_logit": 5.376193523406982,
            "text": "54.3% (391/720), and gene duplication",
            "probability": 0.00033010425977408886
        },
        {
            "start_logit": -1.2684799432754517,
            "end_logit": 5.086733818054199,
            "text": "deletion",
            "probability": 0.00025370484218001366
        },
        {
            "start_logit": 5.68460750579834,
            "end_logit": -2.0355100631713867,
            "text": "gene deletion rate was 54.3%",
            "probability": 0.0002142224693670869
        },
        {
            "start_logit": 5.68460750579834,
            "end_logit": -2.3676915168762207,
            "text": "gene",
            "probability": 0.00015367400192189962
        },
        {
            "start_logit": -2.0992064476013184,
            "end_logit": 5.376193523406982,
            "text": "duplication",
            "probability": 0.00014765885134693235
        },
        {
            "start_logit": 5.745833396911621,
            "end_logit": -2.641538619995117,
            "text": "gene duplication rate",
            "probability": 0.0001242396392626688
        },
        {
            "start_logit": 5.68460750579834,
            "end_logit": -2.641538619995117,
            "text": "gene deletion rate was 54.3% (391/720), and gene duplication rate",
            "probability": 0.0001168611561297439
        },
        {
            "start_logit": 5.745833396911621,
            "end_logit": -2.7788453102111816,
            "text": "gene",
            "probability": 0.00010830000974237919
        },
        {
            "start_logit": 5.745833396911621,
            "end_logit": -2.8158860206604004,
            "text": "gene duplication rate was 10.6%",
            "probability": 0.00010436187585582957
        },
        {
            "start_logit": 5.68460750579834,
            "end_logit": -2.7788453102111816,
            "text": "gene deletion rate was 54.3% (391/720), and gene",
            "probability": 0.00010186815052293241
        },
        {
            "start_logit": 5.68460750579834,
            "end_logit": -2.8158860206604004,
            "text": "gene deletion rate was 54.3% (391/720), and gene duplication rate was 10.6%",
            "probability": 9.81638950179331e-05
        },
        {
            "start_logit": 5.745833396911621,
            "end_logit": -3.000979423522949,
            "text": "gene duplication rate was 10.6% (76/720)",
            "probability": 8.672754483995959e-05
        },
        {
            "start_logit": 5.68460750579834,
            "end_logit": -3.000979423522949,
            "text": "gene deletion rate was 54.3% (391/720), and gene duplication rate was 10.6% (76/720)",
            "probability": 8.157686534104869e-05
        },
        {
            "start_logit": 5.68460750579834,
            "end_logit": -3.0167202949523926,
            "text": "gene deletion rate was 54",
            "probability": 8.030277967918664e-05
        },
        {
            "start_logit": -3.3895273208618164,
            "end_logit": 5.376193523406982,
            "text": "391/720), and gene duplication",
            "probability": 4.063311280333437e-05
        }
    ],
    "64162fb0690f196b5100001a_0004": [
        {
            "start_logit": 4.987849235534668,
            "end_logit": 5.550633907318115,
            "text": "gene duplication",
            "probability": 0.5039980411529541
        },
        {
            "start_logit": 4.786516189575195,
            "end_logit": 5.626033782958984,
            "text": "deletion mutant",
            "probability": 0.4443621039390564
        },
        {
            "start_logit": 4.786516189575195,
            "end_logit": 2.308696746826172,
            "text": "deletion mutant occurred in Exon 45-54 was 71.9% (281/391) in all gene deletion",
            "probability": 0.01610778458416462
        },
        {
            "start_logit": 1.0898017883300781,
            "end_logit": 5.550633907318115,
            "text": "gene deletion patients; meanwhile, the rate of gene duplication",
            "probability": 0.010221828706562519
        },
        {
            "start_logit": 4.786516189575195,
            "end_logit": 1.709763765335083,
            "text": "deletion",
            "probability": 0.00884957518428564
        },
        {
            "start_logit": 4.987849235534668,
            "end_logit": 1.0751330852508545,
            "text": "gene duplication occurred in Exon 1-40 was 82.9% (63/76) in all gene duplication",
            "probability": 0.005737779196351767
        },
        {
            "start_logit": -0.7092626094818115,
            "end_logit": 5.626033782958984,
            "text": "The rate of deletion mutant",
            "probability": 0.001823687693104148
        },
        {
            "start_logit": -0.8037720918655396,
            "end_logit": 5.550633907318115,
            "text": "the rate of gene duplication",
            "probability": 0.0015387210296466947
        },
        {
            "start_logit": -1.281266689300537,
            "end_logit": 5.626033782958984,
            "text": "rate of deletion mutant",
            "probability": 0.0010292772203683853
        },
        {
            "start_logit": -1.2112970352172852,
            "end_logit": 5.550633907318115,
            "text": "duplication",
            "probability": 0.0010237031383439898
        },
        {
            "start_logit": 4.786516189575195,
            "end_logit": -0.6127449870109558,
            "text": "deletion mutant occurred in Exon 45-54",
            "probability": 0.0008675007848069072
        },
        {
            "start_logit": -1.3808492422103882,
            "end_logit": 5.550633907318115,
            "text": "rate of gene duplication",
            "probability": 0.0008640490705147386
        },
        {
            "start_logit": -1.4371134042739868,
            "end_logit": 5.550633907318115,
            "text": "deletion patients; meanwhile, the rate of gene duplication",
            "probability": 0.0008167765918187797
        },
        {
            "start_logit": 4.786516189575195,
            "end_logit": -0.7562177777290344,
            "text": "deletion mutant occurred",
            "probability": 0.0007515540346503258
        },
        {
            "start_logit": 4.987849235534668,
            "end_logit": -1.4692332744598389,
            "text": "gene duplication occurred in Exon 1-40",
            "probability": 0.00045054624206386507
        },
        {
            "start_logit": -2.0485286712646484,
            "end_logit": 5.550633907318115,
            "text": "Exon 45-54 was 71.9% (281/391) in all gene deletion patients; meanwhile, the rate of gene duplication",
            "probability": 0.0004431685956660658
        },
        {
            "start_logit": 1.0898017883300781,
            "end_logit": 2.308696746826172,
            "text": "gene deletion",
            "probability": 0.0003995518491137773
        },
        {
            "start_logit": 4.987849235534668,
            "end_logit": -1.782822608947754,
            "text": "gene duplication occurred in Exon 1-40 was 82.9% (63/76) in all gene duplication ones.",
            "probability": 0.0003292679029982537
        },
        {
            "start_logit": 4.786516189575195,
            "end_logit": -1.9859868288040161,
            "text": "deletion mutant occurred in Exon 45-54 was 71.9% (281/391) in all gene deletion patients",
            "probability": 0.00021972449030727148
        },
        {
            "start_logit": -3.1095430850982666,
            "end_logit": 5.626033782958984,
            "text": "mutant",
            "probability": 0.0001653949002502486
        }
    ],
    "64162fb0690f196b5100001a_0005": [
        {
            "start_logit": 4.7170634269714355,
            "end_logit": 4.731369972229004,
            "text": "gene deletion",
            "probability": 0.4253390431404114
        },
        {
            "start_logit": 4.7170634269714355,
            "end_logit": 4.522837162017822,
            "text": "gene deletion and duplication",
            "probability": 0.3452795147895813
        },
        {
            "start_logit": 4.235306262969971,
            "end_logit": 4.522837162017822,
            "text": "duplication",
            "probability": 0.213278129696846
        },
        {
            "start_logit": 0.2594025731086731,
            "end_logit": 4.731369972229004,
            "text": "deletion",
            "probability": 0.004929445218294859
        },
        {
            "start_logit": 0.2594025731086731,
            "end_logit": 4.522837162017822,
            "text": "deletion and duplication",
            "probability": 0.004001597408205271
        },
        {
            "start_logit": 4.7170634269714355,
            "end_logit": -0.69517982006073,
            "text": "gene deletion and duplication, the rate of DMD",
            "probability": 0.0018707456765696406
        },
        {
            "start_logit": 4.235306262969971,
            "end_logit": -0.69517982006073,
            "text": "duplication, the rate of DMD",
            "probability": 0.0011555540841072798
        },
        {
            "start_logit": 4.7170634269714355,
            "end_logit": -1.2730039358139038,
            "text": "gene deletion and duplication, the rate of DMD and IMD was 90.6% (423/467), and BMD",
            "probability": 0.001049709040671587
        },
        {
            "start_logit": 4.7170634269714355,
            "end_logit": -1.6619786024093628,
            "text": "gene deletion and duplication, the rate of DMD and IMD",
            "probability": 0.0007114417967386544
        },
        {
            "start_logit": 4.235306262969971,
            "end_logit": -1.2730039358139038,
            "text": "duplication, the rate of DMD and IMD was 90.6% (423/467), and BMD",
            "probability": 0.0006484021432697773
        },
        {
            "start_logit": 4.7170634269714355,
            "end_logit": -2.0382018089294434,
            "text": "gene",
            "probability": 0.0004883686196990311
        },
        {
            "start_logit": 4.235306262969971,
            "end_logit": -1.6619786024093628,
            "text": "duplication, the rate of DMD and IMD",
            "probability": 0.0004394554707687348
        },
        {
            "start_logit": 4.7170634269714355,
            "end_logit": -2.783078908920288,
            "text": "gene deletion and duplication, the rate of DMD and IMD was 90.6%",
            "probability": 0.00023187391343526542
        },
        {
            "start_logit": 4.235306262969971,
            "end_logit": -2.783078908920288,
            "text": "duplication, the rate of DMD and IMD was 90.6%",
            "probability": 0.0001432278222637251
        },
        {
            "start_logit": 4.7170634269714355,
            "end_logit": -3.6706297397613525,
            "text": "gene deletion and duplication,",
            "probability": 9.545380453346297e-05
        },
        {
            "start_logit": -3.6373085975646973,
            "end_logit": 4.522837162017822,
            "text": "and duplication",
            "probability": 8.126679313136265e-05
        },
        {
            "start_logit": -3.947384834289551,
            "end_logit": 4.731369972229004,
            "text": "In all the patients with gene deletion",
            "probability": 7.341983291553333e-05
        },
        {
            "start_logit": -4.072104454040527,
            "end_logit": 4.731369972229004,
            "text": "with gene deletion",
            "probability": 6.481094169430435e-05
        },
        {
            "start_logit": -3.947384834289551,
            "end_logit": 4.522837162017822,
            "text": "In all the patients with gene deletion and duplication",
            "probability": 5.960037015029229e-05
        },
        {
            "start_logit": 4.235306262969971,
            "end_logit": -3.6706297397613525,
            "text": "duplication,",
            "probability": 5.896153379580937e-05
        }
    ],
    "64162fb0690f196b5100001a_0006": [
        {
            "start_logit": 5.444104194641113,
            "end_logit": 5.878963470458984,
            "text": "deletions, about 7% duplications, about 26% point mutations",
            "probability": 0.18184024095535278
        },
        {
            "start_logit": 5.403397560119629,
            "end_logit": 5.878963470458984,
            "text": "duplications, about 26% point mutations",
            "probability": 0.17458677291870117
        },
        {
            "start_logit": 5.444104194641113,
            "end_logit": 5.727634429931641,
            "text": "deletions",
            "probability": 0.15630346536636353
        },
        {
            "start_logit": 5.444104194641113,
            "end_logit": 5.635219573974609,
            "text": "deletions, about 7% duplications",
            "probability": 0.14250606298446655
        },
        {
            "start_logit": 5.403397560119629,
            "end_logit": 5.635219573974609,
            "text": "duplications",
            "probability": 0.13682161271572113
        },
        {
            "start_logit": 5.444104194641113,
            "end_logit": 4.79147481918335,
            "text": "deletions, about 7% duplications, about 26% point mutations and about 2% unknown mutations",
            "probability": 0.06129138916730881
        },
        {
            "start_logit": 5.403397560119629,
            "end_logit": 4.79147481918335,
            "text": "duplications, about 26% point mutations and about 2% unknown mutations",
            "probability": 0.058846522122621536
        },
        {
            "start_logit": 4.264144420623779,
            "end_logit": 5.878963470458984,
            "text": "point mutations",
            "probability": 0.055877916514873505
        },
        {
            "start_logit": 4.264144420623779,
            "end_logit": 4.79147481918335,
            "text": "point mutations and about 2% unknown mutations",
            "probability": 0.01883430778980255
        },
        {
            "start_logit": 2.762730360031128,
            "end_logit": 4.79147481918335,
            "text": "unknown mutations",
            "probability": 0.004196562338620424
        },
        {
            "start_logit": 0.9109370708465576,
            "end_logit": 5.878963470458984,
            "text": "65% deletions, about 7% duplications, about 26% point mutations",
            "probability": 0.001954162260517478
        },
        {
            "start_logit": 0.9109370708465576,
            "end_logit": 5.727634429931641,
            "text": "65% deletions",
            "probability": 0.0016797292046248913
        },
        {
            "start_logit": 0.9109370708465576,
            "end_logit": 5.635219573974609,
            "text": "65% deletions, about 7% duplications",
            "probability": 0.0015314541524276137
        },
        {
            "start_logit": 0.4056552052497864,
            "end_logit": 5.878963470458984,
            "text": "7% duplications, about 26% point mutations",
            "probability": 0.0011790153803303838
        },
        {
            "start_logit": 0.4056552052497864,
            "end_logit": 5.635219573974609,
            "text": "7% duplications",
            "probability": 0.0009239806095138192
        },
        {
            "start_logit": 0.9109370708465576,
            "end_logit": 4.79147481918335,
            "text": "65% deletions, about 7% duplications, about 26% point mutations and about 2% unknown mutations",
            "probability": 0.0006586733506992459
        },
        {
            "start_logit": 0.4056552052497864,
            "end_logit": 4.79147481918335,
            "text": "7% duplications, about 26% point mutations and about 2% unknown mutations",
            "probability": 0.00039740122156217694
        },
        {
            "start_logit": -1.3609999418258667,
            "end_logit": 5.878963470458984,
            "text": "about 7% duplications, about 26% point mutations",
            "probability": 0.00020149799820501357
        },
        {
            "start_logit": -1.4202964305877686,
            "end_logit": 5.878963470458984,
            "text": "26% point mutations",
            "probability": 0.00018989718228112906
        },
        {
            "start_logit": -1.4778692722320557,
            "end_logit": 5.878963470458984,
            "text": "Xlinked dystrophin gene (about 65% deletions, about 7% duplications, about 26% point mutations",
            "probability": 0.00017927314911503345
        }
    ],
    "63eef3ebf36125a42600000a_0001": [
        {
            "start_logit": 5.970189094543457,
            "end_logit": 7.059739112854004,
            "text": "BDCA2",
            "probability": 0.8675811290740967
        },
        {
            "start_logit": 4.0827412605285645,
            "end_logit": 7.059739112854004,
            "text": "Anti-BDCA2",
            "probability": 0.13140204548835754
        },
        {
            "start_logit": -1.7233151197433472,
            "end_logit": 7.059739112854004,
            "text": "2",
            "probability": 0.00039542451850138605
        },
        {
            "start_logit": 5.970189094543457,
            "end_logit": -1.702376365661621,
            "text": "BDCA",
            "probability": 0.00013582248357124627
        },
        {
            "start_logit": 5.970189094543457,
            "end_logit": -1.9603118896484375,
            "text": "BD",
            "probability": 0.00010494257730897516
        },
        {
            "start_logit": 5.970189094543457,
            "end_logit": -1.9932441711425781,
            "text": "BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.",
            "probability": 0.00010154286428587511
        },
        {
            "start_logit": -3.3336422443389893,
            "end_logit": 7.059739112854004,
            "text": "-BDCA2",
            "probability": 7.901464414317161e-05
        },
        {
            "start_logit": -3.8770980834960938,
            "end_logit": 7.059739112854004,
            "text": "CA2",
            "probability": 4.588678348227404e-05
        },
        {
            "start_logit": 5.970189094543457,
            "end_logit": -3.1581668853759766,
            "text": "BDCA2 Antibody",
            "probability": 3.1675968784838915e-05
        },
        {
            "start_logit": 4.0827412605285645,
            "end_logit": -1.702376365661621,
            "text": "Anti-BDCA",
            "probability": 2.0571393179125153e-05
        },
        {
            "start_logit": 5.970189094543457,
            "end_logit": -3.846081256866455,
            "text": "BDCA2 Antibody Litifilimab",
            "probability": 1.5921072190394625e-05
        },
        {
            "start_logit": 4.0827412605285645,
            "end_logit": -1.9603118896484375,
            "text": "Anti-BD",
            "probability": 1.5894371244939975e-05
        },
        {
            "start_logit": 4.0827412605285645,
            "end_logit": -1.9932441711425781,
            "text": "Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.",
            "probability": 1.537945900054183e-05
        },
        {
            "start_logit": -4.988158702850342,
            "end_logit": 7.059739112854004,
            "text": "Trial of Anti-BDCA2",
            "probability": 1.5106377759366296e-05
        },
        {
            "start_logit": 5.970189094543457,
            "end_logit": -3.9780993461608887,
            "text": "BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus",
            "probability": 1.3952047993370797e-05
        },
        {
            "start_logit": 4.0827412605285645,
            "end_logit": -2.4397153854370117,
            "text": "Anti",
            "probability": 9.841050086834002e-06
        },
        {
            "start_logit": 4.0827412605285645,
            "end_logit": -3.1581668853759766,
            "text": "Anti-BDCA2 Antibody",
            "probability": 4.7975722736737225e-06
        },
        {
            "start_logit": -6.313169479370117,
            "end_logit": 7.059739112854004,
            "text": "of Anti-BDCA2",
            "probability": 4.015274953417247e-06
        },
        {
            "start_logit": 5.970189094543457,
            "end_logit": -5.250949382781982,
            "text": "BDCA2 Antibody Litifilimab for Cutaneous Lupus",
            "probability": 3.907025529770181e-06
        },
        {
            "start_logit": 5.970189094543457,
            "end_logit": -5.440255165100098,
            "text": "BDCA2 Antibody Lit",
            "probability": 3.2331922739103902e-06
        }
    ],
    "63eef3ebf36125a42600000a_0002": [
        {
            "start_logit": 6.814354419708252,
            "end_logit": 7.142207145690918,
            "text": "BDCA2",
            "probability": 0.999484658241272
        },
        {
            "start_logit": -2.3004589080810547,
            "end_logit": 7.142207145690918,
            "text": "2",
            "probability": 0.00010996711353072897
        },
        {
            "start_logit": 6.814354419708252,
            "end_logit": -2.211264133453369,
            "text": "BDCA",
            "probability": 8.66193586261943e-05
        },
        {
            "start_logit": 6.814354419708252,
            "end_logit": -2.496786594390869,
            "text": "BD",
            "probability": 6.510497041745111e-05
        },
        {
            "start_logit": -3.013914108276367,
            "end_logit": 7.142207145690918,
            "text": "monoclonal antibody against BDCA2",
            "probability": 5.387820419855416e-05
        },
        {
            "start_logit": -3.1203575134277344,
            "end_logit": 7.142207145690918,
            "text": "against BDCA2",
            "probability": 4.8437901568831876e-05
        },
        {
            "start_logit": -3.26267671585083,
            "end_logit": 7.142207145690918,
            "text": "CA2",
            "probability": 4.2012325138784945e-05
        },
        {
            "start_logit": -3.616874933242798,
            "end_logit": 7.142207145690918,
            "text": "humanized monoclonal antibody against BDCA2",
            "probability": 2.9481576348189265e-05
        },
        {
            "start_logit": -3.6912715435028076,
            "end_logit": 7.142207145690918,
            "text": "litifilimab, a humanized monoclonal antibody against BDCA2",
            "probability": 2.7367837901692837e-05
        },
        {
            "start_logit": 6.814354419708252,
            "end_logit": -3.8640429973602295,
            "text": "BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied.",
            "probability": 1.6589081496931612e-05
        },
        {
            "start_logit": 6.814354419708252,
            "end_logit": -4.661884784698486,
            "text": "BDCA2,",
            "probability": 7.470057425962295e-06
        },
        {
            "start_logit": -5.345606803894043,
            "end_logit": 7.142207145690918,
            "text": "ifilimab, a humanized monoclonal antibody against BDCA2",
            "probability": 5.2332547966216225e-06
        },
        {
            "start_logit": -5.6049909591674805,
            "end_logit": 7.142207145690918,
            "text": "a humanized monoclonal antibody against BDCA2",
            "probability": 4.037594862893457e-06
        },
        {
            "start_logit": -5.777439594268799,
            "end_logit": 7.142207145690918,
            "text": "antibody against BDCA2",
            "probability": 3.3980447824433213e-06
        },
        {
            "start_logit": -5.801643371582031,
            "end_logit": 7.142207145690918,
            "text": "ilimab, a humanized monoclonal antibody against BDCA2",
            "probability": 3.316788024676498e-06
        },
        {
            "start_logit": -5.950801849365234,
            "end_logit": 7.142207145690918,
            "text": "Whether treatment with litifilimab, a humanized monoclonal antibody against BDCA2",
            "probability": 2.8571892016771017e-06
        },
        {
            "start_logit": 6.814354419708252,
            "end_logit": -5.653676986694336,
            "text": "BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus",
            "probability": 2.770727405732032e-06
        },
        {
            "start_logit": 6.814354419708252,
            "end_logit": -5.720149993896484,
            "text": "BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied",
            "probability": 2.592537157397601e-06
        },
        {
            "start_logit": 6.814354419708252,
            "end_logit": -5.893835067749023,
            "text": "BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively",
            "probability": 2.1791875042254105e-06
        },
        {
            "start_logit": 6.814354419708252,
            "end_logit": -5.982312202453613,
            "text": "BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not",
            "probability": 1.994664216908859e-06
        }
    ],
    "63eef3ebf36125a42600000a_0003": [
        {
            "start_logit": 5.843228816986084,
            "end_logit": 6.991220474243164,
            "text": "BDCA2",
            "probability": 0.8682765364646912
        },
        {
            "start_logit": 3.94917368888855,
            "end_logit": 6.991220474243164,
            "text": "Anti-BDCA2",
            "probability": 0.13064122200012207
        },
        {
            "start_logit": -1.768131136894226,
            "end_logit": 6.991220474243164,
            "text": "2",
            "probability": 0.00042962163570337
        },
        {
            "start_logit": 5.843228816986084,
            "end_logit": -1.7937111854553223,
            "text": "BDCA",
            "probability": 0.00013286496687214822
        },
        {
            "start_logit": 5.843228816986084,
            "end_logit": -1.986484408378601,
            "text": "BD",
            "probability": 0.0001095696643460542
        },
        {
            "start_logit": 5.843228816986084,
            "end_logit": -2.0541937351226807,
            "text": "BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.",
            "probability": 0.00010239630501018837
        },
        {
            "start_logit": -3.2399141788482666,
            "end_logit": 6.991220474243164,
            "text": "-BDCA2",
            "probability": 9.860503632808104e-05
        },
        {
            "start_logit": -3.8761966228485107,
            "end_logit": 6.991220474243164,
            "text": "CA2",
            "probability": 5.2187315304763615e-05
        },
        {
            "start_logit": 5.843228816986084,
            "end_logit": -3.2129323482513428,
            "text": "BDCA2 Antibody",
            "probability": 3.214036041754298e-05
        },
        {
            "start_logit": 3.94917368888855,
            "end_logit": -1.7937111854553223,
            "text": "Anti-BDCA",
            "probability": 1.99909172806656e-05
        },
        {
            "start_logit": 3.94917368888855,
            "end_logit": -1.986484408378601,
            "text": "Anti-BD",
            "probability": 1.6485893866047263e-05
        },
        {
            "start_logit": 5.843228816986084,
            "end_logit": -3.907973527908325,
            "text": "BDCA2 Antibody Litifilimab",
            "probability": 1.6039763067965396e-05
        },
        {
            "start_logit": 3.94917368888855,
            "end_logit": -2.0541937351226807,
            "text": "Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.",
            "probability": 1.5406589227495715e-05
        },
        {
            "start_logit": 5.843228816986084,
            "end_logit": -3.951716184616089,
            "text": "BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus",
            "probability": 1.5353272829088382e-05
        },
        {
            "start_logit": -5.189881324768066,
            "end_logit": 6.991220474243164,
            "text": "Trial of Anti-BDCA2",
            "probability": 1.4029398698767181e-05
        },
        {
            "start_logit": 3.94917368888855,
            "end_logit": -2.3987741470336914,
            "text": "Anti",
            "probability": 1.0915846360148862e-05
        },
        {
            "start_logit": 3.94917368888855,
            "end_logit": -3.2129323482513428,
            "text": "Anti-BDCA2 Antibody",
            "probability": 4.83585017718724e-06
        },
        {
            "start_logit": -6.362701416015625,
            "end_logit": 6.991220474243164,
            "text": "of Anti-BDCA2",
            "probability": 4.341999101598049e-06
        },
        {
            "start_logit": 5.843228816986084,
            "end_logit": -5.328351974487305,
            "text": "BDCA2 Antibody Litifilimab for Systemic Lupus",
            "probability": 3.875571110256715e-06
        },
        {
            "start_logit": 5.843228816986084,
            "end_logit": -5.421638011932373,
            "text": "BDCA2 Antibody Lit",
            "probability": 3.530383764882572e-06
        }
    ],
    "63eef3ebf36125a42600000a_0004": [
        {
            "start_logit": 6.677212715148926,
            "end_logit": 7.104798793792725,
            "text": "BDCA2",
            "probability": 0.9995563626289368
        },
        {
            "start_logit": -2.5018060207366943,
            "end_logit": 7.104798793792725,
            "text": "2",
            "probability": 0.00010313602979294956
        },
        {
            "start_logit": 6.677212715148926,
            "end_logit": -2.2007193565368652,
            "text": "BDCA",
            "probability": 9.088087972486392e-05
        },
        {
            "start_logit": -2.9720094203948975,
            "end_logit": 7.104798793792725,
            "text": "CA2",
            "probability": 6.444714381359518e-05
        },
        {
            "start_logit": 6.677212715148926,
            "end_logit": -2.8872663974761963,
            "text": "BDCA2, in patients with SLE have not been extensively studied.",
            "probability": 4.5741337089566514e-05
        },
        {
            "start_logit": 6.677212715148926,
            "end_logit": -3.082031488418579,
            "text": "BD",
            "probability": 3.76463976863306e-05
        },
        {
            "start_logit": -4.118858337402344,
            "end_logit": 7.104798793792725,
            "text": "binds to BDCA2",
            "probability": 2.047074303845875e-05
        },
        {
            "start_logit": -4.136326313018799,
            "end_logit": 7.104798793792725,
            "text": "litifilimab, a humanized monoclonal antibody that binds to BDCA2",
            "probability": 2.011625656450633e-05
        },
        {
            "start_logit": -4.967475891113281,
            "end_logit": 7.104798793792725,
            "text": "humanized monoclonal antibody that binds to BDCA2",
            "probability": 8.761605386098381e-06
        },
        {
            "start_logit": -5.020692825317383,
            "end_logit": 7.104798793792725,
            "text": "monoclonal antibody that binds to BDCA2",
            "probability": 8.307529242301825e-06
        },
        {
            "start_logit": -5.096490383148193,
            "end_logit": 7.104798793792725,
            "text": "to BDCA2",
            "probability": 7.701107278990094e-06
        },
        {
            "start_logit": -5.1169657707214355,
            "end_logit": 7.104798793792725,
            "text": "The safety and efficacy of subcutaneous litifilimab, a humanized monoclonal antibody that binds to BDCA2",
            "probability": 7.54502798372414e-06
        },
        {
            "start_logit": -5.590121746063232,
            "end_logit": 7.104798793792725,
            "text": "subcutaneous litifilimab, a humanized monoclonal antibody that binds to BDCA2",
            "probability": 4.70080067316303e-06
        },
        {
            "start_logit": -5.599769592285156,
            "end_logit": 7.104798793792725,
            "text": "safety and efficacy of subcutaneous litifilimab, a humanized monoclonal antibody that binds to BDCA2",
            "probability": 4.655668362829601e-06
        },
        {
            "start_logit": -5.600761413574219,
            "end_logit": 7.104798793792725,
            "text": "ifilimab, a humanized monoclonal antibody that binds to BDCA2",
            "probability": 4.6510535867128056e-06
        },
        {
            "start_logit": -5.860625267028809,
            "end_logit": 7.104798793792725,
            "text": "ilimab, a humanized monoclonal antibody that binds to BDCA2",
            "probability": 3.5866867165168514e-06
        },
        {
            "start_logit": 6.677212715148926,
            "end_logit": -5.527563095092773,
            "text": "BDCA2,",
            "probability": 3.2631905924063176e-06
        },
        {
            "start_logit": 6.677212715148926,
            "end_logit": -5.531195640563965,
            "text": "BDCA2, in patients with SLE have not",
            "probability": 3.251358748457278e-06
        },
        {
            "start_logit": 6.677212715148926,
            "end_logit": -5.668562412261963,
            "text": "BDCA2, in patients with SLE have not been extensively studied",
            "probability": 2.8340466542431386e-06
        },
        {
            "start_logit": 6.677212715148926,
            "end_logit": -6.054905414581299,
            "text": "BDCA2, in patients with SLE have not been extensively",
            "probability": 1.9258407064626226e-06
        }
    ],
    "64136fbf201352f04a00003d_0001": [
        {
            "start_logit": 4.604514122009277,
            "end_logit": 4.585474014282227,
            "text": "area under the receiver operator characteristics curve",
            "probability": 0.7247992157936096
        },
        {
            "start_logit": 2.6953611373901367,
            "end_logit": 4.585474014282227,
            "text": "receiver operator characteristics curve",
            "probability": 0.10741950571537018
        },
        {
            "start_logit": 2.235208034515381,
            "end_logit": 4.585474014282227,
            "text": "The area under the receiver operator characteristics curve",
            "probability": 0.06780178099870682
        },
        {
            "start_logit": 4.604514122009277,
            "end_logit": 1.6674370765686035,
            "text": "area under the receiver operator characteristics curve (area under the receiver operating characteristic curve)",
            "probability": 0.03916791081428528
        },
        {
            "start_logit": 4.604514122009277,
            "end_logit": 0.9017603993415833,
            "text": "area under the receiver operator characteristics curve (area under the receiver operating characteristic curve",
            "probability": 0.018213830888271332
        },
        {
            "start_logit": 4.604514122009277,
            "end_logit": 0.8379155397415161,
            "text": "area under the receiver operator characteristics",
            "probability": 0.017087310552597046
        },
        {
            "start_logit": 2.6953611373901367,
            "end_logit": 1.6674370765686035,
            "text": "receiver operator characteristics curve (area under the receiver operating characteristic curve)",
            "probability": 0.005804913584142923
        },
        {
            "start_logit": 2.235208034515381,
            "end_logit": 1.6674370765686035,
            "text": "The area under the receiver operator characteristics curve (area under the receiver operating characteristic curve)",
            "probability": 0.0036639857571572065
        },
        {
            "start_logit": 4.604514122009277,
            "end_logit": -0.8840034008026123,
            "text": "area under",
            "probability": 0.0030538924038410187
        },
        {
            "start_logit": 2.6953611373901367,
            "end_logit": 0.9017603993415833,
            "text": "receiver operator characteristics curve (area under the receiver operating characteristic curve",
            "probability": 0.002699395176023245
        },
        {
            "start_logit": 2.6953611373901367,
            "end_logit": 0.8379155397415161,
            "text": "receiver operator characteristics",
            "probability": 0.0025324395392090082
        },
        {
            "start_logit": 2.235208034515381,
            "end_logit": 0.9017603993415833,
            "text": "The area under the receiver operator characteristics curve (area under the receiver operating characteristic curve",
            "probability": 0.0017038240330293775
        },
        {
            "start_logit": 2.235208034515381,
            "end_logit": 0.8379155397415161,
            "text": "The area under the receiver operator characteristics",
            "probability": 0.0015984430210664868
        },
        {
            "start_logit": 4.604514122009277,
            "end_logit": -1.807405710220337,
            "text": "area under the receiver operator",
            "probability": 0.0012129012029618025
        },
        {
            "start_logit": 0.6480529308319092,
            "end_logit": 1.6674370765686035,
            "text": "area under the receiver operating characteristic curve)",
            "probability": 0.0007493091397918761
        },
        {
            "start_logit": 4.604514122009277,
            "end_logit": -2.4464688301086426,
            "text": "area under the",
            "probability": 0.0006401529535651207
        },
        {
            "start_logit": 4.604514122009277,
            "end_logit": -2.4789977073669434,
            "text": "area under the receiver operator characteristics curve (area under the receiver operating characteristic",
            "probability": 0.0006196645554155111
        },
        {
            "start_logit": -2.7427892684936523,
            "end_logit": 4.585474014282227,
            "text": ". The area under the receiver operator characteristics curve",
            "probability": 0.00046700809616595507
        },
        {
            "start_logit": 4.604514122009277,
            "end_logit": -2.8773813247680664,
            "text": "area under the receiver",
            "probability": 0.0004160455137025565
        },
        {
            "start_logit": 0.6480529308319092,
            "end_logit": 0.9017603993415833,
            "text": "area under the receiver operating characteristic curve",
            "probability": 0.00034844313631765544
        }
    ],
    "64136fbf201352f04a00003d_0002": [
        {
            "start_logit": 5.986565589904785,
            "end_logit": 5.628627777099609,
            "text": "area under receiver operator curve",
            "probability": 0.9237735271453857
        },
        {
            "start_logit": 5.986565589904785,
            "end_logit": 2.3551409244537354,
            "text": "area under receiver operator curve [area under the receiver operating characteristic curve",
            "probability": 0.03498711436986923
        },
        {
            "start_logit": 5.986565589904785,
            "end_logit": 1.9369425773620605,
            "text": "area under receiver operator curve [area under the receiver operating characteristic curve]",
            "probability": 0.02302963100373745
        },
        {
            "start_logit": 1.5070449113845825,
            "end_logit": 5.628627777099609,
            "text": "receiver operator curve",
            "probability": 0.010474524460732937
        },
        {
            "start_logit": 5.986565589904785,
            "end_logit": -0.4885687232017517,
            "text": "area under receiver operator curve [area under the receiver operating characteristic",
            "probability": 0.002036576857790351
        },
        {
            "start_logit": 2.741281747817993,
            "end_logit": 2.3551409244537354,
            "text": "area under the receiver operating characteristic curve",
            "probability": 0.0013630109606310725
        },
        {
            "start_logit": 5.986565589904785,
            "end_logit": -1.2748799324035645,
            "text": "area under",
            "probability": 0.0009277056087739766
        },
        {
            "start_logit": 2.741281747817993,
            "end_logit": 1.9369425773620605,
            "text": "area under the receiver operating characteristic curve]",
            "probability": 0.0008971772040240467
        },
        {
            "start_logit": 5.986565589904785,
            "end_logit": -1.3428575992584229,
            "text": "area under receiver operator",
            "probability": 0.0008667383226566017
        },
        {
            "start_logit": 1.5070449113845825,
            "end_logit": 2.3551409244537354,
            "text": "receiver operator curve [area under the receiver operating characteristic curve",
            "probability": 0.0003967136435676366
        },
        {
            "start_logit": 5.986565589904785,
            "end_logit": -2.413097381591797,
            "text": "area under receiver operator curve [",
            "probability": 0.0002972272632177919
        },
        {
            "start_logit": 1.5070449113845825,
            "end_logit": 1.9369425773620605,
            "text": "receiver operator curve [area under the receiver operating characteristic curve]",
            "probability": 0.00026112954947166145
        },
        {
            "start_logit": 5.986565589904785,
            "end_logit": -3.049612045288086,
            "text": "area under receiver operator curve [area under",
            "probability": 0.0001572728797327727
        },
        {
            "start_logit": 5.986565589904785,
            "end_logit": -3.3063764572143555,
            "text": "area under receiver operator curve [area under the receiver operating",
            "probability": 0.00012165850785095245
        },
        {
            "start_logit": 5.986565589904785,
            "end_logit": -3.3728699684143066,
            "text": "area",
            "probability": 0.00011383214587112889
        },
        {
            "start_logit": 5.986565589904785,
            "end_logit": -3.5416316986083984,
            "text": "area under receiver",
            "probability": 9.615511953597888e-05
        },
        {
            "start_logit": 2.741281747817993,
            "end_logit": -0.4885687232017517,
            "text": "area under the receiver operating characteristic",
            "probability": 7.933996676001698e-05
        },
        {
            "start_logit": 5.986565589904785,
            "end_logit": -4.211395740509033,
            "text": "area under receiver operator curve [area under the",
            "probability": 4.921503204968758e-05
        },
        {
            "start_logit": 5.986565589904785,
            "end_logit": -4.365871906280518,
            "text": "area under receiver operator curve [area",
            "probability": 4.217058449285105e-05
        },
        {
            "start_logit": -1.0993986129760742,
            "end_logit": 2.3551409244537354,
            "text": "receiver operating characteristic curve",
            "probability": 2.9276083296281286e-05
        }
    ],
    "64136fbf201352f04a00003d_0003": [
        {
            "start_logit": 5.161233901977539,
            "end_logit": 5.4109416007995605,
            "text": "area under the receiver operating characteristic curve",
            "probability": 0.9409993886947632
        },
        {
            "start_logit": 1.9377217292785645,
            "end_logit": 5.4109416007995605,
            "text": "receiver operating characteristic curve",
            "probability": 0.03746585175395012
        },
        {
            "start_logit": 5.161233901977539,
            "end_logit": 0.7285335063934326,
            "text": "area under the receiver operating characteristic",
            "probability": 0.008710543625056744
        },
        {
            "start_logit": -0.11388371884822845,
            "end_logit": 5.4109416007995605,
            "text": "the area under the receiver operating characteristic curve",
            "probability": 0.004815426655113697
        },
        {
            "start_logit": 5.161233901977539,
            "end_logit": -0.1725900024175644,
            "text": "area under the receiver operating characteristic curve (area under the receiver operating characteristic curve",
            "probability": 0.003537466051056981
        },
        {
            "start_logit": 5.161233901977539,
            "end_logit": -0.9678300619125366,
            "text": "area under the receiver operating characteristic curve (area under the receiver operating characteristic curve)",
            "probability": 0.001597069320268929
        },
        {
            "start_logit": 5.161233901977539,
            "end_logit": -2.0230660438537598,
            "text": "area under",
            "probability": 0.000555956270545721
        },
        {
            "start_logit": 1.9377217292785645,
            "end_logit": 0.7285335063934326,
            "text": "receiver operating characteristic",
            "probability": 0.000346809858456254
        },
        {
            "start_logit": 5.161233901977539,
            "end_logit": -2.6011805534362793,
            "text": "area under the receiver operating",
            "probability": 0.0003118663444183767
        },
        {
            "start_logit": 5.161233901977539,
            "end_logit": -2.9442338943481445,
            "text": "area under the",
            "probability": 0.00022130059369374067
        },
        {
            "start_logit": 5.161233901977539,
            "end_logit": -2.9689974784851074,
            "text": "area under the receiver operating characteristic curve (area under the receiver operating characteristic",
            "probability": 0.000215887586819008
        },
        {
            "start_logit": 5.161233901977539,
            "end_logit": -3.1195473670959473,
            "text": "area under the receiver",
            "probability": 0.0001857141760410741
        },
        {
            "start_logit": 5.161233901977539,
            "end_logit": -3.2125725746154785,
            "text": "area under the receiver operating characteristic curve (area under",
            "probability": 0.0001692172809271142
        },
        {
            "start_logit": 5.161233901977539,
            "end_logit": -3.2305071353912354,
            "text": "area",
            "probability": 0.00016620944370515645
        },
        {
            "start_logit": 5.161233901977539,
            "end_logit": -3.3297951221466064,
            "text": "area under the receiver operating characteristic curve (area",
            "probability": 0.0001504996616858989
        },
        {
            "start_logit": 1.9377217292785645,
            "end_logit": -0.1725900024175644,
            "text": "receiver operating characteristic curve (area under the receiver operating characteristic curve",
            "probability": 0.000140844116685912
        },
        {
            "start_logit": 5.161233901977539,
            "end_logit": -3.4909276962280273,
            "text": "area under the receiver operating characteristic curve (area under the receiver",
            "probability": 0.0001281021541217342
        },
        {
            "start_logit": 5.161233901977539,
            "end_logit": -3.597193717956543,
            "text": "area under the receiver operating characteristic curve (area under the",
            "probability": 0.00011518758401507512
        },
        {
            "start_logit": 5.161233901977539,
            "end_logit": -3.895009994506836,
            "text": "area under the receiver operating characteristic curve (area under the receiver operating",
            "probability": 8.551960490876809e-05
        },
        {
            "start_logit": -4.195852279663086,
            "end_logit": 5.4109416007995605,
            "text": "The model performance was evaluated using the area under the receiver operating characteristic curve",
            "probability": 8.12565631349571e-05
        }
    ],
    "64136664201352f04a00003b_0001": [
        {
            "start_logit": 5.516686916351318,
            "end_logit": 5.7612128257751465,
            "text": "pain",
            "probability": 0.27283716201782227
        },
        {
            "start_logit": 5.516686916351318,
            "end_logit": 5.36576509475708,
            "text": "pain, sensory disturbances",
            "probability": 0.18372267484664917
        },
        {
            "start_logit": 5.516686916351318,
            "end_logit": 5.2848219871521,
            "text": "pain, sensory disturbances, or autonomic dysfunction",
            "probability": 0.16943754255771637
        },
        {
            "start_logit": 5.21738338470459,
            "end_logit": 5.36576509475708,
            "text": "sensory disturbances",
            "probability": 0.13620001077651978
        },
        {
            "start_logit": 5.21738338470459,
            "end_logit": 5.2848219871521,
            "text": "sensory disturbances, or autonomic dysfunction",
            "probability": 0.12560980021953583
        },
        {
            "start_logit": 5.084378242492676,
            "end_logit": 5.2848219871521,
            "text": "autonomic dysfunction",
            "probability": 0.10996642708778381
        },
        {
            "start_logit": 0.05456423759460449,
            "end_logit": 5.2848219871521,
            "text": "or autonomic dysfunction",
            "probability": 0.0007191835902631283
        },
        {
            "start_logit": 5.516686916351318,
            "end_logit": -1.518730878829956,
            "text": "pain, sensory disturbances,",
            "probability": 0.00018804606224875897
        },
        {
            "start_logit": -1.8584859371185303,
            "end_logit": 5.7612128257751465,
            "text": "with pain",
            "probability": 0.000170964834978804
        },
        {
            "start_logit": 5.516686916351318,
            "end_logit": -1.7057697772979736,
            "text": "pain, sensory",
            "probability": 0.00015596748562529683
        },
        {
            "start_logit": 5.21738338470459,
            "end_logit": -1.518730878829956,
            "text": "sensory disturbances,",
            "probability": 0.00013940494682174176
        },
        {
            "start_logit": 5.516686916351318,
            "end_logit": -1.962839126586914,
            "text": "pain, sensory disturbances, or autonomic",
            "probability": 0.00012061197048751637
        },
        {
            "start_logit": 5.21738338470459,
            "end_logit": -1.7057697772979736,
            "text": "sensory",
            "probability": 0.00011562411236809567
        },
        {
            "start_logit": -1.8584859371185303,
            "end_logit": 5.36576509475708,
            "text": "with pain, sensory disturbances",
            "probability": 0.00011512402852531523
        },
        {
            "start_logit": -1.8584859371185303,
            "end_logit": 5.2848219871521,
            "text": "with pain, sensory disturbances, or autonomic dysfunction",
            "probability": 0.0001061726943589747
        },
        {
            "start_logit": -2.502995729446411,
            "end_logit": 5.7612128257751465,
            "text": "Selective small fiber neuropathy (without large fiber affection) manifests with pain",
            "probability": 8.974278171081096e-05
        },
        {
            "start_logit": 5.21738338470459,
            "end_logit": -1.962839126586914,
            "text": "sensory disturbances, or autonomic",
            "probability": 8.941379928728566e-05
        },
        {
            "start_logit": 5.084378242492676,
            "end_logit": -1.962839126586914,
            "text": "autonomic",
            "probability": 7.82782444730401e-05
        },
        {
            "start_logit": -2.6515369415283203,
            "end_logit": 5.7612128257751465,
            "text": "manifests with pain",
            "probability": 7.735507097095251e-05
        },
        {
            "start_logit": -2.502995729446411,
            "end_logit": 5.36576509475708,
            "text": "Selective small fiber neuropathy (without large fiber affection) manifests with pain, sensory disturbances",
            "probability": 6.04308552283328e-05
        }
    ],
    "64136664201352f04a00003b_0002": [
        {
            "start_logit": 5.105531215667725,
            "end_logit": 5.615609169006348,
            "text": "Neuropathic pain",
            "probability": 0.3955945670604706
        },
        {
            "start_logit": 5.105531215667725,
            "end_logit": 5.039525508880615,
            "text": "Neuropathic pain (Neuropathic pain) is a main feature of Fabry disease (Fabry disease) as consequence of small fiber neuropathy. Restless legs syndrome",
            "probability": 0.2223619967699051
        },
        {
            "start_logit": 5.087518692016602,
            "end_logit": 5.039525508880615,
            "text": "Restless legs syndrome",
            "probability": 0.21839264035224915
        },
        {
            "start_logit": 5.105531215667725,
            "end_logit": 3.707545280456543,
            "text": "Neuropathic pain (Neuropathic pain",
            "probability": 0.05869331955909729
        },
        {
            "start_logit": 3.5369372367858887,
            "end_logit": 5.039525508880615,
            "text": "Neuropathic pain) is a main feature of Fabry disease (Fabry disease) as consequence of small fiber neuropathy. Restless legs syndrome",
            "probability": 0.04632643237709999
        },
        {
            "start_logit": 5.105531215667725,
            "end_logit": 3.1082568168640137,
            "text": "Neuropathic pain (Neuropathic pain)",
            "probability": 0.03223452344536781
        },
        {
            "start_logit": 3.5369372367858887,
            "end_logit": 3.707545280456543,
            "text": "Neuropathic pain",
            "probability": 0.012228049337863922
        },
        {
            "start_logit": 3.5369372367858887,
            "end_logit": 3.1082568168640137,
            "text": "Neuropathic pain)",
            "probability": 0.006715673487633467
        },
        {
            "start_logit": 5.087518692016602,
            "end_logit": 0.9662315249443054,
            "text": "Restless legs syndrome (Restless legs syndrome",
            "probability": 0.0037173088639974594
        },
        {
            "start_logit": 5.087518692016602,
            "end_logit": -0.5445302128791809,
            "text": "Restless legs syndrome (Restless legs syndrome)",
            "probability": 0.0008205653284676373
        },
        {
            "start_logit": 3.5369372367858887,
            "end_logit": 0.9662315249443054,
            "text": "Neuropathic pain) is a main feature of Fabry disease (Fabry disease) as consequence of small fiber neuropathy. Restless legs syndrome (Restless legs syndrome",
            "probability": 0.0007885327213443816
        },
        {
            "start_logit": -1.1666858196258545,
            "end_logit": 5.039525508880615,
            "text": "Fabry disease) as consequence of small fiber neuropathy. Restless legs syndrome",
            "probability": 0.0004198280512355268
        },
        {
            "start_logit": -2.048062562942505,
            "end_logit": 5.615609169006348,
            "text": "pain",
            "probability": 0.0003093743580393493
        },
        {
            "start_logit": -1.6079846620559692,
            "end_logit": 5.039525508880615,
            "text": "Fabry disease (Fabry disease) as consequence of small fiber neuropathy. Restless legs syndrome",
            "probability": 0.0002700335462577641
        },
        {
            "start_logit": 5.105531215667725,
            "end_logit": -1.8213999271392822,
            "text": "Neuropathic pain (Neuropathic pain) is a main feature of Fabry disease (Fabry disease",
            "probability": 0.00023302278714254498
        },
        {
            "start_logit": 5.105531215667725,
            "end_logit": -1.8612759113311768,
            "text": "Neuropathic pain (Neuropathic pain) is a main feature",
            "probability": 0.00022391359379980713
        },
        {
            "start_logit": 5.105531215667725,
            "end_logit": -1.920669674873352,
            "text": "Neuropathic pain (Neuropathic pain) is a main feature of Fabry disease",
            "probability": 0.00021100183948874474
        },
        {
            "start_logit": 5.105531215667725,
            "end_logit": -2.04152512550354,
            "text": "Neuropathic pain (Neuropathic pain) is a main feature of Fabry disease (Fabry disease) as consequence of small fiber neuropathy",
            "probability": 0.0001869817788247019
        },
        {
            "start_logit": -2.048062562942505,
            "end_logit": 5.039525508880615,
            "text": "pain (Neuropathic pain) is a main feature of Fabry disease (Fabry disease) as consequence of small fiber neuropathy. Restless legs syndrome",
            "probability": 0.00017389783170074224
        },
        {
            "start_logit": 5.105531215667725,
            "end_logit": -2.683631658554077,
            "text": "Neuropathic pain (Neuropathic pain) is a main feature of Fabry disease (Fabry disease)",
            "probability": 9.838664846029133e-05
        }
    ],
    "64136664201352f04a00003b_0003": [
        {
            "start_logit": 2.15130352973938,
            "end_logit": 2.0424904823303223,
            "text": "autoantibodies",
            "probability": 0.3449081480503082
        },
        {
            "start_logit": 1.2068414688110352,
            "end_logit": 2.0424904823303223,
            "text": "mall fiber neuropathy (small fiber neuropathy) can be associated with autoantibodies",
            "probability": 0.13413086533546448
        },
        {
            "start_logit": 2.15130352973938,
            "end_logit": 0.6696276664733887,
            "text": "autoantibodies, including those of IgM class",
            "probability": 0.08739298582077026
        },
        {
            "start_logit": 2.15130352973938,
            "end_logit": 0.3595260977745056,
            "text": "autoantibodies, including those of IgM class with specificity for the trisulfated heparan disaccharide",
            "probability": 0.06409162282943726
        },
        {
            "start_logit": 2.15130352973938,
            "end_logit": 0.24395112693309784,
            "text": "autoantibodies, including those of IgM class with specificity for the trisulfated heparan disaccharide (Trisulfated Heparin Disaccharide) antigen.",
            "probability": 0.05709626153111458
        },
        {
            "start_logit": 2.15130352973938,
            "end_logit": 0.015571951866149902,
            "text": "autoantibodies, including those of IgM class with specificity for the trisulfated heparan disaccharide (Trisulfated Heparin Disaccharide) antigen",
            "probability": 0.045438479632139206
        },
        {
            "start_logit": 1.2068414688110352,
            "end_logit": 0.9186747670173645,
            "text": "mall fiber neuropathy",
            "probability": 0.0435975156724453
        },
        {
            "start_logit": 1.2068414688110352,
            "end_logit": 0.6696276664733887,
            "text": "mall fiber neuropathy (small fiber neuropathy) can be associated with autoantibodies, including those of IgM class",
            "probability": 0.03398614749312401
        },
        {
            "start_logit": 1.4096794128417969,
            "end_logit": 0.3595260977745056,
            "text": "specificity for the trisulfated heparan disaccharide",
            "probability": 0.030529377982020378
        },
        {
            "start_logit": 1.4096794128417969,
            "end_logit": 0.24395112693309784,
            "text": "specificity for the trisulfated heparan disaccharide (Trisulfated Heparin Disaccharide) antigen.",
            "probability": 0.027197208255529404
        },
        {
            "start_logit": 1.2068414688110352,
            "end_logit": 0.3595260977745056,
            "text": "mall fiber neuropathy (small fiber neuropathy) can be associated with autoantibodies, including those of IgM class with specificity for the trisulfated heparan disaccharide",
            "probability": 0.02492450550198555
        },
        {
            "start_logit": 1.4096794128417969,
            "end_logit": 0.015571951866149902,
            "text": "specificity for the trisulfated heparan disaccharide (Trisulfated Heparin Disaccharide) antigen",
            "probability": 0.02164415270090103
        },
        {
            "start_logit": 0.6498509049415588,
            "end_logit": 0.6696276664733887,
            "text": "those of IgM class",
            "probability": 0.019471706822514534
        },
        {
            "start_logit": 0.6498509049415588,
            "end_logit": 0.3595260977745056,
            "text": "those of IgM class with specificity for the trisulfated heparan disaccharide",
            "probability": 0.014280013740062714
        },
        {
            "start_logit": 0.6498509049415588,
            "end_logit": 0.24395112693309784,
            "text": "those of IgM class with specificity for the trisulfated heparan disaccharide (Trisulfated Heparin Disaccharide) antigen.",
            "probability": 0.012721406295895576
        },
        {
            "start_logit": 0.6498509049415588,
            "end_logit": 0.015571951866149902,
            "text": "those of IgM class with specificity for the trisulfated heparan disaccharide (Trisulfated Heparin Disaccharide) antigen",
            "probability": 0.010123979300260544
        },
        {
            "start_logit": 2.15130352973938,
            "end_logit": -1.5586308240890503,
            "text": "autoantibodies, including those of IgM class with specificity for the trisulfated heparan disaccharide (Trisulfated Heparin Disaccharide)",
            "probability": 0.009413613006472588
        },
        {
            "start_logit": 2.15130352973938,
            "end_logit": -1.8338449001312256,
            "text": "autoantibodies,",
            "probability": 0.007148786447942257
        },
        {
            "start_logit": 2.15130352973938,
            "end_logit": -2.0047476291656494,
            "text": "autoantibodies, including those of IgM class with specificity for the trisulfated heparan disaccharide (Trisulfated Heparin Disaccharide",
            "probability": 0.006025737151503563
        },
        {
            "start_logit": -0.2378912717103958,
            "end_logit": 0.3595260977745056,
            "text": "trisulfated heparan disaccharide",
            "probability": 0.0058774263598024845
        }
    ],
    "64136664201352f04a00003b_0004": [
        {
            "start_logit": 2.7704319953918457,
            "end_logit": 2.7436575889587402,
            "text": "antibodies to Trisulfated Heparin Disaccharide",
            "probability": 0.1787026822566986
        },
        {
            "start_logit": 2.7704319953918457,
            "end_logit": 2.3831310272216797,
            "text": "antibodies to Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide) and fibroblast growth factor receptor 3",
            "probability": 0.1246110051870346
        },
        {
            "start_logit": 2.7704319953918457,
            "end_logit": 2.307347297668457,
            "text": "antibodies to Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide)",
            "probability": 0.11551648378372192
        },
        {
            "start_logit": 2.313361644744873,
            "end_logit": 2.7436575889587402,
            "text": "novel antibodies to Trisulfated Heparin Disaccharide",
            "probability": 0.11314307898283005
        },
        {
            "start_logit": 2.313361644744873,
            "end_logit": 2.3831310272216797,
            "text": "novel antibodies to Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide) and fibroblast growth factor receptor 3",
            "probability": 0.0788956806063652
        },
        {
            "start_logit": 2.313361644744873,
            "end_logit": 2.307347297668457,
            "text": "novel antibodies to Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide)",
            "probability": 0.07313761115074158
        },
        {
            "start_logit": 2.7704319953918457,
            "end_logit": 1.8470720052719116,
            "text": "antibodies to Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide) and fibroblast growth factor receptor 3 (FGFR-3)",
            "probability": 0.0729035958647728
        },
        {
            "start_logit": 2.1176133155822754,
            "end_logit": 2.3831310272216797,
            "text": "fibroblast growth factor receptor 3",
            "probability": 0.06486953794956207
        },
        {
            "start_logit": 2.313361644744873,
            "end_logit": 1.8470720052719116,
            "text": "novel antibodies to Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide) and fibroblast growth factor receptor 3 (FGFR-3)",
            "probability": 0.04615787789225578
        },
        {
            "start_logit": 2.1176133155822754,
            "end_logit": 1.8470720052719116,
            "text": "fibroblast growth factor receptor 3 (FGFR-3)",
            "probability": 0.03795189410448074
        },
        {
            "start_logit": 0.5702992677688599,
            "end_logit": 2.7436575889587402,
            "text": "Trisulfated Heparin Disaccharide",
            "probability": 0.019798191264271736
        },
        {
            "start_logit": 0.5702992677688599,
            "end_logit": 2.3831310272216797,
            "text": "Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide) and fibroblast growth factor receptor 3",
            "probability": 0.013805458322167397
        },
        {
            "start_logit": 0.5702992677688599,
            "end_logit": 2.307347297668457,
            "text": "Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide)",
            "probability": 0.012797891162335873
        },
        {
            "start_logit": 2.7704319953918457,
            "end_logit": -0.13728263974189758,
            "text": "antibodies to Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide) and fibroblast growth factor receptor 3 (FGFR-3",
            "probability": 0.010022005066275597
        },
        {
            "start_logit": 0.5702992677688599,
            "end_logit": 1.8470720052719116,
            "text": "Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide) and fibroblast growth factor receptor 3 (FGFR-3)",
            "probability": 0.00807687547057867
        },
        {
            "start_logit": 2.7704319953918457,
            "end_logit": -0.5668933391571045,
            "text": "antibodies to Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide",
            "probability": 0.006521944887936115
        },
        {
            "start_logit": 2.313361644744873,
            "end_logit": -0.13728263974189758,
            "text": "novel antibodies to Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide) and fibroblast growth factor receptor 3 (FGFR-3",
            "probability": 0.006345290224999189
        },
        {
            "start_logit": -0.6147637963294983,
            "end_logit": 2.7436575889587402,
            "text": "small fiber neuropathy (small fiber neuropathy) cases are idiopathic, but novel antibodies to Trisulfated Heparin Disaccharide",
            "probability": 0.006052841432392597
        },
        {
            "start_logit": -0.7155028581619263,
            "end_logit": 2.7436575889587402,
            "text": "idiopathic, but novel antibodies to Trisulfated Heparin Disaccharide",
            "probability": 0.005472790915518999
        },
        {
            "start_logit": 2.1176133155822754,
            "end_logit": -0.13728263974189758,
            "text": "fibroblast growth factor receptor 3 (FGFR-3",
            "probability": 0.005217219237238169
        }
    ],
    "6415c53e690f196b51000012_0001": [
        {
            "start_logit": 5.46632194519043,
            "end_logit": 6.002884864807129,
            "text": "October 24, 2016",
            "probability": 0.7868857383728027
        },
        {
            "start_logit": 4.140552520751953,
            "end_logit": 6.002884864807129,
            "text": "2016",
            "probability": 0.20899567008018494
        },
        {
            "start_logit": -0.0544283501803875,
            "end_logit": 6.002884864807129,
            "text": "24, 2016",
            "probability": 0.0031497797463089228
        },
        {
            "start_logit": 5.46632194519043,
            "end_logit": -1.692686676979065,
            "text": "October 24, 2016,",
            "probability": 0.00035790473339147866
        },
        {
            "start_logit": -3.441351890563965,
            "end_logit": 6.002884864807129,
            "text": "On October 24, 2016",
            "probability": 0.00010650208423612639
        },
        {
            "start_logit": 5.46632194519043,
            "end_logit": -2.9913828372955322,
            "text": "October",
            "probability": 9.766768926056102e-05
        },
        {
            "start_logit": 4.140552520751953,
            "end_logit": -1.692686676979065,
            "text": "2016,",
            "probability": 9.505892376182601e-05
        },
        {
            "start_logit": 5.46632194519043,
            "end_logit": -3.1854090690612793,
            "text": "October 24",
            "probability": 8.044267451623455e-05
        },
        {
            "start_logit": 5.46632194519043,
            "end_logit": -3.3189549446105957,
            "text": "October 24, 2016, the U.S. Food and Drug Administration (Food and Drug Administration) approved pembrolizumab",
            "probability": 7.038626063149422e-05
        },
        {
            "start_logit": -3.9106807708740234,
            "end_logit": 6.002884864807129,
            "text": ", 2016",
            "probability": 6.660872895736247e-05
        },
        {
            "start_logit": 5.46632194519043,
            "end_logit": -3.80704927444458,
            "text": "October 24, 2016, the U.S. Food and Drug Administration",
            "probability": 4.3202733650105074e-05
        },
        {
            "start_logit": 4.140552520751953,
            "end_logit": -3.3189549446105957,
            "text": "2016, the U.S. Food and Drug Administration (Food and Drug Administration) approved pembrolizumab",
            "probability": 1.8694485333980992e-05
        },
        {
            "start_logit": 5.46632194519043,
            "end_logit": -4.888605117797852,
            "text": "October 24, 2016, the U.S. Food and Drug Administration (Food and Drug Administration",
            "probability": 1.4648651813331526e-05
        },
        {
            "start_logit": 4.140552520751953,
            "end_logit": -3.80704927444458,
            "text": "2016, the U.S. Food and Drug Administration",
            "probability": 1.1474581697257236e-05
        },
        {
            "start_logit": 4.140552520751953,
            "end_logit": -4.888605117797852,
            "text": "2016, the U.S. Food and Drug Administration (Food and Drug Administration",
            "probability": 3.890660536853829e-06
        },
        {
            "start_logit": -0.0544283501803875,
            "end_logit": -1.692686676979065,
            "text": "24, 2016,",
            "probability": 1.4326365089800674e-06
        },
        {
            "start_logit": -0.0544283501803875,
            "end_logit": -3.1854090690612793,
            "text": "24",
            "probability": 3.2199923793996277e-07
        },
        {
            "start_logit": -0.0544283501803875,
            "end_logit": -3.3189549446105957,
            "text": "24, 2016, the U.S. Food and Drug Administration (Food and Drug Administration) approved pembrolizumab",
            "probability": 2.817452298131684e-07
        },
        {
            "start_logit": -0.0544283501803875,
            "end_logit": -3.80704927444458,
            "text": "24, 2016, the U.S. Food and Drug Administration",
            "probability": 1.7293379528382502e-07
        },
        {
            "start_logit": -1.2208491563796997,
            "end_logit": -3.3189549446105957,
            "text": "U.S. Food and Drug Administration (Food and Drug Administration) approved pembrolizumab",
            "probability": 8.775802484706219e-08
        }
    ],
    "6417949d690f196b51000035_0001": [
        {
            "start_logit": -2.6996679306030273,
            "end_logit": 0.060693398118019104,
            "text": "gene therapies",
            "probability": 0.38279539346694946
        },
        {
            "start_logit": -3.393195390701294,
            "end_logit": 0.060693398118019104,
            "text": "the area of gene therapies",
            "probability": 0.19132491946220398
        },
        {
            "start_logit": -3.4620187282562256,
            "end_logit": 0.060693398118019104,
            "text": "area of gene therapies",
            "probability": 0.17860020697116852
        },
        {
            "start_logit": -5.040517807006836,
            "end_logit": 0.060693398118019104,
            "text": "therapeutic targets: 1) the area of gene therapies",
            "probability": 0.03684244304895401
        },
        {
            "start_logit": -5.278951644897461,
            "end_logit": 0.060693398118019104,
            "text": "therapies",
            "probability": 0.029026715084910393
        },
        {
            "start_logit": -5.335099220275879,
            "end_logit": 0.060693398118019104,
            "text": "major therapeutic targets: 1) the area of gene therapies",
            "probability": 0.02744184620678425
        },
        {
            "start_logit": -5.50259256362915,
            "end_logit": 0.060693398118019104,
            "text": "therapeutic options, divided into two major therapeutic targets: 1) the area of gene therapies",
            "probability": 0.0232098251581192
        },
        {
            "start_logit": -5.549661636352539,
            "end_logit": 0.060693398118019104,
            "text": "has experienced great advances in the field of therapeutic options, divided into two major therapeutic targets: 1) the area of gene therapies",
            "probability": 0.022142672911286354
        },
        {
            "start_logit": -5.567439079284668,
            "end_logit": 0.060693398118019104,
            "text": "last ten years, has experienced great advances in the field of therapeutic options, divided into two major therapeutic targets: 1) the area of gene therapies",
            "probability": 0.021752510219812393
        },
        {
            "start_logit": -5.6301984786987305,
            "end_logit": 0.060693398118019104,
            "text": ", has experienced great advances in the field of therapeutic options, divided into two major therapeutic targets: 1) the area of gene therapies",
            "probability": 0.02042929269373417
        },
        {
            "start_logit": -2.6996679306030273,
            "end_logit": -3.2354660034179688,
            "text": "gene therapies and 2) trying to reverse or block the pathophysiological processes of the disease, such as inflammation, fibrosis, muscle regeneration",
            "probability": 0.014173032715916634
        },
        {
            "start_logit": -3.666534900665283,
            "end_logit": -2.705080509185791,
            "text": "clinical trials",
            "probability": 0.009160122834146023
        },
        {
            "start_logit": -3.393195390701294,
            "end_logit": -3.2354660034179688,
            "text": "the area of gene therapies and 2) trying to reverse or block the pathophysiological processes of the disease, such as inflammation, fibrosis, muscle regeneration",
            "probability": 0.0070838239043951035
        },
        {
            "start_logit": -3.4025583267211914,
            "end_logit": -3.2354660034179688,
            "text": "muscle regeneration",
            "probability": 0.007017806638032198
        },
        {
            "start_logit": -2.6996679306030273,
            "end_logit": -3.981231212615967,
            "text": "gene therapies and 2) trying to reverse or block the pathophysiological processes of the disease, such as inflammation, fibrosis",
            "probability": 0.006723280064761639
        },
        {
            "start_logit": -3.4620187282562256,
            "end_logit": -3.2354660034179688,
            "text": "area of gene therapies and 2) trying to reverse or block the pathophysiological processes of the disease, such as inflammation, fibrosis, muscle regeneration",
            "probability": 0.006612684577703476
        },
        {
            "start_logit": -3.851552963256836,
            "end_logit": -3.2354660034179688,
            "text": "fibrosis, muscle regeneration",
            "probability": 0.004479250870645046
        },
        {
            "start_logit": -2.6996679306030273,
            "end_logit": -4.453751564025879,
            "text": "gene therapies and 2) trying to reverse or block the pathophysiological processes of the disease, such as inflammation",
            "probability": 0.004191486164927483
        },
        {
            "start_logit": -4.061118125915527,
            "end_logit": -3.2354660034179688,
            "text": "inflammation, fibrosis, muscle regeneration",
            "probability": 0.0036323892418295145
        },
        {
            "start_logit": -3.393195390701294,
            "end_logit": -3.981231212615967,
            "text": "the area of gene therapies and 2) trying to reverse or block the pathophysiological processes of the disease, such as inflammation, fibrosis",
            "probability": 0.003360359463840723
        }
    ],
    "6417949d690f196b51000035_0002": [
        {
            "start_logit": 5.470393180847168,
            "end_logit": 5.644370079040527,
            "text": "gene replacement",
            "probability": 0.2531789541244507
        },
        {
            "start_logit": 5.470393180847168,
            "end_logit": 5.526034832000732,
            "text": "gene replacement, exon skipping",
            "probability": 0.22492361068725586
        },
        {
            "start_logit": 5.068381309509277,
            "end_logit": 5.526034832000732,
            "text": "exon skipping",
            "probability": 0.15046779811382294
        },
        {
            "start_logit": 5.470393180847168,
            "end_logit": 5.095636367797852,
            "text": "gene replacement, exon skipping, suppression of stop codons",
            "probability": 0.14625664055347443
        },
        {
            "start_logit": 5.318006992340088,
            "end_logit": 5.095636367797852,
            "text": "suppression of stop codons",
            "probability": 0.1255841702222824
        },
        {
            "start_logit": 5.068381309509277,
            "end_logit": 5.095636367797852,
            "text": "exon skipping, suppression of stop codons",
            "probability": 0.09784170985221863
        },
        {
            "start_logit": 5.470393180847168,
            "end_logit": -1.249269723892212,
            "text": "gene replacement, exon sk",
            "probability": 0.0002567780902609229
        },
        {
            "start_logit": 5.068381309509277,
            "end_logit": -1.249269723892212,
            "text": "exon sk",
            "probability": 0.0001717775739962235
        },
        {
            "start_logit": 5.470393180847168,
            "end_logit": -1.7750744819641113,
            "text": "gene replacement, exon skipping, suppression of stop codons.",
            "probability": 0.0001517762430012226
        },
        {
            "start_logit": -1.9855598211288452,
            "end_logit": 5.644370079040527,
            "text": "replacement",
            "probability": 0.00014633503451477736
        },
        {
            "start_logit": 5.318006992340088,
            "end_logit": -1.7750744819641113,
            "text": "suppression of stop codons.",
            "probability": 0.00013032366405241191
        },
        {
            "start_logit": -1.9855598211288452,
            "end_logit": 5.526034832000732,
            "text": "replacement, exon skipping",
            "probability": 0.00013000376929994673
        },
        {
            "start_logit": 5.470393180847168,
            "end_logit": -2.056718349456787,
            "text": "gene replacement, exon skipping, suppression",
            "probability": 0.00011452159378677607
        },
        {
            "start_logit": 5.470393180847168,
            "end_logit": -2.05942702293396,
            "text": "gene",
            "probability": 0.00011421178351156414
        },
        {
            "start_logit": 5.068381309509277,
            "end_logit": -1.7750744819641113,
            "text": "exon skipping, suppression of stop codons.",
            "probability": 0.00010153417679248378
        },
        {
            "start_logit": 5.318006992340088,
            "end_logit": -2.056718349456787,
            "text": "suppression",
            "probability": 9.833472722675651e-05
        },
        {
            "start_logit": 5.470393180847168,
            "end_logit": -2.2791213989257812,
            "text": "gene replacement, exon skipping, suppression of",
            "probability": 9.168514225166291e-05
        },
        {
            "start_logit": -1.9855598211288452,
            "end_logit": 5.095636367797852,
            "text": "replacement, exon skipping, suppression of stop codons",
            "probability": 8.453498594462872e-05
        },
        {
            "start_logit": 5.318006992340088,
            "end_logit": -2.2791213989257812,
            "text": "suppression of",
            "probability": 7.872601418057457e-05
        },
        {
            "start_logit": 5.068381309509277,
            "end_logit": -2.056718349456787,
            "text": "exon skipping, suppression",
            "probability": 7.661186828045174e-05
        }
    ],
    "6417949d690f196b51000035_0003": [
        {
            "start_logit": 5.276709079742432,
            "end_logit": 5.187886714935303,
            "text": "CRISPR/Cas9",
            "probability": 0.9972472786903381
        },
        {
            "start_logit": 5.276709079742432,
            "end_logit": -2.076563835144043,
            "text": "CRISPR",
            "probability": 0.0006980589241720736
        },
        {
            "start_logit": 5.276709079742432,
            "end_logit": -2.448535203933716,
            "text": "CRISPR/Cas9 offers exciting perspectives for restoring dystrophin expression",
            "probability": 0.00048122351290658116
        },
        {
            "start_logit": -2.582453966140747,
            "end_logit": 5.187886714935303,
            "text": "Cas9",
            "probability": 0.00038513378240168095
        },
        {
            "start_logit": 5.276709079742432,
            "end_logit": -2.921535015106201,
            "text": "CRISPR/Cas9 offers exciting perspectives for restoring dystrophin expression in patients with DMD.",
            "probability": 0.00029986497247591615
        },
        {
            "start_logit": 5.276709079742432,
            "end_logit": -3.7043533325195312,
            "text": "CRISPR/Cas9 offers exciting perspectives for restoring dystrophin expression in patients with DMD",
            "probability": 0.00013707298785448074
        },
        {
            "start_logit": -3.624464750289917,
            "end_logit": 5.187886714935303,
            "text": "gene editing tool referred to as CRISPR/Cas9",
            "probability": 0.00013585395936388522
        },
        {
            "start_logit": 5.276709079742432,
            "end_logit": -3.878720760345459,
            "text": "CRISPR/",
            "probability": 0.00011513974459376186
        },
        {
            "start_logit": -3.9047162532806396,
            "end_logit": 5.187886714935303,
            "text": "promising gene editing tool referred to as CRISPR/Cas9",
            "probability": 0.00010265038872603327
        },
        {
            "start_logit": -3.941061496734619,
            "end_logit": 5.187886714935303,
            "text": "a promising gene editing tool referred to as CRISPR/Cas9",
            "probability": 9.898649295791984e-05
        },
        {
            "start_logit": 5.276709079742432,
            "end_logit": -4.211113452911377,
            "text": "CRISPR/Cas9 offers exciting perspectives for restoring dystrophin",
            "probability": 8.257888111984357e-05
        },
        {
            "start_logit": 5.276709079742432,
            "end_logit": -4.648892879486084,
            "text": "CRISPR/Cas9 offers exciting perspectives",
            "probability": 5.330202839104459e-05
        },
        {
            "start_logit": -5.07528018951416,
            "end_logit": 5.187886714935303,
            "text": "/Cas9",
            "probability": 3.184130400768481e-05
        },
        {
            "start_logit": -5.077796936035156,
            "end_logit": 5.187886714935303,
            "text": "More recently, a promising gene editing tool referred to as CRISPR/Cas9",
            "probability": 3.176129757775925e-05
        },
        {
            "start_logit": -5.3661112785339355,
            "end_logit": 5.187886714935303,
            "text": "referred to as CRISPR/Cas9",
            "probability": 2.3805905584595166e-05
        },
        {
            "start_logit": 5.276709079742432,
            "end_logit": -5.653111934661865,
            "text": "CRISPR/Cas9 offers",
            "probability": 1.9526165488059632e-05
        },
        {
            "start_logit": -5.664562702178955,
            "end_logit": 5.187886714935303,
            "text": ", a promising gene editing tool referred to as CRISPR/Cas9",
            "probability": 1.7663180187810212e-05
        },
        {
            "start_logit": -5.782608509063721,
            "end_logit": 5.187886714935303,
            "text": "as CRISPR/Cas9",
            "probability": 1.5696479749749415e-05
        },
        {
            "start_logit": 5.276709079742432,
            "end_logit": -6.125650405883789,
            "text": "CRISPR/Cas9 offers exciting",
            "probability": 1.2172951755928807e-05
        },
        {
            "start_logit": 5.276709079742432,
            "end_logit": -6.287798881530762,
            "text": "CRISPR/Cas9 offers exciting perspectives for restoring dystrophin expression in patients",
            "probability": 1.0350852789997589e-05
        }
    ],
    "6417949d690f196b51000035_0004": [
        {
            "start_logit": 2.7694106101989746,
            "end_logit": 3.305097818374634,
            "text": "Adeno-associated virus-vectorized gene therapies",
            "probability": 0.2831990718841553
        },
        {
            "start_logit": 2.7694106101989746,
            "end_logit": 2.9485692977905273,
            "text": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation",
            "probability": 0.1982683539390564
        },
        {
            "start_logit": 2.7694106101989746,
            "end_logit": 2.736586093902588,
            "text": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement",
            "probability": 0.16039477288722992
        },
        {
            "start_logit": 2.4017581939697266,
            "end_logit": 2.9485692977905273,
            "text": "antisense oligonucleotide-mediated pre-mRNA splicing modulation",
            "probability": 0.13727262616157532
        },
        {
            "start_logit": 1.831468105316162,
            "end_logit": 2.9485692977905273,
            "text": "gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation",
            "probability": 0.07760864496231079
        },
        {
            "start_logit": 2.7694106101989746,
            "end_logit": 1.8639755249023438,
            "text": "Adeno-associated virus",
            "probability": 0.06702245026826859
        },
        {
            "start_logit": 1.831468105316162,
            "end_logit": 2.736586093902588,
            "text": "gene replacement",
            "probability": 0.06278371065855026
        },
        {
            "start_logit": 2.7694106101989746,
            "end_logit": -1.3834917545318604,
            "text": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide",
            "probability": 0.002605331828817725
        },
        {
            "start_logit": 2.4017581939697266,
            "end_logit": -1.3834917545318604,
            "text": "antisense oligonucleotide",
            "probability": 0.0018038225825875998
        },
        {
            "start_logit": 2.7694106101989746,
            "end_logit": -1.8452746868133545,
            "text": "Adeno-associated virus-vectorized",
            "probability": 0.0016417743172496557
        },
        {
            "start_logit": 2.7694106101989746,
            "end_logit": -1.8547265529632568,
            "text": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression",
            "probability": 0.0016263296129181981
        },
        {
            "start_logit": 1.831468105316162,
            "end_logit": -1.3834917545318604,
            "text": "gene replacement or antisense oligonucleotide",
            "probability": 0.0010198112577199936
        },
        {
            "start_logit": 2.7694106101989746,
            "end_logit": -2.3959314823150635,
            "text": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing",
            "probability": 0.0009465990005992353
        },
        {
            "start_logit": -3.022263765335083,
            "end_logit": 3.305097818374634,
            "text": "gene therapies",
            "probability": 0.0008645686903037131
        },
        {
            "start_logit": 2.4017581939697266,
            "end_logit": -2.3959314823150635,
            "text": "antisense oligonucleotide-mediated pre-mRNA splicing",
            "probability": 0.0006553854909725487
        },
        {
            "start_logit": -3.022263765335083,
            "end_logit": 2.9485692977905273,
            "text": "gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation",
            "probability": 0.0006052867975085974
        },
        {
            "start_logit": -3.022263765335083,
            "end_logit": 2.736586093902588,
            "text": "gene therapies to restore dystrophin protein expression using gene replacement",
            "probability": 0.0004896636819466949
        },
        {
            "start_logit": -3.309880018234253,
            "end_logit": 2.9485692977905273,
            "text": "using gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation",
            "probability": 0.0004539947840385139
        },
        {
            "start_logit": 1.831468105316162,
            "end_logit": -2.3959314823150635,
            "text": "gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing",
            "probability": 0.00037052950938232243
        },
        {
            "start_logit": -3.309880018234253,
            "end_logit": 2.736586093902588,
            "text": "using gene replacement",
            "probability": 0.0003672721213661134
        }
    ],
    "641368ee201352f04a00003c_0001": [
        {
            "start_logit": 5.962204933166504,
            "end_logit": 6.164054870605469,
            "text": "glioblastoma",
            "probability": 0.3275388777256012
        },
        {
            "start_logit": 5.7384467124938965,
            "end_logit": 6.15527868270874,
            "text": "astrocytoma",
            "probability": 0.25958192348480225
        },
        {
            "start_logit": 5.12960958480835,
            "end_logit": 6.164054870605469,
            "text": "oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q codeleted, and glioblastoma",
            "probability": 0.14245297014713287
        },
        {
            "start_logit": 5.7384467124938965,
            "end_logit": 5.096410274505615,
            "text": "astrocytoma, isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant, oligodendroglioma",
            "probability": 0.09003548324108124
        },
        {
            "start_logit": 5.12960958480835,
            "end_logit": 5.096410274505615,
            "text": "oligodendroglioma",
            "probability": 0.04897778853774071
        },
        {
            "start_logit": 5.7384467124938965,
            "end_logit": 4.426573753356934,
            "text": "astrocytoma, isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant, oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q codeleted",
            "probability": 0.04607943817973137
        },
        {
            "start_logit": 4.549233436584473,
            "end_logit": 5.096410274505615,
            "text": "isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant, oligodendroglioma",
            "probability": 0.027412256225943565
        },
        {
            "start_logit": 5.12960958480835,
            "end_logit": 4.426573753356934,
            "text": "oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q codeleted",
            "probability": 0.02506643906235695
        },
        {
            "start_logit": 4.549233436584473,
            "end_logit": 4.426573753356934,
            "text": "isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant, oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q codeleted",
            "probability": 0.014029386453330517
        },
        {
            "start_logit": 5.7384467124938965,
            "end_logit": 2.3859946727752686,
            "text": "astrocytoma, isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant",
            "probability": 0.005988182965666056
        },
        {
            "start_logit": 1.2762014865875244,
            "end_logit": 6.164054870605469,
            "text": "isocitrate dehydrogenase-mutant and 1p/19q codeleted, and glioblastoma",
            "probability": 0.0030210460536181927
        },
        {
            "start_logit": 5.962204933166504,
            "end_logit": 1.360787272453308,
            "text": "glioblastoma, isocitrate dehydrogenase-wildtype",
            "probability": 0.0026867687702178955
        },
        {
            "start_logit": 4.549233436584473,
            "end_logit": 2.3859946727752686,
            "text": "isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant",
            "probability": 0.0018231673166155815
        },
        {
            "start_logit": 5.12960958480835,
            "end_logit": 1.360787272453308,
            "text": "oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q codeleted, and glioblastoma, isocitrate dehydrogenase-wildtype",
            "probability": 0.001168526941910386
        },
        {
            "start_logit": 0.24641582369804382,
            "end_logit": 6.164054870605469,
            "text": "isocitrate dehydrogenase)-mutant, oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q codeleted, and glioblastoma",
            "probability": 0.001078765606507659
        },
        {
            "start_logit": 5.7384467124938965,
            "end_logit": 0.657777726650238,
            "text": "astrocytoma, isocitrate dehydrogenase",
            "probability": 0.0010635065846145153
        },
        {
            "start_logit": -0.19863107800483704,
            "end_logit": 6.164054870605469,
            "text": "1p/19q codeleted, and glioblastoma",
            "probability": 0.0006912667886354029
        },
        {
            "start_logit": 1.2762014865875244,
            "end_logit": 4.426573753356934,
            "text": "isocitrate dehydrogenase-mutant and 1p/19q codeleted",
            "probability": 0.0005315925227478147
        },
        {
            "start_logit": 5.7384467124938965,
            "end_logit": -0.31600791215896606,
            "text": "astrocytoma, isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant, oligodendroglioma, isocitrate dehydrogenase-mutant",
            "probability": 0.00040163384983316064
        },
        {
            "start_logit": 0.24641582369804382,
            "end_logit": 5.096410274505615,
            "text": "isocitrate dehydrogenase)-mutant, oligodendroglioma",
            "probability": 0.00037089840043336153
        }
    ],
    "641368ee201352f04a00003c_0002": [
        {
            "start_logit": 5.632927894592285,
            "end_logit": 5.738651275634766,
            "text": "intermediate-risk, expecting astrocytoma, isocitrate dehydrogenase-mutant; and (3) high-risk",
            "probability": 0.1391029804944992
        },
        {
            "start_logit": 5.622282981872559,
            "end_logit": 5.738651275634766,
            "text": "high-risk",
            "probability": 0.13763010501861572
        },
        {
            "start_logit": 5.632927894592285,
            "end_logit": 5.723671913146973,
            "text": "intermediate-risk",
            "probability": 0.1370348334312439
        },
        {
            "start_logit": 5.632927894592285,
            "end_logit": 5.313774108886719,
            "text": "intermediate-risk, expecting astrocytoma, isocitrate dehydrogenase-mutant; and (3) high-risk, expecting glioblastoma",
            "probability": 0.09095249325037003
        },
        {
            "start_logit": 5.622282981872559,
            "end_logit": 5.313774108886719,
            "text": "high-risk, expecting glioblastoma",
            "probability": 0.08998945355415344
        },
        {
            "start_logit": 5.4197001457214355,
            "end_logit": 5.4447150230407715,
            "text": "low-risk",
            "probability": 0.08376795053482056
        },
        {
            "start_logit": 5.4197001457214355,
            "end_logit": 5.317811965942383,
            "text": "low-risk, expecting oligodendroglioma",
            "probability": 0.07378444820642471
        },
        {
            "start_logit": 5.632927894592285,
            "end_logit": 5.032463073730469,
            "text": "intermediate-risk, expecting astrocytoma",
            "probability": 0.06865035742521286
        },
        {
            "start_logit": 4.659675598144531,
            "end_logit": 5.313774108886719,
            "text": "glioblastoma",
            "probability": 0.03436659649014473
        },
        {
            "start_logit": 4.134045600891113,
            "end_logit": 5.738651275634766,
            "text": "astrocytoma, isocitrate dehydrogenase-mutant; and (3) high-risk",
            "probability": 0.03107278048992157
        },
        {
            "start_logit": 4.134045600891113,
            "end_logit": 5.313774108886719,
            "text": "astrocytoma, isocitrate dehydrogenase-mutant; and (3) high-risk, expecting glioblastoma",
            "probability": 0.020316941663622856
        },
        {
            "start_logit": 3.6922240257263184,
            "end_logit": 5.723671913146973,
            "text": "isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant, and 1p/19q-codeleted; (2) intermediate-risk",
            "probability": 0.01967857964336872
        },
        {
            "start_logit": 4.030359745025635,
            "end_logit": 5.317811965942383,
            "text": "expecting oligodendroglioma",
            "probability": 0.01838999055325985
        },
        {
            "start_logit": 4.134045600891113,
            "end_logit": 5.032463073730469,
            "text": "astrocytoma",
            "probability": 0.015335094183683395
        },
        {
            "start_logit": 5.4197001457214355,
            "end_logit": 3.274914264678955,
            "text": "low-risk, expecting oligodendroglioma, isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant, and 1p/19q-codeleted",
            "probability": 0.009566331282258034
        },
        {
            "start_logit": 3.3558831214904785,
            "end_logit": 5.317811965942383,
            "text": "oligodendroglioma",
            "probability": 0.009368284605443478
        },
        {
            "start_logit": 2.7989935874938965,
            "end_logit": 5.738651275634766,
            "text": "expecting astrocytoma, isocitrate dehydrogenase-mutant; and (3) high-risk",
            "probability": 0.008176635019481182
        },
        {
            "start_logit": 2.7989935874938965,
            "end_logit": 5.313774108886719,
            "text": "expecting astrocytoma, isocitrate dehydrogenase-mutant; and (3) high-risk, expecting glioblastoma",
            "probability": 0.005346293561160564
        },
        {
            "start_logit": 2.7989935874938965,
            "end_logit": 5.032463073730469,
            "text": "expecting astrocytoma",
            "probability": 0.004035345744341612
        },
        {
            "start_logit": 2.356466293334961,
            "end_logit": 5.313774108886719,
            "text": "expecting glioblastoma",
            "probability": 0.0034345153253525496
        }
    ],
    "6415bc8d690f196b5100000f_0001": [
        {
            "start_logit": 6.000010967254639,
            "end_logit": 5.919124603271484,
            "text": "8%",
            "probability": 0.8420612812042236
        },
        {
            "start_logit": 6.000010967254639,
            "end_logit": 3.7244551181793213,
            "text": "8% and 10-12%",
            "probability": 0.09380170702934265
        },
        {
            "start_logit": 6.000010967254639,
            "end_logit": 1.970536708831787,
            "text": "8% and 10-12%, respectively.",
            "probability": 0.016236543655395508
        },
        {
            "start_logit": 4.116544723510742,
            "end_logit": 3.7244551181793213,
            "text": "10-12%",
            "probability": 0.014263679273426533
        },
        {
            "start_logit": 1.7885469198226929,
            "end_logit": 5.919124603271484,
            "text": "reduced time and costs by online counseling with about 8%",
            "probability": 0.012483257800340652
        },
        {
            "start_logit": 1.3581678867340088,
            "end_logit": 5.919124603271484,
            "text": "costs by online counseling with about 8%",
            "probability": 0.008117393590509892
        },
        {
            "start_logit": 2.603093385696411,
            "end_logit": 3.7244551181793213,
            "text": "12%",
            "probability": 0.0031401333399116993
        },
        {
            "start_logit": 4.116544723510742,
            "end_logit": 1.970536708831787,
            "text": "10-12%, respectively.",
            "probability": 0.00246896268799901
        },
        {
            "start_logit": 1.7885469198226929,
            "end_logit": 3.7244551181793213,
            "text": "reduced time and costs by online counseling with about 8% and 10-12%",
            "probability": 0.0013905768282711506
        },
        {
            "start_logit": 6.000010967254639,
            "end_logit": -0.6010131239891052,
            "text": "8% and 10-12%, respectively",
            "probability": 0.0012407482136040926
        },
        {
            "start_logit": 1.3581678867340088,
            "end_logit": 3.7244551181793213,
            "text": "costs by online counseling with about 8% and 10-12%",
            "probability": 0.0009042401798069477
        },
        {
            "start_logit": -0.9114053249359131,
            "end_logit": 5.919124603271484,
            "text": "We estimated reduced time and costs by online counseling with about 8%",
            "probability": 0.0008389835129491985
        },
        {
            "start_logit": -0.9241536259651184,
            "end_logit": 5.919124603271484,
            "text": "about 8%",
            "probability": 0.0008283559582196176
        },
        {
            "start_logit": 2.603093385696411,
            "end_logit": 1.970536708831787,
            "text": "12%, respectively.",
            "probability": 0.0005435394705273211
        },
        {
            "start_logit": 1.7885469198226929,
            "end_logit": 2.652144432067871,
            "text": "reduced time",
            "probability": 0.00047587897279299796
        },
        {
            "start_logit": -1.506309986114502,
            "end_logit": 5.919124603271484,
            "text": "estimated reduced time and costs by online counseling with about 8%",
            "probability": 0.0004627961607184261
        },
        {
            "start_logit": 1.7885469198226929,
            "end_logit": 1.970536708831787,
            "text": "reduced time and costs by online counseling with about 8% and 10-12%, respectively.",
            "probability": 0.00024070109066087753
        },
        {
            "start_logit": 4.116544723510742,
            "end_logit": -0.6010131239891052,
            "text": "10-12%, respectively",
            "probability": 0.00018867077596951276
        },
        {
            "start_logit": 1.3581678867340088,
            "end_logit": 1.970536708831787,
            "text": "costs by online counseling with about 8% and 10-12%, respectively.",
            "probability": 0.00015651890134904534
        },
        {
            "start_logit": -2.593491554260254,
            "end_logit": 5.919124603271484,
            "text": "time and costs by online counseling with about 8%",
            "probability": 0.00015603886276949197
        }
    ],
    "6402bc2d201352f04a000005_0001": [
        {
            "start_logit": 6.17222785949707,
            "end_logit": 6.428349018096924,
            "text": "CD20",
            "probability": 0.8701849579811096
        },
        {
            "start_logit": 6.17222785949707,
            "end_logit": 4.400623321533203,
            "text": "CD20 on B cells and engage T cells via CD3",
            "probability": 0.11454645544290543
        },
        {
            "start_logit": 4.11520528793335,
            "end_logit": 4.400623321533203,
            "text": "CD3",
            "probability": 0.01464294083416462
        },
        {
            "start_logit": 6.17222785949707,
            "end_logit": -2.4505691528320312,
            "text": "CD20 on B cells and engage T cells via CD3 in a 1:1 or 2:1 CD20:CD3",
            "probability": 0.00012121228064643219
        },
        {
            "start_logit": 6.17222785949707,
            "end_logit": -2.5348455905914307,
            "text": "CD20 on B cells and engage T cells via CD3 in a 1:1 or 2:1 CD20",
            "probability": 0.00011141556751681492
        },
        {
            "start_logit": -3.042691230773926,
            "end_logit": 6.428349018096924,
            "text": "regions that target CD20",
            "probability": 8.662104664836079e-05
        },
        {
            "start_logit": -3.5866661071777344,
            "end_logit": 6.428349018096924,
            "text": "different monospecific antigen-binding regions that target CD20",
            "probability": 5.027796942158602e-05
        },
        {
            "start_logit": -3.790327310562134,
            "end_logit": 6.428349018096924,
            "text": "monospecific antigen-binding regions that target CD20",
            "probability": 4.1013692680280656e-05
        },
        {
            "start_logit": 6.17222785949707,
            "end_logit": -3.5425374507904053,
            "text": "CD20 on B cells and engage T cells via CD3 in a 1:1 or 2:1 CD20:CD3 antigen binding fragment",
            "probability": 4.0673421608516946e-05
        },
        {
            "start_logit": -4.02148962020874,
            "end_logit": 6.428349018096924,
            "text": "two different monospecific antigen-binding regions that target CD20",
            "probability": 3.25489163515158e-05
        },
        {
            "start_logit": -4.309283256530762,
            "end_logit": 6.428349018096924,
            "text": "antigen-binding regions that target CD20",
            "probability": 2.4408975150436163e-05
        },
        {
            "start_logit": 6.17222785949707,
            "end_logit": -4.077901840209961,
            "text": "CD20 on B cells and engage T cells via CD3 in a 1:1 or 2:1 CD20:CD3 antigen binding fragment (Fab",
            "probability": 2.381249942118302e-05
        },
        {
            "start_logit": 4.11520528793335,
            "end_logit": -2.4505691528320312,
            "text": "CD3 in a 1:1 or 2:1 CD20:CD3",
            "probability": 1.549506123410538e-05
        },
        {
            "start_logit": 4.11520528793335,
            "end_logit": -2.5348455905914307,
            "text": "CD3 in a 1:1 or 2:1 CD20",
            "probability": 1.424269430572167e-05
        },
        {
            "start_logit": -4.861536979675293,
            "end_logit": 6.428349018096924,
            "text": "target CD20",
            "probability": 1.4051050129637588e-05
        },
        {
            "start_logit": 6.17222785949707,
            "end_logit": -4.690845966339111,
            "text": "CD20 on B cells and engage T cells via CD3 in a 1:1 or 2:1 CD20:CD3 antigen binding fragment (Fab)",
            "probability": 1.290051204705378e-05
        },
        {
            "start_logit": -3.042691230773926,
            "end_logit": 4.400623321533203,
            "text": "regions that target CD20 on B cells and engage T cells via CD3",
            "probability": 1.1402317795727868e-05
        },
        {
            "start_logit": 6.17222785949707,
            "end_logit": -4.952555179595947,
            "text": "CD20 on B cells and engage T cells",
            "probability": 9.929973202815745e-06
        },
        {
            "start_logit": 6.17222785949707,
            "end_logit": -5.186036109924316,
            "text": "CD20 on B cells and engage T",
            "probability": 7.862277925596572e-06
        },
        {
            "start_logit": 6.17222785949707,
            "end_logit": -5.213559150695801,
            "text": "CD20 on B cells and engage T cells via CD3 in a 1:1 or",
            "probability": 7.648834980500396e-06
        }
    ],
    "6402bc2d201352f04a000005_0002": [
        {
            "start_logit": 6.153393745422363,
            "end_logit": 6.421064853668213,
            "text": "CD20",
            "probability": 0.44255203008651733
        },
        {
            "start_logit": 6.153393745422363,
            "end_logit": 6.047914505004883,
            "text": "CD20/CD3",
            "probability": 0.30472418665885925
        },
        {
            "start_logit": 5.962682723999023,
            "end_logit": 6.047914505004883,
            "text": "CD3",
            "probability": 0.25181540846824646
        },
        {
            "start_logit": -1.6167958974838257,
            "end_logit": 6.421064853668213,
            "text": "anti-CD20",
            "probability": 0.00018681579967960715
        },
        {
            "start_logit": -1.6167958974838257,
            "end_logit": 6.047914505004883,
            "text": "anti-CD20/CD3",
            "probability": 0.0001286341284867376
        },
        {
            "start_logit": 6.153393745422363,
            "end_logit": -1.7671256065368652,
            "text": "CD20/CD3 T",
            "probability": 0.00012299243826419115
        },
        {
            "start_logit": -2.177460193634033,
            "end_logit": 6.421064853668213,
            "text": "Lunsumio\u00ae), an anti-CD20",
            "probability": 0.00010664002184057608
        },
        {
            "start_logit": 5.962682723999023,
            "end_logit": -1.7671256065368652,
            "text": "CD3 T",
            "probability": 0.00010163733531953767
        },
        {
            "start_logit": -2.177460193634033,
            "end_logit": 6.047914505004883,
            "text": "Lunsumio\u00ae), an anti-CD20/CD3",
            "probability": 7.342827302636579e-05
        },
        {
            "start_logit": 6.153393745422363,
            "end_logit": -2.71504545211792,
            "text": "CD20/CD3 T-cell",
            "probability": 4.7665271267760545e-05
        },
        {
            "start_logit": 5.962682723999023,
            "end_logit": -2.71504545211792,
            "text": "CD3 T-cell",
            "probability": 3.938917143386789e-05
        },
        {
            "start_logit": 6.153393745422363,
            "end_logit": -3.627281427383423,
            "text": "CD20/CD3 T-cell engaging",
            "probability": 1.914356653287541e-05
        },
        {
            "start_logit": 5.962682723999023,
            "end_logit": -3.627281427383423,
            "text": "CD3 T-cell engaging",
            "probability": 1.5819694453966804e-05
        },
        {
            "start_logit": -4.142436981201172,
            "end_logit": 6.421064853668213,
            "text": "-CD20",
            "probability": 1.494656771683367e-05
        },
        {
            "start_logit": 6.153393745422363,
            "end_logit": -3.9753503799438477,
            "text": "CD20/CD3 T-cell engaging bispecific antibody",
            "probability": 1.35163154482143e-05
        },
        {
            "start_logit": 5.962682723999023,
            "end_logit": -3.9753503799438477,
            "text": "CD3 T-cell engaging bispecific antibody",
            "probability": 1.1169496247021016e-05
        },
        {
            "start_logit": -4.142436981201172,
            "end_logit": 6.047914505004883,
            "text": "-CD20/CD3",
            "probability": 1.0291637408954557e-05
        },
        {
            "start_logit": -4.3648176193237305,
            "end_logit": 6.047914505004883,
            "text": "/CD3",
            "probability": 8.239593626058195e-06
        },
        {
            "start_logit": -5.358893394470215,
            "end_logit": 6.421064853668213,
            "text": "Mosunetuzumab (Lunsumio\u00ae), an anti-CD20",
            "probability": 4.4283460738370195e-06
        },
        {
            "start_logit": 6.153393745422363,
            "end_logit": -5.279993534088135,
            "text": "CD20/CD3 T-cell engaging bispecific",
            "probability": 3.666560132842278e-06
        }
    ],
    "6402bc2d201352f04a000005_0003": [
        {
            "start_logit": 6.297527313232422,
            "end_logit": 6.548270225524902,
            "text": "CD20",
            "probability": 0.4453832507133484
        },
        {
            "start_logit": 6.297527313232422,
            "end_logit": 6.20401668548584,
            "text": "CD20\u2009\u00d7\u2009CD3",
            "probability": 0.31566500663757324
        },
        {
            "start_logit": 6.018607139587402,
            "end_logit": 6.20401668548584,
            "text": "CD3",
            "probability": 0.2388322502374649
        },
        {
            "start_logit": 6.297527313232422,
            "end_logit": -3.6029086112976074,
            "text": "CD20\u2009\u00d7\u2009CD3 T-cell",
            "probability": 1.7383335944032297e-05
        },
        {
            "start_logit": 6.297527313232422,
            "end_logit": -3.7279391288757324,
            "text": "CD20\u2009\u00d7\u2009CD3 T",
            "probability": 1.534027251182124e-05
        },
        {
            "start_logit": 6.018607139587402,
            "end_logit": -3.6029086112976074,
            "text": "CD3 T-cell",
            "probability": 1.315222561970586e-05
        },
        {
            "start_logit": -3.836740493774414,
            "end_logit": 6.20401668548584,
            "text": "\u00d7\u2009CD3",
            "probability": 1.2530542335298378e-05
        },
        {
            "start_logit": 6.018607139587402,
            "end_logit": -3.7279391288757324,
            "text": "CD3 T",
            "probability": 1.1606443877099082e-05
        },
        {
            "start_logit": 6.297527313232422,
            "end_logit": -4.4052205085754395,
            "text": "CD20\u2009\u00d7\u2009CD3 T-cell-engaging bispecific monoclonal antibody",
            "probability": 7.792791620886419e-06
        },
        {
            "start_logit": -4.93430757522583,
            "end_logit": 6.548270225524902,
            "text": "Mosunetuzumab is a CD20",
            "probability": 5.8994314713345375e-06
        },
        {
            "start_logit": 6.018607139587402,
            "end_logit": -4.4052205085754395,
            "text": "CD3 T-cell-engaging bispecific monoclonal antibody",
            "probability": 5.896034053876065e-06
        },
        {
            "start_logit": 6.297527313232422,
            "end_logit": -4.785678386688232,
            "text": "CD20\u2009\u00d7\u2009CD3 T-cell-engaging",
            "probability": 5.3267549446900375e-06
        },
        {
            "start_logit": -4.93430757522583,
            "end_logit": 6.20401668548584,
            "text": "Mosunetuzumab is a CD20\u2009\u00d7\u2009CD3",
            "probability": 4.181217263976578e-06
        },
        {
            "start_logit": 6.018607139587402,
            "end_logit": -4.785678386688232,
            "text": "CD3 T-cell-engaging",
            "probability": 4.030220679851482e-06
        },
        {
            "start_logit": 6.297527313232422,
            "end_logit": -5.263387680053711,
            "text": "CD20\u2009\u00d7\u2009CD3 T-cell-engaging bispecific",
            "probability": 3.303665152998292e-06
        },
        {
            "start_logit": -5.667691230773926,
            "end_logit": 6.548270225524902,
            "text": "BACKGROUND: Mosunetuzumab is a CD20",
            "probability": 2.8333843147265725e-06
        },
        {
            "start_logit": 6.297527313232422,
            "end_logit": -5.424289703369141,
            "text": "CD20\u2009\u00d7\u2009CD3 T-cell-engaging bispecific monoclonal antibody that redirects T cells",
            "probability": 2.8126594315835973e-06
        },
        {
            "start_logit": 6.018607139587402,
            "end_logit": -5.263387680053711,
            "text": "CD3 T-cell-engaging bispecific",
            "probability": 2.4995540570671437e-06
        },
        {
            "start_logit": 6.297527313232422,
            "end_logit": -5.56839656829834,
            "text": "CD20\u2009\u00d7\u2009CD3 T-cell-engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells",
            "probability": 2.4351870706595946e-06
        },
        {
            "start_logit": 6.297527313232422,
            "end_logit": -5.580151081085205,
            "text": "CD20\u2009\u00d7\u2009CD3 T-cell-engaging bispecific monoclonal antibody that redirects T",
            "probability": 2.4067289814411197e-06
        }
    ],
    "6402bc2d201352f04a000005_0004": [
        {
            "start_logit": 6.143446922302246,
            "end_logit": 6.239123344421387,
            "text": "CD20",
            "probability": 0.3499937355518341
        },
        {
            "start_logit": 6.143446922302246,
            "end_logit": 6.177835464477539,
            "text": "CD20 \u00d7 CD3",
            "probability": 0.3291874825954437
        },
        {
            "start_logit": 6.117585182189941,
            "end_logit": 6.177835464477539,
            "text": "CD3",
            "probability": 0.32078325748443604
        },
        {
            "start_logit": 6.143446922302246,
            "end_logit": -5.330430030822754,
            "text": "CD20 \u00d7 CD3 BsAbs including odronextamab",
            "probability": 3.3072506084863562e-06
        },
        {
            "start_logit": 6.117585182189941,
            "end_logit": -5.330430030822754,
            "text": "CD3 BsAbs including odronextamab",
            "probability": 3.222815848857863e-06
        },
        {
            "start_logit": 6.143446922302246,
            "end_logit": -5.442179203033447,
            "text": "CD20 \u00d7 CD3 BsAbs including odronextamab, mosunetuzumab, glofitamab",
            "probability": 2.9575685402960517e-06
        },
        {
            "start_logit": 6.117585182189941,
            "end_logit": -5.442179203033447,
            "text": "CD3 BsAbs including odronextamab, mosunetuzumab, glofitamab",
            "probability": 2.882061153286486e-06
        },
        {
            "start_logit": 6.143446922302246,
            "end_logit": -5.469047546386719,
            "text": "CD20 \u00d7 CD3 BsAbs including odronextamab, mosunetuzumab, glofitamab, and epcoritamab",
            "probability": 2.879163275792962e-06
        },
        {
            "start_logit": 6.117585182189941,
            "end_logit": -5.469047546386719,
            "text": "CD3 BsAbs including odronextamab, mosunetuzumab, glofitamab, and epcoritamab",
            "probability": 2.8056576866219984e-06
        },
        {
            "start_logit": 6.143446922302246,
            "end_logit": -5.811010360717773,
            "text": "CD20 \u00d7 CD3 BsAbs",
            "probability": 2.045284418272786e-06
        },
        {
            "start_logit": 6.117585182189941,
            "end_logit": -5.811010360717773,
            "text": "CD3 BsAbs",
            "probability": 1.9930675989598967e-06
        },
        {
            "start_logit": 6.143446922302246,
            "end_logit": -5.952340126037598,
            "text": "CD20 \u00d7 CD3 BsAbs including odronextamab, mosunetuzumab",
            "probability": 1.775722012098413e-06
        },
        {
            "start_logit": -5.989170551300049,
            "end_logit": 6.177835464477539,
            "text": "\u00d7 CD3",
            "probability": 1.771391907823272e-06
        },
        {
            "start_logit": 6.117585182189941,
            "end_logit": -5.952340126037598,
            "text": "CD3 BsAbs including odronextamab, mosunetuzumab",
            "probability": 1.7303873391938396e-06
        },
        {
            "start_logit": 6.143446922302246,
            "end_logit": -6.184845924377441,
            "text": "CD20 \u00d7 CD3 BsAbs including odronextamab, mosunetuzumab, gl",
            "probability": 1.4073398233449552e-06
        },
        {
            "start_logit": 6.143446922302246,
            "end_logit": -6.199045658111572,
            "text": "CD20 \u00d7 CD3 BsA",
            "probability": 1.3874964679416735e-06
        },
        {
            "start_logit": 6.143446922302246,
            "end_logit": -6.209467887878418,
            "text": "CD20 \u00d7 CD3 BsAbs including odronextamab, mosunetuzumab, glofita",
            "probability": 1.3731115586779197e-06
        },
        {
            "start_logit": 6.117585182189941,
            "end_logit": -6.184845924377441,
            "text": "CD3 BsAbs including odronextamab, mosunetuzumab, gl",
            "probability": 1.3714102351514157e-06
        },
        {
            "start_logit": 6.143446922302246,
            "end_logit": -6.2192487716674805,
            "text": "CD20 \u00d7 CD3 BsAbs including odronextamab, mosunetuzumab, glofitamab, and epcorita",
            "probability": 1.3597466477222042e-06
        },
        {
            "start_logit": 6.117585182189941,
            "end_logit": -6.199045658111572,
            "text": "CD3 BsA",
            "probability": 1.3520734682970215e-06
        }
    ],
    "6415c6b6690f196b51000015_0001": [
        {
            "start_logit": -1.393049716949463,
            "end_logit": 2.4959208965301514,
            "text": "randomized, open-label, active-controlled trials",
            "probability": 0.4183400869369507
        },
        {
            "start_logit": -1.5607010126113892,
            "end_logit": 2.4959208965301514,
            "text": "Approval was based on two randomized, open-label, active-controlled trials",
            "probability": 0.3537687361240387
        },
        {
            "start_logit": -3.1862728595733643,
            "end_logit": 2.4959208965301514,
            "text": "two randomized, open-label, active-controlled trials",
            "probability": 0.06962136924266815
        },
        {
            "start_logit": -3.5385804176330566,
            "end_logit": 2.4959208965301514,
            "text": "active-controlled trials",
            "probability": 0.048948269337415695
        },
        {
            "start_logit": -3.957836151123047,
            "end_logit": 2.4959208965301514,
            "text": "open-label, active-controlled trials",
            "probability": 0.03218524903059006
        },
        {
            "start_logit": -1.1175211668014526,
            "end_logit": -1.244201421737671,
            "text": "progression-free survival",
            "probability": 0.01308806985616684
        },
        {
            "start_logit": -1.393049716949463,
            "end_logit": -1.244201421737671,
            "text": "randomized, open-label, active-controlled trials demonstrating statistically significant improvements in progression-free survival",
            "probability": 0.009936077520251274
        },
        {
            "start_logit": -5.171619892120361,
            "end_logit": 2.4959208965301514,
            "text": "trials",
            "probability": 0.009561307728290558
        },
        {
            "start_logit": -5.270009994506836,
            "end_logit": 2.4959208965301514,
            "text": "based on two randomized, open-label, active-controlled trials",
            "probability": 0.008665368892252445
        },
        {
            "start_logit": -1.5607010126113892,
            "end_logit": -1.244201421737671,
            "text": "Approval was based on two randomized, open-label, active-controlled trials demonstrating statistically significant improvements in progression-free survival",
            "probability": 0.008402430452406406
        },
        {
            "start_logit": -1.1175211668014526,
            "end_logit": -2.138643264770508,
            "text": "progression-free survival (progression-free survival) and overall survival",
            "probability": 0.005350870080292225
        },
        {
            "start_logit": -1.393049716949463,
            "end_logit": -2.138643264770508,
            "text": "randomized, open-label, active-controlled trials demonstrating statistically significant improvements in progression-free survival (progression-free survival) and overall survival",
            "probability": 0.00406222278252244
        },
        {
            "start_logit": -1.1175211668014526,
            "end_logit": -2.4224042892456055,
            "text": "progression-free survival (progression-free survival) and overall survival (overall survival",
            "probability": 0.004028919152915478
        },
        {
            "start_logit": -1.1175211668014526,
            "end_logit": -2.695002794265747,
            "text": "progression-free survival (progression-free survival",
            "probability": 0.0030676135793328285
        },
        {
            "start_logit": -1.393049716949463,
            "end_logit": -2.695002794265747,
            "text": "randomized, open-label, active-controlled trials demonstrating statistically significant improvements in progression-free survival (progression-free survival",
            "probability": 0.0023288417141884565
        },
        {
            "start_logit": -2.0458779335021973,
            "end_logit": -2.138643264770508,
            "text": "overall survival",
            "probability": 0.0021146771032363176
        },
        {
            "start_logit": -1.5607010126113892,
            "end_logit": -2.695002794265747,
            "text": "Approval was based on two randomized, open-label, active-controlled trials demonstrating statistically significant improvements in progression-free survival (progression-free survival",
            "probability": 0.001969382166862488
        },
        {
            "start_logit": -3.1862728595733643,
            "end_logit": -1.244201421737671,
            "text": "two randomized, open-label, active-controlled trials demonstrating statistically significant improvements in progression-free survival",
            "probability": 0.0016535914037376642
        },
        {
            "start_logit": -2.0458779335021973,
            "end_logit": -2.4224042892456055,
            "text": "overall survival (overall survival",
            "probability": 0.0015922386664897203
        },
        {
            "start_logit": -2.5212230682373047,
            "end_logit": -2.138643264770508,
            "text": "progression-free survival) and overall survival",
            "probability": 0.0013146328274160624
        }
    ],
    "640c8309201352f04a000024_0001": [
        {
            "start_logit": 5.75044584274292,
            "end_logit": 5.764750003814697,
            "text": "alkaline phosphatase",
            "probability": 0.9916989803314209
        },
        {
            "start_logit": 0.4508466422557831,
            "end_logit": 5.764750003814697,
            "text": "bile acid retention, whether within the hepatocyte or in the bile ducts of any caliber. Biochemically, it is defined by a level of alkaline phosphatase",
            "probability": 0.0049521429464221
        },
        {
            "start_logit": -1.8299994468688965,
            "end_logit": 5.764750003814697,
            "text": "phosphatase",
            "probability": 0.0005060976254753768
        },
        {
            "start_logit": 1.875529408454895,
            "end_logit": 1.9964525699615479,
            "text": "hepatitis",
            "probability": 0.0004753070534206927
        },
        {
            "start_logit": -2.00441312789917,
            "end_logit": 5.764750003814697,
            "text": "level of alkaline phosphatase",
            "probability": 0.0004250963684171438
        },
        {
            "start_logit": 1.875529408454895,
            "end_logit": 1.743302583694458,
            "text": "hepatitis), withjaundice",
            "probability": 0.0003690053417813033
        },
        {
            "start_logit": 5.75044584274292,
            "end_logit": -2.418121576309204,
            "text": "alkaline",
            "probability": 0.000277079117950052
        },
        {
            "start_logit": 5.75044584274292,
            "end_logit": -2.775378942489624,
            "text": "alkaline phosphatase that is 1.67-times higher than the upper limit of normal",
            "probability": 0.00019384254119358957
        },
        {
            "start_logit": -2.8218557834625244,
            "end_logit": 5.764750003814697,
            "text": "bile ducts of any caliber. Biochemically, it is defined by a level of alkaline phosphatase",
            "probability": 0.00018770527094602585
        },
        {
            "start_logit": -2.852848529815674,
            "end_logit": 5.764750003814697,
            "text": "it is defined by a level of alkaline phosphatase",
            "probability": 0.00018197702593170106
        },
        {
            "start_logit": -3.0840532779693604,
            "end_logit": 5.764750003814697,
            "text": "a level of alkaline phosphatase",
            "probability": 0.00014441274106502533
        },
        {
            "start_logit": 5.75044584274292,
            "end_logit": -3.1272125244140625,
            "text": "alkaline phosphatase that is 1.67-times higher than the upper limit of normal. Cholestatic diseases can be associated with an inflammatory process of the liver",
            "probability": 0.00013634833157993853
        },
        {
            "start_logit": 1.875529408454895,
            "end_logit": 0.6160169839859009,
            "text": "hepatitis), withjaundice (yellowing of the skin and mucus membranes, associated with elevated serum bilirubin",
            "probability": 0.00011952501517953351
        },
        {
            "start_logit": -3.3332908153533936,
            "end_logit": 5.764750003814697,
            "text": "Biochemically, it is defined by a level of alkaline phosphatase",
            "probability": 0.00011255459685344249
        },
        {
            "start_logit": 5.75044584274292,
            "end_logit": -3.5282182693481445,
            "text": "alkaline phosphatase that is 1.67",
            "probability": 9.130504622589797e-05
        },
        {
            "start_logit": -0.5977873206138611,
            "end_logit": 1.743302583694458,
            "text": "withjaundice",
            "probability": 3.110891339019872e-05
        },
        {
            "start_logit": 0.4508466422557831,
            "end_logit": 0.6072777509689331,
            "text": "bile acid retention",
            "probability": 2.8505684895208105e-05
        },
        {
            "start_logit": 0.36445415019989014,
            "end_logit": 0.6160169839859009,
            "text": "bilirubin",
            "probability": 2.6375873858341947e-05
        },
        {
            "start_logit": 1.875529408454895,
            "end_logit": -1.068175196647644,
            "text": "hepatitis)",
            "probability": 2.2183148757903837e-05
        },
        {
            "start_logit": -1.0166795253753662,
            "end_logit": 1.743302583694458,
            "text": "jaundice",
            "probability": 2.0462675820454024e-05
        }
    ],
    "640c8309201352f04a000024_0002": [
        {
            "start_logit": 5.619007110595703,
            "end_logit": 5.457906723022461,
            "text": "alkaline phosphatase",
            "probability": 0.2824171483516693
        },
        {
            "start_logit": 5.6317901611328125,
            "end_logit": 5.436831951141357,
            "text": "conjugated bilirubin",
            "probability": 0.2800852358341217
        },
        {
            "start_logit": 5.619007110595703,
            "end_logit": 5.436831951141357,
            "text": "alkaline phosphatase, and conjugated bilirubin",
            "probability": 0.27652764320373535
        },
        {
            "start_logit": 3.8139429092407227,
            "end_logit": 5.457906723022461,
            "text": "liver transaminases, alkaline phosphatase",
            "probability": 0.046447426080703735
        },
        {
            "start_logit": 3.8139429092407227,
            "end_logit": 5.436831951141357,
            "text": "liver transaminases, alkaline phosphatase, and conjugated bilirubin",
            "probability": 0.04547877609729767
        },
        {
            "start_logit": 3.8139429092407227,
            "end_logit": 5.399420738220215,
            "text": "liver transaminases",
            "probability": 0.04380881413817406
        },
        {
            "start_logit": 2.050330400466919,
            "end_logit": 5.457906723022461,
            "text": "transaminases, alkaline phosphatase",
            "probability": 0.007962223142385483
        },
        {
            "start_logit": 2.050330400466919,
            "end_logit": 5.436831951141357,
            "text": "transaminases, alkaline phosphatase, and conjugated bilirubin",
            "probability": 0.007796180434525013
        },
        {
            "start_logit": 2.050330400466919,
            "end_logit": 5.399420738220215,
            "text": "transaminases",
            "probability": 0.007509900722652674
        },
        {
            "start_logit": 5.619007110595703,
            "end_logit": -1.6027166843414307,
            "text": "alkaline",
            "probability": 0.00024238257901743054
        },
        {
            "start_logit": 5.6317901611328125,
            "end_logit": -1.6182641983032227,
            "text": "conjugated",
            "probability": 0.00024171338009182364
        },
        {
            "start_logit": 5.619007110595703,
            "end_logit": -1.6182641983032227,
            "text": "alkaline phosphatase, and conjugated",
            "probability": 0.00023864320246502757
        },
        {
            "start_logit": -1.5251550674438477,
            "end_logit": 5.457906723022461,
            "text": "elevated liver transaminases, alkaline phosphatase",
            "probability": 0.0002229568490292877
        },
        {
            "start_logit": -1.5251550674438477,
            "end_logit": 5.436831951141357,
            "text": "elevated liver transaminases, alkaline phosphatase, and conjugated bilirubin",
            "probability": 0.0002183072647312656
        },
        {
            "start_logit": -1.5521306991577148,
            "end_logit": 5.436831951141357,
            "text": "bilirubin",
            "probability": 0.00021249699057079852
        },
        {
            "start_logit": -1.5251550674438477,
            "end_logit": 5.399420738220215,
            "text": "elevated liver transaminases",
            "probability": 0.00021029097842983902
        },
        {
            "start_logit": -2.017437696456909,
            "end_logit": 5.457906723022461,
            "text": "phosphatase",
            "probability": 0.00013627779844682664
        },
        {
            "start_logit": -2.017437696456909,
            "end_logit": 5.436831951141357,
            "text": "phosphatase, and conjugated bilirubin",
            "probability": 0.00013343589671421796
        },
        {
            "start_logit": 3.8139429092407227,
            "end_logit": -1.2744076251983643,
            "text": "liver",
            "probability": 5.5354732467094436e-05
        },
        {
            "start_logit": 5.619007110595703,
            "end_logit": -3.089219093322754,
            "text": "alkaline phosphatase,",
            "probability": 5.4817784985061735e-05
        }
    ],
    "640c8309201352f04a000024_0003": [
        {
            "start_logit": 5.667439937591553,
            "end_logit": 5.710235595703125,
            "text": "conjugated bilirubin",
            "probability": 0.3947906494140625
        },
        {
            "start_logit": 5.667439937591553,
            "end_logit": 5.450128078460693,
            "text": "conjugated bilirubin and alkaline phosphatase",
            "probability": 0.30437108874320984
        },
        {
            "start_logit": 5.624256134033203,
            "end_logit": 5.450128078460693,
            "text": "alkaline phosphatase",
            "probability": 0.2915070652961731
        },
        {
            "start_logit": 5.667439937591553,
            "end_logit": 0.5233300924301147,
            "text": "conjugated bilirubin and alkaline phosphatase suggestive of cholestatic jaundice",
            "probability": 0.0022065930534154177
        },
        {
            "start_logit": 5.624256134033203,
            "end_logit": 0.5233300924301147,
            "text": "alkaline phosphatase suggestive of cholestatic jaundice",
            "probability": 0.002113332273438573
        },
        {
            "start_logit": -0.16819027066230774,
            "end_logit": 5.710235595703125,
            "text": "bilirubin",
            "probability": 0.0011534122750163078
        },
        {
            "start_logit": -0.16819027066230774,
            "end_logit": 5.450128078460693,
            "text": "bilirubin and alkaline phosphatase",
            "probability": 0.0008892446057870984
        },
        {
            "start_logit": -0.9039708971977234,
            "end_logit": 5.710235595703125,
            "text": "liver enzymes with elevated conjugated bilirubin",
            "probability": 0.000552636047359556
        },
        {
            "start_logit": -0.9039708971977234,
            "end_logit": 5.450128078460693,
            "text": "liver enzymes with elevated conjugated bilirubin and alkaline phosphatase",
            "probability": 0.00042606511851772666
        },
        {
            "start_logit": -1.293286919593811,
            "end_logit": 5.710235595703125,
            "text": "elevated conjugated bilirubin",
            "probability": 0.00037442208849824965
        },
        {
            "start_logit": 5.667439937591553,
            "end_logit": -1.3861112594604492,
            "text": "conjugated bilirubin and alkaline",
            "probability": 0.00032693572575226426
        },
        {
            "start_logit": 5.624256134033203,
            "end_logit": -1.3861112594604492,
            "text": "alkaline",
            "probability": 0.0003131178964395076
        },
        {
            "start_logit": -1.2294422388076782,
            "end_logit": 5.450128078460693,
            "text": "phosphatase",
            "probability": 0.0003076986176893115
        },
        {
            "start_logit": -1.293286919593811,
            "end_logit": 5.450128078460693,
            "text": "elevated conjugated bilirubin and alkaline phosphatase",
            "probability": 0.0002886676520574838
        },
        {
            "start_logit": 5.667439937591553,
            "end_logit": -1.9501981735229492,
            "text": "conjugated",
            "probability": 0.0001859869807958603
        },
        {
            "start_logit": -3.280813694000244,
            "end_logit": 5.710235595703125,
            "text": "abnormal liver enzymes with elevated conjugated bilirubin",
            "probability": 5.1308543334016576e-05
        },
        {
            "start_logit": -3.280813694000244,
            "end_logit": 5.450128078460693,
            "text": "abnormal liver enzymes with elevated conjugated bilirubin and alkaline phosphatase",
            "probability": 3.955726060667075e-05
        },
        {
            "start_logit": -3.6639580726623535,
            "end_logit": 5.710235595703125,
            "text": "Initial laboratory tests showed abnormal liver enzymes with elevated conjugated bilirubin",
            "probability": 3.497777652228251e-05
        },
        {
            "start_logit": 5.667439937591553,
            "end_logit": -3.639423370361328,
            "text": "conjugated bilirubin and alkaline phosphatase suggestive of cholestatic jaundice.",
            "probability": 3.43448446074035e-05
        },
        {
            "start_logit": 5.624256134033203,
            "end_logit": -3.639423370361328,
            "text": "alkaline phosphatase suggestive of cholestatic jaundice.",
            "probability": 3.289325468358584e-05
        }
    ],
    "640c8309201352f04a000024_0004": [
        {
            "start_logit": 5.653753280639648,
            "end_logit": 5.6543755531311035,
            "text": "alanine aminotransferase",
            "probability": 0.08534795790910721
        },
        {
            "start_logit": 5.653753280639648,
            "end_logit": 5.563660144805908,
            "text": "alanine aminotransferase, aspartate aminotransferase",
            "probability": 0.07794637978076935
        },
        {
            "start_logit": 5.812747001647949,
            "end_logit": 5.254644393920898,
            "text": "gamma-glutamyl transpeptidase",
            "probability": 0.06708762049674988
        },
        {
            "start_logit": 5.463387489318848,
            "end_logit": 5.563660144805908,
            "text": "aspartate aminotransferase",
            "probability": 0.0644349530339241
        },
        {
            "start_logit": 5.812747001647949,
            "end_logit": 5.14957332611084,
            "text": "gamma-glutamyl transpeptidase, cholesterol, total serum tasting bile acids and total and conjugated bilirubin",
            "probability": 0.060396336019039154
        },
        {
            "start_logit": 5.653753280639648,
            "end_logit": 5.254644393920898,
            "text": "alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase",
            "probability": 0.05722585693001747
        },
        {
            "start_logit": 5.636751651763916,
            "end_logit": 5.254644393920898,
            "text": "alkaline phosphatase, gamma-glutamyl transpeptidase",
            "probability": 0.056261125952005386
        },
        {
            "start_logit": 5.653753280639648,
            "end_logit": 5.18830680847168,
            "text": "alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase",
            "probability": 0.053552813827991486
        },
        {
            "start_logit": 5.636751651763916,
            "end_logit": 5.18830680847168,
            "text": "alkaline phosphatase",
            "probability": 0.052650000900030136
        },
        {
            "start_logit": 5.653753280639648,
            "end_logit": 5.14957332611084,
            "text": "alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, cholesterol, total serum tasting bile acids and total and conjugated bilirubin",
            "probability": 0.05151817947626114
        },
        {
            "start_logit": 5.636751651763916,
            "end_logit": 5.14957332611084,
            "text": "alkaline phosphatase, gamma-glutamyl transpeptidase, cholesterol, total serum tasting bile acids and total and conjugated bilirubin",
            "probability": 0.05064971745014191
        },
        {
            "start_logit": 5.463387489318848,
            "end_logit": 5.254644393920898,
            "text": "aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase",
            "probability": 0.04730614274740219
        },
        {
            "start_logit": 5.463387489318848,
            "end_logit": 5.18830680847168,
            "text": "aspartate aminotransferase, alkaline phosphatase",
            "probability": 0.04426978901028633
        },
        {
            "start_logit": 5.463387489318848,
            "end_logit": 5.14957332611084,
            "text": "aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, cholesterol, total serum tasting bile acids and total and conjugated bilirubin",
            "probability": 0.04258785396814346
        },
        {
            "start_logit": 5.415276527404785,
            "end_logit": 5.14957332611084,
            "text": "total serum tasting bile acids and total and conjugated bilirubin",
            "probability": 0.0405874140560627
        },
        {
            "start_logit": 5.3763556480407715,
            "end_logit": 5.14957332611084,
            "text": "cholesterol, total serum tasting bile acids and total and conjugated bilirubin",
            "probability": 0.0390380434691906
        },
        {
            "start_logit": 5.812747001647949,
            "end_logit": 4.443717002868652,
            "text": "gamma-glutamyl transpeptidase, cholesterol, total serum tasting bile acids",
            "probability": 0.029816806316375732
        },
        {
            "start_logit": 5.812747001647949,
            "end_logit": 4.411937713623047,
            "text": "gamma-glutamyl transpeptidase, cholesterol",
            "probability": 0.028884148225188255
        },
        {
            "start_logit": 5.653753280639648,
            "end_logit": 4.443717002868652,
            "text": "alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, cholesterol, total serum tasting bile acids",
            "probability": 0.02543378621339798
        },
        {
            "start_logit": 5.636751651763916,
            "end_logit": 4.443717002868652,
            "text": "alkaline phosphatase, gamma-glutamyl transpeptidase, cholesterol, total serum tasting bile acids",
            "probability": 0.0250050388276577
        }
    ],
    "6415c599690f196b51000013_0001": [
        {
            "start_logit": 7.58729362487793,
            "end_logit": 6.028872489929199,
            "text": "Merck & Co., Inc",
            "probability": 0.5479835867881775
        },
        {
            "start_logit": 7.58729362487793,
            "end_logit": 5.679840087890625,
            "text": "Merck & Co.",
            "probability": 0.3865313231945038
        },
        {
            "start_logit": 7.58729362487793,
            "end_logit": 3.8239588737487793,
            "text": "Merck & Co., Inc.",
            "probability": 0.06042072921991348
        },
        {
            "start_logit": 7.58729362487793,
            "end_logit": 0.6927230358123779,
            "text": "Merck & Co",
            "probability": 0.0026381979696452618
        },
        {
            "start_logit": 7.58729362487793,
            "end_logit": 0.360967755317688,
            "text": "Merck & Co.,",
            "probability": 0.001893336302600801
        },
        {
            "start_logit": -0.7824928164482117,
            "end_logit": 6.028872489929199,
            "text": "pembrolizumab (Keytruda; Merck & Co., Inc",
            "probability": 0.00012700345541816205
        },
        {
            "start_logit": 7.58729362487793,
            "end_logit": -2.564455509185791,
            "text": "Merc",
            "probability": 0.00010156226198887452
        },
        {
            "start_logit": -0.7824928164482117,
            "end_logit": 5.679840087890625,
            "text": "pembrolizumab (Keytruda; Merck & Co.",
            "probability": 8.958446414908394e-05
        },
        {
            "start_logit": -1.5709117650985718,
            "end_logit": 6.028872489929199,
            "text": "Food and Drug Administration (Food and Drug Administration) approved pembrolizumab (Keytruda; Merck & Co., Inc",
            "probability": 5.773107477580197e-05
        },
        {
            "start_logit": -1.5709117650985718,
            "end_logit": 5.679840087890625,
            "text": "Food and Drug Administration (Food and Drug Administration) approved pembrolizumab (Keytruda; Merck & Co.",
            "probability": 4.072174124303274e-05
        },
        {
            "start_logit": 7.58729362487793,
            "end_logit": -3.8009109497070312,
            "text": "Merck & Co., Inc.,",
            "probability": 2.949489135062322e-05
        },
        {
            "start_logit": -2.6334474086761475,
            "end_logit": 6.028872489929199,
            "text": "Food and Drug Administration) approved pembrolizumab (Keytruda; Merck & Co., Inc",
            "probability": 1.995060119952541e-05
        },
        {
            "start_logit": -2.6334474086761475,
            "end_logit": 5.679840087890625,
            "text": "Food and Drug Administration) approved pembrolizumab (Keytruda; Merck & Co.",
            "probability": 1.4072561498323921e-05
        },
        {
            "start_logit": -0.7824928164482117,
            "end_logit": 3.8239588737487793,
            "text": "pembrolizumab (Keytruda; Merck & Co., Inc.",
            "probability": 1.40033998832223e-05
        },
        {
            "start_logit": 7.58729362487793,
            "end_logit": -4.733038425445557,
            "text": "Merck & Co., Inc., https://www.merck.com",
            "probability": 1.1612582056841347e-05
        },
        {
            "start_logit": 0.8627617359161377,
            "end_logit": 1.5766862630844116,
            "text": "U.S. Food and Drug Administration",
            "probability": 7.669739716220647e-06
        },
        {
            "start_logit": -1.5709117650985718,
            "end_logit": 3.8239588737487793,
            "text": "Food and Drug Administration (Food and Drug Administration) approved pembrolizumab (Keytruda; Merck & Co., Inc.",
            "probability": 6.36542790743988e-06
        },
        {
            "start_logit": -4.011425018310547,
            "end_logit": 6.028872489929199,
            "text": "Keytruda; Merck & Co., Inc",
            "probability": 5.029305611969903e-06
        },
        {
            "start_logit": -4.128119945526123,
            "end_logit": 6.028872489929199,
            "text": "Inc",
            "probability": 4.475359219213715e-06
        },
        {
            "start_logit": -4.011425018310547,
            "end_logit": 5.679840087890625,
            "text": "Keytruda; Merck & Co.",
            "probability": 3.547522283042781e-06
        }
    ],
    "6414638c201352f04a000047_0001": [
        {
            "start_logit": 6.281047821044922,
            "end_logit": 6.5155229568481445,
            "text": "thalidomide",
            "probability": 0.9992799162864685
        },
        {
            "start_logit": -1.3116017580032349,
            "end_logit": 6.5155229568481445,
            "text": "Cereblon is a well-known target of thalidomide",
            "probability": 0.0005037805531173944
        },
        {
            "start_logit": 6.281047821044922,
            "end_logit": -3.115238666534424,
            "text": "thalidomide and its derivatives.",
            "probability": 6.562968337675557e-05
        },
        {
            "start_logit": 6.281047821044922,
            "end_logit": -3.717231273651123,
            "text": "thalidomide and its derivatives",
            "probability": 3.594667214201763e-05
        },
        {
            "start_logit": -3.996788501739502,
            "end_logit": 6.5155229568481445,
            "text": "target of thalidomide",
            "probability": 3.4362103178864345e-05
        },
        {
            "start_logit": -4.3567214012146,
            "end_logit": 6.5155229568481445,
            "text": "well-known target of thalidomide",
            "probability": 2.3975211661309004e-05
        },
        {
            "start_logit": -4.57211971282959,
            "end_logit": 6.5155229568481445,
            "text": "of thalidomide",
            "probability": 1.9329310816829093e-05
        },
        {
            "start_logit": -4.801573276519775,
            "end_logit": 6.5155229568481445,
            "text": "known target of thalidomide",
            "probability": 1.536618947284296e-05
        },
        {
            "start_logit": -5.706860065460205,
            "end_logit": 6.5155229568481445,
            "text": "a well-known target of thalidomide",
            "probability": 6.214484528754838e-06
        },
        {
            "start_logit": -5.901989936828613,
            "end_logit": 6.5155229568481445,
            "text": "lon is a well-known target of thalidomide",
            "probability": 5.1128267841704655e-06
        },
        {
            "start_logit": 6.281047821044922,
            "end_logit": -5.844263076782227,
            "text": "thalidomide and its",
            "probability": 4.284501301299315e-06
        },
        {
            "start_logit": 6.281047821044922,
            "end_logit": -6.176227569580078,
            "text": "thalidomide and",
            "probability": 3.0741844057047274e-06
        },
        {
            "start_logit": -6.4278645515441895,
            "end_logit": 6.5155229568481445,
            "text": "is a well-known target of thalidomide",
            "probability": 3.0218775464163627e-06
        },
        {
            "start_logit": -1.3116017580032349,
            "end_logit": -3.115238666534424,
            "text": "Cereblon is a well-known target of thalidomide and its derivatives.",
            "probability": 3.30867848674643e-08
        },
        {
            "start_logit": -1.3116017580032349,
            "end_logit": -3.717231273651123,
            "text": "Cereblon is a well-known target of thalidomide and its derivatives",
            "probability": 1.8122280565080473e-08
        },
        {
            "start_logit": -1.3116017580032349,
            "end_logit": -4.20797872543335,
            "text": "Cereblon",
            "probability": 1.109389291542584e-08
        },
        {
            "start_logit": -1.3116017580032349,
            "end_logit": -5.654184341430664,
            "text": "Cereblon is a well-known target",
            "probability": 2.6121917962029784e-09
        },
        {
            "start_logit": -3.996788501739502,
            "end_logit": -3.115238666534424,
            "text": "target of thalidomide and its derivatives.",
            "probability": 2.256799414013244e-09
        },
        {
            "start_logit": -1.3116017580032349,
            "end_logit": -5.805500030517578,
            "text": "Cereb",
            "probability": 2.2453741088668266e-09
        },
        {
            "start_logit": -1.3116017580032349,
            "end_logit": -5.844263076782227,
            "text": "Cereblon is a well-known target of thalidomide and its",
            "probability": 2.1600059518789294e-09
        }
    ],
    "6414638c201352f04a000047_0002": [
        {
            "start_logit": 5.961223602294922,
            "end_logit": 6.591055870056152,
            "text": "thalidomide",
            "probability": 0.9643167853355408
        },
        {
            "start_logit": 2.620840072631836,
            "end_logit": 6.591055870056152,
            "text": "DHFO and its analogs, with structural features that are slightly different from thalidomide",
            "probability": 0.0341593474149704
        },
        {
            "start_logit": 2.620840072631836,
            "end_logit": 2.803192377090454,
            "text": "DHFO",
            "probability": 0.000773501698859036
        },
        {
            "start_logit": -2.912393569946289,
            "end_logit": 6.591055870056152,
            "text": "its analogs, with structural features that are slightly different from thalidomide",
            "probability": 0.0001350382372038439
        },
        {
            "start_logit": -3.053762197494507,
            "end_logit": 6.591055870056152,
            "text": "FO and its analogs, with structural features that are slightly different from thalidomide",
            "probability": 0.00011723600619006902
        },
        {
            "start_logit": -3.1041622161865234,
            "end_logit": 6.591055870056152,
            "text": "from thalidomide",
            "probability": 0.00011147376790177077
        },
        {
            "start_logit": -3.28186297416687,
            "end_logit": 6.591055870056152,
            "text": "analogs, with structural features that are slightly different from thalidomide",
            "probability": 9.332501940662041e-05
        },
        {
            "start_logit": 5.961223602294922,
            "end_logit": -3.169894218444824,
            "text": "thalidomide but stronger cereblon-binding affinity.",
            "probability": 5.560232966672629e-05
        },
        {
            "start_logit": -3.831090211868286,
            "end_logit": 6.591055870056152,
            "text": "cereblon inhibitors, namely DHFO and its analogs, with structural features that are slightly different from thalidomide",
            "probability": 5.388550562201999e-05
        },
        {
            "start_logit": -3.9039220809936523,
            "end_logit": 6.591055870056152,
            "text": "namely DHFO and its analogs, with structural features that are slightly different from thalidomide",
            "probability": 5.010042150388472e-05
        },
        {
            "start_logit": 5.961223602294922,
            "end_logit": -3.791611671447754,
            "text": "thalidomide but stronger cereblon-binding affinity",
            "probability": 2.9859635105822235e-05
        },
        {
            "start_logit": -4.607838153839111,
            "end_logit": 6.591055870056152,
            "text": "structural features that are slightly different from thalidomide",
            "probability": 2.478190799592994e-05
        },
        {
            "start_logit": -4.857583999633789,
            "end_logit": 6.591055870056152,
            "text": "We have identified novel cereblon inhibitors, namely DHFO and its analogs, with structural features that are slightly different from thalidomide",
            "probability": 1.9305067326058634e-05
        },
        {
            "start_logit": -5.00915002822876,
            "end_logit": 6.591055870056152,
            "text": "different from thalidomide",
            "probability": 1.6590031009400263e-05
        },
        {
            "start_logit": 5.961223602294922,
            "end_logit": -4.687173843383789,
            "text": "thalidomide but stronger",
            "probability": 1.2194017472211272e-05
        },
        {
            "start_logit": 2.620840072631836,
            "end_logit": -1.4917885065078735,
            "text": "DHFO and its analogs",
            "probability": 1.0548111276875716e-05
        },
        {
            "start_logit": -5.640899181365967,
            "end_logit": 6.591055870056152,
            "text": "slightly different from thalidomide",
            "probability": 8.820264156383928e-06
        },
        {
            "start_logit": 5.961223602294922,
            "end_logit": -5.695225715637207,
            "text": "thalidomide but",
            "probability": 4.44995339421439e-06
        },
        {
            "start_logit": 5.961223602294922,
            "end_logit": -5.704827308654785,
            "text": "thalidomide but stronger cereblon",
            "probability": 4.4074304241803475e-06
        },
        {
            "start_logit": -3.053762197494507,
            "end_logit": 2.803192377090454,
            "text": "FO",
            "probability": 2.6546856588538503e-06
        }
    ],
    "6414638c201352f04a000047_0003": [
        {
            "start_logit": 6.109528541564941,
            "end_logit": 6.488592624664307,
            "text": "immunomodulatory drugs",
            "probability": 0.96209317445755
        },
        {
            "start_logit": 6.109528541564941,
            "end_logit": 2.3019983768463135,
            "text": "immunomodulatory drugs (immunomodulatory drugs) thalidomide",
            "probability": 0.014621839858591557
        },
        {
            "start_logit": 6.109528541564941,
            "end_logit": 2.0315918922424316,
            "text": "immunomodulatory drugs (immunomodulatory drugs) thalidomide, lenalidomide",
            "probability": 0.011157485656440258
        },
        {
            "start_logit": 6.109528541564941,
            "end_logit": 1.7242159843444824,
            "text": "immunomodulatory drugs (immunomodulatory drugs) thalidomide, lenalidomide, and pomalidomide",
            "probability": 0.008204922080039978
        },
        {
            "start_logit": 6.109528541564941,
            "end_logit": 0.336051881313324,
            "text": "immunomodulatory drugs (immunomodulatory drugs",
            "probability": 0.0020473990589380264
        },
        {
            "start_logit": 2.349304676055908,
            "end_logit": 2.3019983768463135,
            "text": "thalidomide",
            "probability": 0.00034037508885376155
        },
        {
            "start_logit": 2.349304676055908,
            "end_logit": 2.0315918922424316,
            "text": "thalidomide, lenalidomide",
            "probability": 0.00025972974253818393
        },
        {
            "start_logit": 2.349304676055908,
            "end_logit": 1.7242159843444824,
            "text": "thalidomide, lenalidomide, and pomalidomide",
            "probability": 0.00019099851488135755
        },
        {
            "start_logit": -2.6512696743011475,
            "end_logit": 6.488592624664307,
            "text": "drugs",
            "probability": 0.0001508171553723514
        },
        {
            "start_logit": 1.7188106775283813,
            "end_logit": 2.0315918922424316,
            "text": "lenalidomide",
            "probability": 0.00013826158829033375
        },
        {
            "start_logit": 6.109528541564941,
            "end_logit": -2.409353494644165,
            "text": "immunomodulatory drugs (immunomodulatory",
            "probability": 0.00013148861762601882
        },
        {
            "start_logit": 6.109528541564941,
            "end_logit": -2.6224310398101807,
            "text": "immunomodulatory",
            "probability": 0.00010625508730299771
        },
        {
            "start_logit": 6.109528541564941,
            "end_logit": -2.6491622924804688,
            "text": "immunomodulatory drugs (immunomodulatory drugs)",
            "probability": 0.00010345235205022618
        },
        {
            "start_logit": 1.7188106775283813,
            "end_logit": 1.7242159843444824,
            "text": "lenalidomide, and pomalidomide",
            "probability": 0.00010167399159399793
        },
        {
            "start_logit": 6.109528541564941,
            "end_logit": -2.7464568614959717,
            "text": "immunomodulatory drugs (immunomodulatory drugs) thalidomide, lenalidomide, and pomalidomide. immunomodulatory drugs",
            "probability": 9.386112651554868e-05
        },
        {
            "start_logit": -3.2931134700775146,
            "end_logit": 6.488592624664307,
            "text": "the immunomodulatory drugs",
            "probability": 7.93782455730252e-05
        },
        {
            "start_logit": 1.1696804761886597,
            "end_logit": 1.7242159843444824,
            "text": "pomalidomide",
            "probability": 5.8711815654532984e-05
        },
        {
            "start_logit": 0.3070630133152008,
            "end_logit": 2.3019983768463135,
            "text": "immunomodulatory drugs) thalidomide",
            "probability": 4.415941293700598e-05
        },
        {
            "start_logit": 6.109528541564941,
            "end_logit": -3.5438802242279053,
            "text": "immunomodulatory drugs (immunomodulatory drugs) thalidomide, lenalidomide, and pomalidomide.",
            "probability": 4.2283332732040435e-05
        },
        {
            "start_logit": 0.3070630133152008,
            "end_logit": 2.0315918922424316,
            "text": "immunomodulatory drugs) thalidomide, lenalidomide",
            "probability": 3.369672049302608e-05
        }
    ],
    "6414638c201352f04a000047_0004": [
        {
            "start_logit": 5.205739498138428,
            "end_logit": 5.3426618576049805,
            "text": "immunomodulatory agents",
            "probability": 0.296346515417099
        },
        {
            "start_logit": 5.205739498138428,
            "end_logit": 5.057188987731934,
            "text": "immunomodulatory agents (immunomodulatory drugs\u00ae) lenalidomide",
            "probability": 0.2227514386177063
        },
        {
            "start_logit": 5.056051731109619,
            "end_logit": 5.057188987731934,
            "text": "lenalidomide",
            "probability": 0.19178399443626404
        },
        {
            "start_logit": 5.205739498138428,
            "end_logit": 4.336548328399658,
            "text": "immunomodulatory agents (immunomodulatory drugs\u00ae) lenalidomide (Lenacapavir) and pomalidomide",
            "probability": 0.10835538059473038
        },
        {
            "start_logit": 5.056051731109619,
            "end_logit": 4.336548328399658,
            "text": "lenalidomide (Lenacapavir) and pomalidomide",
            "probability": 0.09329146891832352
        },
        {
            "start_logit": 4.4129438400268555,
            "end_logit": 4.336548328399658,
            "text": "pomalidomide",
            "probability": 0.04903925955295563
        },
        {
            "start_logit": 5.205739498138428,
            "end_logit": 1.967137098312378,
            "text": "immunomodulatory agents (immunomodulatory drugs\u00ae) lenalidomide (Lenacapavir",
            "probability": 0.010135103017091751
        },
        {
            "start_logit": 5.056051731109619,
            "end_logit": 1.967137098312378,
            "text": "lenalidomide (Lenacapavir",
            "probability": 0.008726087398827076
        },
        {
            "start_logit": 2.041898727416992,
            "end_logit": 4.336548328399658,
            "text": "Lenacapavir) and pomalidomide",
            "probability": 0.004579434636980295
        },
        {
            "start_logit": 5.205739498138428,
            "end_logit": 0.6847141981124878,
            "text": "immunomodulatory",
            "probability": 0.0028111182618886232
        },
        {
            "start_logit": 5.205739498138428,
            "end_logit": 0.5283127427101135,
            "text": "immunomodulatory agents (immunomodulatory drugs\u00ae) lenalidomide (Lenacapavir) and pomalidomide (pomalidomide",
            "probability": 0.0024041123688220978
        },
        {
            "start_logit": 5.205739498138428,
            "end_logit": 0.45123669505119324,
            "text": "immunomodulatory agents (immunomodulatory drugs",
            "probability": 0.0022257743403315544
        },
        {
            "start_logit": 5.056051731109619,
            "end_logit": 0.5283127427101135,
            "text": "lenalidomide (Lenacapavir) and pomalidomide (pomalidomide",
            "probability": 0.002069884678348899
        },
        {
            "start_logit": 0.4467805027961731,
            "end_logit": 5.057188987731934,
            "text": "immunomodulatory drugs\u00ae) lenalidomide",
            "probability": 0.0019099905621260405
        },
        {
            "start_logit": 4.4129438400268555,
            "end_logit": 0.5283127427101135,
            "text": "pomalidomide (pomalidomide",
            "probability": 0.001088047749362886
        },
        {
            "start_logit": 0.4467805027961731,
            "end_logit": 4.336548328399658,
            "text": "immunomodulatory drugs\u00ae) lenalidomide (Lenacapavir) and pomalidomide",
            "probability": 0.0009290967136621475
        },
        {
            "start_logit": 5.205739498138428,
            "end_logit": -1.130023717880249,
            "text": "immunomodulatory agents (immunomodulatory drugs\u00ae) lenalidomide (Lenacapavir)",
            "probability": 0.00045787665294483304
        },
        {
            "start_logit": 2.041898727416992,
            "end_logit": 1.967137098312378,
            "text": "Lenacapavir",
            "probability": 0.00042834109626710415
        },
        {
            "start_logit": 5.056051731109619,
            "end_logit": -1.130023717880249,
            "text": "lenalidomide (Lenacapavir)",
            "probability": 0.0003942211624234915
        },
        {
            "start_logit": -1.7845897674560547,
            "end_logit": 5.3426618576049805,
            "text": "Cereblon (cereblon)-targeting immunomodulatory agents",
            "probability": 0.0002728592080529779
        }
    ],
    "6414638c201352f04a000047_0005": [
        {
            "start_logit": 6.404759407043457,
            "end_logit": 6.679690361022949,
            "text": "Thalidomide",
            "probability": 0.9998619556427002
        },
        {
            "start_logit": 6.404759407043457,
            "end_logit": -3.1150588989257812,
            "text": "Thalidomide, well known for its potent teratogenicity",
            "probability": 5.573582893703133e-05
        },
        {
            "start_logit": 6.404759407043457,
            "end_logit": -3.585287094116211,
            "text": "Thalidomide, well known for its potent teratogenicity, has been re-evaluated as a clinically effective drug for the treatment of multiple myeloma",
            "probability": 3.482707325019874e-05
        },
        {
            "start_logit": 6.404759407043457,
            "end_logit": -3.6433515548706055,
            "text": "Thalidomide, well known for its potent teratogenicity,",
            "probability": 3.286245191702619e-05
        },
        {
            "start_logit": 6.404759407043457,
            "end_logit": -5.1842780113220215,
            "text": "Thalidomide, well known",
            "probability": 7.038566764094867e-06
        },
        {
            "start_logit": 6.404759407043457,
            "end_logit": -5.203467845916748,
            "text": "Thalidomide, well known for its potent teratogenicity, has been re-evaluated as a clinically effective drug for the treatment of multiple myeloma.",
            "probability": 6.904786005179631e-06
        },
        {
            "start_logit": -1.3550070524215698,
            "end_logit": -1.0026699304580688,
            "text": "thalidomide",
            "probability": 1.9656646088606067e-07
        },
        {
            "start_logit": -1.3550070524215698,
            "end_logit": -1.409095287322998,
            "text": "thalidomide had been unclear until recently, we identified cereblon (cereblon",
            "probability": 1.3091850803448324e-07
        },
        {
            "start_logit": -1.6527806520462036,
            "end_logit": -1.409095287322998,
            "text": "cereblon (cereblon",
            "probability": 9.720302074356368e-08
        },
        {
            "start_logit": -1.3550070524215698,
            "end_logit": -1.8366341590881348,
            "text": "thalidomide had been unclear until recently, we identified cereblon",
            "probability": 8.537361395610787e-08
        },
        {
            "start_logit": -1.6527806520462036,
            "end_logit": -1.8366341590881348,
            "text": "cereblon",
            "probability": 6.338732561061988e-08
        },
        {
            "start_logit": -2.100092887878418,
            "end_logit": -1.409095287322998,
            "text": "cereblon",
            "probability": 6.214624193034979e-08
        },
        {
            "start_logit": -1.3550070524215698,
            "end_logit": -2.891186475753784,
            "text": "thalidomide had been unclear until recently, we identified cereblon (cereblon) as a primary direct target of this drug b",
            "probability": 2.9739767981595833e-08
        },
        {
            "start_logit": -1.6527806520462036,
            "end_logit": -2.891186475753784,
            "text": "cereblon (cereblon) as a primary direct target of this drug b",
            "probability": 2.2080829609194552e-08
        },
        {
            "start_logit": -2.100092887878418,
            "end_logit": -2.891186475753784,
            "text": "cereblon) as a primary direct target of this drug b",
            "probability": 1.4117263802404523e-08
        },
        {
            "start_logit": -4.097629070281982,
            "end_logit": -1.0026699304580688,
            "text": "potent teratogenicity, has been re-evaluated as a clinically effective drug for the treatment of multiple myeloma. Although the direct target of thalidomide",
            "probability": 1.2659122639036013e-08
        },
        {
            "start_logit": -1.3550070524215698,
            "end_logit": -4.065134525299072,
            "text": "thalidomide had been unclear until recently, we identified cereblon (cereblon)",
            "probability": 9.193867889223384e-09
        },
        {
            "start_logit": -4.51210880279541,
            "end_logit": -1.0026699304580688,
            "text": "teratogenicity, has been re-evaluated as a clinically effective drug for the treatment of multiple myeloma. Although the direct target of thalidomide",
            "probability": 8.363691073043356e-09
        },
        {
            "start_logit": -4.555049896240234,
            "end_logit": -1.0026699304580688,
            "text": "multiple myeloma. Although the direct target of thalidomide",
            "probability": 8.01213939638501e-09
        },
        {
            "start_logit": -1.3550070524215698,
            "end_logit": -4.213729381561279,
            "text": "thalidomide had been unclear until recently, we identified cereblon (cereblon) as a primary direct target",
            "probability": 7.924355394095528e-09
        }
    ],
    "6414638c201352f04a000047_0006": [
        {
            "start_logit": 7.031940937042236,
            "end_logit": 7.467247009277344,
            "text": "immunomodulatory drugs",
            "probability": 0.9996293783187866
        },
        {
            "start_logit": -1.6723911762237549,
            "end_logit": 7.467247009277344,
            "text": "drugs",
            "probability": 0.00016580434748902917
        },
        {
            "start_logit": 7.031940937042236,
            "end_logit": -2.268688201904297,
            "text": "immunomodulatory drugs remained unclear for a long time until 2010 when the protein cereblon",
            "probability": 5.909844549023546e-05
        },
        {
            "start_logit": 7.031940937042236,
            "end_logit": -2.3333561420440674,
            "text": "immunomodulatory drugs remained unclear for a long time until 2010 when the protein cereblon (cereblon",
            "probability": 5.539764242712408e-05
        },
        {
            "start_logit": 7.031940937042236,
            "end_logit": -2.780756950378418,
            "text": "immunomodulatory",
            "probability": 3.5415050660958514e-05
        },
        {
            "start_logit": -3.912436008453369,
            "end_logit": 7.467247009277344,
            "text": "The molecular mechanism of action of immunomodulatory drugs",
            "probability": 1.7650496374699287e-05
        },
        {
            "start_logit": -4.91088342666626,
            "end_logit": 7.467247009277344,
            "text": "of immunomodulatory drugs",
            "probability": 6.503344138764078e-06
        },
        {
            "start_logit": 7.031940937042236,
            "end_logit": -4.568829536437988,
            "text": "immunomodulatory drugs remained unclear for a long time until 2010",
            "probability": 5.924310244154185e-06
        },
        {
            "start_logit": 7.031940937042236,
            "end_logit": -4.692684173583984,
            "text": "immunomodulatory drugs remained unclear for a long time until 2010 when the protein cereblon (cereblon) was identified as a primary direct target. immunomodulatory",
            "probability": 5.2341720220283605e-06
        },
        {
            "start_logit": 7.031940937042236,
            "end_logit": -4.894381046295166,
            "text": "immunomodulatory drugs remained unclear for a long time until 2010 when the protein cereblon (cereblon) was identified as a primary direct",
            "probability": 4.2781143747561146e-06
        },
        {
            "start_logit": 7.031940937042236,
            "end_logit": -4.9604363441467285,
            "text": "immunomodulatory drugs remained unclear for a long time until 2010 when the protein cereblon (cereblon) was identified as a primary",
            "probability": 4.004653419542592e-06
        },
        {
            "start_logit": 7.031940937042236,
            "end_logit": -4.984774589538574,
            "text": "immunomodulatory drugs remained unclear for a long time until 2010 when the protein cereblon (cereb",
            "probability": 3.908365215465892e-06
        },
        {
            "start_logit": 7.031940937042236,
            "end_logit": -5.118134498596191,
            "text": "immunomodulatory drugs remained unclear for a long time until 2010 when the protein cereblon (cereblon) was identified as a primary direct target",
            "probability": 3.420406301302137e-06
        },
        {
            "start_logit": 7.031940937042236,
            "end_logit": -5.591610908508301,
            "text": "immunomodulatory drugs remained unclear for a long time until 2010 when the protein cereblon (cereblo",
            "probability": 2.1303426365193445e-06
        },
        {
            "start_logit": 7.031940937042236,
            "end_logit": -5.716994762420654,
            "text": "immunomodulatory drugs remained unclear for a long time until 2010 when the protein cereblon (cereblon)",
            "probability": 1.879298565654608e-06
        },
        {
            "start_logit": -1.6723911762237549,
            "end_logit": -2.268688201904297,
            "text": "drugs remained unclear for a long time until 2010 when the protein cereblon",
            "probability": 9.802403333480925e-09
        },
        {
            "start_logit": -1.6723911762237549,
            "end_logit": -2.3333561420440674,
            "text": "drugs remained unclear for a long time until 2010 when the protein cereblon (cereblon",
            "probability": 9.18857523402039e-09
        },
        {
            "start_logit": -1.4817646741867065,
            "end_logit": -2.922210454940796,
            "text": "immunomodulatory drugs",
            "probability": 6.170211452882768e-09
        },
        {
            "start_logit": -1.6723911762237549,
            "end_logit": -2.922210454940796,
            "text": "drugs remained unclear for a long time until 2010 when the protein cereblon (cereblon) was identified as a primary direct target. immunomodulatory drugs",
            "probability": 5.099319189127982e-09
        },
        {
            "start_logit": -2.97949481010437,
            "end_logit": -2.268688201904297,
            "text": "cereblon",
            "probability": 2.6525552865308555e-09
        }
    ],
    "63f03a20f36125a42600001c_0001": [
        {
            "start_logit": 6.03938102722168,
            "end_logit": 5.912276268005371,
            "text": "cilgavimab",
            "probability": 0.36058762669563293
        },
        {
            "start_logit": 5.884122848510742,
            "end_logit": 5.969825267791748,
            "text": "tixagevimab",
            "probability": 0.32702162861824036
        },
        {
            "start_logit": 5.884122848510742,
            "end_logit": 5.912276268005371,
            "text": "tixagevimab [AZD8895] and cilgavimab",
            "probability": 0.3087330162525177
        },
        {
            "start_logit": 0.08330556005239487,
            "end_logit": 5.969825267791748,
            "text": "long-acting monoclonal antibodies (tixagevimab",
            "probability": 0.0009892663219943643
        },
        {
            "start_logit": 0.08330556005239487,
            "end_logit": 5.912276268005371,
            "text": "long-acting monoclonal antibodies (tixagevimab [AZD8895] and cilgavimab",
            "probability": 0.0009339421521872282
        },
        {
            "start_logit": 5.884122848510742,
            "end_logit": -1.4370017051696777,
            "text": "tixagevima",
            "probability": 0.0001985327689908445
        },
        {
            "start_logit": 5.884122848510742,
            "end_logit": -1.605484962463379,
            "text": "ti",
            "probability": 0.00016774934192653745
        },
        {
            "start_logit": 6.03938102722168,
            "end_logit": -1.8033442497253418,
            "text": "cilgavima",
            "probability": 0.0001607531012268737
        },
        {
            "start_logit": 6.03938102722168,
            "end_logit": -1.809021234512329,
            "text": "cil",
            "probability": 0.00015984314086381346
        },
        {
            "start_logit": 5.884122848510742,
            "end_logit": -1.8033442497253418,
            "text": "tixagevimab [AZD8895] and cilgavima",
            "probability": 0.00013763585593551397
        },
        {
            "start_logit": 5.884122848510742,
            "end_logit": -1.809021234512329,
            "text": "tixagevimab [AZD8895] and cil",
            "probability": 0.00013685676094610244
        },
        {
            "start_logit": 6.03938102722168,
            "end_logit": -2.24499249458313,
            "text": "cilgavi",
            "probability": 0.0001033603839459829
        },
        {
            "start_logit": 5.884122848510742,
            "end_logit": -2.134948492050171,
            "text": "tixage",
            "probability": 9.879105346044526e-05
        },
        {
            "start_logit": 5.884122848510742,
            "end_logit": -2.2302284240722656,
            "text": "tixagevi",
            "probability": 8.981278369901702e-05
        },
        {
            "start_logit": 5.884122848510742,
            "end_logit": -2.24499249458313,
            "text": "tixagevimab [AZD8895] and cilgavi",
            "probability": 8.849654841469601e-05
        },
        {
            "start_logit": 5.884122848510742,
            "end_logit": -2.317108154296875,
            "text": "tixa",
            "probability": 8.233923290390521e-05
        },
        {
            "start_logit": -2.4290685653686523,
            "end_logit": 5.969825267791748,
            "text": "b",
            "probability": 8.020534733077511e-05
        },
        {
            "start_logit": 6.03938102722168,
            "end_logit": -2.5356616973876953,
            "text": "cilgavimab [AZD1061]",
            "probability": 7.72890416556038e-05
        },
        {
            "start_logit": 6.03938102722168,
            "end_logit": -2.539175271987915,
            "text": "cilga",
            "probability": 7.701798313064501e-05
        },
        {
            "start_logit": -2.4290685653686523,
            "end_logit": 5.912276268005371,
            "text": "b [AZD8895] and cilgavimab",
            "probability": 7.571987225674093e-05
        }
    ],
    "63f03a20f36125a42600001c_0002": [
        {
            "start_logit": 5.928390979766846,
            "end_logit": 5.958624839782715,
            "text": "tixagevimab",
            "probability": 0.37623193860054016
        },
        {
            "start_logit": 5.928390979766846,
            "end_logit": 5.810953140258789,
            "text": "tixagevimab-cilgavimab",
            "probability": 0.3245803415775299
        },
        {
            "start_logit": 5.84061861038208,
            "end_logit": 5.810953140258789,
            "text": "cilgavimab",
            "probability": 0.2973056435585022
        },
        {
            "start_logit": 5.928390979766846,
            "end_logit": -1.4271727800369263,
            "text": "tixagevima",
            "probability": 0.0002332622098037973
        },
        {
            "start_logit": 5.928390979766846,
            "end_logit": -1.5334889888763428,
            "text": "tixagevimab-cilgavima",
            "probability": 0.0002097354590659961
        },
        {
            "start_logit": 5.928390979766846,
            "end_logit": -1.5404908657073975,
            "text": "ti",
            "probability": 0.0002082720457110554
        },
        {
            "start_logit": 5.84061861038208,
            "end_logit": -1.5334889888763428,
            "text": "cilgavima",
            "probability": 0.00019211125618312508
        },
        {
            "start_logit": 5.928390979766846,
            "end_logit": -2.06557035446167,
            "text": "tixagevimab-cil",
            "probability": 0.00012319462257437408
        },
        {
            "start_logit": 5.84061861038208,
            "end_logit": -2.06557035446167,
            "text": "cil",
            "probability": 0.00011284250649623573
        },
        {
            "start_logit": 5.928390979766846,
            "end_logit": -2.1662685871124268,
            "text": "tixagevi",
            "probability": 0.00011139326670672745
        },
        {
            "start_logit": -2.2176239490509033,
            "end_logit": 5.958624839782715,
            "text": "b",
            "probability": 0.00010906520037679002
        },
        {
            "start_logit": -2.2176239490509033,
            "end_logit": 5.810953140258789,
            "text": "b-cilgavimab",
            "probability": 9.409210906596854e-05
        },
        {
            "start_logit": 5.928390979766846,
            "end_logit": -2.4977176189422607,
            "text": "tixagevimab-cilgavimab) for prevention of Covid-19",
            "probability": 7.996735075721517e-05
        },
        {
            "start_logit": 5.84061861038208,
            "end_logit": -2.4977176189422607,
            "text": "cilgavimab) for prevention of Covid-19",
            "probability": 7.324764010263607e-05
        },
        {
            "start_logit": 5.928390979766846,
            "end_logit": -2.6299304962158203,
            "text": "tixagevimab-cilgavi",
            "probability": 7.006369560258463e-05
        },
        {
            "start_logit": 5.84061861038208,
            "end_logit": -2.6299304962158203,
            "text": "cilgavi",
            "probability": 6.417620170395821e-05
        },
        {
            "start_logit": -2.8403663635253906,
            "end_logit": 5.958624839782715,
            "text": "xagevimab",
            "probability": 5.8510329836281016e-05
        },
        {
            "start_logit": -2.8403663635253906,
            "end_logit": 5.810953140258789,
            "text": "xagevimab-cilgavimab",
            "probability": 5.0477698096074164e-05
        },
        {
            "start_logit": -2.8783953189849854,
            "end_logit": 5.810953140258789,
            "text": "b",
            "probability": 4.859413456870243e-05
        },
        {
            "start_logit": 5.928390979766846,
            "end_logit": -3.1163477897644043,
            "text": "tixage",
            "probability": 4.307694689487107e-05
        }
    ],
    "63f03a20f36125a42600001c_0003": [
        {
            "start_logit": 6.11712121963501,
            "end_logit": 6.072312831878662,
            "text": "Tixagevimab",
            "probability": 0.4081972539424896
        },
        {
            "start_logit": 6.11712121963501,
            "end_logit": 5.785006046295166,
            "text": "Tixagevimab-Cilgavimab",
            "probability": 0.3062628209590912
        },
        {
            "start_logit": 6.041817665100098,
            "end_logit": 5.785006046295166,
            "text": "Cilgavimab",
            "probability": 0.28404727578163147
        },
        {
            "start_logit": 6.11712121963501,
            "end_logit": -1.5893933773040771,
            "text": "Ti",
            "probability": 0.0001920584763865918
        },
        {
            "start_logit": 6.11712121963501,
            "end_logit": -1.6717514991760254,
            "text": "Tixagevima",
            "probability": 0.0001768746878951788
        },
        {
            "start_logit": 6.11712121963501,
            "end_logit": -1.9300049543380737,
            "text": "Tixagevimab-Cilgavima",
            "probability": 0.0001366179494652897
        },
        {
            "start_logit": 6.11712121963501,
            "end_logit": -1.9943203926086426,
            "text": "Tixagevimab-Cil",
            "probability": 0.00012810785847250372
        },
        {
            "start_logit": 6.041817665100098,
            "end_logit": -1.9300049543380737,
            "text": "Cilgavima",
            "probability": 0.0001267078914679587
        },
        {
            "start_logit": 6.041817665100098,
            "end_logit": -1.9943203926086426,
            "text": "Cil",
            "probability": 0.00011881510727107525
        },
        {
            "start_logit": -2.06933856010437,
            "end_logit": 6.072312831878662,
            "text": "b",
            "probability": 0.00011364122474333271
        },
        {
            "start_logit": -2.06933856010437,
            "end_logit": 5.785006046295166,
            "text": "b-Cilgavimab",
            "probability": 8.526290184818208e-05
        },
        {
            "start_logit": 6.11712121963501,
            "end_logit": -2.426486015319824,
            "text": "Tixagevi",
            "probability": 8.315509330714121e-05
        },
        {
            "start_logit": -2.7545676231384277,
            "end_logit": 6.072312831878662,
            "text": "xagevimab",
            "probability": 5.727229290641844e-05
        },
        {
            "start_logit": 6.11712121963501,
            "end_logit": -2.970710515975952,
            "text": "Tixagevimab-Cilgavi",
            "probability": 4.8254194553010166e-05
        },
        {
            "start_logit": 6.041817665100098,
            "end_logit": -2.970710515975952,
            "text": "Cilgavi",
            "probability": 4.475390596780926e-05
        },
        {
            "start_logit": -2.7545676231384277,
            "end_logit": 5.785006046295166,
            "text": "xagevimab-Cilgavimab",
            "probability": 4.297034683986567e-05
        },
        {
            "start_logit": 6.11712121963501,
            "end_logit": -3.2515828609466553,
            "text": "Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2",
            "probability": 3.6437933886190876e-05
        },
        {
            "start_logit": 6.11712121963501,
            "end_logit": -3.283203601837158,
            "text": "Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS",
            "probability": 3.530375397531316e-05
        },
        {
            "start_logit": 6.041817665100098,
            "end_logit": -3.2515828609466553,
            "text": "Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2",
            "probability": 3.379477857379243e-05
        },
        {
            "start_logit": 6.041817665100098,
            "end_logit": -3.283203601837158,
            "text": "Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS",
            "probability": 3.274287155363709e-05
        }
    ],
    "63f03a20f36125a42600001c_0004": [
        {
            "start_logit": 6.047055244445801,
            "end_logit": 6.095861434936523,
            "text": "Tixagevimab",
            "probability": 0.3768896460533142
        },
        {
            "start_logit": 6.047055244445801,
            "end_logit": 5.926340103149414,
            "text": "Tixagevimab-Cilgavimab",
            "probability": 0.3181207776069641
        },
        {
            "start_logit": 5.998581409454346,
            "end_logit": 5.926340103149414,
            "text": "Cilgavimab",
            "probability": 0.3030678927898407
        },
        {
            "start_logit": 6.047055244445801,
            "end_logit": -1.4072985649108887,
            "text": "Ti",
            "probability": 0.00020779410260729492
        },
        {
            "start_logit": 6.047055244445801,
            "end_logit": -1.6169753074645996,
            "text": "Tixagevima",
            "probability": 0.00016848908853717148
        },
        {
            "start_logit": 6.047055244445801,
            "end_logit": -1.6274473667144775,
            "text": "Tixagevimab-Cilgavimab, (Evusheld",
            "probability": 0.0001667338947299868
        },
        {
            "start_logit": -1.6788222789764404,
            "end_logit": 6.095861434936523,
            "text": "b",
            "probability": 0.00016630608297418803
        },
        {
            "start_logit": 5.998581409454346,
            "end_logit": -1.6274473667144775,
            "text": "Cilgavimab, (Evusheld",
            "probability": 0.00015884435561019927
        },
        {
            "start_logit": 6.047055244445801,
            "end_logit": -1.6865283250808716,
            "text": "Tixagevimab-Cil",
            "probability": 0.0001571684260852635
        },
        {
            "start_logit": 5.998581409454346,
            "end_logit": -1.6865283250808716,
            "text": "Cil",
            "probability": 0.00014973159704823047
        },
        {
            "start_logit": -1.6788222789764404,
            "end_logit": 5.926340103149414,
            "text": "b-Cilgavimab",
            "probability": 0.00014037376968190074
        },
        {
            "start_logit": 6.047055244445801,
            "end_logit": -2.0267746448516846,
            "text": "Tixagevimab-Cilgavima",
            "probability": 0.00011184029426658526
        },
        {
            "start_logit": 5.998581409454346,
            "end_logit": -2.0267746448516846,
            "text": "Cilgavima",
            "probability": 0.00010654822108335793
        },
        {
            "start_logit": 6.047055244445801,
            "end_logit": -2.371725559234619,
            "text": "Tixagevi",
            "probability": 7.92114733485505e-05
        },
        {
            "start_logit": -2.6306381225585938,
            "end_logit": 6.095861434936523,
            "text": "xagevimab",
            "probability": 6.42007144051604e-05
        },
        {
            "start_logit": 6.047055244445801,
            "end_logit": -2.72127103805542,
            "text": "Tixage",
            "probability": 5.5844713642727584e-05
        },
        {
            "start_logit": -2.6306381225585938,
            "end_logit": 5.926340103149414,
            "text": "xagevimab-Cilgavimab",
            "probability": 5.4189818911254406e-05
        },
        {
            "start_logit": -2.681319236755371,
            "end_logit": 5.926340103149414,
            "text": "b",
            "probability": 5.15118517796509e-05
        },
        {
            "start_logit": 6.047055244445801,
            "end_logit": -2.960786819458008,
            "text": "Tixa",
            "probability": 4.395030191517435e-05
        },
        {
            "start_logit": 6.047055244445801,
            "end_logit": -3.079270839691162,
            "text": "Tixagevimab-Cilgavi",
            "probability": 3.903953984263353e-05
        }
    ],
    "640ddd9d201352f04a000028_0001": [
        {
            "start_logit": 6.181772232055664,
            "end_logit": 6.0315351486206055,
            "text": "Nivolumab and Pembrolizumab",
            "probability": 0.3486817181110382
        },
        {
            "start_logit": 6.181772232055664,
            "end_logit": 5.961385250091553,
            "text": "Nivolumab",
            "probability": 0.325060099363327
        },
        {
            "start_logit": 6.10720157623291,
            "end_logit": 6.0315351486206055,
            "text": "Pembrolizumab",
            "probability": 0.3236261010169983
        },
        {
            "start_logit": 0.01774345338344574,
            "end_logit": 6.0315351486206055,
            "text": "programmed cell death protein 1 (programmed death 1) inhibitors, Nivolumab and Pembrolizumab",
            "probability": 0.0007335429545491934
        },
        {
            "start_logit": 0.01774345338344574,
            "end_logit": 5.961385250091553,
            "text": "programmed cell death protein 1 (programmed death 1) inhibitors, Nivolumab",
            "probability": 0.0006838483968749642
        },
        {
            "start_logit": 6.181772232055664,
            "end_logit": -1.404677391052246,
            "text": "Niv",
            "probability": 0.00020555267110466957
        },
        {
            "start_logit": -1.2625882625579834,
            "end_logit": 6.0315351486206055,
            "text": "programmed death 1) inhibitors, Nivolumab and Pembrolizumab",
            "probability": 0.00020388458506204188
        },
        {
            "start_logit": -1.2625882625579834,
            "end_logit": 5.961385250091553,
            "text": "programmed death 1) inhibitors, Nivolumab",
            "probability": 0.00019007231458090246
        },
        {
            "start_logit": 6.181772232055664,
            "end_logit": -1.8338980674743652,
            "text": "Nivolumab and Pem",
            "probability": 0.00013381813187152147
        },
        {
            "start_logit": 6.10720157623291,
            "end_logit": -1.8338980674743652,
            "text": "Pem",
            "probability": 0.0001242021971847862
        },
        {
            "start_logit": -2.712131977081299,
            "end_logit": 6.0315351486206055,
            "text": "ab and Pembrolizumab",
            "probability": 4.784713019034825e-05
        },
        {
            "start_logit": -2.712131977081299,
            "end_logit": 5.961385250091553,
            "text": "ab",
            "probability": 4.460565833142027e-05
        },
        {
            "start_logit": -2.8566770553588867,
            "end_logit": 6.0315351486206055,
            "text": "umab",
            "probability": 4.140764576732181e-05
        },
        {
            "start_logit": 6.181772232055664,
            "end_logit": -3.0453405380249023,
            "text": "Nivolum",
            "probability": 3.984668364864774e-05
        },
        {
            "start_logit": -2.9578731060028076,
            "end_logit": 6.0315351486206055,
            "text": "olumab and Pembrolizumab",
            "probability": 3.742238914128393e-05
        },
        {
            "start_logit": 6.181772232055664,
            "end_logit": -3.115265369415283,
            "text": "Nivolumab and Pembroliz",
            "probability": 3.7155576137593016e-05
        },
        {
            "start_logit": -2.9578731060028076,
            "end_logit": 5.961385250091553,
            "text": "olumab",
            "probability": 3.4887194487964734e-05
        },
        {
            "start_logit": 6.10720157623291,
            "end_logit": -3.115265369415283,
            "text": "Pembroliz",
            "probability": 3.4485678042983636e-05
        },
        {
            "start_logit": 6.181772232055664,
            "end_logit": -3.7325706481933594,
            "text": "Nivolumab and Pembr",
            "probability": 2.0041577954543754e-05
        },
        {
            "start_logit": -3.6134636402130127,
            "end_logit": 6.0315351486206055,
            "text": "brolizumab",
            "probability": 1.94272961380193e-05
        }
    ],
    "640ddd9d201352f04a000028_0002": [
        {
            "start_logit": 6.187944412231445,
            "end_logit": 6.211109161376953,
            "text": "nivolumab and pembrolizumab",
            "probability": 0.3514668345451355
        },
        {
            "start_logit": 6.10958194732666,
            "end_logit": 6.211109161376953,
            "text": "pembrolizumab",
            "probability": 0.32497650384902954
        },
        {
            "start_logit": 6.187944412231445,
            "end_logit": 6.114394187927246,
            "text": "nivolumab",
            "probability": 0.31906676292419434
        },
        {
            "start_logit": 0.5841003656387329,
            "end_logit": 6.211109161376953,
            "text": "programmed death 1 (programmed death 1) receptor, nivolumab and pembrolizumab",
            "probability": 0.001294689835049212
        },
        {
            "start_logit": 0.5841003656387329,
            "end_logit": 6.114394187927246,
            "text": "programmed death 1 (programmed death 1) receptor, nivolumab",
            "probability": 0.00117533840239048
        },
        {
            "start_logit": -0.5516515374183655,
            "end_logit": 6.211109161376953,
            "text": "programmed death 1) receptor, nivolumab and pembrolizumab",
            "probability": 0.00041582927224226296
        },
        {
            "start_logit": -0.5516515374183655,
            "end_logit": 6.114394187927246,
            "text": "programmed death 1) receptor, nivolumab",
            "probability": 0.00037749591865576804
        },
        {
            "start_logit": 6.187944412231445,
            "end_logit": -0.7050780057907104,
            "text": "niv",
            "probability": 0.000348515750374645
        },
        {
            "start_logit": 6.187944412231445,
            "end_logit": -1.296876311302185,
            "text": "nivolumab and pem",
            "probability": 0.00019284465815871954
        },
        {
            "start_logit": 6.10958194732666,
            "end_logit": -1.296876311302185,
            "text": "pem",
            "probability": 0.00017830981232691556
        },
        {
            "start_logit": 6.187944412231445,
            "end_logit": -1.9192135334014893,
            "text": "nivolum",
            "probability": 0.00010349757212679833
        },
        {
            "start_logit": 6.187944412231445,
            "end_logit": -2.408348321914673,
            "text": "nivolumab and pembroliz",
            "probability": 6.346021837089211e-05
        },
        {
            "start_logit": 6.10958194732666,
            "end_logit": -2.408348321914673,
            "text": "pembroliz",
            "probability": 5.867718209628947e-05
        },
        {
            "start_logit": -2.554208755493164,
            "end_logit": 6.211109161376953,
            "text": "umab",
            "probability": 5.613263783743605e-05
        },
        {
            "start_logit": -2.5555121898651123,
            "end_logit": 6.211109161376953,
            "text": "ab and pembrolizumab",
            "probability": 5.6059503549477085e-05
        },
        {
            "start_logit": -2.5555121898651123,
            "end_logit": 6.114394187927246,
            "text": "ab",
            "probability": 5.0891645514639094e-05
        },
        {
            "start_logit": -3.09739351272583,
            "end_logit": 6.211109161376953,
            "text": "olumab and pembrolizumab",
            "probability": 3.2607200409984216e-05
        },
        {
            "start_logit": -3.09739351272583,
            "end_logit": 6.114394187927246,
            "text": "olumab",
            "probability": 2.960126948892139e-05
        },
        {
            "start_logit": 6.187944412231445,
            "end_logit": -3.214001178741455,
            "text": "nivolumab and pembroli",
            "probability": 2.8353792004054412e-05
        },
        {
            "start_logit": 6.187944412231445,
            "end_logit": -3.2379262447357178,
            "text": "nivolumab and pembr",
            "probability": 2.768345621007029e-05
        }
    ],
    "640ddd9d201352f04a000028_0003": [
        {
            "start_logit": 6.157845497131348,
            "end_logit": 6.06624698638916,
            "text": "nivolumab and pembrolizumab",
            "probability": 0.33763644099235535
        },
        {
            "start_logit": 6.157845497131348,
            "end_logit": 6.044445037841797,
            "text": "nivolumab",
            "probability": 0.3303549885749817
        },
        {
            "start_logit": 6.072588920593262,
            "end_logit": 6.06624698638916,
            "text": "pembrolizumab",
            "probability": 0.31004366278648376
        },
        {
            "start_logit": 2.609982490539551,
            "end_logit": 6.06624698638916,
            "text": "programmed cell death protein 1 (programmed death 1) inhibitors, nivolumab and pembrolizumab",
            "probability": 0.009719233959913254
        },
        {
            "start_logit": 2.609982490539551,
            "end_logit": 6.044445037841797,
            "text": "programmed cell death protein 1 (programmed death 1) inhibitors, nivolumab",
            "probability": 0.00950962770730257
        },
        {
            "start_logit": 0.051423296332359314,
            "end_logit": 6.06624698638916,
            "text": "programmed death 1) inhibitors, nivolumab and pembrolizumab",
            "probability": 0.0007524259854108095
        },
        {
            "start_logit": 0.051423296332359314,
            "end_logit": 6.044445037841797,
            "text": "programmed death 1) inhibitors, nivolumab",
            "probability": 0.0007361992029473186
        },
        {
            "start_logit": 2.609982490539551,
            "end_logit": 2.4762513637542725,
            "text": "programmed cell death protein 1",
            "probability": 0.0002682358317542821
        },
        {
            "start_logit": 6.157845497131348,
            "end_logit": -1.191321611404419,
            "text": "niv",
            "probability": 0.00023797285393811762
        },
        {
            "start_logit": 6.157845497131348,
            "end_logit": -1.6461809873580933,
            "text": "nivolumab and pem",
            "probability": 0.0001510025904281065
        },
        {
            "start_logit": 6.072588920593262,
            "end_logit": -1.6461809873580933,
            "text": "pem",
            "probability": 0.00013866212975699455
        },
        {
            "start_logit": -2.355670928955078,
            "end_logit": 6.06624698638916,
            "text": "ab and pembrolizumab",
            "probability": 6.777602538932115e-05
        },
        {
            "start_logit": -2.355670928955078,
            "end_logit": 6.044445037841797,
            "text": "ab",
            "probability": 6.631437281612307e-05
        },
        {
            "start_logit": 6.157845497131348,
            "end_logit": -2.511930465698242,
            "text": "nivolum",
            "probability": 6.353224307531491e-05
        },
        {
            "start_logit": -2.5900747776031494,
            "end_logit": 6.06624698638916,
            "text": "umab",
            "probability": 5.3613715863320976e-05
        },
        {
            "start_logit": 6.157845497131348,
            "end_logit": -2.781252861022949,
            "text": "nivolumab and pembroliz",
            "probability": 4.853208520216867e-05
        },
        {
            "start_logit": 6.072588920593262,
            "end_logit": -2.781252861022949,
            "text": "pembroliz",
            "probability": 4.456588430912234e-05
        },
        {
            "start_logit": -2.8870272636413574,
            "end_logit": 6.06624698638916,
            "text": "olumab and pembrolizumab",
            "probability": 3.9839258533902466e-05
        },
        {
            "start_logit": -2.8870272636413574,
            "end_logit": 6.044445037841797,
            "text": "olumab",
            "probability": 3.8980040699243546e-05
        },
        {
            "start_logit": -3.2257227897644043,
            "end_logit": 6.06624698638916,
            "text": "e programmed cell death protein 1 (programmed death 1) inhibitors, nivolumab and pembrolizumab",
            "probability": 2.8393413231242448e-05
        }
    ],
    "640ddd9d201352f04a000028_0004": [
        {
            "start_logit": 6.266470909118652,
            "end_logit": 6.1942057609558105,
            "text": "pembrolizumab",
            "probability": 0.8534634113311768
        },
        {
            "start_logit": 6.266470909118652,
            "end_logit": 4.274405479431152,
            "text": "pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolumab",
            "probability": 0.1251487284898758
        },
        {
            "start_logit": 4.241604804992676,
            "end_logit": 4.274405479431152,
            "text": "nivolumab",
            "probability": 0.016521073877811432
        },
        {
            "start_logit": 0.263717383146286,
            "end_logit": 6.1942057609558105,
            "text": "programmed death 1 (programmed death 1) inhibitor, pembrolizumab",
            "probability": 0.002109707798808813
        },
        {
            "start_logit": -0.14446568489074707,
            "end_logit": 6.1942057609558105,
            "text": "programmed death 1) inhibitor, pembrolizumab",
            "probability": 0.0014026542194187641
        },
        {
            "start_logit": 6.266470909118652,
            "end_logit": -1.7432869672775269,
            "text": "pem",
            "probability": 0.00030477248947136104
        },
        {
            "start_logit": -1.8460009098052979,
            "end_logit": 6.1942057609558105,
            "text": "The first programmed death 1 (programmed death 1) inhibitor, pembrolizumab",
            "probability": 0.00025584871764294803
        },
        {
            "start_logit": -1.9942054748535156,
            "end_logit": 6.1942057609558105,
            "text": "umab",
            "probability": 0.00022060691844671965
        },
        {
            "start_logit": 6.266470909118652,
            "end_logit": -2.5210723876953125,
            "text": "pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolum",
            "probability": 0.00014001928502693772
        },
        {
            "start_logit": 6.266470909118652,
            "end_logit": -2.885610342025757,
            "text": "pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; niv",
            "probability": 9.724582923809066e-05
        },
        {
            "start_logit": -3.252500057220459,
            "end_logit": 6.1942057609558105,
            "text": "brolizumab",
            "probability": 6.268281867960468e-05
        },
        {
            "start_logit": 0.263717383146286,
            "end_logit": 2.43772029876709,
            "text": "programmed death 1",
            "probability": 4.929485294269398e-05
        },
        {
            "start_logit": 6.266470909118652,
            "end_logit": -3.740157127380371,
            "text": "pembrolizumab,",
            "probability": 4.137577343499288e-05
        },
        {
            "start_logit": 6.266470909118652,
            "end_logit": -3.926792621612549,
            "text": "pembroliz",
            "probability": 3.433137317188084e-05
        },
        {
            "start_logit": -3.8601090908050537,
            "end_logit": 6.1942057609558105,
            "text": "olizumab",
            "probability": 3.4140306524932384e-05
        },
        {
            "start_logit": -1.9942054748535156,
            "end_logit": 4.274405479431152,
            "text": "umab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolumab",
            "probability": 3.2348954846384004e-05
        },
        {
            "start_logit": -4.267867565155029,
            "end_logit": 6.1942057609558105,
            "text": "zumab",
            "probability": 2.2708059987053275e-05
        },
        {
            "start_logit": -4.365102767944336,
            "end_logit": 6.1942057609558105,
            "text": "first programmed death 1 (programmed death 1) inhibitor, pembrolizumab",
            "probability": 2.0604000383173116e-05
        },
        {
            "start_logit": 6.266470909118652,
            "end_logit": -4.4718499183654785,
            "text": "pembr",
            "probability": 1.9905621229554527e-05
        },
        {
            "start_logit": 4.241604804992676,
            "end_logit": -2.5210723876953125,
            "text": "nivolum",
            "probability": 1.848415740823839e-05
        }
    ],
    "6414c4cf690f196b51000006_0001": [
        {
            "start_logit": 5.876968860626221,
            "end_logit": 5.0872721672058105,
            "text": "skin picking disorder",
            "probability": 0.4613025188446045
        },
        {
            "start_logit": 5.220118522644043,
            "end_logit": 5.218949794769287,
            "text": "Dermatillomania",
            "probability": 0.2728387415409088
        },
        {
            "start_logit": 5.220118522644043,
            "end_logit": 5.0872721672058105,
            "text": "Dermatillomania or skin picking disorder",
            "probability": 0.23917686939239502
        },
        {
            "start_logit": 5.876968860626221,
            "end_logit": 0.7628912925720215,
            "text": "skin picking disorder (skin picking disorder) is a chronic, recurrent, and treatment resistant neuropsychiatric disorder",
            "probability": 0.0061084502376616
        },
        {
            "start_logit": 5.876968860626221,
            "end_logit": 0.33524075150489807,
            "text": "skin picking",
            "probability": 0.003982950001955032
        },
        {
            "start_logit": 5.220118522644043,
            "end_logit": 0.7628912925720215,
            "text": "Dermatillomania or skin picking disorder (skin picking disorder) is a chronic, recurrent, and treatment resistant neuropsychiatric disorder",
            "probability": 0.0031671205069869757
        },
        {
            "start_logit": 5.876968860626221,
            "end_logit": 0.03913077712059021,
            "text": "skin picking disorder (skin picking disorder",
            "probability": 0.0029621415305882692
        },
        {
            "start_logit": 5.876968860626221,
            "end_logit": -0.11178417503833771,
            "text": "skin picking disorder (skin picking disorder)",
            "probability": 0.002547207986935973
        },
        {
            "start_logit": 5.220118522644043,
            "end_logit": 0.33524075150489807,
            "text": "Dermatillomania or skin picking",
            "probability": 0.002065087202936411
        },
        {
            "start_logit": 5.220118522644043,
            "end_logit": 0.03913077712059021,
            "text": "Dermatillomania or skin picking disorder (skin picking disorder",
            "probability": 0.0015358164673671126
        },
        {
            "start_logit": 5.220118522644043,
            "end_logit": -0.11178417503833771,
            "text": "Dermatillomania or skin picking disorder (skin picking disorder)",
            "probability": 0.0013206808362156153
        },
        {
            "start_logit": 5.876968860626221,
            "end_logit": -1.6367919445037842,
            "text": "skin picking disorder (skin picking disorder) is a chronic, recurrent, and treatment resistant neuropsychiatric disorder with an underestimated prevalence",
            "probability": 0.0005543218576349318
        },
        {
            "start_logit": 5.876968860626221,
            "end_logit": -1.7048256397247314,
            "text": "skin picking disorder (skin picking",
            "probability": 0.0005178633145987988
        },
        {
            "start_logit": -1.0291858911514282,
            "end_logit": 5.0872721672058105,
            "text": "picking disorder",
            "probability": 0.00046204146929085255
        },
        {
            "start_logit": 5.876968860626221,
            "end_logit": -2.241044044494629,
            "text": "skin picking disorder (skin picking disorder) is a chronic, recurrent, and treatment resistant",
            "probability": 0.00030292736482806504
        },
        {
            "start_logit": 5.220118522644043,
            "end_logit": -1.6367919445037842,
            "text": "Dermatillomania or skin picking disorder (skin picking disorder) is a chronic, recurrent, and treatment resistant neuropsychiatric disorder with an underestimated prevalence",
            "probability": 0.0002874056517612189
        },
        {
            "start_logit": 5.220118522644043,
            "end_logit": -1.7048256397247314,
            "text": "Dermatillomania or skin picking disorder (skin picking",
            "probability": 0.0002685028302948922
        },
        {
            "start_logit": 5.876968860626221,
            "end_logit": -2.5554044246673584,
            "text": "skin picking disorder (skin pick",
            "probability": 0.0002212145336670801
        },
        {
            "start_logit": -1.0921010971069336,
            "end_logit": 4.25755500793457,
            "text": "neuropsychiatric disorder with an underestimated prevalence that has a concerning negative impact on an individual's health and quality of life.",
            "probability": 0.00018924115283880383
        },
        {
            "start_logit": 5.876968860626221,
            "end_logit": -2.7129805088043213,
            "text": "skin pick",
            "probability": 0.0001889639679575339
        }
    ],
    "63eefa3bf36125a426000012_0001": [
        {
            "start_logit": 6.879608154296875,
            "end_logit": 7.003635406494141,
            "text": "Japanese spotted fever (Japanese spotted fever), R. japonica",
            "probability": 0.4241841435432434
        },
        {
            "start_logit": 6.771703720092773,
            "end_logit": 7.003635406494141,
            "text": "R. japonica",
            "probability": 0.38079574704170227
        },
        {
            "start_logit": 6.879608154296875,
            "end_logit": 6.088510513305664,
            "text": "Japanese spotted fever",
            "probability": 0.16987158358097076
        },
        {
            "start_logit": 2.9861812591552734,
            "end_logit": 7.003635406494141,
            "text": "Rickettsia species LON strains closely related to an agent of Japanese spotted fever (Japanese spotted fever), R. japonica",
            "probability": 0.008642923086881638
        },
        {
            "start_logit": 2.589315176010132,
            "end_logit": 7.003635406494141,
            "text": "Japanese spotted fever), R. japonica",
            "probability": 0.005811710376292467
        },
        {
            "start_logit": 2.9861812591552734,
            "end_logit": 6.088510513305664,
            "text": "Rickettsia species LON strains closely related to an agent of Japanese spotted fever",
            "probability": 0.0034612014424055815
        },
        {
            "start_logit": 6.879608154296875,
            "end_logit": 2.164346694946289,
            "text": "Japanese spotted fever (Japanese spotted fever",
            "probability": 0.003356433706358075
        },
        {
            "start_logit": 6.879608154296875,
            "end_logit": 0.8727434277534485,
            "text": "Japanese spotted fever (Japanese spotted fever), R. japonica, were isolated in Japan from Haemaphysalis longicornis",
            "probability": 0.0009224480600096285
        },
        {
            "start_logit": 6.771703720092773,
            "end_logit": 0.8727434277534485,
            "text": "R. japonica, were isolated in Japan from Haemaphysalis longicornis",
            "probability": 0.000828094023745507
        },
        {
            "start_logit": 6.879608154296875,
            "end_logit": 0.37367016077041626,
            "text": "Japanese spotted fever (Japanese spotted fever)",
            "probability": 0.0005600116564892232
        },
        {
            "start_logit": 6.771703720092773,
            "end_logit": 0.07801300287246704,
            "text": "R. japonica, were isolated in Japan from Haemaphysalis longicornis ticks in 2001.",
            "probability": 0.0003740524407476187
        },
        {
            "start_logit": -0.32309064269065857,
            "end_logit": 7.003635406494141,
            "text": "spotted fever (Japanese spotted fever), R. japonica",
            "probability": 0.00031583636882714927
        },
        {
            "start_logit": 6.879608154296875,
            "end_logit": -0.8558515906333923,
            "text": "Japanese spotted fever (Japanese spotted fever), R. japonica,",
            "probability": 0.0001637655805097893
        },
        {
            "start_logit": 6.771703720092773,
            "end_logit": -0.8558515906333923,
            "text": "R. japonica,",
            "probability": 0.00014701453619636595
        },
        {
            "start_logit": -0.32309064269065857,
            "end_logit": 6.088510513305664,
            "text": "spotted fever",
            "probability": 0.0001264819293282926
        },
        {
            "start_logit": -1.2627009153366089,
            "end_logit": 7.003635406494141,
            "text": "japonica",
            "probability": 0.000123422549222596
        },
        {
            "start_logit": 6.879608154296875,
            "end_logit": -1.2045246362686157,
            "text": "Japanese",
            "probability": 0.00011555683886399493
        },
        {
            "start_logit": -1.6555616855621338,
            "end_logit": 7.003635406494141,
            "text": ". japonica",
            "probability": 8.332539437105879e-05
        },
        {
            "start_logit": 2.9861812591552734,
            "end_logit": 2.164346694946289,
            "text": "Rickettsia species LON strains closely related to an agent of Japanese spotted fever (Japanese spotted fever",
            "probability": 6.838867557235062e-05
        },
        {
            "start_logit": -2.211468458175659,
            "end_logit": 7.003635406494141,
            "text": "LON strains closely related to an agent of Japanese spotted fever (Japanese spotted fever), R. japonica",
            "probability": 4.779141818289645e-05
        }
    ],
    "63eefa3bf36125a426000012_0002": [
        {
            "start_logit": 6.038163661956787,
            "end_logit": 6.602503299713135,
            "text": "Japanese spotted fever",
            "probability": 0.8541204333305359
        },
        {
            "start_logit": 6.038163661956787,
            "end_logit": 3.9480199813842773,
            "text": "Japanese spotted fever (Japanese spotted fever; a spotted fever group rickettsiosis) are tick-borne zoonoses",
            "probability": 0.06007467582821846
        },
        {
            "start_logit": 6.038163661956787,
            "end_logit": 3.020923137664795,
            "text": "Japanese spotted fever (Japanese spotted fever; a spotted fever group rickettsiosis",
            "probability": 0.023771608248353004
        },
        {
            "start_logit": 6.038163661956787,
            "end_logit": 2.8452999591827393,
            "text": "Japanese spotted fever (Japanese spotted fever",
            "probability": 0.019942816346883774
        },
        {
            "start_logit": 1.4906046390533447,
            "end_logit": 6.602503299713135,
            "text": "fever with thrombocytopenia syndrome (SFTS) and Japanese spotted fever",
            "probability": 0.009047726169228554
        },
        {
            "start_logit": 4.068661212921143,
            "end_logit": 3.996674060821533,
            "text": "tick-borne zoonoses that are becoming a significant public health threat in Japan and East Asia.",
            "probability": 0.00879990216344595
        },
        {
            "start_logit": 4.068661212921143,
            "end_logit": 3.9480199813842773,
            "text": "tick-borne zoonoses",
            "probability": 0.00838200282305479
        },
        {
            "start_logit": 1.153058409690857,
            "end_logit": 6.602503299713135,
            "text": "spotted fever",
            "probability": 0.006455723196268082
        },
        {
            "start_logit": 6.038163661956787,
            "end_logit": 1.1226139068603516,
            "text": "Japanese spotted fever (Japanese spotted fever; a spotted fever",
            "probability": 0.0035615037195384502
        },
        {
            "start_logit": 2.0293242931365967,
            "end_logit": 3.9480199813842773,
            "text": "Japanese spotted fever; a spotted fever group rickettsiosis) are tick-borne zoonoses",
            "probability": 0.0010906237876042724
        },
        {
            "start_logit": 6.038163661956787,
            "end_logit": -0.24319881200790405,
            "text": "Japanese spotted fever (Japanese spotted fever; a spotted fever group rickettsiosis)",
            "probability": 0.0009088002843782306
        },
        {
            "start_logit": -1.0460076332092285,
            "end_logit": 6.602503299713135,
            "text": "thrombocytopenia syndrome (SFTS) and Japanese spotted fever",
            "probability": 0.0007159828091971576
        },
        {
            "start_logit": 1.4906046390533447,
            "end_logit": 3.9480199813842773,
            "text": "fever with thrombocytopenia syndrome (SFTS) and Japanese spotted fever (Japanese spotted fever; a spotted fever group rickettsiosis) are tick-borne zoonoses",
            "probability": 0.000636373064480722
        },
        {
            "start_logit": 1.153058409690857,
            "end_logit": 3.9480199813842773,
            "text": "spotted fever (Japanese spotted fever; a spotted fever group rickettsiosis) are tick-borne zoonoses",
            "probability": 0.00045406437129713595
        },
        {
            "start_logit": 2.0293242931365967,
            "end_logit": 3.020923137664795,
            "text": "Japanese spotted fever; a spotted fever group rickettsiosis",
            "probability": 0.0004315605037845671
        },
        {
            "start_logit": 2.0293242931365967,
            "end_logit": 2.8452999591827393,
            "text": "Japanese spotted fever",
            "probability": 0.0003620508941821754
        },
        {
            "start_logit": 0.771483302116394,
            "end_logit": 3.996674060821533,
            "text": "rickettsiosis) are tick-borne zoonoses that are becoming a significant public health threat in Japan and East Asia.",
            "probability": 0.00032548554008826613
        },
        {
            "start_logit": 6.038163661956787,
            "end_logit": -1.2974259853363037,
            "text": "Japanese spotted fever (Japanese spotted fever; a spotted fever group rickettsiosis) are tick-borne zoon",
            "probability": 0.0003166820970363915
        },
        {
            "start_logit": 0.771483302116394,
            "end_logit": 3.9480199813842773,
            "text": "rickettsiosis) are tick-borne zoonoses",
            "probability": 0.00031002837931737304
        },
        {
            "start_logit": -1.943065881729126,
            "end_logit": 6.602503299713135,
            "text": "Severe fever with thrombocytopenia syndrome (SFTS) and Japanese spotted fever",
            "probability": 0.00029195440583862364
        }
    ],
    "63eefa3bf36125a426000012_0003": [
        {
            "start_logit": 7.173117637634277,
            "end_logit": 7.473908424377441,
            "text": "Rickettsia japonica",
            "probability": 0.8451545238494873
        },
        {
            "start_logit": 7.173117637634277,
            "end_logit": 5.387082099914551,
            "text": "Rickettsia japonica is a member of SFG rickettsiae causing Japanese spotted fever",
            "probability": 0.10486702620983124
        },
        {
            "start_logit": 7.173117637634277,
            "end_logit": 3.994418144226074,
            "text": "Rickettsia japonica is a member of SFG rickettsiae causing Japanese spotted fever (Japanese spotted fever) and can transmit to humans via infected ticks.",
            "probability": 0.026050297543406487
        },
        {
            "start_logit": 4.968594074249268,
            "end_logit": 5.387082099914551,
            "text": "Japanese spotted fever",
            "probability": 0.011567160487174988
        },
        {
            "start_logit": 7.173117637634277,
            "end_logit": 2.540748357772827,
            "text": "Rickettsia japonica is a member of SFG rickettsiae",
            "probability": 0.006088243331760168
        },
        {
            "start_logit": 4.968594074249268,
            "end_logit": 3.994418144226074,
            "text": "Japanese spotted fever (Japanese spotted fever) and can transmit to humans via infected ticks.",
            "probability": 0.002873429097235203
        },
        {
            "start_logit": 7.173117637634277,
            "end_logit": 1.443901538848877,
            "text": "Rickettsia japonica is a member of SFG rickettsiae causing Japanese spotted fever (Japanese spotted fever",
            "probability": 0.002033000811934471
        },
        {
            "start_logit": 7.173117637634277,
            "end_logit": -0.12265753746032715,
            "text": "Rickettsia japonica is a member of SFG rickettsiae causing Japanese spotted fever (Japanese spotted fever)",
            "probability": 0.00042441365076228976
        },
        {
            "start_logit": 4.968594074249268,
            "end_logit": 1.443901538848877,
            "text": "Japanese spotted fever (Japanese spotted fever",
            "probability": 0.00022424616327043623
        },
        {
            "start_logit": 7.173117637634277,
            "end_logit": -1.1582973003387451,
            "text": "Rickettsia japonica is",
            "probability": 0.0001506664848420769
        },
        {
            "start_logit": 0.24855895340442657,
            "end_logit": 5.387082099914551,
            "text": "spotted fever",
            "probability": 0.00010311962978448719
        },
        {
            "start_logit": 7.173117637634277,
            "end_logit": -1.6787993907928467,
            "text": "Rickettsia",
            "probability": 8.952936332207173e-05
        },
        {
            "start_logit": -0.057530827820301056,
            "end_logit": 5.387082099914551,
            "text": "SFG rickettsiae causing Japanese spotted fever",
            "probability": 7.592912879772484e-05
        },
        {
            "start_logit": 7.173117637634277,
            "end_logit": -2.0330255031585693,
            "text": "Rickettsia japonica is a member of SFG rickettsiae causing Japanese",
            "probability": 6.28242123639211e-05
        },
        {
            "start_logit": 0.9384381771087646,
            "end_logit": 3.994418144226074,
            "text": "Japanese spotted fever) and can transmit to humans via infected ticks.",
            "probability": 5.1065297157038e-05
        },
        {
            "start_logit": 4.968594074249268,
            "end_logit": -0.12265753746032715,
            "text": "Japanese spotted fever (Japanese spotted fever)",
            "probability": 4.68141479359474e-05
        },
        {
            "start_logit": -2.7127954959869385,
            "end_logit": 7.473908424377441,
            "text": "japonica",
            "probability": 4.3006952182622626e-05
        },
        {
            "start_logit": 7.173117637634277,
            "end_logit": -2.6540050506591797,
            "text": "Ricketts",
            "probability": 3.37628553097602e-05
        },
        {
            "start_logit": 7.173117637634277,
            "end_logit": -2.6841530799865723,
            "text": "Rickettsia japonica is a member of SFG rickettsiae causing Japanese spotted",
            "probability": 3.276014467701316e-05
        },
        {
            "start_logit": 7.173117637634277,
            "end_logit": -2.829150676727295,
            "text": "Rickettsia japonica is a member",
            "probability": 2.8338352421997115e-05
        }
    ],
    "6414c0f7690f196b51000001_0001": [
        {
            "start_logit": 5.376955986022949,
            "end_logit": 5.470512866973877,
            "text": "hyperammonaemic encephalopathy",
            "probability": 0.757785439491272
        },
        {
            "start_logit": 3.8016443252563477,
            "end_logit": 5.470512866973877,
            "text": "asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy",
            "probability": 0.1568184196949005
        },
        {
            "start_logit": 3.8016443252563477,
            "end_logit": 4.008049964904785,
            "text": "asymptomatic carrier state",
            "probability": 0.036329321563243866
        },
        {
            "start_logit": 2.170856475830078,
            "end_logit": 5.470512866973877,
            "text": "severe neonatal presentation with hyperammonaemic encephalopathy",
            "probability": 0.030701154842972755
        },
        {
            "start_logit": 0.7237154245376587,
            "end_logit": 5.470512866973877,
            "text": "neonatal presentation with hyperammonaemic encephalopathy",
            "probability": 0.00722219655290246
        },
        {
            "start_logit": 3.8016443252563477,
            "end_logit": 1.5254976749420166,
            "text": "asymptomatic carrier state to severe neonatal presentation",
            "probability": 0.0030345788691192865
        },
        {
            "start_logit": 5.376955986022949,
            "end_logit": -0.16185733675956726,
            "text": "hyperammonaemic encephalopathy.",
            "probability": 0.002712931716814637
        },
        {
            "start_logit": -0.9203194379806519,
            "end_logit": 5.470512866973877,
            "text": "carrier state to severe neonatal presentation with hyperammonaemic encephalopathy",
            "probability": 0.0013953205198049545
        },
        {
            "start_logit": -1.4113898277282715,
            "end_logit": 5.470512866973877,
            "text": "encephalopathy",
            "probability": 0.0008538958500139415
        },
        {
            "start_logit": 2.170856475830078,
            "end_logit": 1.5254976749420166,
            "text": "severe neonatal presentation",
            "probability": 0.0005940955015830696
        },
        {
            "start_logit": 3.8016443252563477,
            "end_logit": -0.16185733675956726,
            "text": "asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy.",
            "probability": 0.0005614220281131566
        },
        {
            "start_logit": -2.317422866821289,
            "end_logit": 5.470512866973877,
            "text": "ammonaemic encephalopathy",
            "probability": 0.00034507998498156667
        },
        {
            "start_logit": -0.9203194379806519,
            "end_logit": 4.008049964904785,
            "text": "carrier state",
            "probability": 0.00032324696076102555
        },
        {
            "start_logit": -2.5003607273101807,
            "end_logit": 5.470512866973877,
            "text": "The disease severity ranges from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy",
            "probability": 0.0002873893827199936
        },
        {
            "start_logit": 3.8016443252563477,
            "end_logit": -1.015684723854065,
            "text": "asymptomatic carrier state to severe",
            "probability": 0.00023904348199721426
        },
        {
            "start_logit": -2.813765287399292,
            "end_logit": 5.470512866973877,
            "text": "presentation with hyperammonaemic encephalopathy",
            "probability": 0.00021006858150940388
        },
        {
            "start_logit": -2.8392012119293213,
            "end_logit": 5.470512866973877,
            "text": "urea cycle defect. The disease severity ranges from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy",
            "probability": 0.00020479258091654629
        },
        {
            "start_logit": 0.7237154245376587,
            "end_logit": 1.5254976749420166,
            "text": "neonatal presentation",
            "probability": 0.00013975618639960885
        },
        {
            "start_logit": -3.280146360397339,
            "end_logit": 5.470512866973877,
            "text": "ranges from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy",
            "probability": 0.00013176933862268925
        },
        {
            "start_logit": 2.170856475830078,
            "end_logit": -0.16185733675956726,
            "text": "severe neonatal presentation with hyperammonaemic encephalopathy.",
            "probability": 0.0001099125511245802
        }
    ],
    "6414c0f7690f196b51000001_0002": [
        {
            "start_logit": 3.8266618251800537,
            "end_logit": 5.041247844696045,
            "text": "lethal neonatal hyperammonemic events",
            "probability": 0.23588857054710388
        },
        {
            "start_logit": 4.182586193084717,
            "end_logit": 4.426695823669434,
            "text": "moderate symptoms",
            "probability": 0.18213199079036713
        },
        {
            "start_logit": 3.4576921463012695,
            "end_logit": 5.041247844696045,
            "text": "neonatal hyperammonemic events",
            "probability": 0.16310426592826843
        },
        {
            "start_logit": 3.8266618251800537,
            "end_logit": 4.426695823669434,
            "text": "lethal neonatal hyperammonemic events to moderate symptoms",
            "probability": 0.1275882124900818
        },
        {
            "start_logit": 3.4576921463012695,
            "end_logit": 4.426695823669434,
            "text": "neonatal hyperammonemic events to moderate symptoms",
            "probability": 0.08822038769721985
        },
        {
            "start_logit": 4.182586193084717,
            "end_logit": 3.498262882232666,
            "text": "moderate symptoms and even asymptomatic individual",
            "probability": 0.07197357714176178
        },
        {
            "start_logit": 3.8266618251800537,
            "end_logit": 3.498262882232666,
            "text": "lethal neonatal hyperammonemic events to moderate symptoms and even asymptomatic individual",
            "probability": 0.05041932314634323
        },
        {
            "start_logit": 3.4576921463012695,
            "end_logit": 3.498262882232666,
            "text": "neonatal hyperammonemic events to moderate symptoms and even asymptomatic individual",
            "probability": 0.03486226871609688
        },
        {
            "start_logit": 2.302705764770508,
            "end_logit": 3.498262882232666,
            "text": "even asymptomatic individual",
            "probability": 0.010983770713210106
        },
        {
            "start_logit": 0.7363362312316895,
            "end_logit": 5.041247844696045,
            "text": "hyperammonemic events",
            "probability": 0.010729898698627949
        },
        {
            "start_logit": 2.0382142066955566,
            "end_logit": 3.498262882232666,
            "text": "asymptomatic individual",
            "probability": 0.008431099355220795
        },
        {
            "start_logit": 0.7363362312316895,
            "end_logit": 4.426695823669434,
            "text": "hyperammonemic events to moderate symptoms",
            "probability": 0.005803621839731932
        },
        {
            "start_logit": 0.7363362312316895,
            "end_logit": 3.498262882232666,
            "text": "hyperammonemic events to moderate symptoms and even asymptomatic individual",
            "probability": 0.0022934316657483578
        },
        {
            "start_logit": -0.8314529657363892,
            "end_logit": 5.041247844696045,
            "text": "high phenotypic heterogeneity, ranging from lethal neonatal hyperammonemic events",
            "probability": 0.002237244974821806
        },
        {
            "start_logit": -0.7313295602798462,
            "end_logit": 4.426695823669434,
            "text": "symptoms",
            "probability": 0.0013375191483646631
        },
        {
            "start_logit": -0.8314529657363892,
            "end_logit": 4.426695823669434,
            "text": "high phenotypic heterogeneity, ranging from lethal neonatal hyperammonemic events to moderate symptoms",
            "probability": 0.0012100880267098546
        },
        {
            "start_logit": -1.7206413745880127,
            "end_logit": 5.041247844696045,
            "text": "Due to high phenotypic heterogeneity, ranging from lethal neonatal hyperammonemic events",
            "probability": 0.0009194830781780183
        },
        {
            "start_logit": -1.8119187355041504,
            "end_logit": 5.041247844696045,
            "text": "ranging from lethal neonatal hyperammonemic events",
            "probability": 0.0008392716990783811
        },
        {
            "start_logit": -0.7313295602798462,
            "end_logit": 3.498262882232666,
            "text": "symptoms and even asymptomatic individual",
            "probability": 0.0005285507068037987
        },
        {
            "start_logit": -1.7206413745880127,
            "end_logit": 4.426695823669434,
            "text": "Due to high phenotypic heterogeneity, ranging from lethal neonatal hyperammonemic events to moderate symptoms",
            "probability": 0.0004973331233486533
        }
    ],
    "6414c0f7690f196b51000001_0003": [
        {
            "start_logit": 5.744806289672852,
            "end_logit": 5.085907936096191,
            "text": "hyperammonemia",
            "probability": 0.9990119934082031
        },
        {
            "start_logit": -2.365220069885254,
            "end_logit": 5.085907936096191,
            "text": "results in hyperammonemia",
            "probability": 0.0003002140438184142
        },
        {
            "start_logit": -2.63706636428833,
            "end_logit": 5.085907936096191,
            "text": "ammonemia",
            "probability": 0.00022875463764648885
        },
        {
            "start_logit": 5.744806289672852,
            "end_logit": -3.8408358097076416,
            "text": "hyper",
            "probability": 0.00013265854795463383
        },
        {
            "start_logit": -3.548248052597046,
            "end_logit": 5.085907936096191,
            "text": "Deficiency of ornithine transcarbamylase, an enzyme in the urea cycle, results in hyperammonemia",
            "probability": 9.19704616535455e-05
        },
        {
            "start_logit": 5.744806289672852,
            "end_logit": -4.458186626434326,
            "text": "hyperammon",
            "probability": 7.155225466703996e-05
        },
        {
            "start_logit": -4.173336505889893,
            "end_logit": 5.085907936096191,
            "text": "emia",
            "probability": 4.922392690787092e-05
        },
        {
            "start_logit": -4.339030742645264,
            "end_logit": 5.085907936096191,
            "text": "in hyperammonemia",
            "probability": 4.170764805166982e-05
        },
        {
            "start_logit": -4.859583854675293,
            "end_logit": 5.085907936096191,
            "text": "ornithine transcarbamylase, an enzyme in the urea cycle, results in hyperammonemia",
            "probability": 2.4782355467323214e-05
        },
        {
            "start_logit": -4.973875522613525,
            "end_logit": 5.085907936096191,
            "text": "urea cycle, results in hyperammonemia",
            "probability": 2.2105816242401488e-05
        },
        {
            "start_logit": -5.446407318115234,
            "end_logit": 5.085907936096191,
            "text": ", results in hyperammonemia",
            "probability": 1.3781243069388438e-05
        },
        {
            "start_logit": -6.30174446105957,
            "end_logit": 5.085907936096191,
            "text": "enzyme in the urea cycle, results in hyperammonemia",
            "probability": 5.858955319126835e-06
        },
        {
            "start_logit": -6.408304214477539,
            "end_logit": 5.085907936096191,
            "text": "an enzyme in the urea cycle, results in hyperammonemia",
            "probability": 5.266740117804147e-06
        },
        {
            "start_logit": -2.365220069885254,
            "end_logit": -3.8408358097076416,
            "text": "results in hyper",
            "probability": 3.9865348355760943e-08
        },
        {
            "start_logit": -2.365220069885254,
            "end_logit": -4.458186626434326,
            "text": "results in hyperammon",
            "probability": 2.150221334318303e-08
        },
        {
            "start_logit": -2.63706636428833,
            "end_logit": -4.458186626434326,
            "text": "ammon",
            "probability": 1.6384063883378985e-08
        },
        {
            "start_logit": -3.548248052597046,
            "end_logit": -3.8408358097076416,
            "text": "Deficiency of ornithine transcarbamylase, an enzyme in the urea cycle, results in hyper",
            "probability": 1.221272327711631e-08
        },
        {
            "start_logit": -3.548248052597046,
            "end_logit": -4.4438276290893555,
            "text": "Deficiency of ornithine transcarbamylase",
            "probability": 6.682467468266395e-09
        },
        {
            "start_logit": -3.548248052597046,
            "end_logit": -4.458186626434326,
            "text": "Deficiency of ornithine transcarbamylase, an enzyme in the urea cycle, results in hyperammon",
            "probability": 6.58720189505857e-09
        },
        {
            "start_logit": -4.339030742645264,
            "end_logit": -3.8408358097076416,
            "text": "in hyper",
            "probability": 5.538342673361285e-09
        }
    ],
    "6414c0f7690f196b51000001_0004": [
        {
            "start_logit": 5.8759846687316895,
            "end_logit": 6.122873306274414,
            "text": "seizures",
            "probability": 0.11276453733444214
        },
        {
            "start_logit": 5.704807758331299,
            "end_logit": 6.122873306274414,
            "text": "developmental delay (38 percent), and seizures",
            "probability": 0.09502357244491577
        },
        {
            "start_logit": 5.564885139465332,
            "end_logit": 6.122873306274414,
            "text": "Stage II coma (46 percent), delayed physical growth (38 percent), developmental delay (38 percent), and seizures",
            "probability": 0.08261596411466599
        },
        {
            "start_logit": 5.429831027984619,
            "end_logit": 6.122873306274414,
            "text": "delayed physical growth (38 percent), developmental delay (38 percent), and seizures",
            "probability": 0.07217893749475479
        },
        {
            "start_logit": 5.719684600830078,
            "end_logit": 5.563949108123779,
            "text": "ataxia (77 percent), Stage II coma (46 percent), delayed physical growth (38 percent), developmental delay",
            "probability": 0.05515120550990105
        },
        {
            "start_logit": 5.704807758331299,
            "end_logit": 5.563949108123779,
            "text": "developmental delay",
            "probability": 0.054336778819561005
        },
        {
            "start_logit": 5.563045024871826,
            "end_logit": 5.690432548522949,
            "text": "lethargy",
            "probability": 0.053512830287218094
        },
        {
            "start_logit": 5.564885139465332,
            "end_logit": 5.563949108123779,
            "text": "Stage II coma (46 percent), delayed physical growth (38 percent), developmental delay",
            "probability": 0.047241754829883575
        },
        {
            "start_logit": 5.719684600830078,
            "end_logit": 5.407860279083252,
            "text": "ataxia",
            "probability": 0.04718088358640671
        },
        {
            "start_logit": 5.719684600830078,
            "end_logit": 5.395792484283447,
            "text": "ataxia (77 percent), Stage II coma",
            "probability": 0.04661494120955467
        },
        {
            "start_logit": 5.429831027984619,
            "end_logit": 5.563949108123779,
            "text": "delayed physical growth (38 percent), developmental delay",
            "probability": 0.041273657232522964
        },
        {
            "start_logit": 5.563045024871826,
            "end_logit": 5.407860279083252,
            "text": "lethargy (100 percent), protein avoidance (92 percent), ataxia",
            "probability": 0.04034024477005005
        },
        {
            "start_logit": 5.564885139465332,
            "end_logit": 5.395792484283447,
            "text": "Stage II coma",
            "probability": 0.03992978110909462
        },
        {
            "start_logit": 5.563045024871826,
            "end_logit": 5.395792484283447,
            "text": "lethargy (100 percent), protein avoidance (92 percent), ataxia (77 percent), Stage II coma",
            "probability": 0.039856359362602234
        },
        {
            "start_logit": 5.563045024871826,
            "end_logit": 5.288993835449219,
            "text": "lethargy (100 percent), protein avoidance",
            "probability": 0.03581918776035309
        },
        {
            "start_logit": 5.719684600830078,
            "end_logit": 4.913492679595947,
            "text": "ataxia (77 percent), Stage II coma (46 percent), delayed physical growth",
            "probability": 0.028778288513422012
        },
        {
            "start_logit": 5.173257350921631,
            "end_logit": 5.407860279083252,
            "text": "protein avoidance (92 percent), ataxia",
            "probability": 0.0273184422403574
        },
        {
            "start_logit": 4.885368347167969,
            "end_logit": 5.690432548522949,
            "text": "episodic vomiting and lethargy",
            "probability": 0.027173584327101707
        },
        {
            "start_logit": 5.173257350921631,
            "end_logit": 5.395792484283447,
            "text": "protein avoidance (92 percent), ataxia (77 percent), Stage II coma",
            "probability": 0.026990750804543495
        },
        {
            "start_logit": 4.837304592132568,
            "end_logit": 5.690432548522949,
            "text": "extreme irritability (100 percent), episodic vomiting and lethargy",
            "probability": 0.025898396968841553
        }
    ],
    "63eef60ef36125a42600000c_0001": [
        {
            "start_logit": 7.357844352722168,
            "end_logit": 7.978761672973633,
            "text": "rheumatoid arthritis",
            "probability": 0.9998846054077148
        },
        {
            "start_logit": -2.369278907775879,
            "end_logit": 7.978761672973633,
            "text": "arthritis",
            "probability": 5.9636742662405595e-05
        },
        {
            "start_logit": 7.357844352722168,
            "end_logit": -3.5641982555389404,
            "text": "rheumatoid",
            "probability": 9.702998795546591e-06
        },
        {
            "start_logit": -4.234164237976074,
            "end_logit": 7.978761672973633,
            "text": "Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis",
            "probability": 9.238565326086245e-06
        },
        {
            "start_logit": -4.713639736175537,
            "end_logit": 7.978761672973633,
            "text": "in patients with rheumatoid arthritis",
            "probability": 5.7196730267605744e-06
        },
        {
            "start_logit": -4.86978816986084,
            "end_logit": 7.978761672973633,
            "text": "patients with rheumatoid arthritis",
            "probability": 4.892790002486436e-06
        },
        {
            "start_logit": -4.888526916503906,
            "end_logit": 7.978761672973633,
            "text": "interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis",
            "probability": 4.801958766620373e-06
        },
        {
            "start_logit": -5.0905256271362305,
            "end_logit": 7.978761672973633,
            "text": "with rheumatoid arthritis",
            "probability": 3.923661097360309e-06
        },
        {
            "start_logit": -5.323019981384277,
            "end_logit": 7.978761672973633,
            "text": "monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis",
            "probability": 3.1097140436031623e-06
        },
        {
            "start_logit": -5.476239204406738,
            "end_logit": 7.978761672973633,
            "text": "in combination with methotrexate in patients with rheumatoid arthritis",
            "probability": 2.667953367563314e-06
        },
        {
            "start_logit": -5.502389430999756,
            "end_logit": 7.978761672973633,
            "text": "methotrexate in patients with rheumatoid arthritis",
            "probability": 2.5990914309659274e-06
        },
        {
            "start_logit": 7.357844352722168,
            "end_logit": -5.057842254638672,
            "text": "rheumatoid arthritis inadequately controlled by methotrexate",
            "probability": 2.1788371213915525e-06
        },
        {
            "start_logit": -6.044757843017578,
            "end_logit": 7.978761672973633,
            "text": "combination with methotrexate in patients with rheumatoid arthritis",
            "probability": 1.5110322237887885e-06
        },
        {
            "start_logit": 7.357844352722168,
            "end_logit": -5.605384349822998,
            "text": "rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety",
            "probability": 1.2601726666616742e-06
        },
        {
            "start_logit": 7.357844352722168,
            "end_logit": -6.0795745849609375,
            "text": "rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III",
            "probability": 7.843177058930451e-07
        },
        {
            "start_logit": 7.357844352722168,
            "end_logit": -6.159402847290039,
            "text": "rheumatoid arthritis inadequately controlled by methotrexate: efficacy",
            "probability": 7.241408752634015e-07
        },
        {
            "start_logit": 7.357844352722168,
            "end_logit": -6.1931633949279785,
            "text": "rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study",
            "probability": 7.001018502705847e-07
        },
        {
            "start_logit": 7.357844352722168,
            "end_logit": -6.237978458404541,
            "text": "rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.",
            "probability": 6.694194212286675e-07
        },
        {
            "start_logit": 7.357844352722168,
            "end_logit": -6.354128360748291,
            "text": "rheumatoid arthritis inadequately controlled",
            "probability": 5.960120574854955e-07
        },
        {
            "start_logit": 7.357844352722168,
            "end_logit": -6.39127779006958,
            "text": "rheumatoid arthritis inadequately controlled by methotrexate:",
            "probability": 5.742767257288506e-07
        }
    ],
    "63eef60ef36125a42600000c_0002": [
        {
            "start_logit": 5.492736339569092,
            "end_logit": 7.874371528625488,
            "text": "rheumatoid arthritis",
            "probability": 0.9987152814865112
        },
        {
            "start_logit": -1.6855669021606445,
            "end_logit": 7.874371528625488,
            "text": "active rheumatoid arthritis",
            "probability": 0.0007619814714416862
        },
        {
            "start_logit": -2.5399444103240967,
            "end_logit": 7.874371528625488,
            "text": "arthritis",
            "probability": 0.0003242596285417676
        },
        {
            "start_logit": -4.25624942779541,
            "end_logit": 7.874371528625488,
            "text": "olokizumab (olokizumab) in patients with active rheumatoid arthritis",
            "probability": 5.8278877986595035e-05
        },
        {
            "start_logit": -4.736630916595459,
            "end_logit": 7.874371528625488,
            "text": "olokizumab) in patients with active rheumatoid arthritis",
            "probability": 3.604826270020567e-05
        },
        {
            "start_logit": -5.391076564788818,
            "end_logit": 7.874371528625488,
            "text": "patients with active rheumatoid arthritis",
            "probability": 1.8735367120825686e-05
        },
        {
            "start_logit": -5.696133136749268,
            "end_logit": 7.874371528625488,
            "text": "in patients with active rheumatoid arthritis",
            "probability": 1.3809482879878487e-05
        },
        {
            "start_logit": -5.702408790588379,
            "end_logit": 7.874371528625488,
            "text": "with active rheumatoid arthritis",
            "probability": 1.372309634461999e-05
        },
        {
            "start_logit": -5.843854904174805,
            "end_logit": 7.874371528625488,
            "text": "safety of olokizumab (olokizumab) in patients with active rheumatoid arthritis",
            "probability": 1.191304727399256e-05
        },
        {
            "start_logit": -5.884334564208984,
            "end_logit": 7.874371528625488,
            "text": "OBJECTIVE: To evaluate the efficacy and safety of olokizumab (olokizumab) in patients with active rheumatoid arthritis",
            "probability": 1.1440441085142083e-05
        },
        {
            "start_logit": -6.128050804138184,
            "end_logit": 7.874371528625488,
            "text": "efficacy and safety of olokizumab (olokizumab) in patients with active rheumatoid arthritis",
            "probability": 8.965988854470197e-06
        },
        {
            "start_logit": -6.15374755859375,
            "end_logit": 7.874371528625488,
            "text": "okizumab (olokizumab) in patients with active rheumatoid arthritis",
            "probability": 8.738526048546191e-06
        },
        {
            "start_logit": 5.492736339569092,
            "end_logit": -4.192441463470459,
            "text": "rheumatoid arthritis despite treatment with methotrexate",
            "probability": 5.7397314776608255e-06
        },
        {
            "start_logit": 5.492736339569092,
            "end_logit": -4.211131572723389,
            "text": "rheumatoid arthritis despite treatment with methotrexate (methotrexate",
            "probability": 5.633452019537799e-06
        },
        {
            "start_logit": 5.492736339569092,
            "end_logit": -4.974689483642578,
            "text": "rheumatoid arthritis despite treatment with methotrexate (methotrexate)",
            "probability": 2.6252207590005128e-06
        },
        {
            "start_logit": 5.492736339569092,
            "end_logit": -5.939411163330078,
            "text": "rheumatoid",
            "probability": 1.000443376142357e-06
        },
        {
            "start_logit": 5.492736339569092,
            "end_logit": -6.29139518737793,
            "text": "rheumatoid arthritis despite treatment with methotrexate (methotrexate).",
            "probability": 7.03603177498735e-07
        },
        {
            "start_logit": 5.492736339569092,
            "end_logit": -6.304598808288574,
            "text": "rheumatoid arthritis despite",
            "probability": 6.943733978914679e-07
        },
        {
            "start_logit": 5.492736339569092,
            "end_logit": -6.595422744750977,
            "text": "rheumatoid arthritis despite treatment",
            "probability": 5.191469654164393e-07
        },
        {
            "start_logit": -1.6855669021606445,
            "end_logit": -4.192441463470459,
            "text": "active rheumatoid arthritis despite treatment with methotrexate",
            "probability": 4.379195228665367e-09
        }
    ],
    "63eef60ef36125a42600000c_0003": [
        {
            "start_logit": 7.3989973068237305,
            "end_logit": 8.312315940856934,
            "text": "rheumatoid arthritis",
            "probability": 0.999825656414032
        },
        {
            "start_logit": -1.4892059564590454,
            "end_logit": 8.312315940856934,
            "text": "arthritis",
            "probability": 0.0001379834138788283
        },
        {
            "start_logit": 7.3989973068237305,
            "end_logit": -3.808407783508301,
            "text": "rheumatoid",
            "probability": 5.4445354180643335e-06
        },
        {
            "start_logit": -5.0124311447143555,
            "end_logit": 8.312315940856934,
            "text": "olokizumab was associated with significant improvement in signs, symptoms and physical function of rheumatoid arthritis",
            "probability": 4.071077910339227e-06
        },
        {
            "start_logit": -5.112789630889893,
            "end_logit": 8.312315940856934,
            "text": "physical function of rheumatoid arthritis",
            "probability": 3.682341230160091e-06
        },
        {
            "start_logit": -5.189318656921387,
            "end_logit": 8.312315940856934,
            "text": "CONCLUSIONS: Treatment with olokizumab was associated with significant improvement in signs, symptoms and physical function of rheumatoid arthritis",
            "probability": 3.4110501019313233e-06
        },
        {
            "start_logit": -5.333845615386963,
            "end_logit": 8.312315940856934,
            "text": "of rheumatoid arthritis",
            "probability": 2.952029035441228e-06
        },
        {
            "start_logit": -5.519524574279785,
            "end_logit": 8.312315940856934,
            "text": "improvement in signs, symptoms and physical function of rheumatoid arthritis",
            "probability": 2.45177989199874e-06
        },
        {
            "start_logit": -5.7658233642578125,
            "end_logit": 8.312315940856934,
            "text": "Treatment with olokizumab was associated with significant improvement in signs, symptoms and physical function of rheumatoid arthritis",
            "probability": 1.916528617584845e-06
        },
        {
            "start_logit": -5.9120025634765625,
            "end_logit": 8.312315940856934,
            "text": "significant improvement in signs, symptoms and physical function of rheumatoid arthritis",
            "probability": 1.6558860806981102e-06
        },
        {
            "start_logit": -5.968132972717285,
            "end_logit": 8.312315940856934,
            "text": "associated with significant improvement in signs, symptoms and physical function of rheumatoid arthritis",
            "probability": 1.5655010656701052e-06
        },
        {
            "start_logit": -6.02276611328125,
            "end_logit": 8.312315940856934,
            "text": "signs, symptoms and physical function of rheumatoid arthritis",
            "probability": 1.4822671801084653e-06
        },
        {
            "start_logit": -6.116626262664795,
            "end_logit": 8.312315940856934,
            "text": "function of rheumatoid arthritis",
            "probability": 1.3494715176420868e-06
        },
        {
            "start_logit": -6.122875213623047,
            "end_logit": 8.312315940856934,
            "text": "okizumab was associated with significant improvement in signs, symptoms and physical function of rheumatoid arthritis",
            "probability": 1.341064489679411e-06
        },
        {
            "start_logit": 7.3989973068237305,
            "end_logit": -5.359833717346191,
            "text": "rheumatoid arthritis without discernible differences between the two regimens",
            "probability": 1.1539450497366488e-06
        },
        {
            "start_logit": -6.347079753875732,
            "end_logit": 8.312315940856934,
            "text": "symptoms and physical function of rheumatoid arthritis",
            "probability": 1.0717143368310644e-06
        },
        {
            "start_logit": 7.3989973068237305,
            "end_logit": -5.460752010345459,
            "text": "rheumatoid arthritis without discernible differences",
            "probability": 1.043174734149943e-06
        },
        {
            "start_logit": 7.3989973068237305,
            "end_logit": -5.704235553741455,
            "text": "rheumatoid arthritis without discernible differences between the two regimens.",
            "probability": 8.177359518413141e-07
        },
        {
            "start_logit": 7.3989973068237305,
            "end_logit": -6.008246898651123,
            "text": "rheumatoid arthritis without discernible differences between the two",
            "probability": 6.033690738149744e-07
        },
        {
            "start_logit": 7.3989973068237305,
            "end_logit": -6.425277233123779,
            "text": "rheumatoid arthritis without",
            "probability": 3.97620766534601e-07
        }
    ],
    "63eef60ef36125a42600000c_0004": [
        {
            "start_logit": 6.788809299468994,
            "end_logit": 7.542241096496582,
            "text": "Rheumatoid Arthritis",
            "probability": 0.9999097585678101
        },
        {
            "start_logit": -2.9625420570373535,
            "end_logit": 7.542241096496582,
            "text": "Arthritis",
            "probability": 5.82106331421528e-05
        },
        {
            "start_logit": -4.807462215423584,
            "end_logit": 7.542241096496582,
            "text": "in Rheumatoid Arthritis",
            "probability": 9.199497071676888e-06
        },
        {
            "start_logit": 6.788809299468994,
            "end_logit": -4.4245500564575195,
            "text": "Rheumatoid",
            "probability": 6.3511070038657635e-06
        },
        {
            "start_logit": -5.328896999359131,
            "end_logit": 7.542241096496582,
            "text": "Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis",
            "probability": 5.461448381538503e-06
        },
        {
            "start_logit": -5.85630464553833,
            "end_logit": 7.542241096496582,
            "text": "Adalimumab in Rheumatoid Arthritis",
            "probability": 3.2229768294200767e-06
        },
        {
            "start_logit": 6.788809299468994,
            "end_logit": -5.275150775909424,
            "text": "Rheumatoid Arthritis.",
            "probability": 2.7129265163239324e-06
        },
        {
            "start_logit": -6.515522480010986,
            "end_logit": 7.542241096496582,
            "text": "Placebo or Adalimumab in Rheumatoid Arthritis",
            "probability": 1.6671034472892643e-06
        },
        {
            "start_logit": -6.674054145812988,
            "end_logit": 7.542241096496582,
            "text": "versus Placebo or Adalimumab in Rheumatoid Arthritis",
            "probability": 1.4227000519895228e-06
        },
        {
            "start_logit": -6.958163261413574,
            "end_logit": 7.542241096496582,
            "text": "okizumab versus Placebo or Adalimumab in Rheumatoid Arthritis",
            "probability": 1.0708440640883055e-06
        },
        {
            "start_logit": -7.155211448669434,
            "end_logit": 7.542241096496582,
            "text": "or Adalimumab in Rheumatoid Arthritis",
            "probability": 8.793248298388789e-07
        },
        {
            "start_logit": -2.9625420570373535,
            "end_logit": -5.275150775909424,
            "text": "Arthritis.",
            "probability": 1.579354147462908e-10
        },
        {
            "start_logit": -4.807462215423584,
            "end_logit": -4.4245500564575195,
            "text": "in Rheumatoid",
            "probability": 5.843226597024298e-11
        },
        {
            "start_logit": -5.328896999359131,
            "end_logit": -4.4245500564575195,
            "text": "Olokizumab versus Placebo or Adalimumab in Rheumatoid",
            "probability": 3.4689376371410674e-11
        },
        {
            "start_logit": -4.807462215423584,
            "end_logit": -5.275150775909424,
            "text": "in Rheumatoid Arthritis.",
            "probability": 2.4959811995017844e-11
        },
        {
            "start_logit": -5.85630464553833,
            "end_logit": -4.4245500564575195,
            "text": "Adalimumab in Rheumatoid",
            "probability": 2.0471319084336415e-11
        },
        {
            "start_logit": -5.328896999359131,
            "end_logit": -5.275150775909424,
            "text": "Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.",
            "probability": 1.4817844867787144e-11
        },
        {
            "start_logit": -6.515522480010986,
            "end_logit": -4.4245500564575195,
            "text": "Placebo or Adalimumab in Rheumatoid",
            "probability": 1.058890735511353e-11
        },
        {
            "start_logit": -5.328896999359131,
            "end_logit": -5.666204929351807,
            "text": "Olokizumab versus Placebo or Adalimumab",
            "probability": 1.0021953752992196e-11
        },
        {
            "start_logit": -6.674054145812988,
            "end_logit": -4.4245500564575195,
            "text": "versus Placebo or Adalimumab in Rheumatoid",
            "probability": 9.036535408846191e-12
        }
    ],
    "63eef60ef36125a42600000c_0005": [
        {
            "start_logit": 7.226531028747559,
            "end_logit": 7.937229156494141,
            "text": "rheumatoid arthritis",
            "probability": 0.9993731379508972
        },
        {
            "start_logit": -0.9888260960578918,
            "end_logit": 7.937229156494141,
            "text": "interleukin-6 is involved in the pathogenesis of rheumatoid arthritis",
            "probability": 0.0002702984493225813
        },
        {
            "start_logit": 7.226531028747559,
            "end_logit": -0.38003456592559814,
            "text": "rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis",
            "probability": 0.00024411022604908794
        },
        {
            "start_logit": -2.2521159648895264,
            "end_logit": 7.937229156494141,
            "text": "arthritis",
            "probability": 7.64193682698533e-05
        },
        {
            "start_logit": 7.226531028747559,
            "end_logit": -3.5074477195739746,
            "text": "rheumatoid",
            "probability": 1.0699596714403015e-05
        },
        {
            "start_logit": 7.226531028747559,
            "end_logit": -4.22841739654541,
            "text": "rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6",
            "probability": 5.203008186072111e-06
        },
        {
            "start_logit": -5.03355598449707,
            "end_logit": 7.937229156494141,
            "text": "BACKGROUND: The cytokine interleukin-6 is involved in the pathogenesis of rheumatoid arthritis",
            "probability": 4.734123194793938e-06
        },
        {
            "start_logit": -5.612316131591797,
            "end_logit": 7.937229156494141,
            "text": "of rheumatoid arthritis",
            "probability": 2.653915998962475e-06
        },
        {
            "start_logit": -5.814232349395752,
            "end_logit": 7.937229156494141,
            "text": "pathogenesis of rheumatoid arthritis",
            "probability": 2.168682158298907e-06
        },
        {
            "start_logit": 7.226531028747559,
            "end_logit": -5.251015663146973,
            "text": "rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid",
            "probability": 1.8713099052547477e-06
        },
        {
            "start_logit": 7.226531028747559,
            "end_logit": -5.257946968078613,
            "text": "rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly",
            "probability": 1.8583840528663131e-06
        },
        {
            "start_logit": -6.152904510498047,
            "end_logit": 7.937229156494141,
            "text": "The cytokine interleukin-6 is involved in the pathogenesis of rheumatoid arthritis",
            "probability": 1.5456553228432313e-06
        },
        {
            "start_logit": 7.226531028747559,
            "end_logit": -5.505681991577148,
            "text": "rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis.",
            "probability": 1.450592776564008e-06
        },
        {
            "start_logit": 7.226531028747559,
            "end_logit": -5.825716495513916,
            "text": "rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine",
            "probability": 1.0533107115406892e-06
        },
        {
            "start_logit": 7.226531028747559,
            "end_logit": -6.053282260894775,
            "text": "rheumatoid arthritis. Olokizumab, a humanized",
            "probability": 8.389303616240795e-07
        },
        {
            "start_logit": 7.226531028747559,
            "end_logit": -6.263430118560791,
            "text": "rheumatoid arthritis. Olokizumab",
            "probability": 6.799232892262808e-07
        },
        {
            "start_logit": 7.226531028747559,
            "end_logit": -6.3975300788879395,
            "text": "rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly,",
            "probability": 5.945947236796201e-07
        },
        {
            "start_logit": 7.226531028747559,
            "end_logit": -6.424342155456543,
            "text": "rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested",
            "probability": 5.788639327874989e-07
        },
        {
            "start_logit": -0.7624478340148926,
            "end_logit": -0.38003456592559814,
            "text": "rheumatoid arthritis",
            "probability": 8.27974133699172e-08
        },
        {
            "start_logit": -2.2521159648895264,
            "end_logit": -0.38003456592559814,
            "text": "arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis",
            "probability": 1.866647103554442e-08
        }
    ],
    "63eef60ef36125a42600000c_0006": [
        {
            "start_logit": 6.9886908531188965,
            "end_logit": 7.886953353881836,
            "text": "rheumatoid arthritis",
            "probability": 0.9998494386672974
        },
        {
            "start_logit": -2.048236846923828,
            "end_logit": 7.886953353881836,
            "text": "arthritis",
            "probability": 0.00011891772010130808
        },
        {
            "start_logit": 6.9886908531188965,
            "end_logit": -4.004924297332764,
            "text": "rheumatoid",
            "probability": 6.844749805168249e-06
        },
        {
            "start_logit": 6.9886908531188965,
            "end_logit": -4.174307823181152,
            "text": "rheumatoid arthritis who were receiving maintenance methotrexate",
            "probability": 5.778232662123628e-06
        },
        {
            "start_logit": -5.284430503845215,
            "end_logit": 7.886953353881836,
            "text": "In patients with rheumatoid arthritis",
            "probability": 4.675041964219417e-06
        },
        {
            "start_logit": -5.5415520668029785,
            "end_logit": 7.886953353881836,
            "text": "patients with rheumatoid arthritis",
            "probability": 3.6150911455479218e-06
        },
        {
            "start_logit": -5.549820423126221,
            "end_logit": 7.886953353881836,
            "text": "with rheumatoid arthritis",
            "probability": 3.5853236113325693e-06
        },
        {
            "start_logit": -6.015888214111328,
            "end_logit": 7.886953353881836,
            "text": "CONCLUSIONS: In patients with rheumatoid arthritis",
            "probability": 2.2496631117974175e-06
        },
        {
            "start_logit": 6.9886908531188965,
            "end_logit": -5.537440776824951,
            "text": "rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo and noninferior to adalimumab",
            "probability": 1.478407284594141e-06
        },
        {
            "start_logit": 6.9886908531188965,
            "end_logit": -5.868951320648193,
            "text": "rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo and noninferior to adalimumab in producing an ACR20 response at 12 weeks",
            "probability": 1.061257876244781e-06
        },
        {
            "start_logit": 6.9886908531188965,
            "end_logit": -6.457674026489258,
            "text": "rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo",
            "probability": 5.890364036531537e-07
        },
        {
            "start_logit": 6.9886908531188965,
            "end_logit": -6.507157325744629,
            "text": "rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo and noninferior to adalimumab in producing an ACR20 response",
            "probability": 5.605977548839292e-07
        },
        {
            "start_logit": 6.9886908531188965,
            "end_logit": -6.544519424438477,
            "text": "rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo and noninferior to adalimumab in producing an ACR20 response at 12",
            "probability": 5.400395934884727e-07
        },
        {
            "start_logit": 6.9886908531188965,
            "end_logit": -6.555713176727295,
            "text": "rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo and noninferior to adalimumab in producing an ACR20",
            "probability": 5.340280608834291e-07
        },
        {
            "start_logit": -2.095207691192627,
            "end_logit": -1.5093185901641846,
            "text": "rheumatoid arthritis",
            "probability": 9.421027513667468e-09
        },
        {
            "start_logit": -2.048236846923828,
            "end_logit": -4.174307823181152,
            "text": "arthritis who were receiving maintenance methotrexate",
            "probability": 6.872376556721349e-10
        },
        {
            "start_logit": -5.5928730964660645,
            "end_logit": -1.5093185901641846,
            "text": "olokizumab in patients with rheumatoid arthritis",
            "probability": 2.851553160265752e-10
        },
        {
            "start_logit": -5.644885063171387,
            "end_logit": -1.5093185901641846,
            "text": "Larger and longer trials are required to determine the efficacy and safety of olokizumab in patients with rheumatoid arthritis",
            "probability": 2.7070304331466843e-10
        },
        {
            "start_logit": -5.972549915313721,
            "end_logit": -1.5093185901641846,
            "text": "arthritis",
            "probability": 1.950697381403188e-10
        },
        {
            "start_logit": -2.048236846923828,
            "end_logit": -5.537440776824951,
            "text": "arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo and noninferior to adalimumab",
            "probability": 1.7583529077214166e-10
        }
    ],
    "63f03fc8f36125a426000021_0001": [
        {
            "start_logit": 8.114579200744629,
            "end_logit": 8.0889253616333,
            "text": "human immunodeficiency virus",
            "probability": 0.9998577833175659
        },
        {
            "start_logit": 8.114579200744629,
            "end_logit": -2.086320400238037,
            "text": "human immunodeficiency virus type 1",
            "probability": 3.809652480413206e-05
        },
        {
            "start_logit": -2.196413993835449,
            "end_logit": 8.0889253616333,
            "text": "virus",
            "probability": 3.326065416331403e-05
        },
        {
            "start_logit": 8.114579200744629,
            "end_logit": -2.3432998657226562,
            "text": "human",
            "probability": 2.94632300210651e-05
        },
        {
            "start_logit": -2.841214179992676,
            "end_logit": 8.0889253616333,
            "text": "immunodeficiency virus",
            "probability": 1.745410554576665e-05
        },
        {
            "start_logit": 8.114579200744629,
            "end_logit": -3.051830530166626,
            "text": "human immunodeficiency",
            "probability": 1.4506730622088071e-05
        },
        {
            "start_logit": -5.5062971115112305,
            "end_logit": 8.0889253616333,
            "text": "Viral Resistance to human immunodeficiency virus",
            "probability": 1.2146938388468698e-06
        },
        {
            "start_logit": -5.5279388427734375,
            "end_logit": 8.0889253616333,
            "text": "Mechanistic Bases of Viral Resistance to human immunodeficiency virus",
            "probability": 1.1886880884048878e-06
        },
        {
            "start_logit": 8.114579200744629,
            "end_logit": -5.568808078765869,
            "text": "human immunodeficiency virus type 1 Capsid Inhibitor Lenacapavir",
            "probability": 1.1707380735970219e-06
        },
        {
            "start_logit": -5.619987964630127,
            "end_logit": 8.0889253616333,
            "text": "Structural and Mechanistic Bases of Viral Resistance to human immunodeficiency virus",
            "probability": 1.0841548601092654e-06
        },
        {
            "start_logit": 8.114579200744629,
            "end_logit": -5.871783256530762,
            "text": "human immunodeficiency virus type 1 Capsid",
            "probability": 8.64728008309612e-07
        },
        {
            "start_logit": 8.114579200744629,
            "end_logit": -5.989810466766357,
            "text": "human immunodeficiency virus type 1 Capsid Inhibitor Lenacapavir.",
            "probability": 7.684598131163511e-07
        },
        {
            "start_logit": 8.114579200744629,
            "end_logit": -6.040605068206787,
            "text": "human immunodeficiency virus type 1 Capsid Inhibitor",
            "probability": 7.304010409825423e-07
        },
        {
            "start_logit": -6.32319974899292,
            "end_logit": 8.0889253616333,
            "text": "of Viral Resistance to human immunodeficiency virus",
            "probability": 5.366494519876142e-07
        },
        {
            "start_logit": -6.404810905456543,
            "end_logit": 8.0889253616333,
            "text": "Resistance to human immunodeficiency virus",
            "probability": 4.945921432408795e-07
        },
        {
            "start_logit": -6.44746732711792,
            "end_logit": 8.0889253616333,
            "text": "Bases of Viral Resistance to human immunodeficiency virus",
            "probability": 4.739385417451558e-07
        },
        {
            "start_logit": -6.531774520874023,
            "end_logit": 8.0889253616333,
            "text": "to human immunodeficiency virus",
            "probability": 4.356198246568965e-07
        },
        {
            "start_logit": 8.114579200744629,
            "end_logit": -6.6272172927856445,
            "text": "human immunodeficiency virus type",
            "probability": 4.0625494079904456e-07
        },
        {
            "start_logit": -2.196413993835449,
            "end_logit": -2.086320400238037,
            "text": "virus type 1",
            "probability": 1.2672956017922843e-09
        },
        {
            "start_logit": -2.841214179992676,
            "end_logit": -2.086320400238037,
            "text": "immunodeficiency virus type 1",
            "probability": 6.650353601145298e-10
        }
    ],
    "63f03fc8f36125a426000021_0002": [
        {
            "start_logit": 7.141928195953369,
            "end_logit": 7.429567337036133,
            "text": "human immunodeficiency virus",
            "probability": 0.999638557434082
        },
        {
            "start_logit": 7.141928195953369,
            "end_logit": -1.032059907913208,
            "text": "human immunodeficiency virus type 1",
            "probability": 0.0002113513764925301
        },
        {
            "start_logit": -3.084157943725586,
            "end_logit": 7.429567337036133,
            "text": "immunodeficiency virus",
            "probability": 3.620015559135936e-05
        },
        {
            "start_logit": -3.3152785301208496,
            "end_logit": 7.429567337036133,
            "text": "virus",
            "probability": 2.8730011763400398e-05
        },
        {
            "start_logit": 7.141928195953369,
            "end_logit": -3.721696376800537,
            "text": "human",
            "probability": 1.4351950085256249e-05
        },
        {
            "start_logit": 7.141928195953369,
            "end_logit": -3.7412116527557373,
            "text": "human immunodeficiency virus type 1 capsid",
            "probability": 1.4074586033530068e-05
        },
        {
            "start_logit": 7.141928195953369,
            "end_logit": -3.9429543018341064,
            "text": "human immunodeficiency",
            "probability": 1.1503226232889574e-05
        },
        {
            "start_logit": 7.141928195953369,
            "end_logit": -3.967284679412842,
            "text": "human immunodeficiency virus type 1 capsid (capsid",
            "probability": 1.1226728929614183e-05
        },
        {
            "start_logit": -4.572395324707031,
            "end_logit": 7.429567337036133,
            "text": "Lenacapavir (Lenacapavir) is a long-acting, highly potent human immunodeficiency virus",
            "probability": 8.172918569471221e-06
        },
        {
            "start_logit": -5.065580368041992,
            "end_logit": 7.429567337036133,
            "text": "Lenacapavir) is a long-acting, highly potent human immunodeficiency virus",
            "probability": 4.991023615730228e-06
        },
        {
            "start_logit": 7.141928195953369,
            "end_logit": -4.981443881988525,
            "text": "human immunodeficiency virus type 1 capsid (capsid)",
            "probability": 4.072016508871457e-06
        },
        {
            "start_logit": -5.368838310241699,
            "end_logit": 7.429567337036133,
            "text": "long-acting, highly potent human immunodeficiency virus",
            "probability": 3.6854148675047327e-06
        },
        {
            "start_logit": -5.77507209777832,
            "end_logit": 7.429567337036133,
            "text": "highly potent human immunodeficiency virus",
            "probability": 2.4550549824198242e-06
        },
        {
            "start_logit": 7.141928195953369,
            "end_logit": -5.771522521972656,
            "text": "human immunodeficiency virus type 1 capsid (capsid) inhibitor.",
            "probability": 1.8479172467777971e-06
        },
        {
            "start_logit": -6.159390449523926,
            "end_logit": 7.429567337036133,
            "text": "potent human immunodeficiency virus",
            "probability": 1.6716829804863664e-06
        },
        {
            "start_logit": 7.141928195953369,
            "end_logit": -5.92064094543457,
            "text": "human immunodeficiency virus type 1 capsid (capsid) inhibitor",
            "probability": 1.5919199540803675e-06
        },
        {
            "start_logit": -6.278335094451904,
            "end_logit": 7.429567337036133,
            "text": "acapavir (Lenacapavir) is a long-acting, highly potent human immunodeficiency virus",
            "probability": 1.4842146356386365e-06
        },
        {
            "start_logit": -6.3335490226745605,
            "end_logit": 7.429567337036133,
            "text": "acting, highly potent human immunodeficiency virus",
            "probability": 1.404486511091818e-06
        },
        {
            "start_logit": -6.364875316619873,
            "end_logit": 7.429567337036133,
            "text": "vir) is a long-acting, highly potent human immunodeficiency virus",
            "probability": 1.3611712574856938e-06
        },
        {
            "start_logit": 7.141928195953369,
            "end_logit": -6.110726356506348,
            "text": "human immunodeficiency virus type",
            "probability": 1.3163415815142798e-06
        }
    ],
    "63f03fc8f36125a426000021_0003": [
        {
            "start_logit": 6.670097351074219,
            "end_logit": 6.647632598876953,
            "text": "human immunodeficiency virus",
            "probability": 0.5228583216667175
        },
        {
            "start_logit": 6.670097351074219,
            "end_logit": 6.555510997772217,
            "text": "human immunodeficiency virus type 1",
            "probability": 0.47684404253959656
        },
        {
            "start_logit": 6.670097351074219,
            "end_logit": -2.257695198059082,
            "text": "human immunodeficiency virus type",
            "probability": 7.093315798556432e-05
        },
        {
            "start_logit": -2.6794955730438232,
            "end_logit": 6.647632598876953,
            "text": "immunodeficiency virus",
            "probability": 4.5489090553019196e-05
        },
        {
            "start_logit": -2.6794955730438232,
            "end_logit": 6.555510997772217,
            "text": "immunodeficiency virus type 1",
            "probability": 4.148581137997098e-05
        },
        {
            "start_logit": 6.670097351074219,
            "end_logit": -3.4279541969299316,
            "text": "human",
            "probability": 2.2009617168805562e-05
        },
        {
            "start_logit": -3.693284511566162,
            "end_logit": 6.647632598876953,
            "text": "virus",
            "probability": 1.6505331586813554e-05
        },
        {
            "start_logit": -3.694596767425537,
            "end_logit": 6.647632598876953,
            "text": "lenacapavir accesses unoccupied hydrophobic pockets in the complex to potently impair human immunodeficiency virus",
            "probability": 1.648368561291136e-05
        },
        {
            "start_logit": -3.693284511566162,
            "end_logit": 6.555510997772217,
            "text": "virus type 1",
            "probability": 1.5052774870127905e-05
        },
        {
            "start_logit": -3.694596767425537,
            "end_logit": 6.555510997772217,
            "text": "lenacapavir accesses unoccupied hydrophobic pockets in the complex to potently impair human immunodeficiency virus type 1",
            "probability": 1.5033034287625924e-05
        },
        {
            "start_logit": 6.670097351074219,
            "end_logit": -3.867405891418457,
            "text": "human immunodeficiency",
            "probability": 1.418276133335894e-05
        },
        {
            "start_logit": -4.569437026977539,
            "end_logit": 6.555510997772217,
            "text": "1",
            "probability": 6.2677045207237825e-06
        },
        {
            "start_logit": -4.832426071166992,
            "end_logit": 6.647632598876953,
            "text": "impair human immunodeficiency virus",
            "probability": 5.283255177346291e-06
        },
        {
            "start_logit": -4.832426071166992,
            "end_logit": 6.555510997772217,
            "text": "impair human immunodeficiency virus type 1",
            "probability": 4.818300567421829e-06
        },
        {
            "start_logit": -4.926342010498047,
            "end_logit": 6.647632598876953,
            "text": "The investigational drug lenacapavir accesses unoccupied hydrophobic pockets in the complex to potently impair human immunodeficiency virus",
            "probability": 4.809659913007636e-06
        },
        {
            "start_logit": -4.926342010498047,
            "end_logit": 6.555510997772217,
            "text": "The investigational drug lenacapavir accesses unoccupied hydrophobic pockets in the complex to potently impair human immunodeficiency virus type 1",
            "probability": 4.386384262033971e-06
        },
        {
            "start_logit": -5.160640239715576,
            "end_logit": 6.647632598876953,
            "text": "investigational drug lenacapavir accesses unoccupied hydrophobic pockets in the complex to potently impair human immunodeficiency virus",
            "probability": 3.805044343607733e-06
        },
        {
            "start_logit": -5.1679277420043945,
            "end_logit": 6.647632598876953,
            "text": "unoccupied hydrophobic pockets in the complex to potently impair human immunodeficiency virus",
            "probability": 3.7774179872940294e-06
        },
        {
            "start_logit": 6.670097351074219,
            "end_logit": -5.211967945098877,
            "text": "human immunodeficiency virus type 1 inside the nucleus without displacing the tightly bound cellular cofactor",
            "probability": 3.696793100971263e-06
        },
        {
            "start_logit": 6.670097351074219,
            "end_logit": -5.246570587158203,
            "text": "human immunodeficiency virus type 1 inside the nucleus",
            "probability": 3.5710604606720153e-06
        }
    ],
    "63f03fc8f36125a426000021_0004": [
        {
            "start_logit": 6.046738624572754,
            "end_logit": 6.642157077789307,
            "text": "human immunodeficiency virus",
            "probability": 0.9313473105430603
        },
        {
            "start_logit": 6.046738624572754,
            "end_logit": 4.01303768157959,
            "text": "human immunodeficiency virus type\u00a01",
            "probability": 0.06718919426202774
        },
        {
            "start_logit": 6.046738624572754,
            "end_logit": -0.9442384839057922,
            "text": "human immunodeficiency virus type\u00a01 (human immunodeficiency virus type 1",
            "probability": 0.00047247804468497634
        },
        {
            "start_logit": 6.046738624572754,
            "end_logit": -1.3816585540771484,
            "text": "human immunodeficiency virus type\u00a01 (human immunodeficiency virus",
            "probability": 0.00030507921474054456
        },
        {
            "start_logit": -2.2599096298217773,
            "end_logit": 6.642157077789307,
            "text": "Sunlenca\u00ae) is a long-acting capsid inhibitor of human immunodeficiency virus",
            "probability": 0.00022992180311121047
        },
        {
            "start_logit": 6.046738624572754,
            "end_logit": -2.7919278144836426,
            "text": "human immunodeficiency",
            "probability": 7.446295057889074e-05
        },
        {
            "start_logit": -3.3962059020996094,
            "end_logit": 6.642157077789307,
            "text": "immunodeficiency virus",
            "probability": 7.38061498850584e-05
        },
        {
            "start_logit": -3.6798596382141113,
            "end_logit": 6.642157077789307,
            "text": "Lenacapavir (Sunlenca\u00ae) is a long-acting capsid inhibitor of human immunodeficiency virus",
            "probability": 5.5578071624040604e-05
        },
        {
            "start_logit": -3.978353261947632,
            "end_logit": 6.642157077789307,
            "text": "virus",
            "probability": 4.12353256251663e-05
        },
        {
            "start_logit": 6.046738624572754,
            "end_logit": -3.386369228363037,
            "text": "human",
            "probability": 4.109396104468033e-05
        },
        {
            "start_logit": 6.046738624572754,
            "end_logit": -3.812889814376831,
            "text": "human immunodeficiency virus type\u00a01 (human immunodeficiency",
            "probability": 2.682515150809195e-05
        },
        {
            "start_logit": 6.046738624572754,
            "end_logit": -3.824397087097168,
            "text": "human immunodeficiency virus type\u00a01 (human",
            "probability": 2.6518244339968078e-05
        },
        {
            "start_logit": -4.479597091674805,
            "end_logit": 6.642157077789307,
            "text": "long-acting capsid inhibitor of human immunodeficiency virus",
            "probability": 2.4979384761536494e-05
        },
        {
            "start_logit": -2.2599096298217773,
            "end_logit": 4.01303768157959,
            "text": "Sunlenca\u00ae) is a long-acting capsid inhibitor of human immunodeficiency virus type\u00a01",
            "probability": 1.658700239204336e-05
        },
        {
            "start_logit": -4.8998236656188965,
            "end_logit": 6.642157077789307,
            "text": "lenca\u00ae) is a long-acting capsid inhibitor of human immunodeficiency virus",
            "probability": 1.6408914234489202e-05
        },
        {
            "start_logit": 6.046738624572754,
            "end_logit": -4.411787509918213,
            "text": "human immunodeficiency virus type\u00a01 (human immunodeficiency virus type",
            "probability": 1.4738188838236965e-05
        },
        {
            "start_logit": -5.020773887634277,
            "end_logit": 6.642157077789307,
            "text": "of human immunodeficiency virus",
            "probability": 1.4539586118189618e-05
        },
        {
            "start_logit": 6.046738624572754,
            "end_logit": -4.55169153213501,
            "text": "human immunodeficiency virus type\u00a01 (human immunodeficiency virus type 1)",
            "probability": 1.281399636354763e-05
        },
        {
            "start_logit": 6.046738624572754,
            "end_logit": -4.904475212097168,
            "text": "human immunodeficiency virus type",
            "probability": 9.0047724370379e-06
        },
        {
            "start_logit": -5.6902313232421875,
            "end_logit": 6.642157077789307,
            "text": "ca\u00ae) is a long-acting capsid inhibitor of human immunodeficiency virus",
            "probability": 7.4440622483962215e-06
        }
    ],
    "63f03fc8f36125a426000021_0005": [
        {
            "start_logit": 5.626216888427734,
            "end_logit": 4.678640842437744,
            "text": "HIV",
            "probability": 0.9333994388580322
        },
        {
            "start_logit": 5.626216888427734,
            "end_logit": 1.5974910259246826,
            "text": "HIV infection",
            "probability": 0.04284907504916191
        },
        {
            "start_logit": 4.1071953773498535,
            "end_logit": 2.0765883922576904,
            "text": "human immunodeficiency virus",
            "probability": 0.015146348625421524
        },
        {
            "start_logit": 4.1071953773498535,
            "end_logit": 1.4193731546401978,
            "text": "human immunodeficiency virus type 1 infection",
            "probability": 0.007850241847336292
        },
        {
            "start_logit": 4.1071953773498535,
            "end_logit": -1.6399204730987549,
            "text": "human immunodeficiency virus type 1",
            "probability": 0.00036833982449024916
        },
        {
            "start_logit": -3.9376344680786133,
            "end_logit": 4.678640842437744,
            "text": "antiretroviral(s) in adults with multi-drug resistant HIV",
            "probability": 6.554507126566023e-05
        },
        {
            "start_logit": 5.626216888427734,
            "end_logit": -4.973858833312988,
            "text": "HIV infection,",
            "probability": 5.998468623147346e-05
        },
        {
            "start_logit": -4.0684356689453125,
            "end_logit": 4.678640842437744,
            "text": "multi-drug resistant HIV",
            "probability": 5.750868149334565e-05
        },
        {
            "start_logit": 4.1071953773498535,
            "end_logit": -4.0234055519104,
            "text": "human",
            "probability": 3.3971471566474065e-05
        },
        {
            "start_logit": 5.626216888427734,
            "end_logit": -5.821690082550049,
            "text": "HIV infection, for whom it is otherwise not possible to construct a suppressive anti-viral regimen",
            "probability": 2.569402386143338e-05
        },
        {
            "start_logit": -4.887274265289307,
            "end_logit": 4.678640842437744,
            "text": "lenacapavir received its first approval in the EU for use in combination with other antiretroviral(s) in adults with multi-drug resistant HIV",
            "probability": 2.5358091079397127e-05
        },
        {
            "start_logit": -4.966757774353027,
            "end_logit": 4.678640842437744,
            "text": "resistant HIV",
            "probability": 2.3420570869348012e-05
        },
        {
            "start_logit": -5.071014404296875,
            "end_logit": 4.678640842437744,
            "text": "adults with multi-drug resistant HIV",
            "probability": 2.1101774109411053e-05
        },
        {
            "start_logit": 5.626216888427734,
            "end_logit": -6.036922454833984,
            "text": "HIV infection, for whom it is otherwise not possible to construct a suppressive anti-viral regimen.",
            "probability": 2.071847120532766e-05
        },
        {
            "start_logit": 4.1071953773498535,
            "end_logit": -4.615461349487305,
            "text": "human immunodeficiency virus type 1 infection.",
            "probability": 1.8792630726238713e-05
        },
        {
            "start_logit": 4.1071953773498535,
            "end_logit": -4.767577171325684,
            "text": "human immunodeficiency",
            "probability": 1.6140795196406543e-05
        },
        {
            "start_logit": -3.6931276321411133,
            "end_logit": 2.0765883922576904,
            "text": "immunodeficiency virus",
            "probability": 6.203986686159624e-06
        },
        {
            "start_logit": 4.1071953773498535,
            "end_logit": -5.754245281219482,
            "text": "human immunodeficiency virus type",
            "probability": 6.017556643200805e-06
        },
        {
            "start_logit": -3.6931276321411133,
            "end_logit": 1.4193731546401978,
            "text": "immunodeficiency virus type 1 infection",
            "probability": 3.215481228835415e-06
        },
        {
            "start_logit": -3.9376344680786133,
            "end_logit": 1.5974910259246826,
            "text": "antiretroviral(s) in adults with multi-drug resistant HIV infection",
            "probability": 3.0089404390309937e-06
        }
    ],
    "63f03fc8f36125a426000021_0006": [
        {
            "start_logit": 7.459623336791992,
            "end_logit": 7.810479164123535,
            "text": "human immunodeficiency virus",
            "probability": 0.999887228012085
        },
        {
            "start_logit": -2.993375062942505,
            "end_logit": 7.810479164123535,
            "text": "virus",
            "probability": 2.8858359655714594e-05
        },
        {
            "start_logit": -3.1869959831237793,
            "end_logit": 7.810479164123535,
            "text": "immunodeficiency virus",
            "probability": 2.3778409740771167e-05
        },
        {
            "start_logit": 7.459623336791992,
            "end_logit": -2.985095977783203,
            "text": "human immunodeficiency virus type 1",
            "probability": 2.0487657820922323e-05
        },
        {
            "start_logit": 7.459623336791992,
            "end_logit": -3.2498583793640137,
            "text": "human",
            "probability": 1.5721994714112952e-05
        },
        {
            "start_logit": 7.459623336791992,
            "end_logit": -3.863003730773926,
            "text": "human immunodeficiency",
            "probability": 8.51572895044228e-06
        },
        {
            "start_logit": -5.449888229370117,
            "end_logit": 7.810479164123535,
            "text": "Lenacapavir: a first-in-class human immunodeficiency virus",
            "probability": 2.474123675710871e-06
        },
        {
            "start_logit": -5.598954200744629,
            "end_logit": 7.810479164123535,
            "text": "first-in-class human immunodeficiency virus",
            "probability": 2.131487917722552e-06
        },
        {
            "start_logit": -5.729512691497803,
            "end_logit": 7.810479164123535,
            "text": "class human immunodeficiency virus",
            "probability": 1.8706039099924965e-06
        },
        {
            "start_logit": -5.836112022399902,
            "end_logit": 7.810479164123535,
            "text": "in-class human immunodeficiency virus",
            "probability": 1.6814599348435877e-06
        },
        {
            "start_logit": 7.459623336791992,
            "end_logit": -5.62628698348999,
            "text": "human immunodeficiency virus type 1 capsid",
            "probability": 1.460285716348153e-06
        },
        {
            "start_logit": 7.459623336791992,
            "end_logit": -5.7035088539123535,
            "text": "human immunodeficiency virus type 1 capsid inhibitor",
            "probability": 1.3517624211090151e-06
        },
        {
            "start_logit": 7.459623336791992,
            "end_logit": -5.839093208312988,
            "text": "human immunodeficiency virus type 1 capsid inhibitor.",
            "probability": 1.1803671213783673e-06
        },
        {
            "start_logit": -6.42558479309082,
            "end_logit": 7.810479164123535,
            "text": "acapavir: a first-in-class human immunodeficiency virus",
            "probability": 9.325706287199864e-07
        },
        {
            "start_logit": -6.72002649307251,
            "end_logit": 7.810479164123535,
            "text": "-in-class human immunodeficiency virus",
            "probability": 6.94716391080874e-07
        },
        {
            "start_logit": -6.790289878845215,
            "end_logit": 7.810479164123535,
            "text": "pavir: a first-in-class human immunodeficiency virus",
            "probability": 6.475784175563604e-07
        },
        {
            "start_logit": -6.857877731323242,
            "end_logit": 7.810479164123535,
            "text": "a first-in-class human immunodeficiency virus",
            "probability": 6.052563321645721e-07
        },
        {
            "start_logit": 7.459623336791992,
            "end_logit": -7.107160568237305,
            "text": "human immunodeficiency virus type",
            "probability": 3.3212563721463084e-07
        },
        {
            "start_logit": -2.993375062942505,
            "end_logit": -2.985095977783203,
            "text": "virus type 1",
            "probability": 5.913068923391052e-10
        },
        {
            "start_logit": -3.1869959831237793,
            "end_logit": -2.985095977783203,
            "text": "immunodeficiency virus type 1",
            "probability": 4.872193204441544e-10
        }
    ],
    "63f03fc8f36125a426000021_0007": [
        {
            "start_logit": 7.10076904296875,
            "end_logit": 7.1880035400390625,
            "text": "human immunodeficiency virus type 1",
            "probability": 0.6256930232048035
        },
        {
            "start_logit": 7.10076904296875,
            "end_logit": 6.600313186645508,
            "text": "human immunodeficiency virus",
            "probability": 0.3476406931877136
        },
        {
            "start_logit": 5.2269392013549805,
            "end_logit": 5.8882832527160645,
            "text": "HIV",
            "probability": 0.026188233867287636
        },
        {
            "start_logit": 7.10076904296875,
            "end_logit": -1.0976166725158691,
            "text": "human immunodeficiency virus type 1.",
            "probability": 0.00015774746134411544
        },
        {
            "start_logit": 7.10076904296875,
            "end_logit": -1.3183212280273438,
            "text": "human immunodeficiency virus type 1. In persons with human immunodeficiency virus type 1",
            "probability": 0.0001265060855075717
        },
        {
            "start_logit": 7.10076904296875,
            "end_logit": -2.4025518894195557,
            "text": "human immunodeficiency virus type 1. In persons with human immunodeficiency virus",
            "probability": 4.2779542127391323e-05
        },
        {
            "start_logit": 7.10076904296875,
            "end_logit": -2.7531418800354004,
            "text": "human",
            "probability": 3.0128458092804067e-05
        },
        {
            "start_logit": -2.8990325927734375,
            "end_logit": 7.1880035400390625,
            "text": "immunodeficiency virus type 1",
            "probability": 2.8412052415660582e-05
        },
        {
            "start_logit": -2.8990325927734375,
            "end_logit": 6.600313186645508,
            "text": "immunodeficiency virus",
            "probability": 1.5785995856276713e-05
        },
        {
            "start_logit": 7.10076904296875,
            "end_logit": -3.429501533508301,
            "text": "human immunodeficiency",
            "probability": 1.5319246813305654e-05
        },
        {
            "start_logit": -3.6806557178497314,
            "end_logit": 7.1880035400390625,
            "text": "1",
            "probability": 1.3003136700717732e-05
        },
        {
            "start_logit": -3.9451026916503906,
            "end_logit": 7.1880035400390625,
            "text": "virus type 1",
            "probability": 9.981600669561885e-06
        },
        {
            "start_logit": -4.222716331481934,
            "end_logit": 7.1880035400390625,
            "text": "in persons with human immunodeficiency virus type 1",
            "probability": 7.561954589618836e-06
        },
        {
            "start_logit": -3.9451026916503906,
            "end_logit": 6.600313186645508,
            "text": "virus",
            "probability": 5.545867225009715e-06
        },
        {
            "start_logit": -4.566475868225098,
            "end_logit": 7.1880035400390625,
            "text": "type 1",
            "probability": 5.3621779443346895e-06
        },
        {
            "start_logit": 7.10076904296875,
            "end_logit": -4.675695419311523,
            "text": "human immunodeficiency virus type 1. In persons with human",
            "probability": 4.405775143823121e-06
        },
        {
            "start_logit": -4.222716331481934,
            "end_logit": 6.600313186645508,
            "text": "in persons with human immunodeficiency virus",
            "probability": 4.201490810373798e-06
        },
        {
            "start_logit": -4.289217948913574,
            "end_logit": 6.600313186645508,
            "text": "Lenacapavir demonstrated picomolar potency in vitro with no cross resistance to existing antiretroviral classes and potent antiviral activity in persons with human immunodeficiency virus",
            "probability": 3.931173068849603e-06
        },
        {
            "start_logit": -4.8970160484313965,
            "end_logit": 7.1880035400390625,
            "text": "antiretroviral classes and potent antiviral activity in persons with human immunodeficiency virus type 1",
            "probability": 3.852912868751446e-06
        },
        {
            "start_logit": 7.10076904296875,
            "end_logit": -4.905470848083496,
            "text": "human immunodeficiency virus type 1. In persons with human immunodeficiency",
            "probability": 3.5013222259294707e-06
        }
    ],
    "63f03fc8f36125a426000021_0008": [
        {
            "start_logit": 4.503360748291016,
            "end_logit": 7.270047187805176,
            "text": "human immunodeficiency virus",
            "probability": 0.5642507076263428
        },
        {
            "start_logit": 4.137840270996094,
            "end_logit": 7.270047187805176,
            "text": "multidrug-resistant human immunodeficiency virus",
            "probability": 0.3914971649646759
        },
        {
            "start_logit": 4.503360748291016,
            "end_logit": 4.1388373374938965,
            "text": "human immunodeficiency virus type 1",
            "probability": 0.024637984111905098
        },
        {
            "start_logit": 4.137840270996094,
            "end_logit": 4.1388373374938965,
            "text": "multidrug-resistant human immunodeficiency virus type 1",
            "probability": 0.017094705253839493
        },
        {
            "start_logit": 4.503360748291016,
            "end_logit": 0.5409066081047058,
            "text": "human immunodeficiency virus type 1 and in treatment-naive persons with human immunodeficiency virus type 1",
            "probability": 0.0006745954742655158
        },
        {
            "start_logit": 4.137840270996094,
            "end_logit": 0.5409066081047058,
            "text": "multidrug-resistant human immunodeficiency virus type 1 and in treatment-naive persons with human immunodeficiency virus type 1",
            "probability": 0.0004680582496803254
        },
        {
            "start_logit": -2.808962821960449,
            "end_logit": 7.270047187805176,
            "text": "virus",
            "probability": 0.0003765046421904117
        },
        {
            "start_logit": 4.503360748291016,
            "end_logit": -0.5278756618499756,
            "text": "human immunodeficiency virus type 1 and in treatment-naive persons with human immunodeficiency virus",
            "probability": 0.00023167391191236675
        },
        {
            "start_logit": -3.340195655822754,
            "end_logit": 7.270047187805176,
            "text": "immunodeficiency virus",
            "probability": 0.00022133946185931563
        },
        {
            "start_logit": 4.137840270996094,
            "end_logit": -0.5278756618499756,
            "text": "multidrug-resistant human immunodeficiency virus type 1 and in treatment-naive persons with human immunodeficiency virus",
            "probability": 0.00016074356972239912
        },
        {
            "start_logit": -3.9221420288085938,
            "end_logit": 7.270047187805176,
            "text": "heavily treatment-experienced persons with multidrug-resistant human immunodeficiency virus",
            "probability": 0.0001236866373801604
        },
        {
            "start_logit": -4.375239849090576,
            "end_logit": 7.270047187805176,
            "text": "treatment-experienced persons with multidrug-resistant human immunodeficiency virus",
            "probability": 7.862210622988641e-05
        },
        {
            "start_logit": -4.439743518829346,
            "end_logit": 7.270047187805176,
            "text": "-resistant human immunodeficiency virus",
            "probability": 7.371085666818544e-05
        },
        {
            "start_logit": -5.337770462036133,
            "end_logit": 7.270047187805176,
            "text": "resistant human immunodeficiency virus",
            "probability": 3.0027773391338997e-05
        },
        {
            "start_logit": 1.3723396062850952,
            "end_logit": 0.5409066081047058,
            "text": "human immunodeficiency virus type 1",
            "probability": 2.9461732992785983e-05
        },
        {
            "start_logit": -2.808962821960449,
            "end_logit": 4.1388373374938965,
            "text": "virus type 1",
            "probability": 1.6440058971056715e-05
        },
        {
            "start_logit": 1.3723396062850952,
            "end_logit": -0.5278756618499756,
            "text": "human immunodeficiency virus",
            "probability": 1.0117942110809963e-05
        },
        {
            "start_logit": -3.340195655822754,
            "end_logit": 4.1388373374938965,
            "text": "immunodeficiency virus type 1",
            "probability": 9.664778190199286e-06
        },
        {
            "start_logit": 4.503360748291016,
            "end_logit": -3.807325601577759,
            "text": "human immunodeficiency",
            "probability": 8.722285201656632e-06
        },
        {
            "start_logit": 4.137840270996094,
            "end_logit": -3.807325601577759,
            "text": "multidrug-resistant human immunodeficiency",
            "probability": 6.051830951037118e-06
        }
    ],
    "64041701201352f04a000017_0001": [
        {
            "start_logit": 5.721937656402588,
            "end_logit": 5.5989766120910645,
            "text": "absent or defective abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchidism",
            "probability": 0.19140838086605072
        },
        {
            "start_logit": 5.721937656402588,
            "end_logit": 5.489774703979492,
            "text": "absent or defective abdominal wall muscles",
            "probability": 0.17160698771476746
        },
        {
            "start_logit": 5.588620185852051,
            "end_logit": 5.5989766120910645,
            "text": "bilateral cryptorchidism",
            "probability": 0.1675182431936264
        },
        {
            "start_logit": 5.721937656402588,
            "end_logit": 4.9961442947387695,
            "text": "absent or defective abdominal wall muscles, urinary tract abnormalities",
            "probability": 0.10475009679794312
        },
        {
            "start_logit": 5.113894462585449,
            "end_logit": 5.5989766120910645,
            "text": "urinary tract abnormalities, and bilateral cryptorchidism",
            "probability": 0.1042056754231453
        },
        {
            "start_logit": 4.876564979553223,
            "end_logit": 5.5989766120910645,
            "text": "defective abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchidism",
            "probability": 0.08219028264284134
        },
        {
            "start_logit": 4.876564979553223,
            "end_logit": 5.489774703979492,
            "text": "defective abdominal wall muscles",
            "probability": 0.0736876130104065
        },
        {
            "start_logit": 5.113894462585449,
            "end_logit": 4.9961442947387695,
            "text": "urinary tract abnormalities",
            "probability": 0.057027511298656464
        },
        {
            "start_logit": 4.876564979553223,
            "end_logit": 4.9961442947387695,
            "text": "defective abdominal wall muscles, urinary tract abnormalities",
            "probability": 0.044979386031627655
        },
        {
            "start_logit": 1.0919463634490967,
            "end_logit": 5.5989766120910645,
            "text": "cryptorchidism",
            "probability": 0.0018671584548428655
        },
        {
            "start_logit": 5.721937656402588,
            "end_logit": -1.7882367372512817,
            "text": "absent or defective abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchidism.",
            "probability": 0.00011850455484818667
        },
        {
            "start_logit": 5.721937656402588,
            "end_logit": -1.8976590633392334,
            "text": "absent or defective abdominal wall muscles, urinary tract",
            "probability": 0.00010622177796903998
        },
        {
            "start_logit": 5.588620185852051,
            "end_logit": -1.7882367372512817,
            "text": "bilateral cryptorchidism.",
            "probability": 0.00010371366079198197
        },
        {
            "start_logit": 5.721937656402588,
            "end_logit": -2.163872480392456,
            "text": "absent or defective abdominal wall muscles, urinary tract abnormalities, and bilateral",
            "probability": 8.139515557559207e-05
        },
        {
            "start_logit": 5.588620185852051,
            "end_logit": -2.163872480392456,
            "text": "bilateral",
            "probability": 7.123596151359379e-05
        },
        {
            "start_logit": 5.113894462585449,
            "end_logit": -1.7882367372512817,
            "text": "urinary tract abnormalities, and bilateral cryptorchidism.",
            "probability": 6.451566878240556e-05
        },
        {
            "start_logit": 5.113894462585449,
            "end_logit": -1.8976590633392334,
            "text": "urinary tract",
            "probability": 5.782871812698431e-05
        },
        {
            "start_logit": 5.721937656402588,
            "end_logit": -2.5595202445983887,
            "text": "absent or defective abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchid",
            "probability": 5.479876563185826e-05
        },
        {
            "start_logit": 4.876564979553223,
            "end_logit": -1.7882367372512817,
            "text": "defective abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchidism.",
            "probability": 5.088553371024318e-05
        },
        {
            "start_logit": 5.721937656402588,
            "end_logit": -2.6594438552856445,
            "text": "absent",
            "probability": 4.958773934049532e-05
        }
    ],
    "64041701201352f04a000017_0002": [
        {
            "start_logit": 4.857207298278809,
            "end_logit": 5.27227783203125,
            "text": "bilateral cryptorchidism",
            "probability": 0.24342495203018188
        },
        {
            "start_logit": 4.8178205490112305,
            "end_logit": 5.276878356933594,
            "text": "deficiency or absence of abdominal wall muscles",
            "probability": 0.23510271310806274
        },
        {
            "start_logit": 4.8178205490112305,
            "end_logit": 5.27227783203125,
            "text": "deficiency or absence of abdominal wall muscles, urological abnormalities, and bilateral cryptorchidism",
            "probability": 0.2340235859155655
        },
        {
            "start_logit": 4.8178205490112305,
            "end_logit": 3.995537519454956,
            "text": "deficiency or absence of abdominal wall muscles, urological abnormalities",
            "probability": 0.0652797520160675
        },
        {
            "start_logit": 3.4784626960754395,
            "end_logit": 5.276878356933594,
            "text": "absence of abdominal wall muscles",
            "probability": 0.06160013750195503
        },
        {
            "start_logit": 3.4784626960754395,
            "end_logit": 5.27227783203125,
            "text": "absence of abdominal wall muscles, urological abnormalities, and bilateral cryptorchidism",
            "probability": 0.06131740286946297
        },
        {
            "start_logit": 3.396022319793701,
            "end_logit": 5.27227783203125,
            "text": "urological abnormalities, and bilateral cryptorchidism",
            "probability": 0.056465182453393936
        },
        {
            "start_logit": 3.4784626960754395,
            "end_logit": 3.995537519454956,
            "text": "absence of abdominal wall muscles, urological abnormalities",
            "probability": 0.017104191705584526
        },
        {
            "start_logit": 3.396022319793701,
            "end_logit": 3.995537519454956,
            "text": "urological abnormalities",
            "probability": 0.01575067639350891
        },
        {
            "start_logit": 0.4697180390357971,
            "end_logit": 5.27227783203125,
            "text": "cryptorchidism",
            "probability": 0.0030262351501733065
        },
        {
            "start_logit": 4.857207298278809,
            "end_logit": 0.5439260005950928,
            "text": "bilateral cryptorchidism.",
            "probability": 0.0021521279122680426
        },
        {
            "start_logit": 4.8178205490112305,
            "end_logit": 0.5439260005950928,
            "text": "deficiency or absence of abdominal wall muscles, urological abnormalities, and bilateral cryptorchidism.",
            "probability": 0.002069010166451335
        },
        {
            "start_logit": 3.4784626960754395,
            "end_logit": 0.5439260005950928,
            "text": "absence of abdominal wall muscles, urological abnormalities, and bilateral cryptorchidism.",
            "probability": 0.0005421091336756945
        },
        {
            "start_logit": 3.396022319793701,
            "end_logit": 0.5439260005950928,
            "text": "urological abnormalities, and bilateral cryptorchidism.",
            "probability": 0.0004992100293748081
        },
        {
            "start_logit": -1.6851470470428467,
            "end_logit": 5.276878356933594,
            "text": "abdominal wall muscles",
            "probability": 0.0003524151397868991
        },
        {
            "start_logit": -1.6851470470428467,
            "end_logit": 5.27227783203125,
            "text": "abdominal wall muscles, urological abnormalities, and bilateral cryptorchidism",
            "probability": 0.00035079754889011383
        },
        {
            "start_logit": -1.8783352375030518,
            "end_logit": 5.27227783203125,
            "text": "abnormalities, and bilateral cryptorchidism",
            "probability": 0.000289172021439299
        },
        {
            "start_logit": 4.857207298278809,
            "end_logit": -1.6913905143737793,
            "text": "bilateral cryptorchid",
            "probability": 0.00023018782667350024
        },
        {
            "start_logit": 4.8178205490112305,
            "end_logit": -1.6913905143737793,
            "text": "deficiency or absence of abdominal wall muscles, urological abnormalities, and bilateral cryptorchid",
            "probability": 0.00022129771241452545
        },
        {
            "start_logit": 4.8178205490112305,
            "end_logit": -1.7982884645462036,
            "text": "deficiency",
            "probability": 0.00019886199152097106
        }
    ],
    "64041701201352f04a000017_0003": [
        {
            "start_logit": 5.794008255004883,
            "end_logit": 5.554656505584717,
            "text": "deficiency of the abdominal muscles, malformations of the urinary tract, and bilateral cryptorchidism",
            "probability": 0.21905797719955444
        },
        {
            "start_logit": 5.794008255004883,
            "end_logit": 5.4589715003967285,
            "text": "deficiency of the abdominal muscles",
            "probability": 0.1990688145160675
        },
        {
            "start_logit": 5.498800754547119,
            "end_logit": 5.554656505584717,
            "text": "bilateral cryptorchidism",
            "probability": 0.16306166350841522
        },
        {
            "start_logit": 5.497099876403809,
            "end_logit": 5.554656505584717,
            "text": "malformations of the urinary tract, and bilateral cryptorchidism",
            "probability": 0.16278447210788727
        },
        {
            "start_logit": 5.794008255004883,
            "end_logit": 5.145064353942871,
            "text": "deficiency of the abdominal muscles, malformations of the urinary tract",
            "probability": 0.1454371064901352
        },
        {
            "start_logit": 5.497099876403809,
            "end_logit": 5.145064353942871,
            "text": "malformations of the urinary tract",
            "probability": 0.1080760806798935
        },
        {
            "start_logit": 0.6704981923103333,
            "end_logit": 5.554656505584717,
            "text": "cryptorchidism",
            "probability": 0.0013045081868767738
        },
        {
            "start_logit": 5.794008255004883,
            "end_logit": -1.5965267419815063,
            "text": "deficiency of the abdominal muscles, malformations",
            "probability": 0.00017172735533677042
        },
        {
            "start_logit": 5.497099876403809,
            "end_logit": -1.5965267419815063,
            "text": "malformations",
            "probability": 0.00012761268590111285
        },
        {
            "start_logit": 5.794008255004883,
            "end_logit": -1.9533026218414307,
            "text": "deficiency of the abdominal muscles, malformations of the urinary tract, and bilateral",
            "probability": 0.00012019703717669472
        },
        {
            "start_logit": 5.794008255004883,
            "end_logit": -2.0163395404815674,
            "text": "deficiency",
            "probability": 0.00011285406071692705
        },
        {
            "start_logit": 5.794008255004883,
            "end_logit": -2.0374507904052734,
            "text": "deficiency of the abdominal muscles, malformations of the urinary tract, and bilateral cryptorchid",
            "probability": 0.00011049651948269457
        },
        {
            "start_logit": 5.498800754547119,
            "end_logit": -1.9533026218414307,
            "text": "bilateral",
            "probability": 8.947188325691968e-05
        },
        {
            "start_logit": 5.497099876403809,
            "end_logit": -1.9533026218414307,
            "text": "malformations of the urinary tract, and bilateral",
            "probability": 8.931986667448655e-05
        },
        {
            "start_logit": 5.498800754547119,
            "end_logit": -2.0374507904052734,
            "text": "bilateral cryptorchid",
            "probability": 8.225106284953654e-05
        },
        {
            "start_logit": 5.497099876403809,
            "end_logit": -2.0374507904052734,
            "text": "malformations of the urinary tract, and bilateral cryptorchid",
            "probability": 8.211129170376807e-05
        },
        {
            "start_logit": -2.188582420349121,
            "end_logit": 5.554656505584717,
            "text": "urinary tract, and bilateral cryptorchidism",
            "probability": 7.477627514163032e-05
        },
        {
            "start_logit": 5.794008255004883,
            "end_logit": -2.7049014568328857,
            "text": "deficiency of the abdominal muscles, malformations of the urinary tract, and bilateral cryptorchidism.",
            "probability": 5.6686330935917795e-05
        },
        {
            "start_logit": -2.188582420349121,
            "end_logit": 5.145064353942871,
            "text": "urinary tract",
            "probability": 4.964553227182478e-05
        },
        {
            "start_logit": 5.498800754547119,
            "end_logit": -2.7049014568328857,
            "text": "bilateral cryptorchidism.",
            "probability": 4.219602487864904e-05
        }
    ],
    "64041701201352f04a000017_0004": [
        {
            "start_logit": 5.5530595779418945,
            "end_logit": 5.408151626586914,
            "text": "cryptorchidism",
            "probability": 0.2336869239807129
        },
        {
            "start_logit": 4.822161674499512,
            "end_logit": 5.408151626586914,
            "text": "absence or hypoplasia of the abdominal wall musculature, urinary tract anomalies, and cryptorchidism",
            "probability": 0.11251476407051086
        },
        {
            "start_logit": 4.798432350158691,
            "end_logit": 5.408151626586914,
            "text": "hypoplasia of the abdominal wall musculature, urinary tract anomalies, and cryptorchidism",
            "probability": 0.10987627506256104
        },
        {
            "start_logit": 4.822161674499512,
            "end_logit": 5.246583938598633,
            "text": "absence or hypoplasia of the abdominal wall musculature, urinary tract anomalies",
            "probability": 0.0957285687327385
        },
        {
            "start_logit": 4.798432350158691,
            "end_logit": 5.246583938598633,
            "text": "hypoplasia of the abdominal wall musculature, urinary tract anomalies",
            "probability": 0.09348371624946594
        },
        {
            "start_logit": 4.822161674499512,
            "end_logit": 5.1390533447265625,
            "text": "absence or hypoplasia of the abdominal wall musculature",
            "probability": 0.08596893399953842
        },
        {
            "start_logit": 4.798432350158691,
            "end_logit": 5.1390533447265625,
            "text": "hypoplasia of the abdominal wall musculature",
            "probability": 0.08395297080278397
        },
        {
            "start_logit": 4.4644999504089355,
            "end_logit": 5.408151626586914,
            "text": "urinary tract anomalies, and cryptorchidism",
            "probability": 0.07868268340826035
        },
        {
            "start_logit": 4.4644999504089355,
            "end_logit": 5.246583938598633,
            "text": "urinary tract anomalies",
            "probability": 0.0669439285993576
        },
        {
            "start_logit": 5.5530595779418945,
            "end_logit": 2.6965599060058594,
            "text": "cryptorchidism in males",
            "probability": 0.015524053014814854
        },
        {
            "start_logit": 4.822161674499512,
            "end_logit": 2.6965599060058594,
            "text": "absence or hypoplasia of the abdominal wall musculature, urinary tract anomalies, and cryptorchidism in males",
            "probability": 0.007474465761333704
        },
        {
            "start_logit": 4.798432350158691,
            "end_logit": 2.6965599060058594,
            "text": "hypoplasia of the abdominal wall musculature, urinary tract anomalies, and cryptorchidism in males",
            "probability": 0.007299189455807209
        },
        {
            "start_logit": 4.4644999504089355,
            "end_logit": 2.6965599060058594,
            "text": "urinary tract anomalies, and cryptorchidism in males",
            "probability": 0.005226965062320232
        },
        {
            "start_logit": 5.5530595779418945,
            "end_logit": 0.05037142336368561,
            "text": "cryptorchidism in males.",
            "probability": 0.001100981724448502
        },
        {
            "start_logit": 4.822161674499512,
            "end_logit": 0.05037142336368561,
            "text": "absence or hypoplasia of the abdominal wall musculature, urinary tract anomalies, and cryptorchidism in males.",
            "probability": 0.0005300968186929822
        },
        {
            "start_logit": 4.798432350158691,
            "end_logit": 0.05037142336368561,
            "text": "hypoplasia of the abdominal wall musculature, urinary tract anomalies, and cryptorchidism in males.",
            "probability": 0.0005176659906283021
        },
        {
            "start_logit": 4.822161674499512,
            "end_logit": -0.16923511028289795,
            "text": "absence or hypoplasia",
            "probability": 0.000425579899456352
        },
        {
            "start_logit": 4.798432350158691,
            "end_logit": -0.16923511028289795,
            "text": "hypoplasia",
            "probability": 0.0004156000795774162
        },
        {
            "start_logit": 4.4644999504089355,
            "end_logit": 0.05037142336368561,
            "text": "urinary tract anomalies, and cryptorchidism in males.",
            "probability": 0.00037070177495479584
        },
        {
            "start_logit": 4.822161674499512,
            "end_logit": -0.6024538278579712,
            "text": "absence",
            "probability": 0.00027595405117608607
        }
    ],
    "640c85e9201352f04a000026_0001": [
        {
            "start_logit": 0.6656512022018433,
            "end_logit": -0.8523455858230591,
            "text": "Mantle cell lymphoma",
            "probability": 0.4411184787750244
        },
        {
            "start_logit": 0.6656512022018433,
            "end_logit": -1.529951572418213,
            "text": "Mantle cell",
            "probability": 0.22401376068592072
        },
        {
            "start_logit": 0.6656512022018433,
            "end_logit": -2.7523884773254395,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma",
            "probability": 0.065974660217762
        },
        {
            "start_logit": 0.6656512022018433,
            "end_logit": -2.8469438552856445,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a relatively rare B-cell",
            "probability": 0.060022253543138504
        },
        {
            "start_logit": 0.6656512022018433,
            "end_logit": -3.1547858715057373,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a relatively rare B-cell non-Hodgkin lymphoma, typically presenting with extensive lymphadenopathy",
            "probability": 0.04411822929978371
        },
        {
            "start_logit": 0.6656512022018433,
            "end_logit": -3.2662696838378906,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a relatively rare B-cell non-Hodgkin lymphoma",
            "probability": 0.03946402296423912
        },
        {
            "start_logit": 0.6656512022018433,
            "end_logit": -3.2884023189544678,
            "text": "Mantle cell lymphoma (Mantle cell",
            "probability": 0.038600169122219086
        },
        {
            "start_logit": 0.6656512022018433,
            "end_logit": -3.8391880989074707,
            "text": "Mantle cell lymphoma (Mantle",
            "probability": 0.022252872586250305
        },
        {
            "start_logit": 0.6656512022018433,
            "end_logit": -4.317498683929443,
            "text": "Mantle",
            "probability": 0.013792991638183594
        },
        {
            "start_logit": 0.6656512022018433,
            "end_logit": -4.7243781089782715,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma)",
            "probability": 0.009182331152260303
        },
        {
            "start_logit": 0.6656512022018433,
            "end_logit": -5.029299259185791,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a relatively rare",
            "probability": 0.0067690457217395306
        },
        {
            "start_logit": -1.707340121269226,
            "end_logit": -2.7523884773254395,
            "text": "Mantle cell lymphoma",
            "probability": 0.006148938089609146
        },
        {
            "start_logit": -1.707340121269226,
            "end_logit": -2.8469438552856445,
            "text": "Mantle cell lymphoma) is a relatively rare B-cell",
            "probability": 0.005594161804765463
        },
        {
            "start_logit": -1.707340121269226,
            "end_logit": -3.1547858715057373,
            "text": "Mantle cell lymphoma) is a relatively rare B-cell non-Hodgkin lymphoma, typically presenting with extensive lymphadenopathy",
            "probability": 0.004111887887120247
        },
        {
            "start_logit": 0.6656512022018433,
            "end_logit": -5.625424861907959,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a relatively rare B-cell non-Hodgkin lymphoma, typically presenting with extensive lymphadenopathy,",
            "probability": 0.0037293522618710995
        },
        {
            "start_logit": -1.707340121269226,
            "end_logit": -3.2662696838378906,
            "text": "Mantle cell lymphoma) is a relatively rare B-cell non-Hodgkin lymphoma",
            "probability": 0.003678104840219021
        },
        {
            "start_logit": -1.707340121269226,
            "end_logit": -3.2884023189544678,
            "text": "Mantle cell",
            "probability": 0.003597595728933811
        },
        {
            "start_logit": 0.6656512022018433,
            "end_logit": -5.846428394317627,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a relatively rare B",
            "probability": 0.0029898732900619507
        },
        {
            "start_logit": 0.6656512022018433,
            "end_logit": -5.923809051513672,
            "text": "Mantle cell lymphoma (",
            "probability": 0.0027672387659549713
        },
        {
            "start_logit": -1.707340121269226,
            "end_logit": -3.8391880989074707,
            "text": "Mantle",
            "probability": 0.0020740011241286993
        }
    ],
    "640c85e9201352f04a000026_0002": [
        {
            "start_logit": 2.0200231075286865,
            "end_logit": 0.6226273775100708,
            "text": "mantle cell lymphoma (Mantle cell lymphoma), chronic lymphocytic leukemia",
            "probability": 0.1324048936367035
        },
        {
            "start_logit": 1.4061577320098877,
            "end_logit": 0.9788670539855957,
            "text": "follicular lymphoma",
            "probability": 0.102333664894104
        },
        {
            "start_logit": 2.0200231075286865,
            "end_logit": 0.32825982570648193,
            "text": "mantle cell",
            "probability": 0.09864195436239243
        },
        {
            "start_logit": 1.4061577320098877,
            "end_logit": 0.6226273775100708,
            "text": "follicular lymphoma (follicular lymphoma), mantle cell lymphoma (Mantle cell lymphoma), chronic lymphocytic leukemia",
            "probability": 0.07166475802659988
        },
        {
            "start_logit": 0.9857778549194336,
            "end_logit": 0.9788670539855957,
            "text": "diffuse large cell lymphoma, follicular lymphoma",
            "probability": 0.06721246987581253
        },
        {
            "start_logit": 0.9857778549194336,
            "end_logit": 0.9624540209770203,
            "text": "diffuse large cell",
            "probability": 0.06611832231283188
        },
        {
            "start_logit": 1.4061577320098877,
            "end_logit": 0.32825982570648193,
            "text": "follicular lymphoma (follicular lymphoma), mantle cell",
            "probability": 0.05339043214917183
        },
        {
            "start_logit": 0.9857778549194336,
            "end_logit": 0.6864178776741028,
            "text": "diffuse large cell lymphoma",
            "probability": 0.05016961693763733
        },
        {
            "start_logit": 1.028572916984558,
            "end_logit": 0.6226273775100708,
            "text": "chronic lymphocytic leukemia",
            "probability": 0.04912726208567619
        },
        {
            "start_logit": 0.9857778549194336,
            "end_logit": 0.6226273775100708,
            "text": "diffuse large cell lymphoma, follicular lymphoma (follicular lymphoma), mantle cell lymphoma (Mantle cell lymphoma), chronic lymphocytic leukemia",
            "probability": 0.04706921428442001
        },
        {
            "start_logit": 2.0200231075286865,
            "end_logit": -0.5291808247566223,
            "text": "mantle cell lymphoma",
            "probability": 0.04184851795434952
        },
        {
            "start_logit": 2.0200231075286865,
            "end_logit": -0.7040972709655762,
            "text": "mantle cell lymphoma (Mantle cell lymphoma), chronic lymphocytic leukemia (chronic lymphocytic leukemia), lymphocyte-predominant Hodgkin lymphoma",
            "probability": 0.035132963210344315
        },
        {
            "start_logit": 0.9857778549194336,
            "end_logit": 0.32825982570648193,
            "text": "diffuse large cell lymphoma, follicular lymphoma (follicular lymphoma), mantle cell",
            "probability": 0.03506668657064438
        },
        {
            "start_logit": 0.005510434508323669,
            "end_logit": 0.9788670539855957,
            "text": "large cell lymphoma, follicular lymphoma",
            "probability": 0.025218844413757324
        },
        {
            "start_logit": 0.005510434508323669,
            "end_logit": 0.9624540209770203,
            "text": "large cell",
            "probability": 0.024808300659060478
        },
        {
            "start_logit": 1.4061577320098877,
            "end_logit": -0.5291808247566223,
            "text": "follicular lymphoma (follicular lymphoma), mantle cell lymphoma",
            "probability": 0.0226507019251585
        },
        {
            "start_logit": 2.0200231075286865,
            "end_logit": -1.248169183731079,
            "text": "mantle cell lymphoma (Mantle cell lymphoma",
            "probability": 0.020390477031469345
        },
        {
            "start_logit": 1.4061577320098877,
            "end_logit": -0.7040972709655762,
            "text": "follicular lymphoma (follicular lymphoma), mantle cell lymphoma (Mantle cell lymphoma), chronic lymphocytic leukemia (chronic lymphocytic leukemia), lymphocyte-predominant Hodgkin lymphoma",
            "probability": 0.019015882164239883
        },
        {
            "start_logit": 2.0200231075286865,
            "end_logit": -1.323495864868164,
            "text": "mantle",
            "probability": 0.018910950049757957
        },
        {
            "start_logit": 0.005510434508323669,
            "end_logit": 0.6864178776741028,
            "text": "large cell lymphoma",
            "probability": 0.018824182450771332
        }
    ],
    "640c85e9201352f04a000026_0003": [
        {
            "start_logit": 1.1700284481048584,
            "end_logit": -0.5613822937011719,
            "text": "Mantle cell lymphoma",
            "probability": 0.43568167090415955
        },
        {
            "start_logit": 1.1700284481048584,
            "end_logit": -1.012916088104248,
            "text": "Mantle cell",
            "probability": 0.2773771286010742
        },
        {
            "start_logit": 1.1700284481048584,
            "end_logit": -2.366438865661621,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma",
            "probability": 0.07165444642305374
        },
        {
            "start_logit": 1.1700284481048584,
            "end_logit": -2.4808578491210938,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a subtype of B-cell non-Hodgkin's lymphoma",
            "probability": 0.06390747427940369
        },
        {
            "start_logit": 1.1700284481048584,
            "end_logit": -3.138976812362671,
            "text": "Mantle cell lymphoma (Mantle cell",
            "probability": 0.03309285268187523
        },
        {
            "start_logit": 1.1700284481048584,
            "end_logit": -3.4867172241210938,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a subtype of B-cell",
            "probability": 0.023372892290353775
        },
        {
            "start_logit": 1.1700284481048584,
            "end_logit": -3.648993492126465,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a subtype of B-cell non-Hodgkin's lymphoma seen predominantly in males.",
            "probability": 0.019871780648827553
        },
        {
            "start_logit": 1.1700284481048584,
            "end_logit": -3.849618434906006,
            "text": "Mantle cell lymphoma (Mantle",
            "probability": 0.01625947281718254
        },
        {
            "start_logit": 1.1700284481048584,
            "end_logit": -4.250801086425781,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma)",
            "probability": 0.010886169970035553
        },
        {
            "start_logit": 1.1700284481048584,
            "end_logit": -4.276206016540527,
            "text": "Mantle",
            "probability": 0.010613089427351952
        },
        {
            "start_logit": 1.1700284481048584,
            "end_logit": -4.6276421546936035,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a subtype of B-cell non-Hodgkin's lymphoma seen predominantly in males",
            "probability": 0.007468185853213072
        },
        {
            "start_logit": -1.3940049409866333,
            "end_logit": -2.366438865661621,
            "text": "Mantle cell lymphoma",
            "probability": 0.0055169309489429
        },
        {
            "start_logit": -1.3940049409866333,
            "end_logit": -2.4808578491210938,
            "text": "Mantle cell lymphoma) is a subtype of B-cell non-Hodgkin's lymphoma",
            "probability": 0.0049204640090465546
        },
        {
            "start_logit": 1.1700284481048584,
            "end_logit": -5.069045066833496,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a subtype",
            "probability": 0.004803040064871311
        },
        {
            "start_logit": 1.1700284481048584,
            "end_logit": -5.219640731811523,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a subtype of B-cell non-Hodgkin's",
            "probability": 0.00413155322894454
        },
        {
            "start_logit": -1.3940049409866333,
            "end_logit": -3.138976812362671,
            "text": "Mantle cell",
            "probability": 0.002547936048358679
        },
        {
            "start_logit": 1.1700284481048584,
            "end_logit": -5.787696838378906,
            "text": "Mantle cell lymphoma (",
            "probability": 0.0023410446010529995
        },
        {
            "start_logit": 1.1700284481048584,
            "end_logit": -5.838812351226807,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a subtype of B",
            "probability": 0.0022243871353566647
        },
        {
            "start_logit": -1.3940049409866333,
            "end_logit": -3.4867172241210938,
            "text": "Mantle cell lymphoma) is a subtype of B-cell",
            "probability": 0.0017995622474700212
        },
        {
            "start_logit": -1.3940049409866333,
            "end_logit": -3.648993492126465,
            "text": "Mantle cell lymphoma) is a subtype of B-cell non-Hodgkin's lymphoma seen predominantly in males.",
            "probability": 0.0015299990773200989
        }
    ],
    "6415bb3c690f196b5100000e_0001": [
        {
            "start_logit": 4.409292697906494,
            "end_logit": 4.18472957611084,
            "text": "8%",
            "probability": 0.22545449435710907
        },
        {
            "start_logit": 4.618288040161133,
            "end_logit": 3.9438323974609375,
            "text": "10-12%",
            "probability": 0.21837548911571503
        },
        {
            "start_logit": 4.409292697906494,
            "end_logit": 3.9438323974609375,
            "text": "8% and 10-12%",
            "probability": 0.17718955874443054
        },
        {
            "start_logit": 4.618288040161133,
            "end_logit": 3.560878038406372,
            "text": "10-12%, respectively.",
            "probability": 0.14889799058437347
        },
        {
            "start_logit": 4.409292697906494,
            "end_logit": 3.560878038406372,
            "text": "8% and 10-12%, respectively.",
            "probability": 0.12081573903560638
        },
        {
            "start_logit": 2.531414270401001,
            "end_logit": 3.9438323974609375,
            "text": "12%",
            "probability": 0.027094805613160133
        },
        {
            "start_logit": 2.531414270401001,
            "end_logit": 3.560878038406372,
            "text": "12%, respectively.",
            "probability": 0.018474433571100235
        },
        {
            "start_logit": 1.6643584966659546,
            "end_logit": 4.18472957611084,
            "text": "reduced time and costs by online counseling with about 8%",
            "probability": 0.014486015774309635
        },
        {
            "start_logit": 1.6643584966659546,
            "end_logit": 3.9438323974609375,
            "text": "reduced time and costs by online counseling with about 8% and 10-12%",
            "probability": 0.01138488482683897
        },
        {
            "start_logit": 1.6643584966659546,
            "end_logit": 3.560878038406372,
            "text": "reduced time and costs by online counseling with about 8% and 10-12%, respectively.",
            "probability": 0.007762713357806206
        },
        {
            "start_logit": 4.618288040161133,
            "end_logit": 0.5219312310218811,
            "text": "10-12%, respectively",
            "probability": 0.007130024954676628
        },
        {
            "start_logit": 4.409292697906494,
            "end_logit": 0.5219312310218811,
            "text": "8% and 10-12%, respectively",
            "probability": 0.005785295739769936
        },
        {
            "start_logit": 0.1679612398147583,
            "end_logit": 4.18472957611084,
            "text": "We estimated reduced time and costs by online counseling with about 8%",
            "probability": 0.0032439325004816055
        },
        {
            "start_logit": 1.6643584966659546,
            "end_logit": 2.5074663162231445,
            "text": "reduced time",
            "probability": 0.0027072152588516474
        },
        {
            "start_logit": 0.1679612398147583,
            "end_logit": 3.9438323974609375,
            "text": "We estimated reduced time and costs by online counseling with about 8% and 10-12%",
            "probability": 0.0025494792498648167
        },
        {
            "start_logit": 1.6643584966659546,
            "end_logit": 2.3861026763916016,
            "text": "reduced time and costs",
            "probability": 0.0023978124372661114
        },
        {
            "start_logit": -0.45198506116867065,
            "end_logit": 4.18472957611084,
            "text": "about 8%",
            "probability": 0.0017451486783102155
        },
        {
            "start_logit": 0.1679612398147583,
            "end_logit": 3.560878038406372,
            "text": "We estimated reduced time and costs by online counseling with about 8% and 10-12%, respectively.",
            "probability": 0.001738347695209086
        },
        {
            "start_logit": -0.6758829355239868,
            "end_logit": 4.18472957611084,
            "text": "costs by online counseling with about 8%",
            "probability": 0.0013950668508186936
        },
        {
            "start_logit": -0.45198506116867065,
            "end_logit": 3.9438323974609375,
            "text": "about 8% and 10-12%",
            "probability": 0.0013715516543015838
        }
    ],
    "63f03ae6f36125a42600001d_0001": [
        {
            "start_logit": 6.420699119567871,
            "end_logit": 6.089227676391602,
            "text": "PDE4B",
            "probability": 0.995441198348999
        },
        {
            "start_logit": 6.420699119567871,
            "end_logit": 0.4501339793205261,
            "text": "PDE4B subtype",
            "probability": 0.003539877478033304
        },
        {
            "start_logit": -1.2393715381622314,
            "end_logit": 6.089227676391602,
            "text": "the PDE4B",
            "probability": 0.00046912580728530884
        },
        {
            "start_logit": 6.420699119567871,
            "end_logit": -2.2922487258911133,
            "text": "PDE",
            "probability": 0.00022802718740422279
        },
        {
            "start_logit": 6.420699119567871,
            "end_logit": -2.471945285797119,
            "text": "PDE4B subtype, in patients with idiopathic pulmonary fibrosis.",
            "probability": 0.00019052221614401788
        },
        {
            "start_logit": -3.671393394470215,
            "end_logit": 6.089227676391602,
            "text": "4B",
            "probability": 4.121691745240241e-05
        },
        {
            "start_logit": -3.7642550468444824,
            "end_logit": 6.089227676391602,
            "text": "preferential inhibitor of the PDE4B",
            "probability": 3.756180012715049e-05
        },
        {
            "start_logit": -4.851223945617676,
            "end_logit": 6.089227676391602,
            "text": "oral preferential inhibitor of the PDE4B",
            "probability": 1.2667230294027831e-05
        },
        {
            "start_logit": 6.420699119567871,
            "end_logit": -5.595252990722656,
            "text": "PDE4B subtype,",
            "probability": 8.385137334698811e-06
        },
        {
            "start_logit": 6.420699119567871,
            "end_logit": -5.739337921142578,
            "text": "PDE4B subtype, in patients with idiopathic pulmonary fibrosis",
            "probability": 7.2599700615683105e-06
        },
        {
            "start_logit": -5.561614513397217,
            "end_logit": 6.089227676391602,
            "text": "an oral preferential inhibitor of the PDE4B",
            "probability": 6.22534071226255e-06
        },
        {
            "start_logit": -5.914318084716797,
            "end_logit": 6.089227676391602,
            "text": "inhibitor of the PDE4B",
            "probability": 4.37507742390153e-06
        },
        {
            "start_logit": -5.99103307723999,
            "end_logit": 6.089227676391602,
            "text": "BI 1015550, an oral preferential inhibitor of the PDE4B",
            "probability": 4.05199625674868e-06
        },
        {
            "start_logit": -6.05780029296875,
            "end_logit": 6.089227676391602,
            "text": "double-blind, placebo-controlled trial, we investigated the efficacy and safety of BI 1015550, an oral preferential inhibitor of the PDE4B",
            "probability": 3.7902877920714673e-06
        },
        {
            "start_logit": -6.133968353271484,
            "end_logit": 6.089227676391602,
            "text": "of the PDE4B",
            "probability": 3.5123098314215895e-06
        },
        {
            "start_logit": -1.2393715381622314,
            "end_logit": 0.4501339793205261,
            "text": "the PDE4B subtype",
            "probability": 1.6682522527844412e-06
        },
        {
            "start_logit": -3.671393394470215,
            "end_logit": 0.4501339793205261,
            "text": "4B subtype",
            "probability": 1.4657111080396135e-07
        },
        {
            "start_logit": -3.7642550468444824,
            "end_logit": 0.4501339793205261,
            "text": "preferential inhibitor of the PDE4B subtype",
            "probability": 1.3357306727357354e-07
        },
        {
            "start_logit": -1.2393715381622314,
            "end_logit": -2.2922487258911133,
            "text": "the PDE",
            "probability": 1.0746324363708482e-07
        },
        {
            "start_logit": -1.2393715381622314,
            "end_logit": -2.471945285797119,
            "text": "the PDE4B subtype, in patients with idiopathic pulmonary fibrosis.",
            "probability": 8.978820886795802e-08
        }
    ],
    "63f03ae6f36125a42600001d_0002": [
        {
            "start_logit": 7.647676467895508,
            "end_logit": 7.323407173156738,
            "text": "phosphodiesterase 4B",
            "probability": 0.998218834400177
        },
        {
            "start_logit": 7.647676467895508,
            "end_logit": 0.5093154311180115,
            "text": "phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis.",
            "probability": 0.0010962341912090778
        },
        {
            "start_logit": 7.647676467895508,
            "end_logit": -0.9497603178024292,
            "text": "phosphodiesterase",
            "probability": 0.0002548207121435553
        },
        {
            "start_logit": 7.647676467895508,
            "end_logit": -1.00640070438385,
            "text": "phosphodiesterase 4B inhibitor",
            "probability": 0.00024078888236545026
        },
        {
            "start_logit": -1.1934821605682373,
            "end_logit": 7.323407173156738,
            "text": "preferential phosphodiesterase 4B",
            "probability": 0.00014439735969062895
        },
        {
            "start_logit": -3.2193567752838135,
            "end_logit": 7.323407173156738,
            "text": "4B",
            "probability": 1.9042909116251394e-05
        },
        {
            "start_logit": 7.647676467895508,
            "end_logit": -4.267651081085205,
            "text": "phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis",
            "probability": 9.23193965718383e-06
        },
        {
            "start_logit": -4.9253129959106445,
            "end_logit": 7.323407173156738,
            "text": "a preferential phosphodiesterase 4B",
            "probability": 3.4581657928356435e-06
        },
        {
            "start_logit": -5.093297958374023,
            "end_logit": 7.323407173156738,
            "text": "BI 1015550, a preferential phosphodiesterase 4B",
            "probability": 2.9234176963655045e-06
        },
        {
            "start_logit": -5.144085884094238,
            "end_logit": 7.323407173156738,
            "text": "Phase I studies of BI 1015550, a preferential phosphodiesterase 4B",
            "probability": 2.7786504688265268e-06
        },
        {
            "start_logit": 7.647676467895508,
            "end_logit": -5.692316055297852,
            "text": "phosphodiesterase 4B inhibitor,",
            "probability": 2.2211045234143967e-06
        },
        {
            "start_logit": -5.703470706939697,
            "end_logit": 7.323407173156738,
            "text": ", a preferential phosphodiesterase 4B",
            "probability": 1.588167947375041e-06
        },
        {
            "start_logit": 7.647676467895508,
            "end_logit": -6.096141815185547,
            "text": "phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary",
            "probability": 1.483165760873817e-06
        },
        {
            "start_logit": 7.647676467895508,
            "end_logit": -6.38911771774292,
            "text": "phosphodiesterase 4B inhibitor, in healthy males",
            "probability": 1.1065015996791772e-06
        },
        {
            "start_logit": -6.415782451629639,
            "end_logit": 7.323407173156738,
            "text": "1015550, a preferential phosphodiesterase 4B",
            "probability": 7.790098379700794e-07
        },
        {
            "start_logit": -1.1934821605682373,
            "end_logit": 0.5093154311180115,
            "text": "preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis.",
            "probability": 1.585757871680471e-07
        },
        {
            "start_logit": -1.1934821605682373,
            "end_logit": -0.9497603178024292,
            "text": "preferential phosphodiesterase",
            "probability": 3.6861095509266306e-08
        },
        {
            "start_logit": -1.1934821605682373,
            "end_logit": -1.00640070438385,
            "text": "preferential phosphodiesterase 4B inhibitor",
            "probability": 3.483128452330675e-08
        },
        {
            "start_logit": -3.2193567752838135,
            "end_logit": 0.5093154311180115,
            "text": "4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis.",
            "probability": 2.091271689153018e-08
        },
        {
            "start_logit": -3.2193567752838135,
            "end_logit": -1.00640070438385,
            "text": "4B inhibitor",
            "probability": 4.593494029592193e-09
        }
    ],
    "63f03ae6f36125a42600001d_0003": [
        {
            "start_logit": 7.943604946136475,
            "end_logit": 8.01559829711914,
            "text": "phosphodiesterase 4",
            "probability": 0.9990460276603699
        },
        {
            "start_logit": 7.943604946136475,
            "end_logit": 0.40825003385543823,
            "text": "phosphodiesterase 4 (phosphodiesterase 4",
            "probability": 0.0004963134415447712
        },
        {
            "start_logit": -0.03776686266064644,
            "end_logit": 8.01559829711914,
            "text": "4",
            "probability": 0.0003414440434426069
        },
        {
            "start_logit": 7.943604946136475,
            "end_logit": -1.9433963298797607,
            "text": "phosphodiesterase",
            "probability": 4.725512917502783e-05
        },
        {
            "start_logit": 7.943604946136475,
            "end_logit": -2.551279067993164,
            "text": "phosphodiesterase 4 (phosphodiesterase 4) inhibitor that has antifibrotic properties.",
            "probability": 2.5730545530677773e-05
        },
        {
            "start_logit": -3.282670021057129,
            "end_logit": 8.01559829711914,
            "text": "BI 1015550 is a phosphodiesterase 4",
            "probability": 1.3306873370311223e-05
        },
        {
            "start_logit": 7.943604946136475,
            "end_logit": -3.46390962600708,
            "text": "phosphodiesterase 4 (phosphodiesterase",
            "probability": 1.0329953511245549e-05
        },
        {
            "start_logit": 7.943604946136475,
            "end_logit": -3.8805737495422363,
            "text": "phosphodiesterase 4 (phosphodiesterase 4)",
            "probability": 6.809942078689346e-06
        },
        {
            "start_logit": 7.943604946136475,
            "end_logit": -4.758800029754639,
            "text": "phosphodiesterase 4 (phosphodiesterase 4) inhibitor that has antifibrotic properties",
            "probability": 2.8296624350332422e-06
        },
        {
            "start_logit": -5.103335380554199,
            "end_logit": 8.01559829711914,
            "text": "Introduction: BI 1015550 is a phosphodiesterase 4",
            "probability": 2.154622279704199e-06
        },
        {
            "start_logit": 7.943604946136475,
            "end_logit": -5.237107276916504,
            "text": "phosphodiesterase 4 (",
            "probability": 1.7539134660182754e-06
        },
        {
            "start_logit": 7.943604946136475,
            "end_logit": -5.548043251037598,
            "text": "phosphodiesterase 4 (phosphodiesterase 4) inhibitor that has antifibrotic",
            "probability": 1.2851990049966844e-06
        },
        {
            "start_logit": 7.943604946136475,
            "end_logit": -5.586180686950684,
            "text": "phosphodiesterase 4 (phosphodiesterase 4) inhibitor that has antifibr",
            "probability": 1.237107767337875e-06
        },
        {
            "start_logit": -5.919439792633057,
            "end_logit": 8.01559829711914,
            "text": "a phosphodiesterase 4",
            "probability": 9.526681878924137e-07
        },
        {
            "start_logit": -6.041225433349609,
            "end_logit": 8.01559829711914,
            "text": "1015550 is a phosphodiesterase 4",
            "probability": 8.434330993623007e-07
        },
        {
            "start_logit": 7.943604946136475,
            "end_logit": -6.005103588104248,
            "text": "phosphodiesterase 4 (phosphodiesterase 4) inhibitor",
            "probability": 8.137140525832365e-07
        },
        {
            "start_logit": -6.5520100593566895,
            "end_logit": 8.01559829711914,
            "text": "is a phosphodiesterase 4",
            "probability": 5.060808803136752e-07
        },
        {
            "start_logit": 0.8057292699813843,
            "end_logit": 0.40825003385543823,
            "text": "phosphodiesterase 4",
            "probability": 3.9429031062354625e-07
        },
        {
            "start_logit": -0.03776686266064644,
            "end_logit": 0.40825003385543823,
            "text": "4 (phosphodiesterase 4",
            "probability": 1.6962515303475811e-07
        },
        {
            "start_logit": 0.8057292699813843,
            "end_logit": -2.551279067993164,
            "text": "phosphodiesterase 4) inhibitor that has antifibrotic properties.",
            "probability": 2.0441303760776464e-08
        }
    ],
    "63f03ae6f36125a42600001d_0004": [
        {
            "start_logit": 8.164572715759277,
            "end_logit": 7.49742317199707,
            "text": "PDE4B",
            "probability": 0.9987599849700928
        },
        {
            "start_logit": 8.164572715759277,
            "end_logit": 0.6991505026817322,
            "text": "PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.",
            "probability": 0.001114316750317812
        },
        {
            "start_logit": 8.164572715759277,
            "end_logit": -2.185147285461426,
            "text": "PDE",
            "probability": 6.22836741968058e-05
        },
        {
            "start_logit": -2.4845237731933594,
            "end_logit": 7.49742317199707,
            "text": "BI 1015550 is a PDE4B",
            "probability": 2.3692848117207177e-05
        },
        {
            "start_logit": -2.7299036979675293,
            "end_logit": 7.49742317199707,
            "text": "4B",
            "probability": 1.8537464711698703e-05
        },
        {
            "start_logit": 8.164572715759277,
            "end_logit": -4.045709609985352,
            "text": "PDE4B Inhibitor",
            "probability": 9.690412298368756e-06
        },
        {
            "start_logit": 8.164572715759277,
            "end_logit": -4.660951614379883,
            "text": "PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis",
            "probability": 5.237765890342416e-06
        },
        {
            "start_logit": 8.164572715759277,
            "end_logit": -5.600665092468262,
            "text": "PDE4B Inhibitor and a Clinical Drug Candidate",
            "probability": 2.046603412964032e-06
        },
        {
            "start_logit": 8.164572715759277,
            "end_logit": -6.282760143280029,
            "text": "PDE4B Inhibitor and a Clinical",
            "probability": 1.034673459798796e-06
        },
        {
            "start_logit": 8.164572715759277,
            "end_logit": -6.414689064025879,
            "text": "PDE4B Inhibitor and",
            "probability": 9.067917972060968e-07
        },
        {
            "start_logit": -6.070523262023926,
            "end_logit": 7.49742317199707,
            "text": "1015550 is a PDE4B",
            "probability": 6.565041985595599e-07
        },
        {
            "start_logit": -6.123561859130859,
            "end_logit": 7.49742317199707,
            "text": "a PDE4B",
            "probability": 6.225914148672018e-07
        },
        {
            "start_logit": -6.511380195617676,
            "end_logit": 7.49742317199707,
            "text": "50 is a PDE4B",
            "probability": 4.2245045506206225e-07
        },
        {
            "start_logit": -6.555835723876953,
            "end_logit": 7.49742317199707,
            "text": "is a PDE4B",
            "probability": 4.040814758354827e-07
        },
        {
            "start_logit": -2.4845237731933594,
            "end_logit": 0.6991505026817322,
            "text": "BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.",
            "probability": 2.6434141986442228e-08
        },
        {
            "start_logit": -2.7299036979675293,
            "end_logit": 0.6991505026817322,
            "text": "4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.",
            "probability": 2.0682254131543232e-08
        },
        {
            "start_logit": -4.7811126708984375,
            "end_logit": 0.6991505026817322,
            "text": ".",
            "probability": 2.659312103858724e-09
        },
        {
            "start_logit": -2.4845237731933594,
            "end_logit": -2.185147285461426,
            "text": "BI 1015550 is a PDE",
            "probability": 1.4775097811892124e-09
        },
        {
            "start_logit": -5.966744422912598,
            "end_logit": 0.6991505026817322,
            "text": "a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.",
            "probability": 8.125602968256374e-10
        },
        {
            "start_logit": -6.023468017578125,
            "end_logit": 0.6991505026817322,
            "text": "Idiopathic Pulmonary Fibrosis.",
            "probability": 7.677525282190345e-10
        }
    ],
    "63f03ae6f36125a42600001d_0005": [
        {
            "start_logit": 7.514492511749268,
            "end_logit": 8.208996772766113,
            "text": "phosphodiesterase 4",
            "probability": 0.9992964267730713
        },
        {
            "start_logit": -0.1711556613445282,
            "end_logit": 8.208996772766113,
            "text": "4",
            "probability": 0.0004590494208969176
        },
        {
            "start_logit": 7.514492511749268,
            "end_logit": -0.4270556569099426,
            "text": "phosphodiesterase 4 inhibitor showing a preferential enzymatic inhibition of PDE4B",
            "probability": 0.0001774614938767627
        },
        {
            "start_logit": 7.514492511749268,
            "end_logit": -2.3536953926086426,
            "text": "phosphodiesterase 4 inhibitor showing a preferential enzymatic inhibition of PDE4B.",
            "probability": 2.584491994639393e-05
        },
        {
            "start_logit": -3.15099835395813,
            "end_logit": 8.208996772766113,
            "text": "BI 1015550 is a novel phosphodiesterase 4",
            "probability": 2.3320098989643157e-05
        },
        {
            "start_logit": 7.514492511749268,
            "end_logit": -3.568556308746338,
            "text": "phosphodiesterase",
            "probability": 7.669514161534607e-06
        },
        {
            "start_logit": 7.514492511749268,
            "end_logit": -4.601258277893066,
            "text": "phosphodiesterase 4 inhibitor showing a preferential",
            "probability": 2.7306828087603208e-06
        },
        {
            "start_logit": -5.719192981719971,
            "end_logit": 8.208996772766113,
            "text": "novel phosphodiesterase 4",
            "probability": 1.7880406630865764e-06
        },
        {
            "start_logit": -6.334785461425781,
            "end_logit": 8.208996772766113,
            "text": "a novel phosphodiesterase 4",
            "probability": 9.66115635492315e-07
        },
        {
            "start_logit": -6.436822891235352,
            "end_logit": 8.208996772766113,
            "text": "1015550 is a novel phosphodiesterase 4",
            "probability": 8.723983455638518e-07
        },
        {
            "start_logit": -6.683929443359375,
            "end_logit": 8.208996772766113,
            "text": "is a novel phosphodiesterase 4",
            "probability": 6.813932031946024e-07
        },
        {
            "start_logit": 7.514492511749268,
            "end_logit": -5.990449905395508,
            "text": "phosphodiesterase 4 inhibitor showing a preferential enzymatic",
            "probability": 6.80695052324154e-07
        },
        {
            "start_logit": -6.713184833526611,
            "end_logit": 8.208996772766113,
            "text": "50 is a novel phosphodiesterase 4",
            "probability": 6.61747378671862e-07
        },
        {
            "start_logit": 7.514492511749268,
            "end_logit": -6.255062103271484,
            "text": "phosphodiesterase 4 inhibitor showing a preferential enzymatic inhibition of PDE",
            "probability": 5.224358687883068e-07
        },
        {
            "start_logit": 7.514492511749268,
            "end_logit": -6.331936836242676,
            "text": "phosphodiesterase 4 inhibitor showing a preferential enzymatic inhibition",
            "probability": 4.837791038880823e-07
        },
        {
            "start_logit": 7.514492511749268,
            "end_logit": -6.5068278312683105,
            "text": "phosphodiesterase 4 inhibitor",
            "probability": 4.0615583429826074e-07
        },
        {
            "start_logit": 7.514492511749268,
            "end_logit": -6.624982833862305,
            "text": "phosphodiesterase 4 inhibitor showing a",
            "probability": 3.60892983053418e-07
        },
        {
            "start_logit": -0.1711556613445282,
            "end_logit": -0.4270556569099426,
            "text": "4 inhibitor showing a preferential enzymatic inhibition of PDE4B",
            "probability": 8.152102282110718e-08
        },
        {
            "start_logit": -1.9338704347610474,
            "end_logit": -0.4270556569099426,
            "text": "PDE4B",
            "probability": 1.3987255798042497e-08
        },
        {
            "start_logit": -0.1711556613445282,
            "end_logit": -2.3536953926086426,
            "text": "4 inhibitor showing a preferential enzymatic inhibition of PDE4B.",
            "probability": 1.1872460348172353e-08
        }
    ],
    "63f03ae6f36125a42600001d_0006": [
        {
            "start_logit": 8.249184608459473,
            "end_logit": 8.498939514160156,
            "text": "PDE4B",
            "probability": 0.9997296929359436
        },
        {
            "start_logit": -0.26161494851112366,
            "end_logit": 8.498939514160156,
            "text": "4B",
            "probability": 0.00020122862770222127
        },
        {
            "start_logit": -2.375897169113159,
            "end_logit": 8.498939514160156,
            "text": "preferential inhibition of PDE4B",
            "probability": 2.4292292437166907e-05
        },
        {
            "start_logit": 8.249184608459473,
            "end_logit": -2.1884355545043945,
            "text": "PDE",
            "probability": 2.282521927554626e-05
        },
        {
            "start_logit": -3.8932008743286133,
            "end_logit": 8.498939514160156,
            "text": "unique preferential inhibition of PDE4B",
            "probability": 5.3273597586667165e-06
        },
        {
            "start_logit": -4.094107627868652,
            "end_logit": 8.498939514160156,
            "text": "the unique preferential inhibition of PDE4B",
            "probability": 4.3577201722655445e-06
        },
        {
            "start_logit": 8.249184608459473,
            "end_logit": -4.407980918884277,
            "text": "PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory and antifibrotic potential",
            "probability": 2.4801540803309763e-06
        },
        {
            "start_logit": 8.249184608459473,
            "end_logit": -4.904913902282715,
            "text": "PDE4B by BI 1015550 and its anticipated improved tolerability",
            "probability": 1.5089103726495523e-06
        },
        {
            "start_logit": 8.249184608459473,
            "end_logit": -4.978336811065674,
            "text": "PDE4B by BI 1015550",
            "probability": 1.402090560986835e-06
        },
        {
            "start_logit": 8.249184608459473,
            "end_logit": -5.227570056915283,
            "text": "PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory",
            "probability": 1.0927867606369546e-06
        },
        {
            "start_logit": -5.569108009338379,
            "end_logit": 8.498939514160156,
            "text": "inhibition of PDE4B",
            "probability": 9.969531902243034e-07
        },
        {
            "start_logit": -5.644726276397705,
            "end_logit": 8.498939514160156,
            "text": "summary, the unique preferential inhibition of PDE4B",
            "probability": 9.243455565410841e-07
        },
        {
            "start_logit": 8.249184608459473,
            "end_logit": -5.7225542068481445,
            "text": "PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory and antifibrotic",
            "probability": 6.661420002274099e-07
        },
        {
            "start_logit": 8.249184608459473,
            "end_logit": -5.7897138595581055,
            "text": "PDE4B by BI 1015550 and its anticipated improved",
            "probability": 6.228732445379137e-07
        },
        {
            "start_logit": 8.249184608459473,
            "end_logit": -5.7943315505981445,
            "text": "PDE4B by BI 1015550 and its anticipated improved tolerability in humans",
            "probability": 6.200036750669824e-07
        },
        {
            "start_logit": 8.249184608459473,
            "end_logit": -6.054315090179443,
            "text": "PDE4B by BI 1015550 and its anticipated",
            "probability": 4.780629296874395e-07
        },
        {
            "start_logit": 8.249184608459473,
            "end_logit": -6.135771751403809,
            "text": "PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus",
            "probability": 4.406651044064347e-07
        },
        {
            "start_logit": 8.249184608459473,
            "end_logit": -6.136769771575928,
            "text": "PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory and antifibrotic potential,",
            "probability": 4.402257616220595e-07
        },
        {
            "start_logit": 8.249184608459473,
            "end_logit": -6.166256904602051,
            "text": "PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory and antifibr",
            "probability": 4.2743405970213644e-07
        },
        {
            "start_logit": -2.375897169113159,
            "end_logit": -2.1884355545043945,
            "text": "preferential inhibition of PDE",
            "probability": 5.546263448508171e-10
        }
    ],
    "63eeeaaaf36125a426000004_0001": [
        {
            "start_logit": 6.478776931762695,
            "end_logit": 6.542618751525879,
            "text": "Recessive dystrophic epidermolysis bullosa",
            "probability": 0.8653188943862915
        },
        {
            "start_logit": 6.478776931762695,
            "end_logit": 4.387152671813965,
            "text": "Recessive dystrophic epidermolysis bullosa (Recessive dystrophic epidermolysis bullosa",
            "probability": 0.10024647414684296
        },
        {
            "start_logit": 4.704511642456055,
            "end_logit": 4.387152671813965,
            "text": "Recessive dystrophic epidermolysis bullosa",
            "probability": 0.017002608627080917
        },
        {
            "start_logit": 6.478776931762695,
            "end_logit": 2.203728675842285,
            "text": "Recessive dystrophic epidermolysis bullosa (Recessive dystrophic epidermolysis bullosa)",
            "probability": 0.011293280869722366
        },
        {
            "start_logit": 3.8284683227539062,
            "end_logit": 3.363231658935547,
            "text": "herpes simplex virus type 1",
            "probability": 0.002543147187680006
        },
        {
            "start_logit": 4.704511642456055,
            "end_logit": 2.203728675842285,
            "text": "Recessive dystrophic epidermolysis bullosa)",
            "probability": 0.0019154311157763004
        },
        {
            "start_logit": 6.478776931762695,
            "end_logit": -0.40644893050193787,
            "text": "Recessive dystrophic epidermolysis bullosa (Recessive dystrophic epidermolysis bullosa) is a lifelong genodermatosis",
            "probability": 0.0008302989299409091
        },
        {
            "start_logit": 6.478776931762695,
            "end_logit": -1.478881597518921,
            "text": "Recessive dystrophic epidermolysis bullosa (",
            "probability": 0.00028410751838237047
        },
        {
            "start_logit": 4.704511642456055,
            "end_logit": -0.40644893050193787,
            "text": "Recessive dystrophic epidermolysis bullosa) is a lifelong genodermatosis",
            "probability": 0.0001408252865076065
        },
        {
            "start_logit": 6.478776931762695,
            "end_logit": -2.8556246757507324,
            "text": "Recessive dystrophic",
            "probability": 7.17085858923383e-05
        },
        {
            "start_logit": 6.478776931762695,
            "end_logit": -3.0923843383789062,
            "text": "Recessive dystrophic epidermolysis bull",
            "probability": 5.65910195291508e-05
        },
        {
            "start_logit": -3.286574602127075,
            "end_logit": 6.542618751525879,
            "text": "epidermolysis bullosa",
            "probability": 4.967501445207745e-05
        },
        {
            "start_logit": 3.8284683227539062,
            "end_logit": -0.615276575088501,
            "text": "herpes simplex virus type 1 (herpes simplex virus type 1",
            "probability": 4.7591282054781914e-05
        },
        {
            "start_logit": 6.478776931762695,
            "end_logit": -3.3031668663024902,
            "text": "Recessive",
            "probability": 4.5835928176529706e-05
        },
        {
            "start_logit": 6.478776931762695,
            "end_logit": -3.5255324840545654,
            "text": "Recessive dystrophic epidermolysis bullosa (Recessive dystrophic epidermolysis bullosa) is",
            "probability": 3.669725265353918e-05
        },
        {
            "start_logit": 6.478776931762695,
            "end_logit": -3.557568073272705,
            "text": "Recessive dystrophic epidermolysis",
            "probability": 3.554025897756219e-05
        },
        {
            "start_logit": 6.478776931762695,
            "end_logit": -3.710642099380493,
            "text": "Recessive dystrophic epidermolysis bullosa (Recessive dystrophic",
            "probability": 3.0495915780193172e-05
        },
        {
            "start_logit": -4.2078962326049805,
            "end_logit": 6.542618751525879,
            "text": "osa",
            "probability": 1.977028659894131e-05
        },
        {
            "start_logit": 6.478776931762695,
            "end_logit": -4.362957954406738,
            "text": "Recessive dystrophic epidermolysis bullosa (Recessive dystrophic epidermolysis bull",
            "probability": 1.5883433661656454e-05
        },
        {
            "start_logit": 6.478776931762695,
            "end_logit": -4.416612148284912,
            "text": "Recessive dystrophic epidermolysis bullosa (Recessive",
            "probability": 1.5053687093313783e-05
        }
    ],
    "63eeeaaaf36125a426000004_0002": [
        {
            "start_logit": 8.000564575195312,
            "end_logit": 8.180903434753418,
            "text": "Recessive dystrophic epidermolysis bullosa",
            "probability": 0.9998894929885864
        },
        {
            "start_logit": -2.421412467956543,
            "end_logit": 8.180903434753418,
            "text": "epidermolysis bullosa",
            "probability": 2.9767645173706114e-05
        },
        {
            "start_logit": -2.8143258094787598,
            "end_logit": 8.180903434753418,
            "text": "osa",
            "probability": 2.009574745898135e-05
        },
        {
            "start_logit": 8.000564575195312,
            "end_logit": -2.9106147289276123,
            "text": "Recessive",
            "probability": 1.52393467942602e-05
        },
        {
            "start_logit": -3.285911798477173,
            "end_logit": 8.180903434753418,
            "text": "dystrophic epidermolysis bullosa",
            "probability": 1.2539991985249799e-05
        },
        {
            "start_logit": -3.739835500717163,
            "end_logit": 8.180903434753418,
            "text": "bullosa",
            "probability": 7.96453605289571e-06
        },
        {
            "start_logit": -4.308088779449463,
            "end_logit": 8.180903434753418,
            "text": "B-VEC is an easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 4.512021860136883e-06
        },
        {
            "start_logit": -4.364560127258301,
            "end_logit": 8.180903434753418,
            "text": "olysis bullosa",
            "probability": 4.264284598320955e-06
        },
        {
            "start_logit": 8.000564575195312,
            "end_logit": -5.05033540725708,
            "text": "Recessive dystrophic epidermolysis bullosa.",
            "probability": 1.7934852394319023e-06
        },
        {
            "start_logit": -5.2598466873168945,
            "end_logit": 8.180903434753418,
            "text": "topical molecular corrective therapy promoting wound healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 1.741919845699158e-06
        },
        {
            "start_logit": 8.000564575195312,
            "end_logit": -5.098974227905273,
            "text": "Recessive dystrophic epidermolysis bull",
            "probability": 1.7083388001992716e-06
        },
        {
            "start_logit": -5.418320655822754,
            "end_logit": 8.180903434753418,
            "text": "wound healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 1.4866330957374885e-06
        },
        {
            "start_logit": 8.000564575195312,
            "end_logit": -5.241910934448242,
            "text": "Recessive dystrophic",
            "probability": 1.4808034620727994e-06
        },
        {
            "start_logit": -5.520639419555664,
            "end_logit": 8.180903434753418,
            "text": "safely tolerated, topical molecular corrective therapy promoting wound healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 1.3420457207757863e-06
        },
        {
            "start_logit": 8.000564575195312,
            "end_logit": -5.3841986656188965,
            "text": "Recessive dystrophic epidermolysis",
            "probability": 1.2844062666772516e-06
        },
        {
            "start_logit": -5.583598613739014,
            "end_logit": 8.180903434753418,
            "text": "with Recessive dystrophic epidermolysis bullosa",
            "probability": 1.2601570915649063e-06
        },
        {
            "start_logit": -5.730663299560547,
            "end_logit": 8.180903434753418,
            "text": "molecular corrective therapy promoting wound healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 1.0878152352233883e-06
        },
        {
            "start_logit": -5.78141975402832,
            "end_logit": 8.180903434753418,
            "text": "VEC is an easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 1.033979287967668e-06
        },
        {
            "start_logit": -5.802077770233154,
            "end_logit": 8.180903434753418,
            "text": "in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 1.0128388794328202e-06
        },
        {
            "start_logit": -5.853490352630615,
            "end_logit": 8.180903434753418,
            "text": "easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 9.620822538636276e-07
        }
    ],
    "64138ce8201352f04a000042_0001": [
        {
            "start_logit": 4.448399543762207,
            "end_logit": 6.253200531005859,
            "text": "mouse",
            "probability": 0.9409449696540833
        },
        {
            "start_logit": 4.448399543762207,
            "end_logit": 2.463338851928711,
            "text": "mouse mutation.",
            "probability": 0.021264158189296722
        },
        {
            "start_logit": 0.3728283643722534,
            "end_logit": 6.253200531005859,
            "text": "Hairpatches\" (Hairpatches\") is a naturally occurring, autosomal semi-dominant mouse",
            "probability": 0.01597961038351059
        },
        {
            "start_logit": 4.448399543762207,
            "end_logit": 1.7726234197616577,
            "text": "mouse mutation",
            "probability": 0.010657966136932373
        },
        {
            "start_logit": -0.442076712846756,
            "end_logit": 6.253200531005859,
            "text": "autosomal semi-dominant mouse",
            "probability": 0.007073875050991774
        },
        {
            "start_logit": -2.304560661315918,
            "end_logit": 6.253200531005859,
            "text": "\"Hairpatches\" (Hairpatches\") is a naturally occurring, autosomal semi-dominant mouse",
            "probability": 0.00109847669955343
        },
        {
            "start_logit": -2.31347918510437,
            "end_logit": 6.253200531005859,
            "text": "Hairpatches\") is a naturally occurring, autosomal semi-dominant mouse",
            "probability": 0.0010887231910601258
        },
        {
            "start_logit": -3.1326096057891846,
            "end_logit": 6.253200531005859,
            "text": "naturally occurring, autosomal semi-dominant mouse",
            "probability": 0.0004799255693797022
        },
        {
            "start_logit": 0.3728283643722534,
            "end_logit": 2.463338851928711,
            "text": "Hairpatches\" (Hairpatches\") is a naturally occurring, autosomal semi-dominant mouse mutation.",
            "probability": 0.00036111887311562896
        },
        {
            "start_logit": 1.4246115684509277,
            "end_logit": 0.8269129395484924,
            "text": "renal failure",
            "probability": 0.00020125339506193995
        },
        {
            "start_logit": 0.3728283643722534,
            "end_logit": 1.7726234197616577,
            "text": "Hairpatches\" (Hairpatches\") is a naturally occurring, autosomal semi-dominant mouse mutation",
            "probability": 0.0001809989771572873
        },
        {
            "start_logit": -0.442076712846756,
            "end_logit": 2.463338851928711,
            "text": "autosomal semi-dominant mouse mutation.",
            "probability": 0.00015986057405825704
        },
        {
            "start_logit": -4.610500812530518,
            "end_logit": 6.253200531005859,
            "text": "(Hairpatches\") is a naturally occurring, autosomal semi-dominant mouse",
            "probability": 0.00010947969713015482
        },
        {
            "start_logit": -4.6287031173706055,
            "end_logit": 6.253200531005859,
            "text": "dominant mouse",
            "probability": 0.00010750498768175021
        },
        {
            "start_logit": 1.4246115684509277,
            "end_logit": 0.19968558847904205,
            "text": "renal failure accompanied by patchy alopecia.",
            "probability": 0.00010748345084721223
        },
        {
            "start_logit": -0.442076712846756,
            "end_logit": 1.7726234197616577,
            "text": "autosomal semi-dominant mouse mutation",
            "probability": 8.012486796360463e-05
        },
        {
            "start_logit": 1.4246115684509277,
            "end_logit": -0.8956314921379089,
            "text": "renal failure accompanied by patchy alopecia",
            "probability": 3.5946082789450884e-05
        },
        {
            "start_logit": -2.304560661315918,
            "end_logit": 2.463338851928711,
            "text": "\"Hairpatches\" (Hairpatches\") is a naturally occurring, autosomal semi-dominant mouse mutation.",
            "probability": 2.4824175852700137e-05
        },
        {
            "start_logit": -2.31347918510437,
            "end_logit": 2.463338851928711,
            "text": "Hairpatches\") is a naturally occurring, autosomal semi-dominant mouse mutation.",
            "probability": 2.4603759811725467e-05
        },
        {
            "start_logit": 4.448399543762207,
            "end_logit": -4.54242467880249,
            "text": "mouse mutation. Hairpatches\"/Hairpatches\" homozygotes die in utero",
            "probability": 1.9278957552160136e-05
        }
    ],
    "64138ce8201352f04a000042_0002": [
        {
            "start_logit": 4.62334680557251,
            "end_logit": 5.759577751159668,
            "text": "alopecia in the mouse. A potential model for a newly described heritable human disorder.",
            "probability": 0.558329164981842
        },
        {
            "start_logit": 4.62334680557251,
            "end_logit": 4.502523422241211,
            "text": "alopecia",
            "probability": 0.1588393598794937
        },
        {
            "start_logit": 2.8203141689300537,
            "end_logit": 5.759577751159668,
            "text": "progressive renal disease and alopecia in the mouse. A potential model for a newly described heritable human disorder.",
            "probability": 0.0920117050409317
        },
        {
            "start_logit": 2.503960371017456,
            "end_logit": 5.759577751159668,
            "text": "renal disease and alopecia in the mouse. A potential model for a newly described heritable human disorder.",
            "probability": 0.06705828011035919
        },
        {
            "start_logit": 4.62334680557251,
            "end_logit": 2.7160370349884033,
            "text": "alopecia in the mouse. A potential model for a newly described heritable human disorder",
            "probability": 0.02661321312189102
        },
        {
            "start_logit": 2.8203141689300537,
            "end_logit": 4.502523422241211,
            "text": "progressive renal disease and alopecia",
            "probability": 0.026176486164331436
        },
        {
            "start_logit": 2.503960371017456,
            "end_logit": 4.502523422241211,
            "text": "renal disease and alopecia",
            "probability": 0.019077464938163757
        },
        {
            "start_logit": 2.8203141689300537,
            "end_logit": 3.9899919033050537,
            "text": "progressive renal disease",
            "probability": 0.015679117292165756
        },
        {
            "start_logit": 2.503960371017456,
            "end_logit": 3.9899919033050537,
            "text": "renal disease",
            "probability": 0.011426965706050396
        },
        {
            "start_logit": 2.8203141689300537,
            "end_logit": 2.7160370349884033,
            "text": "progressive renal disease and alopecia in the mouse. A potential model for a newly described heritable human disorder",
            "probability": 0.0043858131393790245
        },
        {
            "start_logit": 0.9049280881881714,
            "end_logit": 4.502523422241211,
            "text": "Hairpatches, a single gene mutation characterized by progressive renal disease and alopecia",
            "probability": 0.0038554021157324314
        },
        {
            "start_logit": 4.62334680557251,
            "end_logit": 0.7767859697341919,
            "text": "alopecia in the mouse",
            "probability": 0.003827287582680583
        },
        {
            "start_logit": 2.503960371017456,
            "end_logit": 2.7160370349884033,
            "text": "renal disease and alopecia in the mouse. A potential model for a newly described heritable human disorder",
            "probability": 0.0031963868532329798
        },
        {
            "start_logit": 0.9049280881881714,
            "end_logit": 3.9899919033050537,
            "text": "Hairpatches, a single gene mutation characterized by progressive renal disease",
            "probability": 0.0023092981427907944
        },
        {
            "start_logit": -1.2967692613601685,
            "end_logit": 5.759577751159668,
            "text": "a newly described heritable human disorder.",
            "probability": 0.0014990512281656265
        },
        {
            "start_logit": -1.4065755605697632,
            "end_logit": 5.759577751159668,
            "text": "human disorder.",
            "probability": 0.0013431609841063619
        },
        {
            "start_logit": -1.4669346809387207,
            "end_logit": 5.759577751159668,
            "text": "newly described heritable human disorder.",
            "probability": 0.0012644872767850757
        },
        {
            "start_logit": -1.5277191400527954,
            "end_logit": 5.759577751159668,
            "text": "disorder.",
            "probability": 0.0011899156961590052
        },
        {
            "start_logit": -1.7402410507202148,
            "end_logit": 5.759577751159668,
            "text": "disease and alopecia in the mouse. A potential model for a newly described heritable human disorder.",
            "probability": 0.0009620973723940551
        },
        {
            "start_logit": -1.7473368644714355,
            "end_logit": 5.759577751159668,
            "text": "heritable human disorder.",
            "probability": 0.00095529475947842
        }
    ],
    "63f9cd0b33942b094c000010_0001": [
        {
            "start_logit": 3.5652949810028076,
            "end_logit": 4.935576915740967,
            "text": "Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer.",
            "probability": 0.6576072573661804
        },
        {
            "start_logit": 2.1684961318969727,
            "end_logit": 4.935576915740967,
            "text": "contributes to metastasis potential of colorectal cancer.",
            "probability": 0.16268394887447357
        },
        {
            "start_logit": 3.5652949810028076,
            "end_logit": 2.5711283683776855,
            "text": "Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer",
            "probability": 0.06181582063436508
        },
        {
            "start_logit": 0.6680722236633301,
            "end_logit": 4.935576915740967,
            "text": "metastasis potential of colorectal cancer.",
            "probability": 0.03628430888056755
        },
        {
            "start_logit": 3.5652949810028076,
            "end_logit": 1.9753422737121582,
            "text": "Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential",
            "probability": 0.034068502485752106
        },
        {
            "start_logit": 2.1684961318969727,
            "end_logit": 2.5711283683776855,
            "text": "contributes to metastasis potential of colorectal cancer",
            "probability": 0.015292472206056118
        },
        {
            "start_logit": 2.1684961318969727,
            "end_logit": 1.9753422737121582,
            "text": "contributes to metastasis potential",
            "probability": 0.008428127504885197
        },
        {
            "start_logit": -1.2120503187179565,
            "end_logit": 4.935576915740967,
            "text": "HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer.",
            "probability": 0.005535947158932686
        },
        {
            "start_logit": 3.5652949810028076,
            "end_logit": -0.29525384306907654,
            "text": "Alternative splicing",
            "probability": 0.003517595585435629
        },
        {
            "start_logit": 0.6680722236633301,
            "end_logit": 2.5711283683776855,
            "text": "metastasis potential of colorectal cancer",
            "probability": 0.003410765901207924
        },
        {
            "start_logit": 3.5652949810028076,
            "end_logit": -0.7133249044418335,
            "text": "Alternative splicing of HSPA12A pre-RNA",
            "probability": 0.0023156870156526566
        },
        {
            "start_logit": 0.6680722236633301,
            "end_logit": 1.9753422737121582,
            "text": "metastasis potential",
            "probability": 0.0018797721713781357
        },
        {
            "start_logit": 3.5652949810028076,
            "end_logit": -1.0802973508834839,
            "text": "Alternative splicing of HSPA12A pre-RNA by SRSF11",
            "probability": 0.0016043746145442128
        },
        {
            "start_logit": -2.5847971439361572,
            "end_logit": 4.935576915740967,
            "text": "SRSF11 contributes to metastasis potential of colorectal cancer.",
            "probability": 0.0014028639998286963
        },
        {
            "start_logit": -2.7586262226104736,
            "end_logit": 4.935576915740967,
            "text": "to metastasis potential of colorectal cancer.",
            "probability": 0.0011790236458182335
        },
        {
            "start_logit": 3.5652949810028076,
            "end_logit": -1.7366572618484497,
            "text": "Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis",
            "probability": 0.0008322468493133783
        },
        {
            "start_logit": 3.5652949810028076,
            "end_logit": -1.8027362823486328,
            "text": "Alternative splicing of HSPA12A",
            "probability": 0.0007790307281538844
        },
        {
            "start_logit": -1.2120503187179565,
            "end_logit": 2.5711283683776855,
            "text": "HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer",
            "probability": 0.0005203852197155356
        },
        {
            "start_logit": -3.752983808517456,
            "end_logit": 4.935576915740967,
            "text": ".",
            "probability": 0.0004361929895821959
        },
        {
            "start_logit": 3.5652949810028076,
            "end_logit": -2.455186367034912,
            "text": "Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of",
            "probability": 0.0004056942998431623
        }
    ],
    "63f9cd0b33942b094c000010_0002": [
        {
            "start_logit": 3.0567593574523926,
            "end_logit": 6.4451518058776855,
            "text": "associated with metastasis in colorectal cancer.",
            "probability": 0.39700818061828613
        },
        {
            "start_logit": 2.8355302810668945,
            "end_logit": 6.4451518058776855,
            "text": "is associated with metastasis in colorectal cancer.",
            "probability": 0.318215012550354
        },
        {
            "start_logit": 2.2429919242858887,
            "end_logit": 6.4451518058776855,
            "text": "metastasis in colorectal cancer.",
            "probability": 0.1759481579065323
        },
        {
            "start_logit": 0.7260940670967102,
            "end_logit": 6.4451518058776855,
            "text": "Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer.",
            "probability": 0.038601525127887726
        },
        {
            "start_logit": 3.0567593574523926,
            "end_logit": 3.629605293273926,
            "text": "associated with metastasis in colorectal cancer",
            "probability": 0.023769669234752655
        },
        {
            "start_logit": 2.8355302810668945,
            "end_logit": 3.629605293273926,
            "text": "is associated with metastasis in colorectal cancer",
            "probability": 0.0190521739423275
        },
        {
            "start_logit": 2.2429919242858887,
            "end_logit": 3.629605293273926,
            "text": "metastasis in colorectal cancer",
            "probability": 0.010534366592764854
        },
        {
            "start_logit": -1.4116472005844116,
            "end_logit": 6.4451518058776855,
            "text": "with metastasis in colorectal cancer.",
            "probability": 0.004551924765110016
        },
        {
            "start_logit": -1.9369268417358398,
            "end_logit": 6.4451518058776855,
            "text": "RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer.",
            "probability": 0.002691962756216526
        },
        {
            "start_logit": 0.7260940670967102,
            "end_logit": 3.629605293273926,
            "text": "Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer",
            "probability": 0.0023111500777304173
        },
        {
            "start_logit": -2.1854612827301025,
            "end_logit": 6.4451518058776855,
            "text": "PTBP1 is associated with metastasis in colorectal cancer.",
            "probability": 0.0020995771046727896
        },
        {
            "start_logit": -2.320859670639038,
            "end_logit": 6.4451518058776855,
            "text": ".",
            "probability": 0.0018337040673941374
        },
        {
            "start_logit": 3.0567593574523926,
            "end_logit": 0.15286602079868317,
            "text": "associated with metastasis",
            "probability": 0.0007346735219471157
        },
        {
            "start_logit": 2.8355302810668945,
            "end_logit": 0.15286602079868317,
            "text": "is associated with metastasis",
            "probability": 0.0005888654268346727
        },
        {
            "start_logit": -3.6633200645446777,
            "end_logit": 6.4451518058776855,
            "text": "microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer.",
            "probability": 0.00047896752948872745
        },
        {
            "start_logit": -3.8222298622131348,
            "end_logit": 6.4451518058776855,
            "text": "cancer.",
            "probability": 0.00040859440923668444
        },
        {
            "start_logit": 2.2429919242858887,
            "end_logit": 0.15286602079868317,
            "text": "metastasis",
            "probability": 0.00032559645478613675
        },
        {
            "start_logit": 3.0567593574523926,
            "end_logit": -0.6834865212440491,
            "text": "associated with",
            "probability": 0.00031832532840780914
        },
        {
            "start_logit": -1.4116472005844116,
            "end_logit": 3.629605293273926,
            "text": "with metastasis in colorectal cancer",
            "probability": 0.00027253280859440565
        },
        {
            "start_logit": 2.8355302810668945,
            "end_logit": -0.6834865212440491,
            "text": "is associated with",
            "probability": 0.00025514824665151536
        }
    ],
    "63f9cd0b33942b094c000010_0003": [
        {
            "start_logit": 4.486715316772461,
            "end_logit": 5.785130500793457,
            "text": "splicing factors",
            "probability": 0.7313663959503174
        },
        {
            "start_logit": 4.486715316772461,
            "end_logit": 4.435762405395508,
            "text": "splicing factors, RBFOX2 and PTBP1, as regulators of microexon splicing",
            "probability": 0.18971945345401764
        },
        {
            "start_logit": 4.486715316772461,
            "end_logit": 2.909193754196167,
            "text": "splicing factors, RBFOX2 and PTBP1, as regulators of microexon splicing in CRC cells.",
            "probability": 0.04122224450111389
        },
        {
            "start_logit": 2.3787221908569336,
            "end_logit": 3.2497873306274414,
            "text": "Differential microexon splicing",
            "probability": 0.007039789110422134
        },
        {
            "start_logit": -0.18171748518943787,
            "end_logit": 5.785130500793457,
            "text": "two splicing factors",
            "probability": 0.006865314673632383
        },
        {
            "start_logit": -0.44894078373908997,
            "end_logit": 5.785130500793457,
            "text": "RNA interference-mediated knockdown experiments identified two splicing factors",
            "probability": 0.005255412310361862
        },
        {
            "start_logit": 0.47292420268058777,
            "end_logit": 4.435762405395508,
            "text": "microexon splicing",
            "probability": 0.0034272402990609407
        },
        {
            "start_logit": 0.039632685482501984,
            "end_logit": 4.435762405395508,
            "text": "regulators of microexon splicing",
            "probability": 0.0022221249528229237
        },
        {
            "start_logit": -0.05697023868560791,
            "end_logit": 4.435762405395508,
            "text": "RBFOX2 and PTBP1, as regulators of microexon splicing",
            "probability": 0.0020175038371235132
        },
        {
            "start_logit": -0.18171748518943787,
            "end_logit": 4.435762405395508,
            "text": "two splicing factors, RBFOX2 and PTBP1, as regulators of microexon splicing",
            "probability": 0.0017808908596634865
        },
        {
            "start_logit": 4.486715316772461,
            "end_logit": -0.31434956192970276,
            "text": "splicing factors, RBFOX2 and PTBP1",
            "probability": 0.0016412109835073352
        },
        {
            "start_logit": -0.44894078373908997,
            "end_logit": 4.435762405395508,
            "text": "RNA interference-mediated knockdown experiments identified two splicing factors, RBFOX2 and PTBP1, as regulators of microexon splicing",
            "probability": 0.001363275689072907
        },
        {
            "start_logit": 4.486715316772461,
            "end_logit": -0.5546056032180786,
            "text": "splicing factors, RBFOX2",
            "probability": 0.0012906920164823532
        },
        {
            "start_logit": 4.486715316772461,
            "end_logit": -0.5775091648101807,
            "text": "splicing factors, RBFOX2 and PTBP1, as regulators of microexon",
            "probability": 0.0012614666484296322
        },
        {
            "start_logit": -0.7292575836181641,
            "end_logit": 4.435762405395508,
            "text": "PTBP1, as regulators of microexon splicing",
            "probability": 0.0010300151770934463
        },
        {
            "start_logit": 0.47292420268058777,
            "end_logit": 2.909193754196167,
            "text": "microexon splicing in CRC cells.",
            "probability": 0.0007446708623319864
        },
        {
            "start_logit": 0.039632685482501984,
            "end_logit": 2.909193754196167,
            "text": "regulators of microexon splicing in CRC cells.",
            "probability": 0.00048282332136295736
        },
        {
            "start_logit": 4.486715316772461,
            "end_logit": -1.6212983131408691,
            "text": "splicing factors, RBFOX2 and PTBP1, as regulators",
            "probability": 0.00044418495963327587
        },
        {
            "start_logit": -0.05697023868560791,
            "end_logit": 2.909193754196167,
            "text": "RBFOX2 and PTBP1, as regulators of microexon splicing in CRC cells.",
            "probability": 0.0004383630584925413
        },
        {
            "start_logit": -0.18171748518943787,
            "end_logit": 2.909193754196167,
            "text": "two splicing factors, RBFOX2 and PTBP1, as regulators of microexon splicing in CRC cells.",
            "probability": 0.0003869517822749913
        }
    ],
    "63f9cd0b33942b094c000010_0004": [
        {
            "start_logit": 1.274467945098877,
            "end_logit": 3.868865489959717,
            "text": "Our data thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis through the regulation of microexon splicing.",
            "probability": 0.28389716148376465
        },
        {
            "start_logit": 1.274467945098877,
            "end_logit": 2.9787814617156982,
            "text": "Our data thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis",
            "probability": 0.11657418310642242
        },
        {
            "start_logit": 0.10989994555711746,
            "end_logit": 3.868865489959717,
            "text": "influence CRC metastasis through the regulation of microexon splicing.",
            "probability": 0.08859223127365112
        },
        {
            "start_logit": 0.09126821160316467,
            "end_logit": 3.868865489959717,
            "text": "CRC metastasis through the regulation of microexon splicing.",
            "probability": 0.08695688098669052
        },
        {
            "start_logit": 0.0897107869386673,
            "end_logit": 3.868865489959717,
            "text": "altered expression of RBFOX2 and PTBP1 might influence CRC metastasis through the regulation of microexon splicing.",
            "probability": 0.0868215411901474
        },
        {
            "start_logit": -0.5448684692382812,
            "end_logit": 3.868865489959717,
            "text": "suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis through the regulation of microexon splicing.",
            "probability": 0.046029187738895416
        },
        {
            "start_logit": 0.10989994555711746,
            "end_logit": 2.9787814617156982,
            "text": "influence CRC metastasis",
            "probability": 0.03637785091996193
        },
        {
            "start_logit": 0.09126821160316467,
            "end_logit": 2.9787814617156982,
            "text": "CRC metastasis",
            "probability": 0.03570634126663208
        },
        {
            "start_logit": 0.0897107869386673,
            "end_logit": 2.9787814617156982,
            "text": "altered expression of RBFOX2 and PTBP1 might influence CRC metastasis",
            "probability": 0.035650771111249924
        },
        {
            "start_logit": 1.274467945098877,
            "end_logit": 1.5637706518173218,
            "text": "Our data thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis through the regulation of microexon splicing",
            "probability": 0.028318559750914574
        },
        {
            "start_logit": -1.3433729410171509,
            "end_logit": 3.868865489959717,
            "text": "regulation of microexon splicing.",
            "probability": 0.02071320079267025
        },
        {
            "start_logit": -1.4001169204711914,
            "end_logit": 3.868865489959717,
            "text": "metastasis through the regulation of microexon splicing.",
            "probability": 0.019570576027035713
        },
        {
            "start_logit": -0.5448684692382812,
            "end_logit": 2.9787814617156982,
            "text": "suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis",
            "probability": 0.018900560215115547
        },
        {
            "start_logit": -1.4431164264678955,
            "end_logit": 3.868865489959717,
            "text": "might influence CRC metastasis through the regulation of microexon splicing.",
            "probability": 0.018746886402368546
        },
        {
            "start_logit": -1.452423095703125,
            "end_logit": 3.868865489959717,
            "text": "PTBP1 might influence CRC metastasis through the regulation of microexon splicing.",
            "probability": 0.018573224544525146
        },
        {
            "start_logit": -1.4704374074935913,
            "end_logit": 3.868865489959717,
            "text": "RBFOX2 and PTBP1 might influence CRC metastasis through the regulation of microexon splicing.",
            "probability": 0.01824163645505905
        },
        {
            "start_logit": -1.7238686084747314,
            "end_logit": 3.868865489959717,
            "text": "microexon splicing.",
            "probability": 0.01415793877094984
        },
        {
            "start_logit": 0.10989994555711746,
            "end_logit": 1.5637706518173218,
            "text": "influence CRC metastasis through the regulation of microexon splicing",
            "probability": 0.008837017230689526
        },
        {
            "start_logit": 0.09126821160316467,
            "end_logit": 1.5637706518173218,
            "text": "CRC metastasis through the regulation of microexon splicing",
            "probability": 0.008673890493810177
        },
        {
            "start_logit": 0.0897107869386673,
            "end_logit": 1.5637706518173218,
            "text": "altered expression of RBFOX2 and PTBP1 might influence CRC metastasis through the regulation of microexon splicing",
            "probability": 0.008660392835736275
        }
    ],
    "63f56f7533942b094c000002_0001": [
        {
            "start_logit": 7.258757591247559,
            "end_logit": 7.919958114624023,
            "text": "aspartoacylase Gene",
            "probability": 0.9872232675552368
        },
        {
            "start_logit": 7.258757591247559,
            "end_logit": 3.557643413543701,
            "text": "aspartoacylase Gene.",
            "probability": 0.012585948221385479
        },
        {
            "start_logit": -2.691030502319336,
            "end_logit": 7.919958114624023,
            "text": "Gene",
            "probability": 4.712781810667366e-05
        },
        {
            "start_logit": -2.7211802005767822,
            "end_logit": 7.919958114624023,
            "text": "White Matter in Canavan Disease Associated with Novel Mutations of aspartoacylase Gene",
            "probability": 4.572814214043319e-05
        },
        {
            "start_logit": -2.95774245262146,
            "end_logit": 7.919958114624023,
            "text": "Cribriform Appearance of White Matter in Canavan Disease Associated with Novel Mutations of aspartoacylase Gene",
            "probability": 3.609489067457616e-05
        },
        {
            "start_logit": -3.814831256866455,
            "end_logit": 7.919958114624023,
            "text": "Canavan Disease Associated with Novel Mutations of aspartoacylase Gene",
            "probability": 1.5318513760576025e-05
        },
        {
            "start_logit": -4.268888473510742,
            "end_logit": 7.919958114624023,
            "text": "Novel Mutations of aspartoacylase Gene",
            "probability": 9.727971701067872e-06
        },
        {
            "start_logit": 7.258757591247559,
            "end_logit": -3.607836961746216,
            "text": "aspart",
            "probability": 9.726524694997352e-06
        },
        {
            "start_logit": 7.258757591247559,
            "end_logit": -3.7319300174713135,
            "text": "aspartoacylase",
            "probability": 8.591416190029122e-06
        },
        {
            "start_logit": -4.682716369628906,
            "end_logit": 7.919958114624023,
            "text": "Mutations of aspartoacylase Gene",
            "probability": 6.4313057919207495e-06
        },
        {
            "start_logit": -5.803047180175781,
            "end_logit": 7.919958114624023,
            "text": "avan Disease Associated with Novel Mutations of aspartoacylase Gene",
            "probability": 2.097711103488109e-06
        },
        {
            "start_logit": -5.868056297302246,
            "end_logit": 7.919958114624023,
            "text": "Appearance of White Matter in Canavan Disease Associated with Novel Mutations of aspartoacylase Gene",
            "probability": 1.9656788481370313e-06
        },
        {
            "start_logit": 7.258757591247559,
            "end_logit": -5.5860676765441895,
            "text": "aspartoac",
            "probability": 1.3453121709972038e-06
        },
        {
            "start_logit": -6.400703430175781,
            "end_logit": 7.919958114624023,
            "text": "of aspartoacylase Gene",
            "probability": 1.1539497108969954e-06
        },
        {
            "start_logit": -6.450162887573242,
            "end_logit": 7.919958114624023,
            "text": "Associated with Novel Mutations of aspartoacylase Gene",
            "probability": 1.0982643061652198e-06
        },
        {
            "start_logit": -6.460050582885742,
            "end_logit": 7.919958114624023,
            "text": "Matter in Canavan Disease Associated with Novel Mutations of aspartoacylase Gene",
            "probability": 1.0874584859266179e-06
        },
        {
            "start_logit": -6.4937357902526855,
            "end_logit": 7.919958114624023,
            "text": "briform Appearance of White Matter in Canavan Disease Associated with Novel Mutations of aspartoacylase Gene",
            "probability": 1.0514378345760633e-06
        },
        {
            "start_logit": -6.554125785827637,
            "end_logit": 7.919958114624023,
            "text": "of White Matter in Canavan Disease Associated with Novel Mutations of aspartoacylase Gene",
            "probability": 9.898202506519738e-07
        },
        {
            "start_logit": -2.691030502319336,
            "end_logit": 3.557643413543701,
            "text": "Gene.",
            "probability": 6.008248760736024e-07
        },
        {
            "start_logit": -2.7211802005767822,
            "end_logit": 3.557643413543701,
            "text": "White Matter in Canavan Disease Associated with Novel Mutations of aspartoacylase Gene.",
            "probability": 5.829806468682364e-07
        }
    ],
    "63f56f7533942b094c000002_0002": [
        {
            "start_logit": 6.62863826751709,
            "end_logit": 6.613611221313477,
            "text": "aspartoacylase or aspartoacylase gene",
            "probability": 0.7056547999382019
        },
        {
            "start_logit": 5.745547771453857,
            "end_logit": 6.613611221313477,
            "text": "aspartoacylase gene",
            "probability": 0.29179051518440247
        },
        {
            "start_logit": 6.62863826751709,
            "end_logit": 0.8335078358650208,
            "text": "aspartoacylase",
            "probability": 0.002179341856390238
        },
        {
            "start_logit": -1.835679054260254,
            "end_logit": 6.613611221313477,
            "text": "the aspartoacylase or aspartoacylase gene",
            "probability": 0.0001487941772211343
        },
        {
            "start_logit": 6.62863826751709,
            "end_logit": -3.2417280673980713,
            "text": "aspart",
            "probability": 3.702311005326919e-05
        },
        {
            "start_logit": 6.62863826751709,
            "end_logit": -3.391468048095703,
            "text": "aspartoacylase or aspartoacylase",
            "probability": 3.187436595908366e-05
        },
        {
            "start_logit": 6.62863826751709,
            "end_logit": -3.4863216876983643,
            "text": "aspartoacylase or aspartoacylase gene that possibly accounts for the severe form of Canavan disease, which probably explains the imaging findings.",
            "probability": 2.898993443523068e-05
        },
        {
            "start_logit": -3.700052261352539,
            "end_logit": 6.613611221313477,
            "text": "gene",
            "probability": 2.306210808455944e-05
        },
        {
            "start_logit": 6.62863826751709,
            "end_logit": -4.163360595703125,
            "text": "aspartoacylase or aspart",
            "probability": 1.4730343536939472e-05
        },
        {
            "start_logit": 5.745547771453857,
            "end_logit": -3.391468048095703,
            "text": "aspartoacylase",
            "probability": 1.3180139831092674e-05
        },
        {
            "start_logit": 5.745547771453857,
            "end_logit": -3.4863216876983643,
            "text": "aspartoacylase gene that possibly accounts for the severe form of Canavan disease, which probably explains the imaging findings.",
            "probability": 1.1987419384240638e-05
        },
        {
            "start_logit": -4.381929397583008,
            "end_logit": 6.613611221313477,
            "text": "Genetic analysis revealed novel mutations in the aspartoacylase or aspartoacylase gene",
            "probability": 1.1661743883450981e-05
        },
        {
            "start_logit": 6.62863826751709,
            "end_logit": -4.526820182800293,
            "text": "aspartoac",
            "probability": 1.024151970341336e-05
        },
        {
            "start_logit": -4.744016647338867,
            "end_logit": 6.613611221313477,
            "text": "novel mutations in the aspartoacylase or aspartoacylase gene",
            "probability": 8.119158337649424e-06
        },
        {
            "start_logit": 6.62863826751709,
            "end_logit": -4.864751815795898,
            "text": "aspartoacylase or aspartoacylase gene that possibly accounts for the severe form of Canavan disease",
            "probability": 7.304703103727661e-06
        },
        {
            "start_logit": 5.745547771453857,
            "end_logit": -4.163360595703125,
            "text": "aspart",
            "probability": 6.091038358135847e-06
        },
        {
            "start_logit": 6.62863826751709,
            "end_logit": -5.0568623542785645,
            "text": "aspartoacylase or aspartoacylase gene that possibly accounts for the severe form of Canavan disease, which probably explains the imaging findings",
            "probability": 6.0279580793576315e-06
        },
        {
            "start_logit": 6.62863826751709,
            "end_logit": -5.130465984344482,
            "text": "aspartoacylase or aspartoac",
            "probability": 5.600208169198595e-06
        },
        {
            "start_logit": 6.62863826751709,
            "end_logit": -5.153933048248291,
            "text": "aspartoacylase or",
            "probability": 5.470322776091052e-06
        },
        {
            "start_logit": 6.62863826751709,
            "end_logit": -5.203742027282715,
            "text": "aspartoacylase or aspartoacylase gene that possibly accounts for the severe form of Canavan disease, which probably explains the imaging",
            "probability": 5.204523858992616e-06
        }
    ],
    "63f56f7533942b094c000002_0003": [
        {
            "start_logit": 4.9772796630859375,
            "end_logit": 3.142502784729004,
            "text": "aspartoacylase",
            "probability": 0.726077139377594
        },
        {
            "start_logit": 4.9772796630859375,
            "end_logit": 1.6630245447158813,
            "text": "aspartoacylase (aspartoacylase).",
            "probability": 0.16536876559257507
        },
        {
            "start_logit": 4.9772796630859375,
            "end_logit": -0.06377480924129486,
            "text": "aspartoacylase (aspartoacylase",
            "probability": 0.029411299154162407
        },
        {
            "start_logit": 1.498727560043335,
            "end_logit": 3.142502784729004,
            "text": "the gene encoding aspartoacylase",
            "probability": 0.022400973364710808
        },
        {
            "start_logit": 4.9772796630859375,
            "end_logit": -0.4197661876678467,
            "text": "aspartoacylase (aspartoacylase)",
            "probability": 0.020601976662874222
        },
        {
            "start_logit": 1.498727560043335,
            "end_logit": 2.4231724739074707,
            "text": "the gene",
            "probability": 0.010911022312939167
        },
        {
            "start_logit": 0.5957910418510437,
            "end_logit": 3.142502784729004,
            "text": "gene encoding aspartoacylase",
            "probability": 0.009080846793949604
        },
        {
            "start_logit": 1.498727560043335,
            "end_logit": 1.6630245447158813,
            "text": "the gene encoding aspartoacylase (aspartoacylase).",
            "probability": 0.005101965740323067
        },
        {
            "start_logit": 0.5957910418510437,
            "end_logit": 2.4231724739074707,
            "text": "gene",
            "probability": 0.004423085600137711
        },
        {
            "start_logit": 0.5957910418510437,
            "end_logit": 1.6630245447158813,
            "text": "gene encoding aspartoacylase (aspartoacylase).",
            "probability": 0.0020682222675532103
        },
        {
            "start_logit": 1.498727560043335,
            "end_logit": -0.06377480924129486,
            "text": "the gene encoding aspartoacylase (aspartoacylase",
            "probability": 0.0009073985856957734
        },
        {
            "start_logit": 1.498727560043335,
            "end_logit": -0.4197661876678467,
            "text": "the gene encoding aspartoacylase (aspartoacylase)",
            "probability": 0.0006356133380904794
        },
        {
            "start_logit": 4.9772796630859375,
            "end_logit": -3.967067241668701,
            "text": "aspartoacylase (aspart",
            "probability": 0.0005933838547207415
        },
        {
            "start_logit": 4.9772796630859375,
            "end_logit": -4.0901103019714355,
            "text": "aspart",
            "probability": 0.0005246851942501962
        },
        {
            "start_logit": -0.8233045935630798,
            "end_logit": 1.6630245447158813,
            "text": "aspartoacylase).",
            "probability": 0.000500370457302779
        },
        {
            "start_logit": 0.5957910418510437,
            "end_logit": -0.06377480924129486,
            "text": "gene encoding aspartoacylase (aspartoacylase",
            "probability": 0.0003678390057757497
        },
        {
            "start_logit": 4.9772796630859375,
            "end_logit": -4.603612899780273,
            "text": "aspartoacylase (aspartoac",
            "probability": 0.0003139695036225021
        },
        {
            "start_logit": 4.9772796630859375,
            "end_logit": -4.767556667327881,
            "text": "aspartoacylase (",
            "probability": 0.00026649408391676843
        },
        {
            "start_logit": 0.5957910418510437,
            "end_logit": -0.4197661876678467,
            "text": "gene encoding aspartoacylase (aspartoacylase)",
            "probability": 0.00025766337057575583
        },
        {
            "start_logit": -3.285482883453369,
            "end_logit": 3.142502784729004,
            "text": "Canavan disease (Canavan disease) is an inherited leukodystrophy resulting from mutations in the gene encoding aspartoacylase",
            "probability": 0.00018728835857473314
        }
    ],
    "63f56f7533942b094c000002_0004": [
        {
            "start_logit": 7.285541534423828,
            "end_logit": 7.76292610168457,
            "text": "aspartoacylase (aspartoacylase) gene",
            "probability": 0.9983999133110046
        },
        {
            "start_logit": -0.051464878022670746,
            "end_logit": 7.76292610168457,
            "text": "aspartoacylase) gene",
            "probability": 0.0006499547162093222
        },
        {
            "start_logit": 7.285541534423828,
            "end_logit": -0.2636164128780365,
            "text": "aspartoacylase",
            "probability": 0.00032615294912829995
        },
        {
            "start_logit": -0.8674021363258362,
            "end_logit": 7.76292610168457,
            "text": "the aspartoacylase (aspartoacylase) gene",
            "probability": 0.0002874260244425386
        },
        {
            "start_logit": 7.285541534423828,
            "end_logit": -1.4446749687194824,
            "text": "aspartoacylase (aspartoacylase)",
            "probability": 0.00010011380800278857
        },
        {
            "start_logit": -2.77040958404541,
            "end_logit": 7.76292610168457,
            "text": "gene",
            "probability": 4.286081457394175e-05
        },
        {
            "start_logit": -2.8247432708740234,
            "end_logit": 7.76292610168457,
            "text": "Canavan disease is caused by mutations of the aspartoacylase (aspartoacylase) gene",
            "probability": 4.0594168240204453e-05
        },
        {
            "start_logit": 7.285541534423828,
            "end_logit": -2.4380784034729004,
            "text": "aspartoacylase (aspartoacylase",
            "probability": 3.707360156113282e-05
        },
        {
            "start_logit": 7.285541534423828,
            "end_logit": -2.6773033142089844,
            "text": "aspartoacylase (aspartoacylase) gene, we introduced the wild-type (wild-type) aspartoacylase gene",
            "probability": 2.9185724997660145e-05
        },
        {
            "start_logit": 7.285541534423828,
            "end_logit": -2.9238393306732178,
            "text": "aspart",
            "probability": 2.280873195559252e-05
        },
        {
            "start_logit": 7.285541534423828,
            "end_logit": -2.966433525085449,
            "text": "aspartoacylase (aspartoacylase) gene, we introduced the wild-type (wild-type",
            "probability": 2.1857618776266463e-05
        },
        {
            "start_logit": 7.285541534423828,
            "end_logit": -3.173868179321289,
            "text": "aspartoacylase (aspartoacylase) gene,",
            "probability": 1.7762951756594703e-05
        },
        {
            "start_logit": 7.285541534423828,
            "end_logit": -4.569870948791504,
            "text": "aspartoacylase (aspart",
            "probability": 4.397834345581941e-06
        },
        {
            "start_logit": -5.139029502868652,
            "end_logit": 7.76292610168457,
            "text": "neurological disease that lacks effective therapy. Because Canavan disease is caused by mutations of the aspartoacylase (aspartoacylase) gene",
            "probability": 4.012194040114991e-06
        },
        {
            "start_logit": -5.389358043670654,
            "end_logit": 7.76292610168457,
            "text": "mutations of the aspartoacylase (aspartoacylase) gene",
            "probability": 3.1236716040439205e-06
        },
        {
            "start_logit": 7.285541534423828,
            "end_logit": -4.9556121826171875,
            "text": "aspartoacylase (",
            "probability": 2.9902914775448153e-06
        },
        {
            "start_logit": 7.285541534423828,
            "end_logit": -4.986263275146484,
            "text": "aspartoacylase (aspartoacylase) gene, we introduced the wild-type (wild-type) aspartoacylase",
            "probability": 2.9000264021306066e-06
        },
        {
            "start_logit": -5.5398712158203125,
            "end_logit": 7.76292610168457,
            "text": "of the aspartoacylase (aspartoacylase) gene",
            "probability": 2.6871912268688902e-06
        },
        {
            "start_logit": 7.285541534423828,
            "end_logit": -5.277292251586914,
            "text": "aspartoac",
            "probability": 2.1677524273400195e-06
        },
        {
            "start_logit": -5.80579948425293,
            "end_logit": 7.76292610168457,
            "text": ") gene",
            "probability": 2.0597162802005187e-06
        }
    ],
    "63f56f7533942b094c000002_0005": [
        {
            "start_logit": 7.614079475402832,
            "end_logit": 8.253984451293945,
            "text": "aspartoacylase gene",
            "probability": 0.9998365640640259
        },
        {
            "start_logit": -2.685804605484009,
            "end_logit": 8.253984451293945,
            "text": "the aspartoacylase gene",
            "probability": 3.3631502446951345e-05
        },
        {
            "start_logit": -2.71083927154541,
            "end_logit": 8.253984451293945,
            "text": "gene",
            "probability": 3.279999509686604e-05
        },
        {
            "start_logit": 7.614079475402832,
            "end_logit": -2.1258721351623535,
            "text": "aspartoacylase",
            "probability": 3.104664938291535e-05
        },
        {
            "start_logit": -3.3174922466278076,
            "end_logit": 8.253984451293945,
            "text": "The compound heterozygous variants of the aspartoacylase gene",
            "probability": 1.788165172911249e-05
        },
        {
            "start_logit": -3.494952440261841,
            "end_logit": 8.253984451293945,
            "text": "compound heterozygous variants of the aspartoacylase gene",
            "probability": 1.4974000805523247e-05
        },
        {
            "start_logit": 7.614079475402832,
            "end_logit": -3.1628129482269287,
            "text": "aspart",
            "probability": 1.1007197826984338e-05
        },
        {
            "start_logit": 7.614079475402832,
            "end_logit": -3.5992743968963623,
            "text": "aspartoacylase gene probably underlay the Canavan disease in this patient, and the result has enabled prenatal diagnosis for this family.",
            "probability": 7.114166237442987e-06
        },
        {
            "start_logit": -5.083258152008057,
            "end_logit": 8.253984451293945,
            "text": "heterozygous variants of the aspartoacylase gene",
            "probability": 3.0587582386942813e-06
        },
        {
            "start_logit": -5.087535381317139,
            "end_logit": 8.253984451293945,
            "text": "variants of the aspartoacylase gene",
            "probability": 3.045706080229138e-06
        },
        {
            "start_logit": 7.614079475402832,
            "end_logit": -4.965441703796387,
            "text": "aspartoac",
            "probability": 1.8147014770875103e-06
        },
        {
            "start_logit": 7.614079475402832,
            "end_logit": -5.2646098136901855,
            "text": "aspartoacylase gene probably underlay the Canavan disease",
            "probability": 1.3454821328195976e-06
        },
        {
            "start_logit": 7.614079475402832,
            "end_logit": -5.354443550109863,
            "text": "aspartoacylase gene probably underlay the Canavan disease in this patient, and the result has enabled prenatal diagnosis",
            "probability": 1.229883082487504e-06
        },
        {
            "start_logit": 7.614079475402832,
            "end_logit": -5.660235404968262,
            "text": "aspartoacylase gene probably underlay the Canavan disease in this patient, and",
            "probability": 9.058580303644703e-07
        },
        {
            "start_logit": -6.401480197906494,
            "end_logit": 8.253984451293945,
            "text": "of the aspartoacylase gene",
            "probability": 8.185563160623133e-07
        },
        {
            "start_logit": 7.614079475402832,
            "end_logit": -6.0751142501831055,
            "text": "aspartoacylase gene probably underlay the Canavan disease in this patient,",
            "probability": 5.982470270282647e-07
        },
        {
            "start_logit": 7.614079475402832,
            "end_logit": -6.0925374031066895,
            "text": "aspartoacylase gene probably underlay the Can",
            "probability": 5.879142577214225e-07
        },
        {
            "start_logit": 7.614079475402832,
            "end_logit": -6.2089409828186035,
            "text": "aspartoacylase gene probably underlay the Canavan disease in this patient",
            "probability": 5.233118258729519e-07
        },
        {
            "start_logit": 7.614079475402832,
            "end_logit": -6.375368118286133,
            "text": "aspartoacylase gene probably",
            "probability": 4.430798128396418e-07
        },
        {
            "start_logit": 7.614079475402832,
            "end_logit": -6.400402069091797,
            "text": "aspartoacylase gene probably underlay the Canavan disease in this patient, and the result",
            "probability": 4.321254039041378e-07
        }
    ],
    "63eeeb70f36125a426000005_0001": [
        {
            "start_logit": 5.816384315490723,
            "end_logit": 7.5890069007873535,
            "text": "DLBCL",
            "probability": 0.9996144771575928
        },
        {
            "start_logit": -3.371513605117798,
            "end_logit": 7.5890069007873535,
            "text": "Relapsed or Refractory DLBCL",
            "probability": 0.00010223012213828042
        },
        {
            "start_logit": -3.5743212699890137,
            "end_logit": 7.5890069007873535,
            "text": "Glofitamab Treatment in Relapsed or Refractory DLBCL",
            "probability": 8.346429240191355e-05
        },
        {
            "start_logit": -3.6332972049713135,
            "end_logit": 7.5890069007873535,
            "text": "Refractory DLBCL",
            "probability": 7.868423563195392e-05
        },
        {
            "start_logit": 5.816384315490723,
            "end_logit": -1.9511394500732422,
            "text": "DLBCL after CAR T-Cell Therapy.",
            "probability": 7.187856681412086e-05
        },
        {
            "start_logit": -5.0251078605651855,
            "end_logit": 7.5890069007873535,
            "text": "in Relapsed or Refractory DLBCL",
            "probability": 1.9562850866350345e-05
        },
        {
            "start_logit": -6.139797210693359,
            "end_logit": 7.5890069007873535,
            "text": "Treatment in Relapsed or Refractory DLBCL",
            "probability": 6.41694759906386e-06
        },
        {
            "start_logit": -6.398561954498291,
            "end_logit": 7.5890069007873535,
            "text": "or Refractory DLBCL",
            "probability": 4.953915322403191e-06
        },
        {
            "start_logit": -6.468127727508545,
            "end_logit": 7.5890069007873535,
            "text": "ofitamab Treatment in Relapsed or Refractory DLBCL",
            "probability": 4.6210061555029824e-06
        },
        {
            "start_logit": -6.8072404861450195,
            "end_logit": 7.5890069007873535,
            "text": "itamab Treatment in Relapsed or Refractory DLBCL",
            "probability": 3.2920163448579842e-06
        },
        {
            "start_logit": -6.848833084106445,
            "end_logit": 7.5890069007873535,
            "text": "b Treatment in Relapsed or Refractory DLBCL",
            "probability": 3.157897936034715e-06
        },
        {
            "start_logit": 5.816384315490723,
            "end_logit": -5.201661109924316,
            "text": "DLBCL after CAR T-Cell Therapy",
            "probability": 2.7855808184540365e-06
        },
        {
            "start_logit": 5.816384315490723,
            "end_logit": -5.761221885681152,
            "text": "DLBCL after CAR T-Cell",
            "probability": 1.5918482176857651e-06
        },
        {
            "start_logit": 5.816384315490723,
            "end_logit": -6.17076301574707,
            "text": "DLBCL after CAR T",
            "probability": 1.0569153801043285e-06
        },
        {
            "start_logit": 5.816384315490723,
            "end_logit": -6.35776948928833,
            "text": "DLBCL after CAR",
            "probability": 8.766457995079691e-07
        },
        {
            "start_logit": 5.816384315490723,
            "end_logit": -7.009644985198975,
            "text": "DLBCL after",
            "probability": 4.567921223497251e-07
        },
        {
            "start_logit": 5.816384315490723,
            "end_logit": -7.3084259033203125,
            "text": "DLBCL after CAR T-",
            "probability": 3.3881255490086915e-07
        },
        {
            "start_logit": -3.371513605117798,
            "end_logit": -1.9511394500732422,
            "text": "Relapsed or Refractory DLBCL after CAR T-Cell Therapy.",
            "probability": 7.350995812061001e-09
        },
        {
            "start_logit": -3.5743212699890137,
            "end_logit": -1.9511394500732422,
            "text": "Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy.",
            "probability": 6.0016072112034635e-09
        },
        {
            "start_logit": -3.6332972049713135,
            "end_logit": -1.9511394500732422,
            "text": "Refractory DLBCL after CAR T-Cell Therapy.",
            "probability": 5.65789637363423e-09
        }
    ],
    "63eeeb70f36125a426000005_0002": [
        {
            "start_logit": 6.207921028137207,
            "end_logit": 6.470363616943359,
            "text": "DLBCL",
            "probability": 0.9999263286590576
        },
        {
            "start_logit": -4.757460117340088,
            "end_logit": 6.470363616943359,
            "text": "CD20xCD3 antibody glofitamab in patients who progressed after CAR T treatment. We report nine consecutive patients with progressive DLBCL",
            "probability": 1.728873758111149e-05
        },
        {
            "start_logit": -4.99553918838501,
            "end_logit": 6.470363616943359,
            "text": "bispecific CD20xCD3 antibody glofitamab in patients who progressed after CAR T treatment. We report nine consecutive patients with progressive DLBCL",
            "probability": 1.3625952306028921e-05
        },
        {
            "start_logit": -5.2592949867248535,
            "end_logit": 6.470363616943359,
            "text": "progressive DLBCL",
            "probability": 1.0466926141816657e-05
        },
        {
            "start_logit": 6.207921028137207,
            "end_logit": -5.367669582366943,
            "text": "DLBCL after preceding CAR T-cell therapy.",
            "probability": 7.223959528346313e-06
        },
        {
            "start_logit": -5.704052448272705,
            "end_logit": 6.470363616943359,
            "text": "We report nine consecutive patients with progressive DLBCL",
            "probability": 6.709087756462395e-06
        },
        {
            "start_logit": -5.790033340454102,
            "end_logit": 6.470363616943359,
            "text": "the bispecific CD20xCD3 antibody glofitamab in patients who progressed after CAR T treatment. We report nine consecutive patients with progressive DLBCL",
            "probability": 6.1563405324704945e-06
        },
        {
            "start_logit": -6.404047966003418,
            "end_logit": 6.470363616943359,
            "text": "nine consecutive patients with progressive DLBCL",
            "probability": 3.3316507597191958e-06
        },
        {
            "start_logit": -6.448864459991455,
            "end_logit": 6.470363616943359,
            "text": "patients who progressed after CAR T treatment. We report nine consecutive patients with progressive DLBCL",
            "probability": 3.185632749591605e-06
        },
        {
            "start_logit": -6.512915134429932,
            "end_logit": 6.470363616943359,
            "text": "CAR T treatment. We report nine consecutive patients with progressive DLBCL",
            "probability": 2.9879877274652245e-06
        },
        {
            "start_logit": 6.207921028137207,
            "end_logit": -6.3581671714782715,
            "text": "DLBCL after preceding CAR T-cell therapy",
            "probability": 2.6829197850020137e-06
        },
        {
            "start_logit": -4.757460117340088,
            "end_logit": -5.0569963455200195,
            "text": "CD20xCD3",
            "probability": 1.7040990840655468e-10
        },
        {
            "start_logit": -4.99553918838501,
            "end_logit": -5.0569963455200195,
            "text": "bispecific CD20xCD3",
            "probability": 1.3430694056904002e-10
        },
        {
            "start_logit": -4.757460117340088,
            "end_logit": -5.805438041687012,
            "text": "CD20xCD3 antibody glofitamab in patients who progressed after CAR T treatment.",
            "probability": 8.062132905717334e-11
        },
        {
            "start_logit": -5.2592949867248535,
            "end_logit": -5.367669582366943,
            "text": "progressive DLBCL after preceding CAR T-cell therapy.",
            "probability": 7.561836573577452e-11
        },
        {
            "start_logit": -4.757460117340088,
            "end_logit": -5.97536563873291,
            "text": "CD20xCD3 antibody",
            "probability": 6.802243490700022e-11
        },
        {
            "start_logit": -5.7157883644104,
            "end_logit": -5.0569963455200195,
            "text": "monotherapy with the bispecific CD20xCD3",
            "probability": 6.535792046458155e-11
        },
        {
            "start_logit": -4.99553918838501,
            "end_logit": -5.7797088623046875,
            "text": "bispecific",
            "probability": 6.519705608720727e-11
        },
        {
            "start_logit": -4.757460117340088,
            "end_logit": -6.032576084136963,
            "text": "CD20xCD3 antibody glofitamab",
            "probability": 6.424003690108648e-11
        },
        {
            "start_logit": -4.99553918838501,
            "end_logit": -5.805438041687012,
            "text": "bispecific CD20xCD3 antibody glofitamab in patients who progressed after CAR T treatment.",
            "probability": 6.354092252358612e-11
        }
    ],
    "63eeeb70f36125a426000005_0003": [
        {
            "start_logit": 6.364295482635498,
            "end_logit": 6.172995567321777,
            "text": "DLBCL",
            "probability": 0.999751627445221
        },
        {
            "start_logit": -3.260124444961548,
            "end_logit": 6.172995567321777,
            "text": "glofitamab treatment is well tolerated and effective in patients with DLBCL",
            "probability": 6.607847171835601e-05
        },
        {
            "start_logit": -3.886091709136963,
            "end_logit": 6.172995567321777,
            "text": "with DLBCL",
            "probability": 3.533503331709653e-05
        },
        {
            "start_logit": -3.9155423641204834,
            "end_logit": 6.172995567321777,
            "text": "patients with DLBCL",
            "probability": 3.4309578040847555e-05
        },
        {
            "start_logit": -4.560863971710205,
            "end_logit": 6.172995567321777,
            "text": "in patients with DLBCL",
            "probability": 1.7995156667893752e-05
        },
        {
            "start_logit": 6.364295482635498,
            "end_logit": -5.131353855133057,
            "text": "DLBCL relapsing after CAR T-cell therapy",
            "probability": 1.2316171705606394e-05
        },
        {
            "start_logit": -4.940409183502197,
            "end_logit": 6.172995567321777,
            "text": "effective in patients with DLBCL",
            "probability": 1.2311791579122655e-05
        },
        {
            "start_logit": -5.0080952644348145,
            "end_logit": 6.172995567321777,
            "text": "Our data suggest that glofitamab treatment is well tolerated and effective in patients with DLBCL",
            "probability": 1.1506031114549842e-05
        },
        {
            "start_logit": 6.364295482635498,
            "end_logit": -5.268261432647705,
            "text": "DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T-cell activity.",
            "probability": 1.0740327525127213e-05
        },
        {
            "start_logit": 6.364295482635498,
            "end_logit": -5.598357200622559,
            "text": "DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T-cell activity",
            "probability": 7.720733265159652e-06
        },
        {
            "start_logit": 6.364295482635498,
            "end_logit": -5.864017486572266,
            "text": "DLBCL relapsing after CAR T-cell",
            "probability": 5.919488557992736e-06
        },
        {
            "start_logit": -5.795444011688232,
            "end_logit": 6.172995567321777,
            "text": "well tolerated and effective in patients with DLBCL",
            "probability": 5.235821390670026e-06
        },
        {
            "start_logit": 6.364295482635498,
            "end_logit": -6.142090797424316,
            "text": "DLBCL relapsing after CAR",
            "probability": 4.48247692474979e-06
        },
        {
            "start_logit": 6.364295482635498,
            "end_logit": -6.244109153747559,
            "text": "DLBCL relapsing",
            "probability": 4.047735274070874e-06
        },
        {
            "start_logit": -6.070943355560303,
            "end_logit": 6.172995567321777,
            "text": "data suggest that glofitamab treatment is well tolerated and effective in patients with DLBCL",
            "probability": 3.974997980549233e-06
        },
        {
            "start_logit": -6.086526870727539,
            "end_logit": 6.172995567321777,
            "text": "suggest that glofitamab treatment is well tolerated and effective in patients with DLBCL",
            "probability": 3.913532054866664e-06
        },
        {
            "start_logit": 6.364295482635498,
            "end_logit": -6.3633809089660645,
            "text": "DLBCL relapsing after CAR T",
            "probability": 3.5926359487348236e-06
        },
        {
            "start_logit": -6.329198837280273,
            "end_logit": 6.172995567321777,
            "text": "is well tolerated and effective in patients with DLBCL",
            "probability": 3.070278353334288e-06
        },
        {
            "start_logit": 6.364295482635498,
            "end_logit": -6.541934967041016,
            "text": "DLBCL relapsing after CAR T-cell therapy and can enhance",
            "probability": 3.005165581271285e-06
        },
        {
            "start_logit": -6.387342929840088,
            "end_logit": 6.172995567321777,
            "text": "that glofitamab treatment is well tolerated and effective in patients with DLBCL",
            "probability": 2.8968495371373137e-06
        }
    ],
    "63eeeb70f36125a426000005_0004": [
        {
            "start_logit": 4.832743167877197,
            "end_logit": 5.013856887817383,
            "text": "DLBCL",
            "probability": 0.9998588562011719
        },
        {
            "start_logit": -5.765057563781738,
            "end_logit": 5.013856887817383,
            "text": "loncastuximab tesirine, oral selective inhibitor of nuclear export selinexor, and several new agents have been investigated for DLBCL",
            "probability": 2.496735396562144e-05
        },
        {
            "start_logit": -5.98109769821167,
            "end_logit": 5.013856887817383,
            "text": "oral selective inhibitor of nuclear export selinexor, and several new agents have been investigated for DLBCL",
            "probability": 2.0116263840463944e-05
        },
        {
            "start_logit": -6.000589370727539,
            "end_logit": 5.013856887817383,
            "text": "selinexor, and several new agents have been investigated for DLBCL",
            "probability": 1.972796962945722e-05
        },
        {
            "start_logit": -6.149282455444336,
            "end_logit": 5.013856887817383,
            "text": "new agents have been investigated for DLBCL",
            "probability": 1.700222674116958e-05
        },
        {
            "start_logit": -6.200503826141357,
            "end_logit": 5.013856887817383,
            "text": "selective inhibitor of nuclear export selinexor, and several new agents have been investigated for DLBCL",
            "probability": 1.615326982573606e-05
        },
        {
            "start_logit": -6.227293014526367,
            "end_logit": 5.013856887817383,
            "text": "several new agents have been investigated for DLBCL",
            "probability": 1.5726289348094724e-05
        },
        {
            "start_logit": -6.2885308265686035,
            "end_logit": 5.013856887817383,
            "text": "for DLBCL",
            "probability": 1.4792146430409048e-05
        },
        {
            "start_logit": -6.467008113861084,
            "end_logit": 5.013856887817383,
            "text": "or, and several new agents have been investigated for DLBCL",
            "probability": 1.2374256584735122e-05
        },
        {
            "start_logit": -3.1042025089263916,
            "end_logit": -3.0069820880889893,
            "text": "CD19",
            "probability": 1.1737101601738686e-07
        },
        {
            "start_logit": -3.1042025089263916,
            "end_logit": -4.841374397277832,
            "text": "CD19 antibody drug tafasitamab combined with lenalidomide, CD19",
            "probability": 1.8745421215271563e-08
        },
        {
            "start_logit": -5.49633264541626,
            "end_logit": -3.0069820880889893,
            "text": "mosunetuzumab, and glofitamab, anti-CD19",
            "probability": 1.0731787902784617e-08
        },
        {
            "start_logit": -5.530515193939209,
            "end_logit": -3.0069820880889893,
            "text": "epcoritamab, mosunetuzumab, and glofitamab, anti-CD19",
            "probability": 1.0371137726394863e-08
        },
        {
            "start_logit": -3.1042025089263916,
            "end_logit": -5.579066753387451,
            "text": "CD19 antibody drug tafasitamab combined with lenalidomide, CD19 antibody drug conjugate loncastuximab tesirine",
            "probability": 8.964349262896576e-09
        },
        {
            "start_logit": -3.1042025089263916,
            "end_logit": -5.6064581871032715,
            "text": "CD19 antibody drug tafasitamab combined with lenalidomide",
            "probability": 8.722135902416994e-09
        },
        {
            "start_logit": -3.1042025089263916,
            "end_logit": -5.739038467407227,
            "text": "CD19 antibody drug tafasitamab",
            "probability": 7.639135546355647e-09
        },
        {
            "start_logit": -3.1042025089263916,
            "end_logit": -5.957555294036865,
            "text": "CD19 antibody drug tafasitamab combined with lenalidomide, CD19 antibody drug conjugate loncastuximab",
            "probability": 6.139645680747208e-09
        },
        {
            "start_logit": -3.1042025089263916,
            "end_logit": -6.069845199584961,
            "text": "CD19 antibody drug tafasitamab combined with lenalidomide, CD19 antibody drug conjugate lon",
            "probability": 5.487526877345772e-09
        },
        {
            "start_logit": -3.1042025089263916,
            "end_logit": -6.126557350158691,
            "text": "CD19 antibody drug tafasitamab combined with lenalidomide, CD19 antibody drug conjugate loncastuximab tesirine, oral",
            "probability": 5.18498266544043e-09
        },
        {
            "start_logit": -4.795206546783447,
            "end_logit": -4.841374397277832,
            "text": "CD19",
            "probability": 3.4554192840374753e-09
        }
    ],
    "63eeeb70f36125a426000005_0005": [
        {
            "start_logit": 5.59481954574585,
            "end_logit": 6.8614020347595215,
            "text": "B-cell non-Hodgkin lymphoma",
            "probability": 0.9969192743301392
        },
        {
            "start_logit": -0.37903326749801636,
            "end_logit": 6.8614020347595215,
            "text": "non-Hodgkin lymphoma",
            "probability": 0.0025365811306983232
        },
        {
            "start_logit": -3.2061893939971924,
            "end_logit": 6.8614020347595215,
            "text": "lymphoma",
            "probability": 0.00015011713549029082
        },
        {
            "start_logit": -3.2949323654174805,
            "end_logit": 6.8614020347595215,
            "text": "Hodgkin lymphoma",
            "probability": 0.00013736939581576735
        },
        {
            "start_logit": 5.59481954574585,
            "end_logit": -2.160179853439331,
            "text": "B-cell non-Hodgkin lymphoma.",
            "probability": 0.00012040287401759997
        },
        {
            "start_logit": -4.421199321746826,
            "end_logit": 6.8614020347595215,
            "text": "cell non-Hodgkin lymphoma",
            "probability": 4.4540822273120284e-05
        },
        {
            "start_logit": -4.441000461578369,
            "end_logit": 6.8614020347595215,
            "text": "-cell non-Hodgkin lymphoma",
            "probability": 4.366753637441434e-05
        },
        {
            "start_logit": -5.1018218994140625,
            "end_logit": 6.8614020347595215,
            "text": "-Hodgkin lymphoma",
            "probability": 2.255108302051667e-05
        },
        {
            "start_logit": -5.988204002380371,
            "end_logit": 6.8614020347595215,
            "text": "NP30179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma",
            "probability": 9.294306437368505e-06
        },
        {
            "start_logit": -6.3774333000183105,
            "end_logit": 6.8614020347595215,
            "text": "relapsed/refractory B-cell non-Hodgkin lymphoma",
            "probability": 6.297622803685954e-06
        },
        {
            "start_logit": 5.59481954574585,
            "end_logit": -5.312255859375,
            "text": "B",
            "probability": 5.14881548951962e-06
        },
        {
            "start_logit": 5.59481954574585,
            "end_logit": -5.464817047119141,
            "text": "B-cell",
            "probability": 4.4202911340107676e-06
        },
        {
            "start_logit": -0.37903326749801636,
            "end_logit": -2.160179853439331,
            "text": "non-Hodgkin lymphoma.",
            "probability": 3.0635530379186093e-07
        },
        {
            "start_logit": -3.2061893939971924,
            "end_logit": -2.160179853439331,
            "text": "lymphoma.",
            "probability": 1.813040562126389e-08
        },
        {
            "start_logit": -3.2949323654174805,
            "end_logit": -2.160179853439331,
            "text": "Hodgkin lymphoma.",
            "probability": 1.6590750107070562e-08
        },
        {
            "start_logit": -4.421199321746826,
            "end_logit": -2.160179853439331,
            "text": "cell non-Hodgkin lymphoma.",
            "probability": 5.379410694672515e-09
        },
        {
            "start_logit": -4.441000461578369,
            "end_logit": -2.160179853439331,
            "text": "-cell non-Hodgkin lymphoma.",
            "probability": 5.2739448364036434e-09
        },
        {
            "start_logit": -5.1018218994140625,
            "end_logit": -2.160179853439331,
            "text": "-Hodgkin lymphoma.",
            "probability": 2.7236060073931867e-09
        },
        {
            "start_logit": -3.265850305557251,
            "end_logit": -4.179816246032715,
            "text": "CD20",
            "probability": 2.2666262200488063e-09
        },
        {
            "start_logit": -3.265850305557251,
            "end_logit": -4.413658142089844,
            "text": "CD20xCD3",
            "probability": 1.7940033902874575e-09
        }
    ]
}
